assay_id,assay_organism,assay_category,tissue_id,assay_tax_id,assay_test_type,assay_strain,src_id,src_assay_id,doc_id,relationship_type,tid,assay_cell_type,confidence_score,assay_tissue,assay_type,description,assay_subcellular_fraction,curated_by
1,,,,,,,1,,11087,H,12052,,8,,B,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,Autocuration
2,,,,,,,1,,684,U,22226,,0,,F,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,Autocuration
3,,,,,,,1,,15453,U,22226,,0,,B,,,Autocuration
4,Bos taurus,,,9913.0,,,1,,17841,H,104729,,4,,B,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,Autocuration
5,Homo sapiens,,,9606.0,,,1,,17430,N,80001,143B,1,,F,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Intermediate
6,Homo sapiens,,,9606.0,,,1,,17430,N,80001,143B,1,,F,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Intermediate
7,Mus musculus,,,10090.0,,,1,,13799,N,80001,143B,1,,F,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,Intermediate
8,Homo sapiens,,,9606.0,,,1,,17774,N,80001,143B,1,,F,In vitro cell cytotoxicity was determined against 143B cell line,,Expert
9,Homo sapiens,,,9606.0,,,1,,3801,N,80001,143B,1,,F,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,Intermediate
10,Homo sapiens,,,9606.0,,,1,,17430,N,80001,143B,1,,F,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Intermediate
11,Homo sapiens,,,9606.0,,,1,,17430,N,80001,143B,1,,F,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Intermediate
12,Homo sapiens,,,9606.0,,,1,,17774,N,80001,143B,1,,F,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,Expert
13,Staphylococcus aureus,,,1280.0,,,1,,11324,N,50185,,1,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate
14,Staphylococcus aureus,,,1280.0,,,1,,11324,N,50185,,1,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate
15,Staphylococcus aureus,,,1280.0,,,1,,11324,N,50185,,1,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate
16,Staphylococcus aureus,,,1280.0,,,1,,11324,N,50185,,1,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate
17,Rattus norvegicus,,,10116.0,,,1,,11347,D,100122,,9,,A,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,Expert
18,,,,,,,1,,16474,H,12054,,8,,B,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration
19,,,,,,,1,,10091,H,12054,,8,,B,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,Autocuration
20,,,,,,,1,,16474,H,12054,,8,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration
21,,,,,,,1,,16474,H,12054,,8,,B,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration
22,,,,,,,1,,16474,H,12054,,8,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration
23,,,,,,,1,,16474,H,12054,,8,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,Autocuration
24,,,,,,,1,,16474,H,12054,,8,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,Autocuration
25,,,,,,,1,,14352,U,22226,,0,,B,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,Autocuration
26,Oryctolagus cuniculus,,,9986.0,,,1,,5646,H,12054,,8,,B,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,Autocuration
27,Oryctolagus cuniculus,,,9986.0,,,1,,5646,H,12054,,8,,B,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,Autocuration
28,,,,,,,1,,10997,H,12426,,8,,B,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,Autocuration
29,soya bean,,,3847.0,,,1,,6309,H,12054,,8,,B,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,Autocuration
30,Glycine max,,,3847.0,,,1,,167,H,12054,,8,,B,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,Autocuration
31,Glycine max,,,3847.0,,,1,,167,H,12054,,8,,B,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,Autocuration
32,Glycine max,,,3847.0,,,1,,11087,H,12054,,8,,B,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,Autocuration
33,Glycine max,,,3847.0,,,1,,11087,H,12054,,8,,B,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,Autocuration
34,Glycine max,,,3847.0,,,1,,13622,H,12054,,8,,B,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,Autocuration
35,Glycine max,,,3847.0,,,1,,13622,H,12054,,8,,B,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,Autocuration
36,Rattus norvegicus,,,10116.0,,,1,,11347,U,22226,,0,,A,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,Autocuration
37,Escherichia coli,,,562.0,,,1,,5926,U,22226,,0,,B,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,Autocuration
38,,,,,,,1,,4567,U,22226,,0,,B,Dissociation constant with dimeric 16S rRNA RNA construct B,,Autocuration
39,,,,,,,1,,3782,M,22222,,3,,B,Dissociation constant towards 16S rRNA construct A,,Intermediate
40,,,,,,,1,,3782,M,22222,,3,,B,Dissociation constant towards 16S rRNA construct B,,Intermediate
41,Escherichia coli,,,562.0,,,1,,4466,M,100263,,3,,B,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,Expert
42,Escherichia coli,,,562.0,,,1,,6592,M,100263,,3,,B,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,Expert
43,,,,,,,1,,898,H,13053,,8,,B,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,Autocuration
44,,,,,,,1,,898,H,13053,,8,,B,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,Autocuration
45,Homo sapiens,,,9606.0,,,1,,13163,H,20001,,8,,B,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Autocuration
46,Homo sapiens,,,9606.0,,,1,,13163,H,20001,,8,,B,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Autocuration
47,Rattus norvegicus,,,10116.0,,,1,,10691,D,12971,,9,,B,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Expert
48,Rattus norvegicus,,,10116.0,,,1,,10691,D,12971,,9,,B,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Expert
49,Rattus norvegicus,,,10116.0,,,1,,10691,D,12971,,9,,B,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Expert
50,Rattus norvegicus,,,10116.0,,,1,,10691,D,12971,,9,,B,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Expert
51,,,,,,,1,,898,H,13053,,8,,B,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,Autocuration
52,,,,,,,1,,912,H,11512,,8,,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,Autocuration
53,,,,,,,1,,912,H,11512,,8,,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,Autocuration
54,,,,,,,1,,912,H,11512,,8,,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,Autocuration
55,Rattus norvegicus,,,10116.0,,,1,,15103,D,104740,,5,,B,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Membranes,Autocuration
56,Homo sapiens,,,9606.0,,,1,,5116,N,80002,1A9,1,,F,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,Intermediate
57,Rattus norvegicus,,,10116.0,,,1,,14578,D,104835,Oocytes,7,,F,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Autocuration
58,Rattus norvegicus,,,10116.0,,,1,,14578,D,104821,Oocytes,7,,F,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Autocuration
59,Rattus norvegicus,,,10116.0,,,1,,14578,D,104848,Oocytes,7,,F,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Autocuration
60,Homo sapiens,,,9606.0,,,1,,4787,N,80002,1A9,1,,F,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,Expert
61,Homo sapiens,,,9606.0,,,1,,4787,N,80002,1A9,1,,F,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,Intermediate
62,Homo sapiens,,,9606.0,,,1,,3547,N,80002,1A9,1,,F,Cytotoxic activity against human ovarian cancer (1A9) cell line,,Intermediate
63,Homo sapiens,,,9606.0,,,1,,3547,N,80002,1A9,1,,F,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,Intermediate
64,Homo sapiens,,,9606.0,,,1,,6726,N,80002,1A9,1,,F,Effective dose of compound against replication of 1A9 cell line was evaluated,,Intermediate
65,Homo sapiens,,,9606.0,,,1,,3455,N,80002,1A9,1,,F,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,Expert
66,Homo sapiens,,,9606.0,,,1,,5726,N,80002,1A9,1,,F,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,Intermediate
67,Homo sapiens,,,9606.0,,,1,,5726,N,80002,1A9,1,,F,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,Intermediate
68,Homo sapiens,,,9606.0,,,1,,5726,N,80002,1A9,1,,F,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,Intermediate
69,Homo sapiens,,,9606.0,,,1,,3395,N,80002,1A9,1,,F,Inhibitory activity against Taxol resistant 1A9 cell lines,,Intermediate
70,Homo sapiens,,,9606.0,,,1,,3415,N,80002,1A9,1,,F,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,Expert
71,Homo sapiens,,,9606.0,,,1,,3415,N,80002,1A9,1,,F,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,Expert
72,Homo sapiens,,,9606.0,,,1,,17099,N,80002,1A9,1,,F,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,Expert
73,Homo sapiens,,,9606.0,,,1,,17099,N,80002,1A9,1,,F,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,Intermediate
74,Homo sapiens,,,9606.0,,,1,,17099,N,80002,1A9,1,,F,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,Intermediate
75,Homo sapiens,,,9606.0,,,1,,17099,N,80002,1A9,1,,F,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,Intermediate
76,Homo sapiens,,,9606.0,,,1,,17721,N,81072,Jurkat,1,,F,Inhibitory concentration against Jurkat cells,,Intermediate
77,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,Intermediate
78,Rattus norvegicus,,,10116.0,,,1,,11347,D,100121,,9,,A,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,Expert
79,,,,,,,1,,17117,H,11231,,8,,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,Expert
80,,,,,,,1,,17117,H,11231,,8,,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,Expert
81,,,,,,,1,,17117,H,11231,,8,,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,Expert
82,Candida albicans,,,5476.0,,,1,,11375,H,11231,,8,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Microsomes,Autocuration
83,Candida albicans,,,5476.0,,,1,,11375,H,11231,,8,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Microsomes,Autocuration
84,Saccharomyces cerevisiae,,,4932.0,,,1,,11375,H,11231,,8,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Microsomes,Autocuration
85,Saccharomyces cerevisiae,,,4932.0,,,1,,11375,H,11231,,8,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Microsomes,Autocuration
86,Sus scrofa,,2107.0,9823.0,,,1,,11375,H,12083,,8,Liver,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Microsomes,Autocuration
87,Rattus norvegicus,,,10116.0,,,1,,791,H,11231,,8,,B,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,Autocuration
88,Rattus norvegicus,,,10116.0,,,1,,791,H,11231,,8,,B,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,Autocuration
89,Rattus norvegicus,,,10116.0,,,1,,791,H,11231,,8,,B,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,Autocuration
90,Rattus norvegicus,,2107.0,10116.0,,,1,,11375,D,12083,,9,Liver,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Microsomes,Autocuration
91,Rattus norvegicus,,2107.0,10116.0,,,1,,11375,D,12083,,9,Liver,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,Autocuration
92,Rattus norvegicus,,2107.0,10116.0,,,1,,153,D,12083,,9,Liver,B,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,Autocuration
93,,,,,,,1,,8269,H,11377,,8,,B,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,Expert
94,,,,,,,1,,8269,H,11377,,8,,B,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,Expert
95,Homo sapiens,,,9606.0,,,1,,17653,N,81020,HepG2,1,,F,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Expert
96,Homo sapiens,,,9606.0,,,1,,14277,N,81020,HepG2,1,,F,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,Intermediate
97,Homo sapiens,,,9606.0,,,1,,1717,N,81020,HepG2,1,,F,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,Intermediate
98,Homo sapiens,,,9606.0,,,1,,14091,N,81020,HepG2,1,,F,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,Intermediate
99,Homo sapiens,,,9606.0,,,1,,14091,N,81020,HepG2,1,,F,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,Intermediate
100,Hepatitis B virus,,,10407.0,,,1,,17653,N,50606,,1,,F,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Expert
101,Homo sapiens,,,9606.0,,,1,,13105,N,81020,HepG2,1,,F,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,Intermediate
102,Homo sapiens,,,9606.0,,,1,,1717,N,81020,HepG2,1,,F,Concentration required to inhibit 50% of 2.2.15 cell line,,Intermediate
103,Homo sapiens,,,9606.0,,,1,,13105,N,81020,HepG2,1,,A,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,Intermediate
104,Homo sapiens,,,9606.0,,,1,,13600,N,50587,2.2.15,1,,F,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,Intermediate
105,Homo sapiens,,,9606.0,,,1,,13467,N,50587,2.2.15,1,,F,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,Intermediate
106,Hepatitis B virus,,,10407.0,,,1,,17477,N,50606,2.2.15,1,,F,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,Expert
107,Homo sapiens,,,9606.0,,,1,,1593,N,50587,2.2.15,1,,F,In vitro anti-HBV activity in 2.2.15 cells,,Intermediate
108,Homo sapiens,,,9606.0,,,1,,1593,N,50587,2.2.15,1,,F,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,Intermediate
109,Homo sapiens,,,9606.0,,,1,,15089,N,50587,2.2.15,1,,F,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,Intermediate
110,Homo sapiens,,,9606.0,,,1,,15089,N,50587,2.2.15,1,,F,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,Intermediate
111,Homo sapiens,,,9606.0,,,1,,1593,N,50587,2.2.15,1,,F,Cytotoxicity in 2.2.15 cells,,Intermediate
112,Homo sapiens,,,9606.0,,,1,,1593,N,50587,2.2.15,1,,F,Cytotoxicity in 2.2.15 cells; Not determined,,Intermediate
113,Homo sapiens,,,9606.0,,,1,,13600,N,50587,2.2.15,1,,F,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,Intermediate
114,Homo sapiens,,,9606.0,,,1,,13467,N,50587,2.2.15,1,,F,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,Intermediate
115,Homo sapiens,,,9606.0,,,1,,13467,N,50587,2.2.15,1,,F,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,Intermediate
116,Homo sapiens,,,9606.0,,,1,,14764,N,81020,HepG2,1,,F,Antiviral activity against HBV was determined in 2.215 cell line,,Intermediate
117,Homo sapiens,,,9606.0,,,1,,6531,U,22226,,0,,B,Inhibition of 20-HETE synthesis in human renal microsomes,Microsomes,Autocuration
118,,,,,,,1,,17322,U,22226,,0,,B,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,Autocuration
119,Homo sapiens,,,9606.0,,,1,,17072,N,80612,2008,1,,F,Inhibitory concentration against 2008 (ovarian) cells,,Intermediate
120,Homo sapiens,,,9606.0,,,1,,16936,N,80612,2008,1,,F,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,Intermediate
121,Homo sapiens,,,9606.0,,,1,,16936,N,80612,2008,1,,F,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,Intermediate
122,Homo sapiens,,,9606.0,,,1,,17146,N,80612,2008,1,,F,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,Intermediate
123,Homo sapiens,,,9606.0,,,1,,17146,N,80612,2008,1,,F,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,Intermediate
124,Homo sapiens,,,9606.0,,,1,,10797,N,80613,2008/R,1,,F,In vitro inhibition of 2008/R ovarian cancer cell line,,Intermediate
125,Homo sapiens,,,9606.0,,,1,,10797,N,80613,2008/R,1,,F,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,Intermediate
126,Homo sapiens,,,9606.0,,,1,,10797,N,80614,2008/S,1,,F,In vitro inhibition of 2008/S ovarian cancer cell line,,Intermediate
127,Homo sapiens,,,9606.0,,,1,,10797,N,80614,2008/S,1,,F,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,Intermediate
128,Homo sapiens,,,9606.0,,,1,,4823,S,100256,,2,,B,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,Expert
129,Homo sapiens,,,9606.0,,,1,,12912,S,100256,,2,,B,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,Intermediate
130,,,,,,,1,,2957,S,100256,,2,,B,Inhibition of chymotrypsin-like activity of 20S proteasome,,Expert
131,,,,,,,1,,2957,S,100256,,2,,B,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,Expert
132,,,,,,,1,,3260,S,100256,,2,,B,Inhibitory activity against 20S proteosome,,Intermediate
133,Homo sapiens,,,9606.0,,,1,,3451,U,22226,,0,,B,Compound was tested for inhibitory activity against tryptase,,Autocuration
134,Homo sapiens,,,9606.0,,,1,,13885,N,81020,HepG2,1,,F,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,Intermediate
135,Homo sapiens,,,9606.0,,,1,,13885,N,81020,HepG2,1,,F,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,Intermediate
136,,,,,,,1,,3676,U,22226,,0,,B,Compound was tested for the inhibition of Alpha-glucosidase,,Autocuration
137,,,,,,,1,,6043,H,235,,8,,B,Inhibitory concentration against human neutrophil elastase (HNE),,Autocuration
138,Rattus norvegicus,,948.0,10116.0,,,1,,11140,U,22226,,0,Heart,F,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,Autocuration
139,,,,,,,1,,10543,H,19640,,8,,F,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,Autocuration
140,,,,,,,1,,10543,H,19640,,8,,F,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,Expert
141,,,,,,,1,,10543,H,19640,,8,,B,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,Autocuration
142,,,,,,,1,,10543,H,19640,,8,,F,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,Expert
143,Mus musculus,,,10090.0,,,1,,11365,N,80360,P338,1,,F,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,Intermediate
144,Mus musculus,,,10090.0,,,1,,11365,N,80360,P338,1,,F,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,Intermediate
145,Homo sapiens,,,9606.0,,,1,,11803,N,80384,PBL,1,,F,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,Intermediate
146,Ovis aries,,,9940.0,,,1,,11803,U,22226,,0,,F,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,Autocuration
147,Ovis aries,,,9940.0,,,1,,11803,U,22226,,0,,F,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,Autocuration
148,,,,,,,1,,12278,H,191,,8,,B,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,Autocuration
149,Homo sapiens,,,9606.0,,,1,,8249,U,22226,,0,,F,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,Autocuration
150,Homo sapiens,,,9606.0,,,1,,8249,U,22226,,0,,F,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,Autocuration
151,Homo sapiens,,,9606.0,,,1,,8249,U,22226,CCRF-CEM,0,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,Autocuration
152,Homo sapiens,,,9606.0,,,1,,8249,U,22226,CCRF-CEM,0,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,Autocuration
153,Homo sapiens,,,9606.0,,,1,,8249,U,22226,CCRF-CEM,0,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,Autocuration
154,Homo sapiens,,,9606.0,,,1,,8249,U,22226,CCRF-CEM,0,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,Autocuration
155,Homo sapiens,,,9606.0,,,1,,8249,U,22226,,0,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,Autocuration
156,Homo sapiens,,,9606.0,,,1,,8249,U,22226,,0,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,Autocuration
157,,,,,,,1,,16992,H,104290,,6,,B,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,Autocuration
158,Streptococcus pyogenes,,,1314.0,,,1,,10543,N,50264,,1,,F,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,Intermediate
159,Human herpesvirus 3,,,10335.0,,,1,,17833,N,50527,,1,,F,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,Intermediate
160,vericilla zoster virus,,,10335.0,,,1,,17290,N,50527,HEL,1,,F,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,Expert
161,vericilla zoster virus,,,10335.0,,,1,,17290,N,50527,,1,,F,Antiviral activity against 07/1 strain of VZV; ND: No data,,Intermediate
162,vericilla zoster virus,,,10335.0,,,1,,17290,N,50527,,1,,F,Antiviral activity against 07/1 strain of VZV; ND=No data,,Intermediate
163,escherichia cloac,,,561.0,,,1,,10932,N,50145,,1,,F,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,Intermediate
164,,,,,,,1,,9707,U,22226,,0,,B,Ratio of Ki at A2 to Ki at A1 receptors,,Autocuration
165,Candida albicans,,,5476.0,,,1,,2346,H,11143,,8,,B,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,Expert
166,Candida glabrata CBS 138,,,284593.0,,,1,,2205,H,18077,,8,,B,"Inhibition of 1,3-beta-glucan synthase",,Expert
167,Homo sapiens,,,9606.0,,,1,,11900,N,80609,1-87 tumor cell line,1,,F,Inhibition of growth of 1-87 human tumor cell line,,Intermediate
168,Rattus norvegicus,,,10116.0,,,1,,14864,D,12166,,9,,B,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,Expert
169,Glycine max,,,3847.0,,,1,,16474,D,100171,,9,,B,Inhibitory activity against soybean 1-lipoxygenase (SLO),,Autocuration
170,Glycine max,,,3847.0,,,1,,16474,D,100171,,9,,B,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,Autocuration
171,Glycine max,,,3847.0,,,1,,16474,D,100171,,9,,B,% inhibition against soybean 1-lipoxygenase (SLO),,Autocuration
172,Glycine max,,,3847.0,,,1,,16474,D,100171,,9,,B,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,Autocuration
173,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,Autocuration
174,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,Autocuration
175,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,Autocuration
176,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,Autocuration
177,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,Autocuration
178,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,Autocuration
179,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,Autocuration
180,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,Autocuration
181,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,Autocuration
182,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,Autocuration
183,Glycine max,,,3847.0,,,1,,3094,D,100171,,9,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,Autocuration
184,Mus musculus,,,10090.0,,,1,,10413,U,22226,,0,,B,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,Autocuration
185,Mus musculus,,,10090.0,,,1,,16929,N,80049,C3H 10T1/2,1,,F,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,Intermediate
186,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,Intermediate
187,,,,,,,1,,16587,H,11489,,8,,B,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,Autocuration
188,,,,,,,1,,16587,H,11862,,8,,B,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,Autocuration
189,,,,,,,1,,16587,H,11862,,8,,B,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,Autocuration
190,,,,,,,1,,16587,H,11489,,8,,B,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,Autocuration
191,,,,,,,1,,16587,H,11862,,8,,B,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,Autocuration
192,Bos taurus,,,9913.0,,,1,,8058,D,12347,,9,,F,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,Expert
193,Rattus norvegicus,,,10116.0,,,1,,9065,D,100120,,9,,B,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,Expert
194,Rattus norvegicus,,2369.0,10116.0,,,1,,8865,D,100120,,9,Adrenal gland,B,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,Expert
195,Rattus norvegicus,,,10116.0,,,1,,9066,D,100120,,9,,B,Inhibition of rat adrenal 11-beta-hydroxylase,,Expert
196,Rattus norvegicus,,,10116.0,,,1,,8394,D,100120,,9,,B,Inhibition of rat adrenal 11-beta-hydroxylase,,Expert
197,Rattus norvegicus,,,10116.0,,,1,,8394,D,100120,,9,,B,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,Expert
198,,,,,,,1,,6431,H,10328,,8,,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,Autocuration
199,,,,,,,1,,6431,H,11490,,8,,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,Autocuration
200,,,,,,,1,,6431,H,11490,,8,,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,Autocuration
201,,,,,,,1,,9295,H,11134,,8,,F,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,Autocuration
202,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,Autocuration
203,,,,,,,1,,13622,H,11134,,8,,B,Compound was tested in vitro for inhibition of 12-LO human platelet,,Autocuration
204,,,,,,,1,,12079,H,11134,,8,,F,Inhibitory concentration against human platelet 12-lipoxygenase,,Autocuration
205,,,,,,,1,,13622,H,11134,,8,,B,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,Autocuration
206,Homo sapiens,,,9606.0,,,1,,12079,D,11134,,9,,F,Inhibitory concentration against human platelet 12-lipoxygenase,,Autocuration
207,,,,,,,1,,13500,H,11835,,8,,B,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,Expert
208,,,,,,,1,,13723,H,11601,,8,,B,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,Expert
209,,,,,,,1,,16474,H,11134,,8,,B,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,Autocuration
210,,,,,,,1,,1630,H,11134,,8,,B,Inhibitory activity against human platelet 12-lipoxygenase,,Autocuration
211,,,,,,,1,,167,H,11134,,8,,B,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,Autocuration
212,,,,,,,1,,16474,H,11134,,8,,B,% inhibition against human platelet 12-lipoxygenase (12-HLO),,Autocuration
213,,,,,,,1,,167,H,11134,,8,,B,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,Autocuration
214,,,,,,,1,,16474,H,11134,,8,,B,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,Autocuration
215,,,,,,,1,,10091,H,11601,,8,,B,Inhibitory activity towards porcine 12-lipoxygenase,,Autocuration
216,,,,,,,1,,11966,H,11601,,8,,B,Tested for inhibition against porcine 12-LO,,Autocuration
217,,,,,,,1,,951,H,12052,,8,,B,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,Autocuration
218,,,,,,,1,,10997,H,12052,,8,,B,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,Autocuration
219,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibition of rat platelet 12-lipoxygenase,,Expert
220,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,Autocuration
221,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,Autocuration
222,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,Autocuration
223,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,Autocuration
224,,,,,,,1,,10193,H,12052,,8,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,Autocuration
225,,,,,,,1,,11087,H,12052,,8,,B,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,Autocuration
226,Homo sapiens,,,9606.0,,,1,,15569,N,80007,41M,1,,F,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,Intermediate
227,Homo sapiens,,,9606.0,,,1,,12989,N,80007,41M,1,,F,In vitro antitumor activity against 41M cell line.,,Expert
228,Homo sapiens,,,9606.0,,,1,,16745,N,80007,41M,1,,F,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,Intermediate
229,Homo sapiens,,,9606.0,,,1,,15569,N,80007,41M,1,,F,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,Intermediate
230,Homo sapiens,,,9606.0,,,1,,12989,N,80007,41M,1,,F,In vitro antitumor activity against 41McisR cell line.,,Expert
231,Homo sapiens,,,9606.0,,,1,,12989,N,80007,41M,1,,F,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,Expert
232,Homo sapiens,,,9606.0,,,1,,16745,N,80007,41M,1,,F,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,Intermediate
233,Homo sapiens,,,9606.0,,,1,,6210,D,84,,9,,B,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,Expert
234,Homo sapiens,,,9606.0,,,1,,6210,D,68,,9,,B,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Expert
235,,,,,,,1,,6226,H,68,,8,,B,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Expert
236,,,,,,,1,,17855,H,10201,,8,,B,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,Expert
237,,,,,,,1,,17855,H,10201,,8,,B,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,Expert
238,,,,,,,1,,17855,H,10201,,8,,B,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,Expert
239,,,,,,,1,,10413,H,12220,,8,,B,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,Autocuration
240,Escherichia coli,,,562.0,,,1,,10413,H,11303,,8,,B,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Autocuration
241,Escherichia coli,,,562.0,,,1,,10413,H,11303,,8,,B,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Autocuration
242,Escherichia coli,,,562.0,,,1,,10413,H,11303,,8,,B,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,Autocuration
243,,,,,,,1,,10413,H,12220,,8,,B,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,Autocuration
244,,,,,,,1,,10413,H,12220,,8,,B,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,Autocuration
245,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Autocuration
246,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,Autocuration
247,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,Autocuration
248,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,Autocuration
249,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Autocuration
250,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Autocuration
251,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,Autocuration
252,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,Autocuration
253,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,Autocuration
254,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,Autocuration
255,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Autocuration
256,Sus scrofa,,,9823.0,,,1,,7587,H,11303,,8,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Autocuration
257,,,,,,,1,,7323,H,11303,,8,,B,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,Autocuration
258,Sus scrofa,,,9823.0,,,1,,7587,U,22226,,0,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,Autocuration
259,Sus scrofa,,,9823.0,,,1,,7587,U,22226,,0,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,Autocuration
260,Saccharomyces cerevisiae,,,4932.0,,,1,,13750,H,100249,,8,,B,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,Expert
261,Rattus norvegicus,,,10116.0,,,1,,7662,U,22226,,0,,B,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Autocuration
262,Rattus norvegicus,,,10116.0,,,1,,7662,U,22226,,0,,B,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Autocuration
263,Rattus norvegicus,,,10116.0,,,1,,7662,U,22226,,0,,B,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,Autocuration
264,,,,,,,1,,12211,H,104698,,6,,F,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,Autocuration
265,,,,,,,1,,12211,H,104698,,6,,F,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,Autocuration
266,Cavia porcellus,,2116.0,10141.0,,,1,,12211,D,20033,,9,Ileum,F,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,Intermediate
267,,,,,,,1,,12211,H,10623,,8,,F,Stimulatory activity of intragastric pressure was tested in the rat,,Expert
268,,,,,,,1,,15453,H,121,,8,,B,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,Autocuration
269,Rattus norvegicus,,,10116.0,,,1,,11884,U,22226,,0,,F,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,Autocuration
270,,,,,,,1,,7185,H,12688,,8,,F,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,Autocuration
271,Homo sapiens,,,9606.0,,,1,,6876,D,121,,9,,B,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,Expert
272,Homo sapiens,,,9606.0,,,1,,6876,D,121,,9,,B,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,Expert
273,,,,,,,1,,11863,H,12198,,8,,F,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,Autocuration
274,,,,,,,1,,11863,H,12198,,8,,B,Inhibition constant of high-affinity 5-HT uptake,,Autocuration
275,,,,,,,1,,11863,H,12198,,8,,F,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,Autocuration
276,,,,,,,1,,11863,H,12198,,8,,F,Maximum rate was determined for high affinity transport of 5-HT,,Autocuration
277,,,,,,,1,,4639,H,104714,,4,,F,Compound was tested for agonistic activity against 5-HT uptake,,Autocuration
278,,,,,,,1,,15796,H,10577,,8,,B,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,Expert
279,Bos taurus,,,9913.0,,,1,,15796,H,105,,8,,B,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,Expert
280,Rattus norvegicus,,,10116.0,,,1,,12801,D,104744,,5,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Autocuration
281,,,,,,,1,,12801,H,104744,,4,,B,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,Autocuration
282,,,,,,,1,,12120,H,104744,,4,,B,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Membranes,Autocuration
283,,,,,,,1,,12120,H,104744,,4,,B,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Membranes,Autocuration
284,,,,,,,1,,11963,H,104744,,4,,B,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration
285,,,,,,,1,,11701,H,51,,8,,F,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,Autocuration
286,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
287,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
288,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
289,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,Autocuration
290,Cavia porcellus,,,10141.0,,,1,,11574,D,105570,,9,,F,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,Intermediate
291,,,,,,,1,,15779,H,279,CHO,8,,B,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration
292,,,,,,,1,,15363,H,107,,8,,B,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,Autocuration
293,Rattus norvegicus,,,10116.0,,,1,,15363,D,12687,,9,,F,Efficacy against 5-hydroxytryptamine 2A receptor,,Expert
294,,,,,,,1,,15329,H,12687,,8,,F,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,Expert
295,,,,,,,1,,15329,H,12687,,8,,F,Relative potency towards 5-HT2A receptor of rat tail artery,,Expert
296,,,,,,,1,,15329,H,12687,,8,,F,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,Expert
297,,,,,,,1,,15329,H,12687,,8,,F,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,Expert
298,,,,,,,1,,15329,H,12687,,8,,F,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,Autocuration
299,,,,,,,1,,15329,H,12687,,8,,F,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,Expert
300,Cavia porcellus,,2116.0,10141.0,,,1,,273,D,20033,,9,Ileum,F,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,Intermediate
301,Cavia porcellus,,2116.0,10141.0,,,1,,273,D,20033,,9,Ileum,F,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,Intermediate
302,Cavia porcellus,,2116.0,10141.0,,,1,,273,D,20033,,9,Ileum,F,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,Intermediate
303,,,,,,,1,,12092,H,10623,,8,,B,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,Autocuration
304,Rattus norvegicus,,,10116.0,,,1,,1317,D,10623,,9,,F,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Expert
305,,,,,,,1,,12409,H,168,,8,,B,Binding affinity against 5-hydroxytryptamine 4 receptor,,Expert
306,Gallus gallus,,,9031.0,,,1,,11126,U,22226,,0,,B,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,Autocuration
307,Homo sapiens,,,9606.0,,,1,,11126,U,22226,,0,,F,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,Autocuration
308,Homo sapiens,,,9606.0,,,1,,11126,U,22226,,0,,F,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Autocuration
309,Homo sapiens,,,9606.0,,,1,,11126,N,80156,HL-60,1,,B,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,Autocuration
310,Homo sapiens,,,9606.0,,,1,,11126,U,22226,,0,,B,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,Autocuration
311,Homo sapiens,,,9606.0,,,1,,11126,U,22226,,0,,B,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Autocuration
312,Homo sapiens,,,9606.0,,,1,,17807,D,104703,Oocytes,7,,B,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Autocuration
313,,,,,,,1,,16575,S,100256,,2,,F,Chymotryptic inhibitory activity against 26S proteasome,,Intermediate
314,,,,,,,1,,15407,S,100256,,2,,B,Inhibitory activity against 26S proteasome degradation of IkB,,Intermediate
315,Homo sapiens,,,9606.0,,,1,,10797,N,81034,A2780,1,,F,In vitro inhibition of 2780/DOX ovarian cancer cell line,,Intermediate
316,Homo sapiens,,,9606.0,,,1,,10797,N,81034,A2780,1,,F,In vitro inhibition of 2780/S ovarian cancer cell line,,Intermediate
317,Homo sapiens,,,9606.0,,,1,,3469,U,22226,,0,,F,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,Autocuration
318,,,,,,,1,,16037,M,22222,,3,,B,Association constant for binding to AATT 28-mer AATT hairpin,,Intermediate
319,,,,,,,1,,16037,M,22222,,3,,B,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,Intermediate
320,,,,,,,1,,16037,M,22222,,3,,B,Reaction Rate Parameter for 28-mer AATT hairpin,,Intermediate
321,,,,,,,1,,16037,M,22222,,3,,B,Reaction Rate Parameter for 28-mer AATT hairpin,,Intermediate
322,Homo sapiens,,,9606.0,,,1,,16524,U,22226,,0,,F,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,Autocuration
323,Homo sapiens,,,9606.0,,,1,,16524,U,22226,,0,,F,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,Autocuration
324,Homo sapiens,,,9606.0,,,1,,16524,U,22226,,0,,F,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,Autocuration
325,Cricetulus griseus,,,10029.0,,,1,,16758,U,22226,,0,,F,Cytotoxicity against cell line 2SC/20 determined by MTT test,,Autocuration
326,Cricetulus griseus,,,10029.0,,,1,,16758,U,22226,,0,,F,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,Autocuration
327,Cricetulus griseus,,,10029.0,,,1,,16758,U,22226,,0,,F,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,Autocuration
328,,,,,,,1,,14360,H,241,,8,,B,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,Autocuration
329,Homo sapiens,,,9606.0,,,1,,14360,D,241,,9,,B,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,Expert
330,Rattus norvegicus,,,10116.0,,,1,,9964,U,22226,,0,,B,Selectivity ratio of ID50 in liver and heart,,Autocuration
331,,,,,,,1,,9964,H,12132,,8,,B,"Selectivity, ratio of relative ID50 in liver and heart",,Autocuration
332,,,,,,,1,,9964,H,12132,,8,,B,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,Autocuration
333,,,,,,,1,,9964,H,12132,,8,,B,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration
334,,,,,,,1,,9964,H,12132,,8,,B,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration
335,,,,,In vivo,,1,,9964,H,12132,,8,,B,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration
336,,,,,In vivo,,1,,9964,H,12132,,8,,F,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration
337,,,,,,,1,,9964,U,22226,,0,,B,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,Autocuration
338,,,,,,,1,,9964,H,12132,,8,,B,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,Autocuration
339,Homo sapiens,,,9606.0,,,1,,9964,U,22226,,0,,B,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,Autocuration
340,,,,,,,1,,9964,H,12132,,8,,B,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,Autocuration
341,,,,,,,1,,9964,H,12132,,8,,F,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,Autocuration
342,,,,,,,1,,9964,H,12132,,8,,B,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,Autocuration
343,Rattus norvegicus,,,10116.0,,,1,,9964,U,22226,,0,,B,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,Autocuration
344,,,,,In vivo,,1,,9964,H,12132,,8,,B,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,Autocuration
345,,,,,,,1,,9964,H,12132,,8,,B,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration
346,Rattus norvegicus,,,10116.0,,,1,,9964,U,22226,,0,,B,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,Autocuration
347,,,,,,,1,,9964,H,12132,,8,,B,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,Autocuration
348,,,,,,,1,,9964,H,12132,,8,,F,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,Autocuration
349,Rattus norvegicus,,,10116.0,,,1,,3796,U,22226,,0,,B,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,Autocuration
350,Escherichia coli,,,562.0,,,1,,4251,H,19690,,8,,B,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Autocuration
351,Escherichia coli,,,562.0,,,1,,4251,H,19690,,8,,B,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Autocuration
352,Escherichia coli,,,562.0,,,1,,4251,H,19690,,8,,B,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Autocuration
353,Escherichia coli,,,562.0,,,1,,4251,H,19690,,8,,B,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Autocuration
354,,,,,,,1,,166,H,19690,,8,,B,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,Autocuration
355,,,,,,,1,,17861,H,19690,,8,,B,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,Autocuration
356,,,,,,,1,,166,H,19690,,8,,B,Inhibition constant against 3-dehydroquinate synthase,,Autocuration
357,,,,,,,1,,166,H,19690,,8,,B,Association rate constant against 3-dehydroquinate synthase,,Autocuration
358,,,,,,,1,,166,H,19690,,8,,B,Rate constant against 3-dehydroquinate synthase,,Autocuration
359,,,,,,,1,,3548,U,22226,,0,,B,Inhibitory activity against fuc-TVII,,Autocuration
360,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,Autocuration
361,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,Autocuration
362,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,Autocuration
363,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,Autocuration
364,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,Autocuration
365,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Microsomes,Autocuration
366,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Microsomes,Autocuration
367,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Microsomes,Autocuration
368,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Microsomes,Autocuration
369,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Microsomes,Autocuration
370,Rattus norvegicus,,2107.0,10116.0,,,1,,9877,D,12236,,9,Liver,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Microsomes,Autocuration
371,,,,,,,1,,3003,H,104832,,4,,B,Inhibitory activity against 3-phosphoglycerate kinase.,,Autocuration
372,,,,,,,1,,3003,H,104832,,4,,B,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,Autocuration
373,,,,,,,1,,3003,H,104832,,4,,B,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,Autocuration
374,Homo sapiens,,,9606.0,,,1,,17185,D,10612,,9,,B,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,Expert
375,Homo sapiens,,,9606.0,,,1,,6072,N,80616,3677 melanoma cell line,1,,F,Cytotoxicity on 3677 melanoma cells,,Intermediate
376,Homo sapiens,,,9606.0,,,1,,6072,N,80616,3677 melanoma cell line,1,,F,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,Intermediate
377,Mus musculus,,,10090.0,,,1,,5018,N,80617,MC-38,1,,F,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,Intermediate
378,Homo sapiens,,,9606.0,,,1,,2852,U,22226,,0,,F,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,Intermediate
379,,,,,,,1,,8663,U,22226,B16,0,,F,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,Autocuration
380,,,,,,,1,,8663,U,22226,B16,0,,F,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,Autocuration
381,Human rhinovirus 14,,,12131.0,,,1,,3245,D,12464,,9,,F,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,Expert
382,Human rhinovirus sp.,,,169066.0,,,1,,3245,N,50085,,1,,F,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,Intermediate
383,human rhinovirus type 14,,,169066.0,,,1,,3877,N,50679,,1,,F,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,Intermediate
384,human rhinovirus type 14,,,169066.0,,,1,,3877,N,50679,,1,,F,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,Intermediate
385,Human rhinovirus 14,,,12131.0,,,1,,5861,D,12464,,9,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Expert
386,Human rhinovirus 14,,,12131.0,,,1,,5861,D,12464,,9,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Expert
387,Human rhinovirus 14,,,12131.0,,,1,,5861,D,12464,,9,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Expert
388,Human rhinovirus 14,,,12131.0,,,1,,5861,D,12464,,9,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,Expert
389,Enterovirus,,,12059.0,,,1,,13748,N,50665,,1,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,Intermediate
390,Enterovirus,,,12059.0,,,1,,13748,N,50665,,1,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,Intermediate
391,Enterovirus,,,12059.0,,,1,,13748,N,50665,,1,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,Intermediate
392,Enterovirus,,,12059.0,,,1,,13748,N,50665,,1,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,Intermediate
393,Human rhinovirus B,,,147712.0,,,1,,13748,H,12464,,8,,B,Inhibition of human rhinovirus 3C protease,,Expert
394,Homo sapiens,,,9606.0,,,1,,17699,U,22226,,0,,B,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,Autocuration
395,Mus musculus,,,10090.0,,,1,,7145,N,80619,3EM 37,1,,F,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,Intermediate
396,Mus musculus,,,10090.0,,,1,,7145,N,80619,3EM 37,1,,F,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,Intermediate
397,Mus musculus,,,10090.0,,,1,,7145,N,80619,3EM 37,1,,F,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,Intermediate
398,Mus musculus,,,10090.0,,,1,,7145,N,80619,3EM 37,1,,F,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,Intermediate
399,Mus musculus,,,10090.0,,,1,,7145,N,80619,3EM 37,1,,F,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,Intermediate
400,Mus musculus,,,10090.0,,,1,,7145,N,80619,3EM 37,1,,F,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,Intermediate
401,Mus musculus,,,10090.0,,,1,,5325,N,80620,3LL cell line,1,,F,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Intermediate
402,Mus musculus,,,10090.0,,,1,,5325,N,80620,3LL cell line,1,,F,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Intermediate
403,Mus musculus,,,10090.0,,,1,,5325,N,80620,3LL cell line,1,,F,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,Expert
404,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,Intermediate
405,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,Intermediate
406,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,Intermediate
407,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,Intermediate
408,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,Intermediate
409,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,Intermediate
410,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,Intermediate
411,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,Intermediate
412,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Intermediate
413,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,Intermediate
414,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,Intermediate
415,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,Intermediate
416,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,Intermediate
417,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Intermediate
418,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,Intermediate
419,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,Intermediate
420,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,Intermediate
421,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,Intermediate
422,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,Intermediate
423,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,Intermediate
424,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,Intermediate
425,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,Intermediate
426,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,Intermediate
427,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,Intermediate
428,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,Intermediate
429,Mus musculus,,,10090.0,,,1,,16169,N,80620,3LL cell line,1,,F,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,Intermediate
430,Homo sapiens,,,9606.0,,,1,,15547,N,80621,3LLD122,1,,F,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,Intermediate
431,,,,,,,1,,8663,U,22226,,0,,F,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,Autocuration
432,,,,,,,1,,8663,U,22226,,0,,F,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,Autocuration
433,,,,,,,1,,8663,U,22226,,0,,F,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,Autocuration
434,,,,,,,1,,8663,U,22226,,0,,F,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,Autocuration
435,Mus musculus,,,10090.0,,,1,,4504,N,80951,NIH3T3,1,,F,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Intermediate
436,Mus musculus,,,10090.0,,,1,,4504,N,80951,NIH3T3,1,,F,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Intermediate
437,,,,,,,1,,12695,H,11169,NIH3T3,8,,F,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,Expert
438,Mus musculus,,,10090.0,,,1,,12695,N,80951,NIH3T3,1,,F,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,Intermediate
439,Mus musculus,,,10090.0,,,1,,12695,N,80951,NIH3T3,1,,F,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,Intermediate
440,Mus musculus,,,10090.0,,,1,,17642,N,80951,NIH3T3,1,,F,Effective dose against murine 3T3 fibroblasts cells,,Expert
441,Mus musculus,,,10090.0,,,1,,17642,N,80951,NIH3T3,1,,F,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,Expert
442,Mus musculus,,,10090.0,,,1,,12340,N,80951,NIH3T3,1,,F,Cytotoxic effect on 3T3 cells,,Expert
443,Mus musculus,,,10090.0,,,1,,12340,N,80951,NIH3T3,1,,F,Cytotoxic effect on 3T3 cells,,Expert
444,Mus musculus,,,10090.0,,,1,,12716,N,80951,NIH3T3,1,,F,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,Intermediate
445,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Intermediate
446,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,Intermediate
447,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,Expert
448,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,Expert
449,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,Intermediate
450,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,Expert
451,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,Expert
452,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,Intermediate
453,Mus musculus,,,10090.0,,,1,,17780,N,80951,NIH3T3,1,,F,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,Expert
454,Mus musculus,,,10090.0,,,1,,12751,D,104860,,7,,F,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,Autocuration
455,Mus musculus,,,10090.0,,,1,,12380,N,80951,NIH3T3,1,,F,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,Expert
456,Mus musculus,,,10090.0,,,1,,14892,N,80951,NIH3T3,1,,F,Inhibitory activity against 3T3 cell line,,Intermediate
457,Mus musculus,,,10090.0,,,1,,12695,N,80951,NIH3T3,1,,F,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,Intermediate
458,,,,,,,1,,12695,H,11169,,8,,F,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,Expert
459,Mus musculus,,,10090.0,,,1,,12695,N,80951,NIH3T3,1,,F,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,Intermediate
460,Mus musculus,,,10090.0,,,1,,12695,N,80951,NIH3T3,1,,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,Intermediate
461,,,,,,,1,,12695,H,11169,,8,,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,Expert
462,,,,,,,1,,12695,H,11169,,8,,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,Expert
463,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Intermediate
464,Mus musculus,,,10090.0,,,1,,6277,N,80951,NIH3T3,1,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,Expert
465,Homo sapiens,,,9606.0,,,1,,4959,D,9,NIH3T3,9,,F,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,Expert
466,Homo sapiens,,,9606.0,,,1,,4959,D,9,NIH3T3,9,,F,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,Expert
467,Homo sapiens,,,9606.0,,,1,,4959,D,188,NIH3T3,9,,F,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,Expert
468,Homo sapiens,,,9606.0,,,1,,4959,D,188,NIH3T3,9,,F,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,Expert
469,Mus musculus,,,10090.0,,,1,,12082,N,80951,NIH3T3,1,,F,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,Intermediate
470,Mus musculus,,,10090.0,,,1,,12082,N,80951,NIH3T3,1,,F,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,Intermediate
471,Mus musculus,,,10090.0,,,1,,12082,N,80951,NIH3T3,1,,F,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,Intermediate
472,Mus musculus,,,10090.0,,,1,,12082,N,80951,NIH3T3,1,,F,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,Intermediate
473,Mus musculus,,,10090.0,,,1,,2643,N,80951,NIH3T3,1,,F,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,Intermediate
474,Mus musculus,,,10090.0,,,1,,11926,N,80951,NIH3T3,1,,F,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,Expert
475,Mus musculus,,,10090.0,,,1,,15204,N,80951,NIH3T3,1,,A,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,Intermediate
476,Mus musculus,,,10090.0,,,1,,15992,N,80951,NIH3T3,1,,F,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,Expert
477,Mus musculus,,,10090.0,,,1,,16279,N,80951,NIH3T3,1,,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,Intermediate
478,Mus musculus,,,10090.0,,,1,,16279,N,80951,NIH3T3,1,,F,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate
479,Mus musculus,,,10090.0,,,1,,16279,N,80951,NIH3T3,1,,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate
480,Mus musculus,,,10090.0,,,1,,16279,N,80951,NIH3T3,1,,F,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate
481,Mus musculus,,,10090.0,,,1,,16279,N,80951,NIH3T3,1,,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate
482,Mus musculus,,,10090.0,,,1,,16279,N,80951,NIH3T3,1,,F,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate
483,Mus musculus,,,10090.0,,,1,,12831,N,80951,NIH3T3,1,,F,Inhibition of swiss 3T3 mouse fibroblast proliferation,,Expert
484,Mus musculus,,,10090.0,,,1,,13497,N,80951,NIH3T3,1,,F,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,Intermediate
485,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,Intermediate
486,Mus musculus,,,10090.0,,,1,,13618,N,80006,3T3-L1,1,,F,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,Intermediate
487,Mus musculus,,,10090.0,,,1,,11902,N,80006,3T3-L1,1,,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,Intermediate
488,Mus musculus,,,10090.0,,,1,,11902,N,80006,3T3-L1,1,,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,Intermediate
489,Mus musculus,,,10090.0,,,1,,11902,N,80006,3T3-L1,1,,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,Intermediate
490,Mus musculus,,,10090.0,,,1,,14840,N,80006,3T3-L1,1,,F,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,Intermediate
491,Mus musculus,,,10090.0,,,1,,14840,N,80006,3T3-L1,1,,F,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,Intermediate
492,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,Intermediate
493,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,Intermediate
494,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,Intermediate
495,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,Intermediate
496,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,Intermediate
497,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,Intermediate
498,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,Intermediate
499,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,Intermediate
500,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,Intermediate
501,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,Expert
502,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,Expert
503,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,Intermediate
504,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,Intermediate
505,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,Intermediate
506,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,Expert
507,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,Expert
508,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,Expert
509,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,Intermediate
510,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,Intermediate
511,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,Intermediate
512,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,Intermediate
513,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,Intermediate
514,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,Intermediate
515,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,Intermediate
516,,,,,,,1,,13715,N,80006,3T3-L1,1,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,Intermediate
517,,,,,,,1,,6411,H,11214,3T3-L1,8,,F,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,Expert
518,Mus musculus,,,10090.0,,,1,,6411,N,80006,3T3-L1,1,,F,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,Intermediate
519,,,,,,,1,,6411,H,11214,3T3-L1,8,,F,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,Expert
520,Mus musculus,,,10090.0,,,1,,3966,N,80006,3T3-L1,1,,F,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,Expert
521,Mus musculus,,,10090.0,,,1,,3966,N,80006,3T3-L1,1,,F,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,Intermediate
522,Mus musculus,,,10090.0,,,1,,15556,N,80006,3T3-L1,1,,F,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,Expert
523,Mus musculus,,,10090.0,,,1,,5845,N,80006,3T3-L1,1,,F,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Expert
524,Mus musculus,,,10090.0,,,1,,14422,N,80006,3T3-L1,1,,F,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Expert
525,Mus musculus,,,10090.0,,,1,,5845,N,80006,3T3-L1,1,,F,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,Expert
526,Mus musculus,,,10090.0,,,1,,14508,N,80006,3T3-L1,1,,F,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,Expert
527,Mus musculus,,,10090.0,,,1,,14508,N,80006,3T3-L1,1,,F,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,Expert
528,Mus musculus,,,10090.0,,,1,,14508,N,80006,3T3-L1,1,,F,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,Expert
529,Rattus norvegicus,,,10116.0,,,1,,6349,N,80622,3Y1 cell line,1,,F,Inhibitory activity against rat fibroblast (3Y1) cell line,,Intermediate
530,Rattus norvegicus,,,10116.0,,,1,,15899,N,80622,3Y1 cell line,1,,F,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,Expert
531,Rattus norvegicus,,,10116.0,,,1,,15899,N,80622,3Y1 cell line,1,,F,Cytotoxicity in 3Y1 cells.,,Expert
532,Rattus norvegicus,,,10116.0,,,1,,15899,N,80622,3Y1 cell line,1,,F,Cytostatic effect in 3Y1 cells.,,Expert
533,Rattus norvegicus,,,10116.0,,,1,,15899,N,80622,3Y1 cell line,1,,F,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,Intermediate
534,Rattus norvegicus,,,10116.0,,,1,,17038,N,80622,3Y1 cell line,1,,F,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,Expert
535,,,,,,,1,,12421,U,22226,,0,,B,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,Autocuration
536,,,,,,,1,,12947,U,22226,,0,,B,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,Autocuration
537,,,,,,,1,,12947,U,22226,,0,,B,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,Autocuration
538,Sus scrofa,,,9823.0,,,1,,4896,D,11607,,9,,B,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,Expert
539,,,,,,,1,,6148,H,11607,,8,,B,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,Autocuration
540,,,,,,,1,,16432,H,11607,,8,,B,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,Autocuration
541,,,,,,,1,,4978,H,11607,,8,,B,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,Expert
542,,,,,,,1,,4978,H,11607,,8,,B,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,Expert
543,,,,,,,1,,3723,H,11607,,8,,B,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,Autocuration
544,,,,,,,1,,3518,H,11607,,8,,B,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,Autocuration
545,,,,,,,1,,4164,H,11607,,8,,B,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,Autocuration
546,,,,,,,1,,3518,H,11607,,8,,B,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,Autocuration
547,Sus scrofa,,,9823.0,,,1,,4164,D,11607,,9,,B,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,Expert
548,,,,,,,1,,3518,H,11607,,8,,B,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,Autocuration
549,,,,,,,1,,3518,H,11607,,8,,B,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,Autocuration
550,,,,,,,1,,4978,H,11607,,8,,B,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,Autocuration
551,,,,,,,1,,4978,H,11607,,8,,B,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,Autocuration
552,,,,,,,1,,6455,H,104733,,4,,B,Binding affinity against melatonin (MT1) receptor (pC1),,Autocuration
553,,,,,,,1,,2222,U,22226,,0,,B,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,Autocuration
554,,,,,,,1,,13020,U,22226,,0,,B,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,Autocuration
555,,,,,,,1,,13021,U,22226,,0,,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,Autocuration
556,,,,,,,1,,14532,H,10619,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,Autocuration
557,,,,,,,1,,14118,H,10619,,8,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Autocuration
558,,,10000000.0,,,,1,,11884,H,51,,8,Hippocampus,B,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,Autocuration
559,,,,,,,1,,13969,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,Expert
560,,,,,,,1,,13392,H,51,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor,,Expert
561,,,,,,,1,,14430,H,51,,8,,B,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,Expert
562,,,10000000.0,,,,1,,12248,H,51,,8,Hippocampus,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,Autocuration
563,,,10000000.0,,,,1,,12249,H,51,,8,Hippocampus,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,Autocuration
564,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
565,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
566,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
567,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
568,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
569,,,10000000.0,,,,1,,12249,H,51,,8,Hippocampus,B,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,Autocuration
570,,,10000000.0,,,,1,,11799,H,51,,8,Hippocampus,B,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,Autocuration
571,Rattus norvegicus,,,10116.0,,,1,,14331,D,10576,,9,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Membranes,Expert
572,Bos taurus,,10000000.0,9913.0,,,1,,11884,H,51,,8,Hippocampus,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,Expert
573,,,10000000.0,,,,1,,14331,H,51,,8,Hippocampus,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,Autocuration
574,,,10000000.0,,,,1,,11701,H,51,,8,Hippocampus,B,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,Autocuration
575,,,10000000.0,,,,1,,11701,H,51,,8,Hippocampus,B,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,Expert
576,,,10000000.0,,,,1,,12248,H,51,,8,Hippocampus,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,Autocuration
577,,,,,,,1,,12248,H,51,CHO,8,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,Autocuration
578,,,10000000.0,,,,1,,12248,H,51,,8,Hippocampus,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,Expert
579,,,10000000.0,,,,1,,12249,H,51,,8,Hippocampus,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,Expert
580,,,,,,,1,,12248,H,51,CHO,8,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration
581,,,10000000.0,,,,1,,11799,H,51,,8,Hippocampus,B,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,Expert
582,,,,,,,1,,634,H,51,,8,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,Autocuration
583,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
584,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
585,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
586,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
587,,,10000000.0,,,,1,,9995,H,51,,8,Hippocampus,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,Autocuration
588,,,10000000.0,,,,1,,12210,H,51,,8,Hippocampus,B,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,Expert
589,,,10000000.0,,,,1,,13311,H,51,,8,Hippocampus,B,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Expert
590,Homo sapiens,,,9606.0,,,1,,2331,D,51,CHO,9,,B,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,Expert
591,Cavia porcellus,,,10141.0,,,1,,1375,H,51,,8,,F,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,Autocuration
592,Cavia porcellus,,,10141.0,,,1,,1375,H,51,,8,,F,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,Autocuration
593,Cavia porcellus,,10000000.0,10141.0,,,1,,11574,H,51,,8,Hippocampus,F,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,Autocuration
594,Cavia porcellus,,2116.0,10141.0,,,1,,12867,H,51,,8,Ileum,B,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,Autocuration
595,Cavia porcellus,,2116.0,10141.0,,,1,,12867,H,51,,8,Ileum,B,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Autocuration
596,Cavia porcellus,,2116.0,10141.0,,,1,,12867,H,51,,8,Ileum,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,Autocuration
597,Cavia porcellus,,2116.0,10141.0,,,1,,12867,H,51,,8,Ileum,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Autocuration
598,Cavia porcellus,,2116.0,10141.0,,,1,,12867,H,51,,8,Ileum,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Autocuration
599,Cavia porcellus,,2116.0,10141.0,,,1,,12867,H,51,,8,Ileum,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,Autocuration
600,Cavia porcellus,,,10141.0,,,1,,11574,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
601,Cavia porcellus,,,10141.0,,,1,,13114,H,51,,8,,B,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
602,Cavia porcellus,,,10141.0,,,1,,13181,H,51,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,Autocuration
603,Cavia porcellus,,10000000.0,10141.0,,,1,,10639,H,106,,8,Hippocampus,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,Autocuration
604,Cavia porcellus,,10000000.0,10141.0,,,1,,10639,H,106,,8,Hippocampus,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,Autocuration
605,Cricetulus griseus,,,10029.0,,,1,,11883,H,11863,CHO,8,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Autocuration
606,,,,,,,1,,17785,H,51,,8,,B,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,Autocuration
607,,,,,,,1,,1558,H,51,HeLa,8,,F,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,Autocuration
608,,,,,,,1,,1558,H,51,HeLa,8,,F,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,Autocuration
609,,,,,,,1,,15740,H,51,,8,,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,Autocuration
610,,,,,,,1,,17624,H,51,CHO,8,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,Autocuration
611,,,,,,,1,,17624,H,51,CHO,8,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,Expert
612,,,,,,,1,,17624,H,51,CHO,8,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,Autocuration
613,,,,,,,1,,17624,H,51,CHO,8,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,Autocuration
614,,,,,,,1,,17624,H,51,CHO,8,,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Expert
615,,,,,,,1,,17624,H,51,CHO,8,,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Expert
616,,,,,,,1,,17624,H,51,CHO,8,,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,Autocuration
617,,,,,,,1,,14256,H,51,,8,,F,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,Autocuration
618,Homo sapiens,,,9606.0,,,1,,3445,D,51,HeLa,9,,B,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Expert
619,Homo sapiens,,,9606.0,,,1,,3445,D,51,HeLa,9,,B,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,Expert
620,Homo sapiens,,,9606.0,,,1,,17200,D,51,CHO,9,,B,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,Expert
621,Homo sapiens,,,9606.0,,,1,,17200,D,51,CHO,9,,B,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Expert
622,,,,,,,1,,15180,H,51,,8,,F,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,Autocuration
623,,,,,,,1,,15180,H,51,,8,,F,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,Autocuration
624,,,,,,,1,,16026,H,51,,8,,F,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,Autocuration
625,,,,,,,1,,2759,H,51,CHO,8,,F,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,Autocuration
626,Homo sapiens,,,9606.0,,,1,,2759,D,51,CHO,9,,F,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Expert
627,,,,,,,1,,2759,H,51,CHO,8,,F,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,Autocuration
628,Homo sapiens,,,9606.0,,,1,,2759,D,51,CHO,9,,F,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Expert
629,,,,,,,1,,2759,H,51,CHO,8,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,Autocuration
630,,,,,,,1,,2759,H,51,CHO,8,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,Autocuration
631,Homo sapiens,,,9606.0,,,1,,2759,D,51,CHO,9,,F,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Expert
632,,,,,,,1,,2759,H,51,CHO,8,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,Autocuration
633,Homo sapiens,,,9606.0,,,1,,2759,D,51,CHO,9,,F,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Expert
634,Homo sapiens,,,9606.0,,,1,,3445,D,51,,9,,F,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,Expert
635,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Expert
636,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,Expert
637,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,Expert
638,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,Autocuration
639,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,Autocuration
640,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,Autocuration
641,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,Expert
642,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,Autocuration
643,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,Autocuration
644,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,Autocuration
645,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,Autocuration
646,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,Expert
647,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,Autocuration
648,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,Autocuration
649,,,,,,,1,,17624,H,51,CHO,8,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,Autocuration
650,,,,,,,1,,6563,H,51,,8,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration
651,,,,,,,1,,6563,H,51,,8,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration
652,,,,,,,1,,6563,H,51,,8,,F,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,Autocuration
653,,,,,,,1,,17296,H,51,HEK293,8,,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration
654,Homo sapiens,,,9606.0,,,1,,6876,D,51,,9,,F,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,Expert
655,,,,,,,1,,6876,H,51,,8,,F,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,Expert
656,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,Expert
657,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,Expert
658,,,,,,,1,,5548,H,51,,8,,F,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,Autocuration
659,,,,,,,1,,5548,H,51,,8,,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,Expert
660,,,,,,,1,,5548,H,51,,8,,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,Autocuration
661,,,,,,,1,,5548,H,51,,8,,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,Autocuration
662,,,,,,,1,,5929,H,51,,8,,F,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,Expert
663,Homo sapiens,,,9606.0,,,1,,5929,D,51,,9,,F,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,Expert
664,Homo sapiens,,,9606.0,,,1,,5929,D,51,,9,,F,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,Expert
665,,,,,,,1,,16245,H,51,,8,,F,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,Autocuration
666,,,,,,,1,,5640,H,51,,8,,F,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,Expert
667,,,,,,,1,,5640,H,51,,8,,F,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,Autocuration
668,,,,,,,1,,14509,H,51,CHO,8,,F,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,Autocuration
669,,,,,,,1,,14509,H,51,CHO,8,,F,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,Expert
670,,,,,,,1,,15331,H,51,,8,,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Autocuration
671,,,,,,,1,,15331,H,51,,8,,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Autocuration
672,,,,,,,1,,6563,H,51,,8,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration
673,,,,,,,1,,6563,H,51,,8,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,Autocuration
674,,,,,,,1,,6563,H,51,,8,,F,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,Autocuration
675,Homo sapiens,,,9606.0,,,1,,6563,D,51,,9,,F,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,Expert
676,,,,,,,1,,6563,H,51,,8,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration
677,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,Expert
678,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Expert
679,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Expert
680,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,Expert
681,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,Expert
682,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Expert
683,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Expert
684,Homo sapiens,,,9606.0,,,1,,5272,D,51,,9,,F,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,Expert
685,Homo sapiens,,,9606.0,,,1,,16146,D,51,,9,,B,Inhibition of human 5-hydroxytryptamine 1A receptor,,Expert
686,,,,,,,1,,17624,H,51,CHO,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Autocuration
687,,,,,,,1,,13706,D,105,HEK293,9,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,Expert
688,,,,,,,1,,15250,H,51,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,Autocuration
689,,,,,,,1,,17624,H,51,CHO,8,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,Autocuration
690,,,,,,,1,,6861,H,51,,8,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,Expert
691,Homo sapiens,,,9606.0,,,1,,17200,D,51,,9,,B,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Expert
692,,,,,,,1,,17624,H,51,CHO,8,,B,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,Autocuration
693,,,,,,,1,,17624,H,51,CHO,8,,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Autocuration
694,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Autocuration
695,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,Autocuration
696,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,Autocuration
697,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Autocuration
698,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,Autocuration
699,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Autocuration
700,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,Autocuration
701,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,Autocuration
702,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,Autocuration
703,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,Autocuration
704,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,Autocuration
705,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,Autocuration
706,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,Autocuration
707,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,Autocuration
708,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,Autocuration
709,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,Autocuration
710,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,Autocuration
711,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,Autocuration
712,Rattus norvegicus,,,10116.0,In vivo,,1,,12058,U,22226,,0,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Autocuration
713,,,,,,,1,,11440,H,105093,,4,,B,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,Autocuration
714,,,1898.0,,,,1,,6238,H,11923,,8,Hypothalamus,B,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,Autocuration
715,,,,,,,1,,10046,H,10577,,8,,B,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,Autocuration
716,,,,,,,1,,10046,H,10577,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,Autocuration
717,,,,,,,1,,10046,H,10577,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,Expert
718,,,,,,,1,,167,H,55,,8,,B,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,Autocuration
719,,,,,,,1,,167,H,55,,8,,B,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,Autocuration
720,,,,,,,1,,11520,H,12166,,8,,F,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,Autocuration
721,,,,,,,1,,11520,H,12166,,8,,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,Autocuration
722,,,,,,,1,,11520,H,12166,,8,,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,Autocuration
723,,,,,,,1,,11520,H,12166,,8,,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,Autocuration
724,Cavia porcellus,,,10141.0,,,1,,135,H,55,,8,,F,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,Autocuration
725,Cavia porcellus,,,10141.0,,,1,,135,H,55,,8,,F,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,Autocuration
726,Cavia porcellus,,,10141.0,,,1,,11311,H,55,,8,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,Autocuration
727,Cavia porcellus,,,10141.0,,,1,,10193,H,55,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Autocuration
728,Homo sapiens,,,9606.0,,,1,,12281,D,55,,9,,B,Inhibitory concentration against 5-lipoxygenase from human whole blood,,Expert
729,,,,,,,1,,11311,H,55,,8,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,Autocuration
730,,,,,,,1,,12576,H,17087,,8,,F,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,Autocuration
731,,,,,,,1,,12281,H,17087,,8,,B,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,Autocuration
732,,,,,,,1,,12576,H,17087,,8,,F,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,Autocuration
733,Sus scrofa,,,9823.0,,,1,,11089,H,55,,8,,B,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Expert
734,,,,,,,1,,11006,H,12166,,8,,B,In vitro inhibition of rat 5-Lipoxygenase,,Expert
735,Rattus norvegicus,,,10116.0,,,1,,11481,D,12166,,9,,B,Inhibitory activity against 5-Lipoxygenase,,Expert
736,,,,,,,1,,10864,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,Expert
737,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,Autocuration
738,,,,,,,1,,11311,H,12166,RBL-1,8,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,Autocuration
739,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,Autocuration
740,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,Autocuration
741,,,,,,,1,,11006,H,12166,,8,,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,Autocuration
742,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,Autocuration
743,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibition of isolated 5-Lipoxygenase,,Autocuration
744,Rattus norvegicus,,,10116.0,,,1,,11481,U,22226,,0,,B,Ratio of IC50 against 5-LO and COX,,Autocuration
745,,,,,,,1,,11006,H,12166,,8,,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,Autocuration
746,,,,,,,1,,11006,H,12166,,8,,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,Autocuration
747,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,Autocuration
748,,,,,,,1,,11006,H,12166,,8,,F,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,Autocuration
749,,,2367.0,,,,1,,4288,H,120,,8,Prostate gland,B,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,Autocuration
750,Columba livia,,,8932.0,,,1,,7587,U,22226,,0,,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,Autocuration
751,Columba livia,,,8932.0,,,1,,7587,U,22226,,0,,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,Autocuration
752,Columba livia,,,8932.0,,,1,,7587,U,22226,,0,,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,Autocuration
753,,,,,,,1,,11249,H,10732,,8,,B,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,Autocuration
754,Rattus norvegicus,,,10116.0,,,1,,8003,D,12198,,9,,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,Expert
755,Rattus norvegicus,,,10116.0,,,1,,8003,D,12198,,9,,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Expert
756,Rattus norvegicus,,,10116.0,,,1,,8003,D,12198,,9,,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Expert
757,,,10000000.0,,,,1,,12416,H,10576,,8,Hippocampus,B,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,Expert
758,,,,,,,1,,16293,H,51,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,Autocuration
759,Oryctolagus cuniculus,,,9986.0,,,1,,13047,U,22226,,0,,B,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Autocuration
760,Oryctolagus cuniculus,,,9986.0,,,1,,13047,U,22226,,0,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Autocuration
761,Oryctolagus cuniculus,,,9986.0,,,1,,13047,U,22226,,0,,B,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,Autocuration
762,Oryctolagus cuniculus,,,9986.0,,,1,,13047,U,22226,,0,,B,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Autocuration
763,,,10000000.0,,,,1,,10085,H,104744,,4,Hippocampus,B,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,Autocuration
764,,,10000000.0,,,,1,,10085,H,104744,,4,Hippocampus,B,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,Autocuration
765,,,10000000.0,,,,1,,10085,H,104744,,4,Hippocampus,B,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,Autocuration
766,,,,,,,1,,9841,H,104744,,4,,B,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Membranes,Autocuration
767,Rattus norvegicus,,,10116.0,,,1,,8822,D,104744,,5,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,Autocuration
768,Rattus norvegicus,,,10116.0,,,1,,9806,D,104744,,5,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,Autocuration
769,Rattus norvegicus,,,10116.0,,,1,,9806,D,104744,,5,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,Autocuration
770,,,,,,,1,,8868,H,104744,,4,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,Autocuration
771,,,10000000.0,,,,1,,9036,H,104744,,4,Hippocampus,B,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,Autocuration
772,,,10000000.0,,,,1,,11374,H,104744,,4,Hippocampus,B,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,Autocuration
773,,,,,,,1,,10881,H,104744,,4,,B,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,Autocuration
774,,,,,,,1,,8822,H,104744,,4,,B,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,Autocuration
775,Rattus norvegicus,,,10116.0,,,1,,9806,D,104744,,5,,B,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,Autocuration
776,,,,,,,1,,15463,H,104744,,4,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration
777,,,,,,,1,,15463,H,104744,,4,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration
778,,,955.0,,,,1,,14542,H,104744,,4,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,Autocuration
779,,,955.0,,,,1,,14542,H,104744,,4,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,Autocuration
780,,,,,,,1,,8569,H,104744,,4,,B,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,Autocuration
781,Rattus norvegicus,,,10116.0,,,1,,10062,D,104744,,5,,B,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,Autocuration
782,,,,,,,1,,4771,H,104744,,4,,B,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,Autocuration
783,,,,,,,1,,10062,H,104744,,4,,B,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,Autocuration
784,,,,,,,1,,10062,H,104744,,4,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,Autocuration
785,,,,,,,1,,10062,H,104744,,4,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,Autocuration
786,,,,,,,1,,15463,H,104744,,4,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,Autocuration
787,,,,,,,1,,15463,H,104744,,4,,B,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,Autocuration
788,,,,,,,1,,9098,H,104744,,4,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,Autocuration
789,Rattus norvegicus,,,10116.0,,,1,,3070,U,22226,,0,,B,Affinity for 5-hydroxytryptamine 1 receptor,,Autocuration
790,,,955.0,,,,1,,14542,H,104744,,4,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,Autocuration
791,,,955.0,,,,1,,14542,H,104744,,4,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,Autocuration
792,,,,,,,1,,6398,H,104744,,4,,B,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,Autocuration
793,,,955.0,,,,1,,1344,H,104744,,4,Brain,B,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,Autocuration
794,,,,,,,1,,11963,H,104744,,4,,B,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration
795,Rattus norvegicus,,,10116.0,,,1,,8908,U,22226,,0,,B,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,Autocuration
796,,,,,,,1,,9098,H,104744,,4,,B,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,Autocuration
797,Rattus norvegicus,,,10116.0,,,1,,8841,D,104744,,5,,B,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,Autocuration
798,Rattus norvegicus,,,10116.0,,,1,,8814,U,22226,,0,,B,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,Autocuration
799,,,,,,,1,,11752,H,104744,,4,,B,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,Autocuration
800,,,955.0,,,,1,,11642,H,104744,,4,Brain,B,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,Autocuration
801,,,,,,,1,,11642,H,104744,,4,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,Autocuration
802,,,955.0,,,,1,,9231,H,104744,,4,Brain,B,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,Autocuration
803,,,955.0,,,,1,,11351,H,104744,,4,Brain,B,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,Autocuration
804,,,,,,,1,,4639,U,22226,,0,,B,Compound was tested for binding affinity against 5-HT1 receptor,,Autocuration
805,,,,,,,1,,1205,U,22226,,0,,B,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,Autocuration
806,,,,,,,1,,10025,H,10576,,8,,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,Expert
807,,,,,,,1,,13241,H,10576,,8,,F,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,Autocuration
808,,,,,In vivo,,1,,16245,H,10576,,8,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,Autocuration
809,,,,,In vivo,,1,,16245,H,10576,,8,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,Autocuration
810,,,,,,,1,,12438,H,10576,,8,,F,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,Autocuration
811,,,,,In vivo,,1,,16245,H,10576,,8,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,Autocuration
812,,,,,In vivo,,1,,16245,H,10576,,8,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,Autocuration
813,,,,,,,1,,15740,H,10576,,8,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,Autocuration
814,,,,,,,1,,15535,H,10576,,8,,F,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,Autocuration
815,,,,,,,1,,15535,H,51,,8,,F,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,Expert
816,,,,,,,1,,15535,H,10576,,8,,F,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,Autocuration
817,,,,,,,1,,9888,H,10576,,8,,B,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,Expert
818,,,10000000.0,,,,1,,10085,H,10576,,8,Hippocampus,B,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,Autocuration
819,,,10000000.0,,,,1,,10085,H,10576,,8,Hippocampus,B,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,Autocuration
820,,,,,,,1,,17331,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Membranes,Expert
821,Rattus norvegicus,,10000000.0,10116.0,,,1,,10845,D,10576,,9,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,Expert
822,Rattus norvegicus,,10000000.0,10116.0,,,1,,10845,D,10576,,9,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,Expert
823,,,10000000.0,,,,1,,10845,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,Expert
824,Rattus norvegicus,,10000000.0,10116.0,,,1,,10845,D,10576,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,Expert
825,Rattus norvegicus,,10000000.0,10116.0,,,1,,10845,D,10576,,9,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,Expert
826,,,,,,,1,,13730,H,10576,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,Expert
827,,,,,,,1,,13508,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,Expert
828,,,10000000.0,,,,1,,13508,H,10576,,8,Hippocampus,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,Expert
829,,,10000000.0,,,,1,,12073,H,10576,,8,Hippocampus,B,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,Expert
830,,,10000000.0,,,,1,,4671,H,10576,,8,Hippocampus,B,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,Autocuration
831,,,10000000.0,,,,1,,13631,H,10576,,8,Hippocampus,B,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,Expert
832,,,,,,,1,,12438,H,10576,,8,,B,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,Autocuration
833,,,,,,,1,,10483,H,10576,,8,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,Autocuration
834,,,10000000.0,,,,1,,10483,H,10576,,8,Hippocampus,B,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,Autocuration
835,,,,,,,1,,12352,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,Intermediate
836,,,10000000.0,,,,1,,14732,H,10576,,8,Hippocampus,B,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,Autocuration
837,Rattus norvegicus,,,10116.0,,,1,,11049,D,10576,,9,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,Expert
838,Rattus norvegicus,,,10116.0,,,1,,11049,D,10576,,9,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,Expert
839,,,,,,,1,,13657,H,10576,,8,,B,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,Expert
840,,,,,,,1,,11473,H,10576,,8,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,Autocuration
841,,,,,,,1,,2014,H,10576,,8,,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,Autocuration
842,,,10000000.0,,,,1,,3086,H,10576,,8,Hippocampus,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,Expert
843,,,,,,,1,,15854,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,Expert
844,,,10000000.0,,,,1,,10922,H,10576,,8,Hippocampus,B,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,Expert
845,,,10000000.0,,,,1,,13346,H,10576,,8,Hippocampus,B,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,Expert
846,,,,,,,1,,15311,H,10576,,8,,B,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,Expert
847,,,10000000.0,,,,1,,10922,H,10576,,8,Hippocampus,B,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,Autocuration
848,,,,,,,1,,10025,H,10576,,8,,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,Autocuration
849,,,,,,,1,,10025,H,10576,,8,,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,Expert
850,,,,,,,1,,9742,H,10576,,8,,B,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,Autocuration
851,,,,,,,1,,9742,H,10576,,8,,F,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,Autocuration
852,,,,,,,1,,12304,H,10576,,8,,B,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,Expert
853,,,10000000.0,,,,1,,15789,H,10576,,8,Hippocampus,B,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,Autocuration
854,,,,,,,1,,9912,H,10576,,8,,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,Autocuration
855,,,,,,,1,,9912,H,10576,,8,,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,Autocuration
856,,,,,,,1,,9912,H,10576,,8,,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,Autocuration
857,,,,,,,1,,16693,H,10576,,8,,B,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,Expert
858,,,,,,,1,,13276,H,10576,,8,,B,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,Expert
859,,,10000000.0,,,,1,,12678,H,10576,,8,Hippocampus,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,Autocuration
860,,,,,,,1,,11825,H,10576,,8,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,Autocuration
861,,,,,,,1,,12443,H,10576,,8,,B,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,Expert
862,,,,,,,1,,13830,H,10576,,8,,B,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Expert
863,,,10000000.0,,,,1,,14286,H,10576,,8,Hippocampus,B,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,Expert
864,Rattus norvegicus,,10000000.0,10116.0,,,1,,14356,D,10576,,9,Hippocampus,B,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,Expert
865,,,,,,,1,,15306,H,10576,,8,,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,Autocuration
866,,,,,,,1,,15306,H,10576,,8,,B,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,Expert
867,Rattus norvegicus,,,10116.0,,,1,,16616,D,10576,,9,,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Expert
868,,,10000000.0,,,,1,,3651,H,10576,,8,Hippocampus,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,Autocuration
869,,,10000000.0,,,,1,,14331,H,10576,,8,Hippocampus,F,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
870,,,10000000.0,,,,1,,14331,H,10576,,8,Hippocampus,F,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
871,Rattus norvegicus,,,10116.0,,,1,,14178,D,10576,,9,,B,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,Expert
872,Rattus norvegicus,,,10116.0,,,1,,10639,D,10576,,9,,B,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,Expert
873,,,10000000.0,,,,1,,12306,H,10576,,8,Hippocampus,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,Autocuration
874,Rattus norvegicus,,,10116.0,,,1,,1348,D,10576,,9,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,Expert
875,,,10000000.0,,,,1,,13605,H,10576,,8,Hippocampus,B,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,Autocuration
876,,,,,,,1,,17624,H,51,CHO,8,,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Autocuration
877,,,,,,,1,,17624,H,51,CHO,8,,F,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,Autocuration
878,,,,,,,1,,17624,H,51,CHO,8,,F,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,Autocuration
879,,,,,,,1,,15267,H,51,,8,,B,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,Autocuration
880,,,,,,,1,,16532,H,51,,8,,B,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,Autocuration
881,,,,,,,1,,6563,H,51,,8,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration
882,,,,,,,1,,4751,H,51,CHO,8,,B,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,Autocuration
883,,,,,,,1,,15463,H,51,,8,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,Autocuration
884,,,,,,,1,,3805,H,51,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,Autocuration
885,,,,,,,1,,5640,H,51,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
886,,,,,,,1,,6563,H,51,,8,,B,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,Autocuration
887,,,,,,,1,,5548,H,51,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,Autocuration
888,,,,,,,1,,6347,H,51,,8,,B,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
889,,,,,,,1,,17296,H,51,HEK293,8,,F,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration
890,,,,,,,1,,13047,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,Autocuration
891,,,,,,,1,,15740,H,51,,8,,B,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,Autocuration
892,,,,,,,1,,5640,H,51,,8,,F,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,Expert
893,,,,,,,1,,5640,H,51,,8,,F,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,Autocuration
894,,,,,,,1,,17211,H,51,HeLa,8,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,Expert
895,,,,,,,1,,4751,H,51,CHO,8,,B,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,Autocuration
896,Homo sapiens,,,9606.0,,,1,,6491,D,51,,9,,B,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,Expert
897,,,,,,,1,,4707,H,51,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,Autocuration
898,Homo sapiens,,,9606.0,,,1,,13910,D,51,,9,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Expert
899,,,,,,,1,,16190,H,51,HeLa,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,Autocuration
900,,,,,,,1,,16633,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
901,,,,,,,1,,11898,H,51,CHO,8,,B,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,Autocuration
902,,,,,,,1,,11898,H,51,CHO,8,,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration
903,,,,,,,1,,14331,H,51,,8,,B,Binding affinity against human 5-hydroxytryptamine 1A receptor,,Autocuration
904,,,,,,,1,,17624,H,51,CHO,8,,B,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,Expert
905,,,,,,,1,,17624,H,51,CHO,8,,B,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,Autocuration
906,,,,,,,1,,3307,H,51,,8,,B,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,Autocuration
907,Homo sapiens,,,9606.0,,,1,,6563,D,51,CHO,9,,B,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Expert
908,,,,,,,1,,14165,H,51,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,Autocuration
909,,,,,,,1,,5732,H,51,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,Autocuration
910,,,,,,,1,,13366,H,51,,8,,B,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,Expert
911,,,,,,,1,,17626,H,51,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,Autocuration
912,,,,,,,1,,6588,H,51,HeLa,8,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,Expert
913,,,,,,,1,,16209,H,51,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,Autocuration
914,,,,,,,1,,15463,H,51,,8,,B,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration
915,,,,,,,1,,15463,H,51,,8,,B,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration
916,,,,,,,1,,14770,H,51,,8,,B,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,Autocuration
917,,,,,,,1,,16245,H,51,Cell line,8,,B,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,Autocuration
918,,,,,,,1,,16245,H,51,,8,,B,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,Autocuration
919,,,,,,,1,,5548,H,51,,8,,B,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
920,,,,,,,1,,5548,H,51,,8,,B,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Expert
921,,,,,,,1,,5548,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
922,,,,,,,1,,6876,H,51,,8,,B,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,Expert
923,,,,,,,1,,2598,H,51,,8,,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
924,,,,,,,1,,17785,H,51,,8,,B,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,Expert
925,,,,,,,1,,6013,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Autocuration
926,,,,,,,1,,5929,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,Expert
927,,,,,,,1,,16633,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
928,,,,,,,1,,1558,H,51,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,Autocuration
929,,,,,,,1,,16026,H,51,,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Expert
930,,,,,,,1,,12469,H,51,,8,,B,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,Autocuration
931,Homo sapiens,,,9606.0,,,1,,15874,D,51,,9,,B,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Expert
932,,,,,,,1,,15874,H,51,,8,,B,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Autocuration
933,,,,,,,1,,3935,H,51,,8,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,Autocuration
934,,,,,,,1,,15818,H,51,,8,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,Autocuration
935,,,,,,,1,,13706,H,51,CHO-K1,8,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,Autocuration
936,,,,,,,1,,13729,H,51,CHO-K1,8,,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,Expert
937,,,,,,,1,,15413,H,51,,8,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,Autocuration
938,,,,,,,1,,15413,H,51,,8,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,Autocuration
939,,,,,,,1,,15413,H,51,,8,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,Autocuration
940,,,,,,,1,,15413,H,51,,8,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,Autocuration
941,Homo sapiens,,,9606.0,,,1,,3445,D,51,HeLa,9,,B,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Expert
942,,,,,,,1,,15740,H,51,,8,,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,Autocuration
943,,,,,,,1,,15740,H,51,,8,,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,Autocuration
944,,,,,,,1,,17626,H,51,,8,,B,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,Autocuration
945,Homo sapiens,,,9606.0,,,1,,4234,D,51,,9,,B,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,Expert
946,,,,,,,1,,5640,H,51,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,Expert
947,Rattus norvegicus,,,10116.0,,,1,,5272,H,51,,8,,B,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,Expert
948,,,,,,,1,,4622,H,51,CHO,8,,B,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,Autocuration
949,,,,,,,1,,17085,H,51,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,Expert
950,,,,,,,1,,3025,H,51,,8,,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,Autocuration
951,,,,,,,1,,15315,H,51,,8,,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Expert
952,,,,,,,1,,15267,H,51,,8,,B,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,Autocuration
953,,,,,,,1,,17158,H,51,HeLa,8,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,Autocuration
954,Homo sapiens,,,9606.0,,,1,,14214,D,51,HeLa,9,,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,Expert
955,,,,,,,1,,17133,H,51,,8,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
956,,,,,,,1,,16532,H,51,,8,,B,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,Autocuration
957,Homo sapiens,,,9606.0,,,1,,2391,D,51,,9,,B,Affinity for 5-hydroxytryptamine 1A receptor subtype,,Expert
958,,,,,,,1,,14447,H,51,,8,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,Autocuration
959,,,,,,,1,,14447,H,51,,8,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,Autocuration
960,,,,,,,1,,15086,H,51,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,Autocuration
961,Homo sapiens,,,9606.0,,,1,,13051,D,51,,9,,B,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Expert
962,,,,,,,1,,16026,H,51,,8,,F,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,Autocuration
963,,,,,,,1,,17085,H,51,,8,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,Expert
964,,,,,,,1,,17133,H,51,,8,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
965,,,,,,,1,,17133,H,51,,8,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,Autocuration
966,,,,,,,1,,17211,H,51,HeLa,8,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,Autocuration
967,,,,,,,1,,17211,H,51,HeLa,8,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,Autocuration
968,,,,,,,1,,17211,H,51,HeLa,8,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,Autocuration
969,,,,,,,1,,17211,H,51,HeLa,8,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,Autocuration
970,,,,,,,1,,16394,H,51,,8,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,Autocuration
971,,,,,,,1,,16394,H,51,,8,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,Autocuration
972,,,,,,,1,,16394,H,51,,8,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,Autocuration
973,,,,,In vivo,,1,,16394,H,51,,8,,F,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,Autocuration
974,,,,,,,1,,16394,H,51,,8,,B,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,Autocuration
975,,,,,,,1,,15740,H,51,,8,,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,Autocuration
976,,,,,,,1,,15740,H,51,,8,,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,Autocuration
977,,,,,,,1,,15740,H,51,,8,,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,Autocuration
978,,,,,,,1,,17296,H,51,HEK293,8,,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration
979,,,,,,,1,,5640,H,51,,8,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,Expert
980,,,,,,,1,,5640,H,51,,8,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,Autocuration
981,,,,,,,1,,5640,H,51,,8,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,Autocuration
982,,,,,,,1,,5640,H,51,,8,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,Autocuration
983,,,,,,,1,,2759,H,51,CHO,8,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,Autocuration
984,,,,,,,1,,16394,H,51,,8,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,Autocuration
985,Homo sapiens,,,9606.0,,,1,,16394,D,51,,9,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,Expert
986,Homo sapiens,,,9606.0,,,1,,3445,D,51,,9,,F,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,Expert
987,,,,,,,1,,4316,H,51,CHO,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,Expert
988,,,,,,,1,,4316,H,51,,8,,B,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,Expert
989,Homo sapiens,,,9606.0,,,1,,15180,D,51,,9,,F,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Expert
990,Homo sapiens,,,9606.0,,,1,,15180,D,51,,9,,F,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Expert
991,,,,,,,1,,15042,H,51,,8,,F,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration
992,,,,,,,1,,15042,H,51,,8,,F,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration
993,,,,,,,1,,15042,H,51,,8,,F,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,Autocuration
994,,,,,,,1,,15042,H,51,,8,,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration
995,,,,,,,1,,15042,H,51,,8,,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration
996,,,,,,,1,,15042,H,51,,8,,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration
997,,,,,,,1,,15042,H,51,,8,,F,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,Autocuration
998,Homo sapiens,,,9606.0,,,1,,15180,D,51,HeLa,9,,F,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Expert
999,Homo sapiens,,,9606.0,,,1,,15180,D,51,HeLa,9,,F,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Expert
1000,Homo sapiens,,,9606.0,,,1,,15180,D,51,HeLa,9,,F,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Expert
1001,,,,,,,1,,16245,H,51,,8,,F,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,Autocuration
1002,,,,,,,1,,16026,H,51,,8,,F,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,Autocuration
1003,,,,,,,1,,17296,H,51,HEK293,8,,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration
1004,,,,,,,1,,2759,H,51,CHO,8,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,Autocuration
1005,,,,,,,1,,2759,H,51,CHO,8,,F,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Autocuration
1006,Homo sapiens,,,9606.0,,,1,,2759,D,51,CHO,9,,F,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,Expert
1007,,,,,,,1,,2759,H,51,CHO,8,,F,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,Autocuration
1008,,,,,,,1,,15419,H,51,,8,,F,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,Expert
1009,,,,,,,1,,15419,H,51,,8,,F,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,Autocuration
1010,,,,,,,1,,16026,H,51,,8,,F,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,Autocuration
1011,,,,,In vitro,,1,,1414,H,51,,8,,B,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,Expert
1012,,,,,In vitro,,1,,1414,H,51,,8,,B,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,Expert
1013,,,,,,,1,,12861,H,51,,8,,B,Binding activity radioligand.,,Autocuration
1014,,,,,,,1,,12861,H,51,,8,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Autocuration
1015,,,,,,,1,,5104,H,51,,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,Autocuration
1016,,,,,,,1,,5105,H,51,,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,Autocuration
1017,,,,,,,1,,16312,H,51,,8,,B,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,Autocuration
1018,Homo sapiens,,,9606.0,,,1,,15180,D,51,,9,,B,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,Expert
1019,,,,,,,1,,5033,H,51,,8,,B,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,Autocuration
1020,Homo sapiens,,,9606.0,,,1,,16909,D,51,CHO,9,,B,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Expert
1021,,,,,,,1,,2590,H,51,,8,,F,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,Autocuration
1022,,,,,,,1,,2590,H,51,,8,,F,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Autocuration
1023,,,,,,,1,,16394,H,51,,8,,B,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,Expert
1024,Homo sapiens,,,9606.0,,,1,,4540,D,51,HEK293,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,Expert
1025,,,,,,,1,,17296,H,51,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,Autocuration
1026,,,,,,,1,,17296,H,51,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,Autocuration
1027,,,,,,,1,,15779,H,51,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,Autocuration
1028,,,,,,,1,,15779,H,51,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,Autocuration
1029,,,,,,,1,,15779,H,51,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,Autocuration
1030,,,,,,,1,,6166,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,Autocuration
1031,,,,,,,1,,15779,H,51,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,Autocuration
1032,,,,,,,1,,4199,H,51,HEK293,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,Autocuration
1033,,,,,,,1,,15316,H,51,,8,,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,Autocuration
1034,,,,,,,1,,14875,H,51,,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,Autocuration
1035,,,,,,,1,,14727,H,51,HeLa,8,,B,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,Expert
1036,,,,,,,1,,14727,H,51,,8,,B,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,Expert
1037,,,,,,,1,,15146,H,51,HEK293,8,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,Autocuration
1038,,,,,,,1,,5213,H,51,HEK293,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,Autocuration
1039,,,,,,,1,,16429,H,51,,8,,B,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,Autocuration
1040,Homo sapiens,,,9606.0,,,1,,15042,D,51,HeLa,9,,B,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,Expert
1041,,,,,,,1,,14818,H,51,HEK293,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,Autocuration
1042,,,,,,,1,,4829,H,51,HEK293,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,Autocuration
1043,,,,,,,1,,17200,D,51,,9,,B,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Expert
1044,Homo sapiens,,,9606.0,,,1,,13051,D,51,,9,,B,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,Autocuration
1045,,,,,,,1,,5486,H,106,,8,,B,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,Autocuration
1046,,,,,,,1,,5254,H,105,,8,,B,Binding affinity against 5-HT1D receptor,,Autocuration
1047,,,,,,,1,,5254,H,105,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
1048,,,,,,,1,,15331,H,107,,8,,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Autocuration
1049,Homo sapiens,,,9606.0,,,1,,13506,H,10576,,8,,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Autocuration
1050,,,,,,,1,,15267,H,51,,8,,B,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,Autocuration
1051,,,,,In vivo,,1,,16616,H,11863,,8,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,Autocuration
1052,,,,,In vivo,,1,,16616,H,11863,,8,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,Autocuration
1053,,,,,In vivo,,1,,16616,H,11863,,8,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,Autocuration
1054,Mus musculus,,,10090.0,,,1,,16616,D,11863,,9,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,Expert
1055,Mus musculus,,,10090.0,,,1,,16616,D,11863,,9,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,Expert
1056,Mus musculus,,,10090.0,,,1,,16616,D,11863,,9,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,Expert
1057,Mus musculus,,,10090.0,,,1,,16616,D,11863,,9,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,Expert
1058,Mus musculus,,,10090.0,,,1,,16616,D,11863,,9,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,Expert
1059,Mus musculus,,,10090.0,,,1,,16616,D,11863,,9,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,Expert
1060,,,10000000.0,,,,1,,10297,H,11863,,8,Hippocampus,B,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,Autocuration
1061,,,,,,,1,,13704,H,11863,,8,,B,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,Expert
1062,Mus musculus,,10000000.0,10090.0,,,1,,10297,D,11863,,9,Hippocampus,B,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,Expert
1063,,,10000000.0,,,,1,,10297,H,11863,,8,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,Autocuration
1064,Mus musculus,,10000000.0,10090.0,,,1,,10297,D,11863,,9,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,Expert
1065,,,10000000.0,,,,1,,10297,H,11863,,8,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,Autocuration
1066,,,,,,,1,,217,H,11863,,8,,B,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,Autocuration
1067,Mus musculus,,10000000.0,10090.0,,,1,,10297,D,11863,,9,Hippocampus,B,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,Expert
1068,Sus scrofa,,,9823.0,,,1,,4921,H,51,,8,,B,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,Autocuration
1069,Sus scrofa,,,9823.0,,,1,,4921,H,51,,8,,B,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,Autocuration
1070,Sus scrofa,,,9823.0,,,1,,4996,H,51,,8,,B,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,Autocuration
1071,Sus scrofa,,,9823.0,,,1,,12918,H,51,,8,,B,Compound was evaluated for the binding affinity at 5- HT1A receptor,,Autocuration
1072,Sus scrofa,,,9823.0,,,1,,5333,H,51,,8,,B,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Autocuration
1073,Sus scrofa,,,9823.0,,,1,,4437,H,51,,8,,B,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Autocuration
1074,Sus scrofa,,,9823.0,,,1,,1742,H,51,,8,,B,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,Autocuration
1075,Sus scrofa,,,9823.0,,,1,,16688,H,51,,8,,B,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,Expert
1076,Sus scrofa,,,9823.0,,,1,,12861,H,51,,8,,B,Binding activity radioligand.,,Autocuration
1077,Sus scrofa,,,9823.0,,,1,,12861,H,51,,8,,B,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Expert
1078,Sus scrofa,,,9823.0,,,1,,12861,H,51,,8,,B,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Autocuration
1079,,,,,,,1,,12490,H,10624,,8,,B,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,Expert
1080,Sus scrofa,,,9823.0,,,1,,11828,H,51,,8,,B,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,Expert
1081,Sus scrofa,,10000000.0,9823.0,,,1,,11866,H,51,,8,Hippocampus,B,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,Autocuration
1082,Sus scrofa,,,9823.0,,,1,,12827,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,Autocuration
1083,Sus scrofa,,,9823.0,,,1,,12918,H,51,,8,,B,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,Autocuration
1084,Sus scrofa,,,9823.0,,,1,,12919,H,51,,8,,F,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,Expert
1085,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,Autocuration
1086,Rattus norvegicus,,,10116.0,,,1,,15796,D,10576,,9,,B,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,Expert
1087,Rattus norvegicus,,10000000.0,10116.0,,,1,,3651,D,10576,,9,Hippocampus,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,Expert
1088,,,,,,,1,,188,H,10576,,8,,B,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,Autocuration
1089,Rattus norvegicus,,,10116.0,,,1,,16616,D,10576,,9,,F,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,Expert
1090,Rattus norvegicus,,10000000.0,10116.0,,,1,,16616,D,10576,,9,Hippocampus,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,Expert
1091,,,10000000.0,,,,1,,12306,H,10576,,8,Hippocampus,B,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,Autocuration
1092,Rattus norvegicus,,10000000.0,10116.0,,,1,,17167,D,10576,,9,Hippocampus,B,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,Expert
1093,,,,,,,1,,14776,H,10576,,8,,B,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,Autocuration
1094,,,,,,,1,,12158,H,10576,,8,,B,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,Expert
1095,,,,,,,1,,13481,H,10576,,8,,B,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,Autocuration
1096,,,,,In vitro,,1,,13427,H,10576,,8,,B,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,Autocuration
1097,,,,,,,1,,10210,H,10576,,8,,B,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,Autocuration
1098,,,,,,,1,,10205,H,10576,,8,,B,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,Autocuration
1099,,,,,,,1,,10205,H,10576,,8,,B,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,Autocuration
1100,,,,,,,1,,10205,H,10576,,8,,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Membranes,Expert
1101,Rattus norvegicus,,,10116.0,,,1,,12280,D,10576,,9,,B,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,Expert
1102,,,,,,,1,,17386,H,10576,,8,,B,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,Expert
1103,,,,,,,1,,13654,H,10576,,8,,B,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,Expert
1104,,,10000000.0,,,,1,,14423,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,Autocuration
1105,,,10000000.0,,,,1,,15412,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,Autocuration
1106,,,10000000.0,,,,1,,12073,H,10576,,8,Hippocampus,B,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
1107,Rattus norvegicus,,,10116.0,,,1,,4101,D,10576,,9,,B,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,Expert
1108,,,,,,,1,,10062,H,10576,,8,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,Autocuration
1109,,,,,,,1,,6238,H,10576,,8,,B,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,Autocuration
1110,,,,,,,1,,16273,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Autocuration
1111,,,,,,,1,,11139,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,Autocuration
1112,,,,,,,1,,16796,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,Expert
1113,Rattus norvegicus,,955.0,10116.0,,,1,,9548,D,10576,,9,Brain,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,Expert
1114,,,955.0,,,,1,,10381,H,10576,,8,Brain,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,Autocuration
1115,,,,,,,1,,13408,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,Autocuration
1116,Rattus norvegicus,,10000000.0,10116.0,,,1,,13825,D,10576,,9,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,Expert
1117,,,10000000.0,,,,1,,11147,H,10576,,8,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,Expert
1118,,,,,,,1,,10552,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,Autocuration
1119,,,2435.0,,,,1,,10552,H,10576,,8,Striatum,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,Autocuration
1120,Rattus norvegicus,,,10116.0,,,1,,17136,D,10576,,9,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Membranes,Expert
1121,Rattus norvegicus,,,10116.0,,,1,,5778,D,10576,,9,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Membranes,Expert
1122,,,10000000.0,,,,1,,13481,H,10576,,8,Hippocampus,B,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
1123,,,10000000.0,,,,1,,13481,H,10576,,8,Hippocampus,B,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,Autocuration
1124,,,10000000.0,,,,1,,13630,H,10576,,8,Hippocampus,B,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,Intermediate
1125,,,,,,,1,,16245,H,10576,,8,,B,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,Expert
1126,,,10000000.0,,,,1,,14509,H,10576,,8,Hippocampus,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,Autocuration
1127,,,10000000.0,,,,1,,14509,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,Expert
1128,,,10000000.0,,,,1,,14509,H,10576,,8,Hippocampus,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,Autocuration
1129,,,10000000.0,,,,1,,14509,H,10576,,8,Hippocampus,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,Autocuration
1130,,,,,,,1,,14256,H,10576,,8,,B,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,Expert
1131,,,,,,,1,,11139,H,10576,,8,,B,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,Autocuration
1132,Rattus norvegicus,,,10116.0,,,1,,11047,D,10576,,9,,B,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,Expert
1133,Rattus norvegicus,,,10116.0,,,1,,11047,D,10576,,9,,B,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,Expert
1134,Rattus norvegicus,,,10116.0,,,1,,11047,D,10576,,9,,B,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,Expert
1135,Rattus norvegicus,,,10116.0,,,1,,2395,D,10576,CHO-K1,9,,B,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Expert
1136,,,,,,,1,,9699,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Autocuration
1137,Rattus norvegicus,,10000000.0,10116.0,,,1,,12028,D,10576,,9,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,Expert
1138,,,10000000.0,,,,1,,12028,H,10576,,8,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,Autocuration
1139,,,,,,,1,,5815,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,Autocuration
1140,,,,,,,1,,16616,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,Expert
1141,,,,,,,1,,5815,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,Autocuration
1142,,,10000000.0,,,,1,,2761,H,10576,,8,Hippocampus,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,Autocuration
1143,,,,,,,1,,13133,H,10576,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,Expert
1144,,,,,,,1,,10444,H,10576,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,Autocuration
1145,Rattus norvegicus,,,10116.0,,,1,,13278,D,10576,,9,,B,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,Expert
1146,,,,,,,1,,15874,H,10576,,8,,B,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Autocuration
1147,,,2435.0,,,,1,,10552,H,10576,,8,Striatum,B,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Membranes,Autocuration
1148,,,,,,,1,,11130,H,10576,,8,,B,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,Autocuration
1149,,,,,In vivo,,1,,11130,H,10576,,8,,B,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,Autocuration
1150,,,955.0,,,,1,,14542,H,10576,,8,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,Autocuration
1151,Rattus norvegicus,,,10116.0,,,1,,13670,D,10576,,9,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Expert
1152,,,,,,,1,,9888,H,10576,,8,,B,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,Expert
1153,Rattus norvegicus,,,10116.0,,,1,,3678,D,10576,,9,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Membranes,Expert
1154,,,10000000.0,,,,1,,11332,H,10576,,8,Hippocampus,B,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,Autocuration
1155,,,10000000.0,,,,1,,11332,H,10576,,8,Hippocampus,B,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,Autocuration
1156,,,,,,,1,,1185,H,10576,,8,,B,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,Expert
1157,,,,,,,1,,2014,H,10576,,8,,B,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,Expert
1158,,,,,,,1,,1185,H,10576,,8,,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,Autocuration
1159,,,,,,,1,,14429,H,10576,,8,,B,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,Expert
1160,,,,,,,1,,16288,H,10576,,8,,B,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,Expert
1161,Rattus norvegicus,,,10116.0,,,1,,5432,D,10576,,9,,B,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,Expert
1162,,,,,,,1,,14429,H,10576,,8,,B,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,Autocuration
1163,,,,,,,1,,13672,H,10576,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,Expert
1164,,,10000000.0,,,,1,,11296,H,10576,,8,Hippocampus,B,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,Expert
1165,,,,,,,1,,11296,H,10576,,8,,B,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,Autocuration
1166,,,,,,,1,,14749,H,10576,CHO,8,,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,Expert
1167,,,,,,,1,,15086,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,Expert
1168,,,10000000.0,,,,1,,13462,H,10576,,8,Hippocampus,B,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,Autocuration
1169,,,,,,,1,,15363,H,10576,,8,,B,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,Autocuration
1170,,,,,,,1,,15363,H,10576,,8,,B,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,Autocuration
1171,,,,,,,1,,10796,H,10576,,8,,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,Autocuration
1172,,,955.0,,,,1,,12816,H,10576,,8,Brain,B,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,Expert
1173,,,10000000.0,,,,1,,13542,H,10576,,8,Hippocampus,B,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,Expert
1174,,,,,,,1,,13308,H,10576,,8,,B,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,Expert
1175,,,10000000.0,,,,1,,13541,H,10576,,8,Hippocampus,B,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,Expert
1176,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,Autocuration
1177,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,Autocuration
1178,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,Autocuration
1179,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,Autocuration
1180,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,Autocuration
1181,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,Autocuration
1182,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,Autocuration
1183,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,Autocuration
1184,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,Autocuration
1185,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,Autocuration
1186,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,Autocuration
1187,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,Autocuration
1188,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,Autocuration
1189,Rattus norvegicus,,10000000.0,10116.0,,,1,,10058,D,10576,,9,Hippocampus,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,Expert
1190,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,Autocuration
1191,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,Autocuration
1192,,,,,,,1,,12879,H,10576,,8,,B,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,Expert
1193,,,,,,,1,,11964,H,10576,,8,,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,Expert
1194,,,,,,,1,,11964,H,10576,,8,,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,Autocuration
1195,,,,,,,1,,11964,H,10576,,8,,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,Autocuration
1196,,,955.0,,,,1,,9548,H,10576,,8,Brain,B,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,Expert
1197,,,,,,,1,,9098,H,10576,,8,,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,Expert
1198,,,,,,,1,,9098,H,10576,,8,,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,Autocuration
1199,,,,,,,1,,9098,H,10576,,8,,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,Autocuration
1200,,,,,,,1,,13248,H,10576,CHO,8,,B,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,Expert
1201,,,,,,,1,,3147,H,10576,,8,,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,Expert
1202,,,,,,,1,,13949,H,10576,,8,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,Expert
1203,,,,,,,1,,11883,H,10576,CHO,8,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Autocuration
1204,,,,,,,1,,11883,H,10576,,8,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,Autocuration
1205,Rattus norvegicus,,,10116.0,,,1,,11883,D,10576,,9,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,Expert
1206,,,,,,,1,,15535,H,10576,,8,,B,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,Expert
1207,,,,,,,1,,15535,H,10576,,8,,B,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,Autocuration
1208,,,,,,,1,,15535,H,10576,,8,,B,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,Autocuration
1209,Homo sapiens,,,9606.0,,,1,,16372,D,51,CHO,9,,B,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Expert
1210,,,,,,,1,,14608,H,10576,,8,,B,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,Expert
1211,Rattus norvegicus,,10000000.0,10116.0,,,1,,4795,D,10576,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,Expert
1212,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration
1213,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,Autocuration
1214,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,Autocuration
1215,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,Autocuration
1216,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,Autocuration
1217,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,Autocuration
1218,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,Autocuration
1219,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,Autocuration
1220,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,Autocuration
1221,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,Autocuration
1222,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,Autocuration
1223,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,Autocuration
1224,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,Autocuration
1225,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,Autocuration
1226,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,Autocuration
1227,,,,,,,1,,9742,H,10576,,8,,B,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,Autocuration
1228,,,,,,,1,,12073,H,10576,,8,,B,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,Autocuration
1229,,,,,,,1,,4101,H,10576,,8,,B,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,Autocuration
1230,,,,,,,1,,15360,H,10576,,8,,B,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,Autocuration
1231,,,10000000.0,,,,1,,11576,H,10576,,8,Hippocampus,B,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,Autocuration
1232,,,,,,,1,,5834,H,10576,,8,,B,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,Expert
1233,Rattus norvegicus,,,10116.0,,,1,,2395,D,10576,CHO-K1,9,,B,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Expert
1234,,,,,,,1,,1375,H,10576,,8,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,Autocuration
1235,,,,,,,1,,1375,H,10576,,8,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,Autocuration
1236,,,,,,,1,,3967,H,10576,,8,,B,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,Autocuration
1237,,,,,,,1,,12884,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,Expert
1238,,,,,,,1,,2343,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,Expert
1239,,,,,,,1,,11511,H,10576,,8,,B,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Autocuration
1240,Rattus norvegicus,,,10116.0,,,1,,11511,D,10576,,9,,B,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Expert
1241,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,Autocuration
1242,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,Autocuration
1243,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,Autocuration
1244,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,Autocuration
1245,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,Autocuration
1246,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,Autocuration
1247,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,Autocuration
1248,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,Autocuration
1249,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,Autocuration
1250,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,Autocuration
1251,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,Autocuration
1252,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,Autocuration
1253,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,Autocuration
1254,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,Autocuration
1255,,,,,In vivo,,1,,16394,H,10576,,8,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,Autocuration
1256,Rattus norvegicus,,,10116.0,,,1,,16616,D,10576,,9,,F,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,Expert
1257,,,,,,,1,,16796,H,10576,,8,,B,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,Autocuration
1258,,,,,,,1,,16796,H,10576,,8,,B,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,Autocuration
1259,,,,,,,1,,15629,H,10576,,8,,B,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,Autocuration
1260,,,,,,,1,,13241,H,10576,,8,,F,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,Autocuration
1261,,,10000000.0,,,,1,,12073,H,10576,,8,Hippocampus,B,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,Expert
1262,,,10000000.0,,,,1,,14286,H,10576,,8,Hippocampus,B,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,Autocuration
1263,,,955.0,,,,1,,14542,H,10576,,8,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,Autocuration
1264,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,Autocuration
1265,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,Autocuration
1266,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,Autocuration
1267,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,Autocuration
1268,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,Expert
1269,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,Autocuration
1270,Rattus norvegicus,,,10116.0,,,1,,13630,D,10576,,9,,F,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,Expert
1271,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,Autocuration
1272,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,Expert
1273,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,Autocuration
1274,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,Expert
1275,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,Autocuration
1276,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,Expert
1277,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,Autocuration
1278,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,Autocuration
1279,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,Autocuration
1280,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,Expert
1281,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,Expert
1282,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,Autocuration
1283,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,Expert
1284,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,Autocuration
1285,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,Autocuration
1286,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,Autocuration
1287,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,Autocuration
1288,,,10000000.0,,,,1,,9783,H,10576,,8,Hippocampus,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,Autocuration
1289,,,10000000.0,,,,1,,9783,H,10576,,8,Hippocampus,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,Expert
1290,Rattus norvegicus,,,10116.0,,,1,,14331,D,10576,,9,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Membranes,Expert
1291,,,10000000.0,,,,1,,15260,H,10576,,8,Hippocampus,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,Expert
1292,,,10000000.0,,,,1,,15260,H,10576,,8,Hippocampus,B,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,Autocuration
1293,,,10000000.0,,,,1,,15260,H,10576,,8,Hippocampus,B,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,Autocuration
1294,Rattus norvegicus,,,10116.0,,,1,,16616,D,10576,,9,,F,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Expert
1295,,,,,,,1,,15629,H,10576,,8,,B,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,Autocuration
1296,,,,,,,1,,15086,H,10576,,8,,B,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,Autocuration
1297,,,,,,,1,,5717,H,10576,,8,,F,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,Expert
1298,,,,,,,1,,12652,H,10576,,8,,B,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,Autocuration
1299,,,10000000.0,,,,1,,14608,H,10576,,8,Hippocampus,B,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,Autocuration
1300,,,10000000.0,,,,1,,12306,H,10576,,8,Hippocampus,B,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,Autocuration
1301,,,10000000.0,,,,1,,12306,H,10576,,8,Hippocampus,B,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,Autocuration
1302,Rattus norvegicus,,,10116.0,,,1,,15247,D,10576,,9,,B,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Expert
1303,,,10000000.0,,,,1,,17529,H,10576,,8,Hippocampus,B,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,Expert
1304,,,10000000.0,,,,1,,14826,H,10576,,8,Hippocampus,B,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
1305,,,10000000.0,,,,1,,14826,H,10576,,8,Hippocampus,B,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
1306,,,10000000.0,,,,1,,13241,H,10576,,8,Hippocampus,B,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,Autocuration
1307,,,10000000.0,,,,1,,14093,H,10576,,8,Hippocampus,B,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,Autocuration
1308,,,10000000.0,,,,1,,14093,H,10576,,8,Hippocampus,B,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,Autocuration
1309,,,955.0,,,,1,,14442,H,10576,,8,Brain,B,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,Autocuration
1310,,,,,,,1,,9919,H,10576,,8,,B,Affinity for 5-hydroxytryptamine 1A receptor site,,Autocuration
1311,,,,,,,1,,9919,H,10576,,8,,B,Affinity for 5-hydroxytryptamine 1A receptor site,,Autocuration
1312,,,10000000.0,,,,1,,11440,H,10576,,8,Hippocampus,B,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,Autocuration
1313,,,,,,,1,,11257,H,10576,,8,,B,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,Autocuration
1314,,,,,,,1,,10330,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,Expert
1315,Rattus norvegicus,,10000000.0,10116.0,,,1,,17331,D,10576,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,Expert
1316,,,,,,,1,,16567,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,Expert
1317,Rattus norvegicus,,,10116.0,,,1,,12058,D,10576,,9,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Expert
1318,,,10000000.0,,,,1,,9699,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,Autocuration
1319,,,,,,,1,,9547,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,Autocuration
1320,,,,,,,1,,10330,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,Autocuration
1321,,,,,,,1,,14331,H,10576,,8,,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Autocuration
1322,Rattus norvegicus,,,10116.0,,,1,,14060,D,10576,,9,,B,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,Expert
1323,,,10000000.0,,,,1,,14744,H,10576,,8,Hippocampus,B,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,Autocuration
1324,,,,,,,1,,13506,H,10576,,8,,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Autocuration
1325,,,955.0,,,,1,,10862,H,10576,,8,Brain,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,Expert
1326,,,955.0,,,,1,,10862,H,10576,,8,Brain,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,Expert
1327,,,,,,,1,,10062,H,10576,,8,,B,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,Expert
1328,,,,,,,1,,12073,H,10576,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,Autocuration
1329,,,,,,,1,,14875,H,106,,8,,B,GTPgammaS radioligand binding assay,,Autocuration
1330,,,,,,,1,,2391,H,106,,8,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,Autocuration
1331,,,,,,,1,,2391,H,106,,8,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,Autocuration
1332,,,,,,,1,,2391,H,106,,8,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,Autocuration
1333,,,,,,,1,,2391,H,106,,8,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,Autocuration
1334,,,,,,,1,,2391,H,106,,8,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,Autocuration
1335,,,,,,,1,,2391,H,106,,8,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,Autocuration
1336,,,,,,,1,,17211,H,106,HeLa,8,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,Expert
1337,,,,,,,1,,17211,H,106,HeLa,8,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,Autocuration
1338,Homo sapiens,,,9606.0,,,1,,6491,D,106,,9,,B,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,Expert
1339,,,,,,,1,,16190,H,106,CHO,8,,B,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Autocuration
1340,,,,,,,1,,14165,H,106,,8,,B,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,Autocuration
1341,,,,,,,1,,14165,H,106,,8,,B,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,Autocuration
1342,Homo sapiens,,,9606.0,,,1,,4234,D,106,,9,,B,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,Expert
1343,,,,,,,1,,6328,H,106,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,Expert
1344,,,,,,,1,,14770,H,106,,8,,B,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,Autocuration
1345,,,,,,,1,,2598,H,106,,8,,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,Autocuration
1346,,,,,,,1,,6897,H,106,,8,,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,Expert
1347,,,,,,,1,,6897,H,106,,8,,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,Autocuration
1348,,,,,,,1,,6013,H,106,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Autocuration
1349,,,,,,,1,,5843,H,106,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Expert
1350,,,,,,,1,,14454,H,106,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,Expert
1351,,,,,,,1,,16209,H,106,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,Autocuration
1352,,,,,,,1,,3935,H,106,,8,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,Autocuration
1353,,,,,,,1,,13729,H,106,CHO-K1,8,,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,Expert
1354,,,,,,,1,,14251,H,106,,8,,F,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,Expert
1355,,,,,,,1,,17085,H,106,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,Expert
1356,,,,,,,1,,3025,H,106,,8,,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,Autocuration
1357,,,,,,,1,,15315,H,106,,8,,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,Expert
1358,Homo sapiens,,,9606.0,,,1,,14214,D,106,,9,,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,Expert
1359,Homo sapiens,,,9606.0,,,1,,3804,D,106,,9,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Expert
1360,Homo sapiens,,,9606.0,,,1,,2391,D,106,,9,,B,Affinity for 5-hydroxytryptamine 1B receptor subtype,,Expert
1361,Homo sapiens,,,9606.0,,,1,,4175,D,106,,9,,B,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Expert
1362,,,,,,,1,,17296,H,106,CHO,8,,B,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,Autocuration
1363,,,,,,,1,,17085,H,106,,8,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,Expert
1364,,,,,,,1,,17211,H,106,HeLa,8,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,Autocuration
1365,,,,,,,1,,17211,H,106,HeLa,8,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,Autocuration
1366,,,,,,,1,,17211,H,106,HeLa,8,,B,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,Autocuration
1367,Homo sapiens,,,9606.0,,,1,,15926,D,106,,9,,B,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,Expert
1368,,,,,,,1,,16312,H,106,CHO-K1,8,,B,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,Autocuration
1369,,,,,,,1,,5843,H,106,,8,,B,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,Expert
1370,,,,,,,1,,5843,H,106,,8,,B,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,Autocuration
1371,,,,,,,1,,16312,H,106,CHO-K1,8,,B,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,Expert
1372,Homo sapiens,,,9606.0,,,1,,15926,D,106,,9,,B,Binding activity against human 5-hydroxytryptamine 1B receptor,,Expert
1373,Homo sapiens,,,9606.0,,,1,,15926,D,106,,9,,B,Binding activity against human 5-hydroxytryptamine 1B receptor,,Expert
1374,Homo sapiens,,,9606.0,,,1,,4540,D,106,CHO,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Expert
1375,,,,,,,1,,6166,H,106,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,Autocuration
1376,,,,,,,1,,17296,H,106,CHO,8,,B,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,Autocuration
1377,,,,,,,1,,17296,H,106,CHO,8,,B,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,Autocuration
1378,,,,,,,1,,17296,H,106,CHO,8,,B,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,Autocuration
1379,,,,,,,1,,15779,H,106,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,Autocuration
1380,,,,,,,1,,15779,H,106,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,Autocuration
1381,,,,,,,1,,15779,H,106,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,Autocuration
1382,,,,,,,1,,4199,H,106,CHO,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,Autocuration
1383,Homo sapiens,,,9606.0,,,1,,14875,D,106,,9,,B,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Expert
1384,,,,,,,1,,15146,H,106,CHO,8,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,Autocuration
1385,,,,,,,1,,5213,H,106,,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,Autocuration
1386,,,,,,,1,,14818,H,106,CHO,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,Autocuration
1387,,,,,,,1,,4829,H,106,CHO,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration
1388,,,,,,,1,,14454,H,106,,8,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,Expert
1389,,,,,,,1,,14454,H,106,,8,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,Expert
1390,,,,,,,1,,14875,H,106,CHO,8,,F,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,Autocuration
1391,,,,,,,1,,14875,H,106,CHO,8,,F,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,Autocuration
1392,,,,,,,1,,15250,H,105,,8,,F,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,Autocuration
1393,,,,,,,1,,15250,H,105,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,Autocuration
1394,,,,,,,1,,15086,H,17105,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,Autocuration
1395,Oryctolagus cuniculus,,,9986.0,,,1,,3025,H,106,,8,,F,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,Autocuration
1396,Oryctolagus cuniculus,,,9986.0,,,1,,14998,H,106,,8,,B,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,Autocuration
1397,Oryctolagus cuniculus,,,9986.0,,,1,,14998,H,106,,8,,B,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,Intermediate
1398,Oryctolagus cuniculus,,,9986.0,,,1,,14998,H,106,,8,,B,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,Autocuration
1399,,,,,,,1,,13969,H,10577,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,Expert
1400,,,,,,,1,,13392,D,10577,,9,,B,Binding affinity for 5-hydroxytryptamine 1B receptor,,Intermediate
1401,Rattus norvegicus,,2435.0,10116.0,,,1,,3651,D,10577,,9,Striatum,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,Expert
1402,,,,,,,1,,10025,H,10577,,8,,B,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,Expert
1403,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,Autocuration
1404,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,Autocuration
1405,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,Autocuration
1406,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,Autocuration
1407,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,Autocuration
1408,,,,,,,1,,13863,H,10576,,8,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,Autocuration
1409,,,10000000.0,,,,1,,4622,H,10576,,8,Hippocampus,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,Autocuration
1410,,,,,,,1,,14911,H,10576,,8,,B,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,Intermediate
1411,,,10000000.0,,,,1,,12678,H,10576,,8,Hippocampus,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,Autocuration
1412,,,10000000.0,,,,1,,12678,H,10576,,8,Hippocampus,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,Expert
1413,,,10000000.0,,,,1,,14235,H,10576,,8,Hippocampus,B,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Expert
1414,,,10000000.0,,,,1,,14949,H,10576,,8,Hippocampus,B,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,Expert
1415,,,10000000.0,,,,1,,14949,H,10576,,8,Hippocampus,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,Expert
1416,,,10000000.0,,,,1,,14949,H,10576,,8,Hippocampus,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,Expert
1417,,,10000000.0,,,,1,,14949,H,10576,,8,Hippocampus,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,Expert
1418,,,10000000.0,,,,1,,14949,H,10576,,8,Hippocampus,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,Expert
1419,,,,,,,1,,16118,H,10576,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,Expert
1420,,,,,,,1,,3268,H,10576,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,Autocuration
1421,,,,,,,1,,3268,H,10576,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,Autocuration
1422,,,,,,,1,,16117,H,10576,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,Expert
1423,,,10000000.0,,,,1,,9783,H,10576,,8,Hippocampus,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,Expert
1424,,,10000000.0,,,,1,,9783,H,10576,,8,Hippocampus,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,Autocuration
1425,Rattus norvegicus,,10000000.0,10116.0,,,1,,14356,D,10576,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,Expert
1426,,,,,,,1,,15740,H,10576,,8,,F,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,Autocuration
1427,,,10000000.0,,,,1,,12306,H,10576,,8,Hippocampus,B,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,Autocuration
1428,Rattus norvegicus,,10000000.0,10116.0,,,1,,13348,D,10576,,9,Hippocampus,B,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,Expert
1429,,,,,,,1,,10394,H,10576,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,Autocuration
1430,,,10000000.0,,,,1,,15260,H,10576,,8,Hippocampus,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,Autocuration
1431,,,10000000.0,,,,1,,10046,H,10576,,8,Hippocampus,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,Expert
1432,,,10000000.0,,,,1,,15260,H,10576,,8,Hippocampus,F,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,Intermediate
1433,,,,,,,1,,12851,H,10576,,8,,B,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,Autocuration
1434,Rattus norvegicus,,10000000.0,10116.0,,,1,,2148,D,10576,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,Expert
1435,,,,,,,1,,13134,H,10576,,8,,B,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,Expert
1436,,,,,,,1,,12462,H,10576,,8,,B,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,Autocuration
1437,,,,,,,1,,12462,H,10576,,8,,B,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,Expert
1438,,,,,,,1,,12462,H,10576,CHO,8,,B,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,Autocuration
1439,,,,,,,1,,11933,H,10576,,8,,B,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,Expert
1440,,,,,,,1,,11933,H,10576,,8,,B,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,Autocuration
1441,Rattus norvegicus,,10000000.0,10116.0,,,1,,403,D,10576,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,Expert
1442,,,10000000.0,,,,1,,15538,H,10576,,8,Hippocampus,B,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
1443,,,10000000.0,,,,1,,15538,H,10576,,8,Hippocampus,B,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,Autocuration
1444,,,10000000.0,,,,1,,15538,H,10576,,8,Hippocampus,B,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,Autocuration
1445,,,,,,,1,,12464,H,10576,,8,,B,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,Intermediate
1446,,,,,,,1,,1455,H,10576,,8,,B,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,Expert
1447,,,,,,,1,,12652,H,10576,,8,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,Autocuration
1448,,,10000000.0,,,,1,,12639,H,10576,,8,Hippocampus,B,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,Autocuration
1449,,,,,,,1,,13949,H,10576,,8,,B,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,Expert
1450,Rattus norvegicus,,,10116.0,,,1,,12463,D,10576,,9,,B,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,Expert
1451,,,10000000.0,,,,1,,14829,H,10576,,8,Hippocampus,B,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,Expert
1452,,,10000000.0,,,,1,,14829,H,10576,,8,Hippocampus,B,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,Autocuration
1453,,,,,,,1,,12092,H,10576,,8,,B,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,Autocuration
1454,,,,,,,1,,403,H,10576,,8,,B,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,Autocuration
1455,,,,,,,1,,403,H,10576,,8,,B,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,Autocuration
1456,,,,,,,1,,3967,H,10576,,8,,B,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,Expert
1457,Rattus norvegicus,,,10116.0,,,1,,12771,D,10576,,9,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,Expert
1458,,,,,,,1,,15086,H,10576,,8,,B,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,Autocuration
1459,,,10000000.0,,,,1,,14909,H,10576,,8,Hippocampus,B,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,Autocuration
1460,,,10000000.0,,,,1,,14949,H,10576,,8,Hippocampus,B,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,Expert
1461,Rattus norvegicus,,10000000.0,10116.0,,,1,,2309,D,10576,,9,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,Expert
1462,,,,,,,1,,4170,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Expert
1463,Rattus norvegicus,,10000000.0,10116.0,,,1,,11642,D,10576,,9,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,Expert
1464,,,10000000.0,,,,1,,11642,H,10576,,8,Hippocampus,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,Autocuration
1465,,,10000000.0,,,,1,,12953,H,10576,,8,Hippocampus,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,Autocuration
1466,,,10000000.0,,,,1,,12953,H,10576,,8,Hippocampus,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,Autocuration
1467,,,10000000.0,,,,1,,12953,H,10576,,8,Hippocampus,B,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,Expert
1468,,,,,,,1,,12903,H,10576,CHO,8,,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,Expert
1469,,,,,,,1,,12536,H,10576,,8,,B,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Expert
1470,,,,,,,1,,10058,H,10576,,8,,B,The inhibition activity of 5-HT1A at 1 uM,,Autocuration
1471,,,,,,,1,,12902,H,10576,CHO-K1,8,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,Expert
1472,,,,,,,1,,14057,H,10576,,8,,B,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,Expert
1473,,,,,,,1,,11296,H,10576,,8,,B,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,Autocuration
1474,,,10000000.0,,,,1,,11296,H,10576,,8,Hippocampus,B,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,Autocuration
1475,,,10000000.0,,,,1,,11296,H,10576,,8,Hippocampus,B,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,Expert
1476,Rattus norvegicus,,,10116.0,,,1,,16616,D,10576,,9,,F,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Membranes,Expert
1477,Rattus norvegicus,,10000000.0,10116.0,,,1,,16616,D,10576,,9,Hippocampus,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,Expert
1478,,,,,,,1,,16567,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,Autocuration
1479,,,,,,,1,,16567,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,Autocuration
1480,,,,,,,1,,16567,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,Autocuration
1481,,,,,,,1,,16567,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,Autocuration
1482,,,,,,,1,,17136,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,Autocuration
1483,,,,,,,1,,17136,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,Autocuration
1484,Rattus norvegicus,,,10116.0,,,1,,16616,D,10576,,9,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,Expert
1485,,,10000000.0,,,,1,,17331,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,Autocuration
1486,,,10000000.0,,,,1,,17331,H,10576,,8,Hippocampus,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,Autocuration
1487,Rattus norvegicus,,10000000.0,10116.0,,,1,,17167,D,10576,,9,Hippocampus,B,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,Expert
1488,,,,,,,1,,15740,H,10576,,8,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,Autocuration
1489,,,,,,,1,,15740,H,10576,,8,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,Autocuration
1490,,,,,,,1,,4671,H,10576,,8,,B,Ratio of binding affinity to 5-HT 1A and D2 receptor,,Autocuration
1491,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,Autocuration
1492,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,Autocuration
1493,,,10000000.0,,,,1,,10058,H,10576,,8,Hippocampus,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,Autocuration
1494,,,,,,,1,,12073,H,10576,,8,,B,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,Autocuration
1495,,,,,,,1,,2759,H,10576,,8,,B,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,Autocuration
1496,,,,,,,1,,2759,H,10576,,8,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,Autocuration
1497,,,,,,,1,,2759,H,10576,,8,,B,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,Autocuration
1498,,,,,,,1,,2759,H,10576,,8,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,Autocuration
1499,,,,,,,1,,2759,H,10576,,8,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,Autocuration
1500,,,955.0,,,,1,,9737,H,10576,,8,Brain,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,Autocuration
1501,,,,,,,1,,9737,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,Autocuration
1502,,,,,,,1,,5717,H,10576,,8,,F,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,Expert
1503,,,10000000.0,,,,1,,12253,H,10576,,8,Hippocampus,B,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,Autocuration
1504,,,,,,,1,,14025,H,10576,,8,,B,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,Autocuration
1505,,,,,,,1,,10425,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,Expert
1506,,,,,,,1,,14998,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,Autocuration
1507,,,10000000.0,,,,1,,13694,H,10576,,8,Hippocampus,B,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,Autocuration
1508,,,10000000.0,,,,1,,13694,H,10576,,8,Hippocampus,B,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,Autocuration
1509,,,,,,,1,,4342,H,10576,,8,,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,Autocuration
1510,Rattus norvegicus,,,10116.0,,,1,,12936,D,10576,,9,,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Expert
1511,Rattus norvegicus,,,10116.0,,,1,,13144,D,10576,,9,,B,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,Expert
1512,,,,,,,1,,13343,H,10576,,8,,B,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,Expert
1513,,,,,,,1,,12132,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,Expert
1514,,,,,,,1,,15419,H,10576,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,Expert
1515,,,10000000.0,,,,1,,1479,H,10576,,8,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,Autocuration
1516,,,,,,,1,,14287,H,10576,,8,,B,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,Expert
1517,,,,,,,1,,13116,H,10576,,8,,B,Binding affinity at 5-hydroxytryptamine 1A receptor,,Expert
1518,Rattus norvegicus,,,10116.0,,,1,,2759,D,10576,,9,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Membranes,Expert
1519,,,,,,,1,,2759,H,10576,,8,,B,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,Autocuration
1520,,,,,,,1,,14748,H,10576,,8,,B,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,Expert
1521,,,,,,,1,,12304,H,10576,,8,,B,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,Autocuration
1522,Rattus norvegicus,,10000000.0,10116.0,,,1,,12409,D,10576,,9,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,Expert
1523,Rattus norvegicus,,10000000.0,10116.0,,,1,,12409,D,10576,,9,Hippocampus,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,Expert
1524,,,10000000.0,,,,1,,13267,H,10576,,8,Hippocampus,B,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,Autocuration
1525,,,,,,,1,,15194,H,10576,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,Autocuration
1526,,,,,,,1,,14256,H,10576,,8,,B,pKi value against rat 5-hydroxytryptamine 1A receptor.,,Expert
1527,,,,,,,1,,16567,H,10576,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,Autocuration
1528,,,,,,,1,,15740,H,10576,,8,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,Autocuration
1529,Rattus norvegicus,,,10116.0,,,1,,13278,D,12687,,9,,B,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Expert
1530,,,,,,,1,,1970,H,10626,,8,,B,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,Expert
1531,,,955.0,,,,1,,10034,H,10576,,8,Brain,B,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,Autocuration
1532,Rattus norvegicus,,,10116.0,,,1,,13348,H,51,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,Autocuration
1533,,,,,,,1,,13630,H,10576,,8,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,Autocuration
1534,,,955.0,,,,1,,10862,H,10576,,8,Brain,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,Autocuration
1535,,,,,,,1,,12058,H,10576,,8,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Autocuration
1536,,,,,,,1,,4639,H,51,,8,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
1537,,,,,,,1,,15453,H,51,,8,,B,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,Expert
1538,,,,,,,1,,4820,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Expert
1539,,,,,,,1,,1089,H,51,,8,,B,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,Autocuration
1540,,,,,,,1,,386,H,51,,8,,B,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Brain membranes,Autocuration
1541,,,,,,,1,,6011,H,51,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,Autocuration
1542,,,,,,,1,,5014,H,51,,8,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,Autocuration
1543,,,,,,,1,,4402,H,51,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,Expert
1544,,,,,,,1,,17066,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Expert
1545,,,,,,,1,,17515,H,51,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,Autocuration
1546,,,,,,,1,,2474,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
1547,,,,,,,1,,4775,H,51,,8,,B,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,Autocuration
1548,Homo sapiens,,,9606.0,,,1,,14294,D,51,,9,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,Expert
1549,Homo sapiens,,,9606.0,,,1,,14294,D,51,,9,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,Expert
1550,,,,,,,1,,12249,H,51,CHO,8,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration
1551,,,,,,,1,,11376,H,51,,8,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,Expert
1552,,,,,In vivo,,1,,2474,H,51,,8,,B,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration
1553,,,10000000.0,,,,1,,13311,H,51,,8,Hippocampus,B,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,Autocuration
1554,,,,,,,1,,4373,H,51,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,Autocuration
1555,,,,,,,1,,1633,H,51,,8,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,Expert
1556,,,,,,,1,,11866,H,51,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,Autocuration
1557,,,,,,,1,,4373,H,51,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,Autocuration
1558,,,,,,,1,,4687,H,51,,8,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,Autocuration
1559,,,,,,,1,,16946,H,11863,,8,,B,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Autocuration
1560,,,,,,,1,,13291,H,11863,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,Autocuration
1561,,,,,,,1,,14159,H,11863,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,Autocuration
1562,,,,,,,1,,10812,H,11863,,8,,B,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,Autocuration
1563,Mus musculus,,,10090.0,,,1,,3032,D,11863,CHO,9,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,Expert
1564,,,,,,,1,,16655,H,11863,,8,,B,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Autocuration
1565,,,,,,,1,,14532,H,11863,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,Autocuration
1566,,,,,,,1,,13944,H,11863,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
1567,,,,,,,1,,13033,H,11863,,8,,B,Binding affinity against serotonergic 5-HT1a receptor,,Autocuration
1568,,,,,,,1,,10321,H,11863,,8,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,Autocuration
1569,Mus musculus,,,10090.0,,,1,,2968,D,11863,,9,,B,Binding affinity for 5-hydroxytryptamine 1A receptor,,Expert
1570,,,,,,,1,,13964,H,11863,,8,,B,Binding affinity at 5-hydroxytryptamine 1A receptor,,Autocuration
1571,,,,,,,1,,15527,H,11863,,8,,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,Autocuration
1572,,,,,,,1,,12248,H,11863,CHO,8,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration
1573,,,,,,,1,,12249,H,11863,CHO,8,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration
1574,,,,,,,1,,15120,H,11863,,8,,B,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,Autocuration
1575,,,,,,,1,,13313,H,11863,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,Autocuration
1576,,,,,,,1,,2613,H,11863,,8,,B,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,Autocuration
1577,,,,,,,1,,16700,H,11863,,8,,B,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,Autocuration
1578,,,,,,,1,,2201,H,11863,,8,,B,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,Autocuration
1579,Mus musculus,,,10090.0,,,1,,1274,D,11863,,9,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Expert
1580,,,,,,,1,,1317,H,11863,,8,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,Autocuration
1581,,,,,,,1,,12146,H,11863,,8,,B,Tested against 5-hydroxytryptamine 1A receptor,,Autocuration
1582,,,,,,,1,,14059,H,11863,,8,,B,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
1583,Oryctolagus cuniculus,,,9986.0,,,1,,14025,H,106,,8,,B,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,Expert
1584,Oryctolagus cuniculus,,,9986.0,,,1,,14025,H,106,,8,,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,Autocuration
1585,Gorilla gorilla,,,9593.0,,,1,,14447,D,105571,HEK293,9,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Intermediate
1586,Cavia porcellus,,,10141.0,In vivo,,1,,3025,H,106,,8,,F,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Autocuration
1587,Cavia porcellus,,,10141.0,In vivo,,1,,3025,H,106,,8,,F,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Autocuration
1588,Cavia porcellus,,,10141.0,,,1,,15329,H,106,,8,,F,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,Autocuration
1589,Cavia porcellus,,,10141.0,,,1,,15329,H,106,,8,,F,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,Autocuration
1590,Cavia porcellus,,,10141.0,,,1,,15847,H,106,,8,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,Autocuration
1591,Cavia porcellus,,,10141.0,,,1,,15847,H,106,,8,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,Autocuration
1592,,,,,,,1,,14165,H,106,,8,,F,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,Autocuration
1593,,,,,,,1,,14214,H,106,,8,,F,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,Autocuration
1594,,,,,,,1,,14214,H,106,,8,,F,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,Autocuration
1595,Homo sapiens,,,9606.0,,,1,,14214,D,106,,9,,F,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,Expert
1596,Homo sapiens,,,9606.0,,,1,,13729,D,106,CHO-K1,9,,F,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,Expert
1597,,,,,,,1,,3025,H,106,CHO,8,,F,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,Autocuration
1598,,,,,,,1,,2391,H,106,,8,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,Autocuration
1599,,,,,,,1,,2391,H,106,,8,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,Autocuration
1600,,,,,,,1,,14956,H,106,CHO,8,,F,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,Expert
1601,,,,,,,1,,2598,H,106,CHO,8,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,Autocuration
1602,,,,,,,1,,2598,H,106,CHO,8,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,Autocuration
1603,,,,,,,1,,2598,H,106,CHO,8,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,Autocuration
1604,,,,,,,1,,2598,H,106,CHO,8,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,Autocuration
1605,,,,,,,1,,14956,H,106,,8,,F,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,Expert
1606,,,,,,,1,,14956,H,106,,8,,F,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,Autocuration
1607,Homo sapiens,,,9606.0,,,1,,14214,D,106,,9,,B,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,Expert
1608,,,,,,,1,,3463,H,106,CHO,8,,B,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,Expert
1609,,,,,,,1,,15331,H,106,,8,,B,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,Autocuration
1610,Homo sapiens,,,9606.0,,,1,,16146,D,106,,9,,B,Binding affinity against 5-hydroxytryptamine 1B receptor,,Expert
1611,Homo sapiens,,,9606.0,,,1,,14159,D,106,CHO,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Expert
1612,,,,,,,1,,14158,H,106,CHO,8,,B,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,Expert
1613,,,,,,,1,,14159,H,106,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,Autocuration
1614,,,,,,,1,,15250,H,106,CHO,8,,B,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,Expert
1615,,,,,,,1,,15250,H,106,CHO,8,,B,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,Expert
1616,,,,,,,1,,15331,H,106,CHO,8,,B,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,Expert
1617,,,,,,,1,,15332,H,106,CHO,8,,B,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,Expert
1618,,,,,,,1,,14956,H,106,CHO,8,,B,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Expert
1619,,,,,,,1,,3805,H,106,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,Autocuration
1620,,,,,,,1,,14875,H,106,,8,,B,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,Autocuration
1621,Oryctolagus cuniculus,,,9986.0,,,1,,14454,H,105,,8,,F,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Autocuration
1622,Oryctolagus cuniculus,,,9986.0,,,1,,14454,H,105,,8,,F,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Expert
1623,,,,,,,1,,16288,H,105,,8,,B,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,Autocuration
1624,,,,,,,1,,16288,H,105,,8,,B,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,Autocuration
1625,,,,,,,1,,16312,H,105,,8,,B,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,Autocuration
1626,Bos taurus,,,9913.0,,,1,,1348,H,105,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,Expert
1627,Bos taurus,,,9913.0,,,1,,5834,H,105,,8,,B,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,Autocuration
1628,Bos taurus,,2435.0,9913.0,,,1,,13366,H,105,,8,Striatum,B,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,Autocuration
1629,Bos taurus,,,9913.0,,,1,,1414,H,105,,8,,B,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,Expert
1630,Bos taurus,,,9913.0,,,1,,14998,H,105,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,Autocuration
1631,Bos taurus,,,9913.0,,,1,,11473,H,105,,8,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Autocuration
1632,Bos taurus,,,9913.0,,,1,,11473,H,105,,8,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Autocuration
1633,Bos taurus,,,9913.0,,,1,,10639,H,105,,8,,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Autocuration
1634,Bos taurus,,,9913.0,,,1,,10639,H,105,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Autocuration
1635,Bos taurus,,,9913.0,,,1,,1375,H,105,,8,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,Autocuration
1636,Bos taurus,,,9913.0,,,1,,1375,H,105,,8,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,Autocuration
1637,Bos taurus,,,9913.0,,,1,,16532,H,105,,8,,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Autocuration
1638,Bos taurus,,,9913.0,,,1,,11147,H,105,,8,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,Autocuration
1639,Bos taurus,,2435.0,9913.0,,,1,,13366,H,105,,8,Striatum,B,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,Autocuration
1640,Bos taurus,,,9913.0,,,1,,10444,H,105,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,Autocuration
1641,Bos taurus,,,9913.0,,,1,,16532,H,105,,8,,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,Autocuration
1642,Bos taurus,,,9913.0,,,1,,16532,H,105,,8,,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Autocuration
1643,Bos taurus,,,9913.0,,,1,,12827,H,105,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,Autocuration
1644,Bos taurus,,,9913.0,,,1,,12827,H,105,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,Autocuration
1645,Bos taurus,,,9913.0,,,1,,12919,H,105,,8,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert
1646,Bos taurus,,,9913.0,,,1,,14025,H,105,,8,,B,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,Autocuration
1647,Bos taurus,,,9913.0,,,1,,12919,H,105,,8,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert
1648,Bos taurus,,,9913.0,,,1,,12919,H,105,,8,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert
1649,Bos taurus,,,9913.0,,,1,,12919,H,105,,8,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert
1650,Gorilla gorilla,,,9593.0,,,1,,14447,H,105,HEK293,8,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Autocuration
1651,Cavia porcellus,,,10141.0,,,1,,1375,D,105570,,9,,B,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,Intermediate
1652,Cavia porcellus,,,10141.0,,,1,,1375,D,105570,,9,,B,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,Intermediate
1653,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,Intermediate
1654,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate
1655,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,Intermediate
1656,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,Intermediate
1657,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,Intermediate
1658,Cavia porcellus,,,10141.0,,,1,,11574,D,105570,,9,,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,Intermediate
1659,Cavia porcellus,,,10141.0,,,1,,1558,D,105570,,9,,B,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,Intermediate
1660,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate
1661,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate
1662,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate
1663,Cavia porcellus,,,10141.0,,,1,,12409,D,105570,,9,,F,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,Intermediate
1664,Cavia porcellus,,,10141.0,,,1,,12253,D,105570,,9,,B,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,Intermediate
1665,Cavia porcellus,,,10141.0,,,1,,12936,D,105570,,9,,B,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,Intermediate
1666,Cavia porcellus,,,10141.0,,,1,,13181,H,105,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,Autocuration
1667,Cavia porcellus,,2435.0,10141.0,,,1,,12409,D,105570,,9,Striatum,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,Intermediate
1668,Cavia porcellus,,,10141.0,,,1,,10639,D,105570,,9,,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,Intermediate
1669,,,,,,,1,,5254,H,51,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration
1670,,,,,,,1,,13051,H,106,,8,,B,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,Autocuration
1671,,,,,,,1,,3463,H,105,,8,,F,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,Expert
1672,,,,,,,1,,15315,H,105,,8,,F,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,Autocuration
1673,,,,,,,1,,6011,H,105,,8,,F,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,Autocuration
1674,Homo sapiens,,,9606.0,,,1,,14159,D,105,CHO,9,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,Expert
1675,,,,,,,1,,14159,H,105,CHO,8,,F,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,Autocuration
1676,,,,,,,1,,15250,H,105,CHO,8,,B,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,Expert
1677,,,,,,,1,,15250,H,105,CHO,8,,B,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,Autocuration
1678,,,,,,,1,,15331,H,105,CHO,8,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Expert
1679,Homo sapiens,,,9606.0,,,1,,15332,D,105,CHO,9,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Expert
1680,,,,,,,1,,15332,H,105,CHO,8,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,Expert
1681,,,,,,,1,,3294,H,105,CHO,8,,F,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,Autocuration
1682,,,,,,,1,,14158,H,105,CHO,8,,F,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,Expert
1683,,,,,,,1,,14956,H,105,CHO,8,,F,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,Expert
1684,,,,,,,1,,12469,H,105,,8,,F,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,Autocuration
1685,,,,,,,1,,3463,H,105,CHO,8,,F,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,Expert
1686,Homo sapiens,,,9606.0,,,1,,15250,D,105,CHO,9,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Expert
1687,Homo sapiens,,,9606.0,,,1,,15250,D,105,CHO,9,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Expert
1688,,,,,,,1,,14956,H,105,,8,,F,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,Expert
1689,,,,,,,1,,14159,H,105,,8,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,Autocuration
1690,Homo sapiens,,,9606.0,,,1,,14159,D,105,,9,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,Expert
1691,Homo sapiens,,,9606.0,,,1,,14499,D,105,CHO,9,,F,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,Expert
1692,,,,,,,1,,15315,H,105,,8,,F,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,Autocuration
1693,,,,,In vitro,,1,,3294,H,105,,8,,B,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,Autocuration
1694,,,,,,,1,,3463,H,105,CHO,8,,B,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,Expert
1695,,,,,,,1,,15331,H,105,,8,,B,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,Autocuration
1696,Homo sapiens,,,9606.0,,,1,,14159,D,105,CHO,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert
1697,,,,,,,1,,14158,H,105,CHO,8,,B,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,Expert
1698,,,,,,,1,,14159,H,105,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,Autocuration
1699,,,,,,,1,,15250,H,105,CHO,8,,B,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,Expert
1700,,,,,,,1,,15250,H,105,CHO,8,,B,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,Expert
1701,,,,,,,1,,15331,H,105,CHO,8,,B,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,Expert
1702,Homo sapiens,,,9606.0,,,1,,15332,D,105,CHO,9,,B,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert
1703,Homo sapiens,,,9606.0,,,1,,14499,D,105,CHO,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert
1704,,,,,,,1,,15332,H,105,CHO,8,,B,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,Expert
1705,,,,,,,1,,14956,H,105,CHO,8,,B,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert
1706,,,,,,,1,,3805,H,105,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,Autocuration
1707,Homo sapiens,,,9606.0,,,1,,6011,D,105,CHO,9,,B,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,Expert
1708,,,,,,,1,,16190,H,105,CHO,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Autocuration
1709,,,,,,,1,,14165,H,105,,8,,B,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,Autocuration
1710,Homo sapiens,,,9606.0,,,1,,4234,D,105,,9,,B,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,Expert
1711,,,,,,,1,,15527,H,105,,8,,B,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,Autocuration
1712,,,,,,,1,,6328,H,105,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,Expert
1713,,,,,,,1,,16209,H,105,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,Autocuration
1714,,,,,,,1,,14770,H,105,,8,,B,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,Autocuration
1715,,,,,,,1,,2598,H,105,,8,,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,Autocuration
1716,,,,,,,1,,6897,H,105,,8,,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,Expert
1717,,,,,,,1,,6013,H,105,,8,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor,,Autocuration
1718,,,,,,,1,,5843,H,105,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,Expert
1719,,,,,,,1,,14454,H,105,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,Expert
1720,,,,,,,1,,14454,H,105,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,Autocuration
1721,,,,,,,1,,14454,H,105,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,Autocuration
1722,,,,,,,1,,15818,H,105,,8,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,Autocuration
1723,,,,,,,1,,13729,H,105,CHO-K1,8,,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,Expert
1724,Homo sapiens,,,9606.0,In vitro,,1,,6011,D,105,,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,Expert
1725,Homo sapiens,,,9606.0,,,1,,4234,D,105,,9,,B,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,Expert
1726,,,,,,,1,,17085,H,105,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,Expert
1727,,,,,,,1,,3025,H,105,,8,,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,Autocuration
1728,,,,,,,1,,15315,H,105,,8,,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,Expert
1729,Homo sapiens,,,9606.0,,,1,,14214,D,105,,9,,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,Expert
1730,Homo sapiens,,,9606.0,,,1,,3804,D,105,,9,,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Expert
1731,,,,,,,1,,16700,H,105,,8,,B,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,Autocuration
1732,Homo sapiens,,,9606.0,,,1,,2391,D,105,,9,,B,Affinity for 5-hydroxytryptamine 1D receptor subtype,,Expert
1733,Homo sapiens,,,9606.0,,,1,,4175,D,105,,9,,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Expert
1734,,,,,,,1,,17085,H,105,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,Autocuration
1735,,,,,,,1,,17085,H,105,,8,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,Expert
1736,Homo sapiens,,,9606.0,,,1,,15926,D,105,,9,,B,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,Expert
1737,,,,,,,1,,16312,H,105,CHO-K1,8,,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,Autocuration
1738,,,,,,,1,,16312,H,105,CHO-K1,8,,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,Autocuration
1739,,,,,,,1,,14956,H,104802,CHO,4,,B,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,Autocuration
1740,,,,,,,1,,3294,H,105,,8,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,Autocuration
1741,,,,,,,1,,12861,H,105,,8,,B,Binding activity radioligand.,,Autocuration
1742,,,,,,,1,,12861,H,105,,8,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Autocuration
1743,,,,,,,1,,16312,H,105,CHO-K1,8,,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,Expert
1744,,,,,,,1,,5104,H,105,,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,Autocuration
1745,,,,,,,1,,5105,H,105,,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,Autocuration
1746,,,,,,,1,,14499,H,105,,8,,B,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,Autocuration
1747,Homo sapiens,,,9606.0,,,1,,15926,D,105,,9,,B,Binding activity against human 5-hydroxytryptamine 1D receptor,,Expert
1748,Homo sapiens,,,9606.0,,,1,,4540,D,105,CHO,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Expert
1749,,,,,,,1,,15779,H,105,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,Autocuration
1750,,,,,,,1,,15779,H,105,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration
1751,,,,,,,1,,6166,H,105,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,Autocuration
1752,,,,,,,1,,15779,H,105,CHO,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,Autocuration
1753,,,,,,,1,,15779,H,105,CHO,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,Autocuration
1754,,,,,,,1,,17451,H,105,HEK293,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,Autocuration
1755,,,,,,,1,,17451,H,105,HEK293,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,Autocuration
1756,,,,,,,1,,17451,H,105,HEK293,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,Autocuration
1757,,,,,,,1,,4199,H,105,CHO,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,Autocuration
1758,Homo sapiens,,,9606.0,,,1,,14875,D,105,,9,,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Expert
1759,,,,,,,1,,15146,H,105,CHO,8,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,Autocuration
1760,,,,,,,1,,5213,H,105,,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,Autocuration
1761,,,,,,,1,,14818,H,105,CHO,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,Autocuration
1762,,,,,,,1,,4829,H,105,CHO,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration
1763,,,,,,,1,,14454,H,105,,8,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,Expert
1764,,,,,,,1,,14454,H,105,,8,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,Expert
1765,,,,,,,1,,5254,H,108,,8,,B,Binding affinity against 5-HT2C receptor,,Autocuration
1766,,,,,,,1,,5254,H,108,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration
1767,,,,,,,1,,10639,H,10577,,8,,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,Autocuration
1768,,,,,,,1,,10639,H,10577,,8,,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,Autocuration
1769,,,,,,,1,,12352,H,10577,,8,,B,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,Expert
1770,,,,,,,1,,9098,H,10577,,8,,B,Binding affinity towards 5-HT1B was determined,,Autocuration
1771,,,,,,,1,,14430,H,10577,,8,,B,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,Expert
1772,,,,,,,1,,13657,H,10577,,8,,B,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,Expert
1773,,,,,,,1,,13657,H,10577,,8,,B,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,Autocuration
1774,,,,,,,1,,15854,H,10577,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,Expert
1775,Rattus norvegicus,,,10116.0,,,1,,10639,D,10577,,9,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,Expert
1776,,,,,,,1,,10025,H,10577,,8,,B,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,Autocuration
1777,,,,,,,1,,10025,H,10577,,8,,B,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,Autocuration
1778,,,,,,,1,,14286,H,10577,,8,,B,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,Autocuration
1779,,,2435.0,,,,1,,3651,H,10577,,8,Striatum,B,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,Autocuration
1780,Rattus norvegicus,,,10116.0,,,1,,14178,D,10577,,9,,B,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,Expert
1781,,,,,,,1,,10639,H,10577,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,Autocuration
1782,,,2435.0,,,,1,,13605,H,10577,,8,Striatum,B,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,Autocuration
1783,,,2435.0,,,,1,,5834,H,10577,,8,Striatum,B,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,Autocuration
1784,,,2435.0,,,,1,,10922,H,10577,,8,Striatum,B,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,Autocuration
1785,,,,,,,1,,14286,H,10577,,8,,B,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,Autocuration
1786,,,,,,,1,,11825,H,10577,,8,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,Autocuration
1787,,,2435.0,,,,1,,14826,H,10577,,8,Striatum,B,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,Autocuration
1788,,,2435.0,,,,1,,9699,H,10577,,8,Striatum,B,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,Autocuration
1789,,,,,,,1,,14423,H,10577,,8,,B,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,Autocuration
1790,,,,,,,1,,10062,H,10577,,8,,B,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,Expert
1791,,,,,,,1,,10062,H,10577,,8,,B,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,Autocuration
1792,Rattus norvegicus,,,10116.0,,,1,,12280,D,10577,,9,,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,Expert
1793,,,2435.0,,,,1,,15412,H,10577,,8,Striatum,B,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,Autocuration
1794,,,2435.0,,,,1,,15412,H,10577,,8,Striatum,B,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,Autocuration
1795,,,,,,,1,,10062,H,10577,,8,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,Autocuration
1796,,,,,,,1,,11147,H,10577,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,Autocuration
1797,,,,,,,1,,9547,H,10577,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,Autocuration
1798,,,,,,,1,,10444,H,10577,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,Autocuration
1799,,,2435.0,,,,1,,12469,H,10577,,8,Striatum,B,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,Autocuration
1800,,,,,,,1,,9098,H,10577,,8,,B,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,Expert
1801,,,,,,,1,,9098,H,10577,,8,,B,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,Autocuration
1802,,,,,,,1,,9699,H,10577,,8,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,Autocuration
1803,,,,,,,1,,10394,H,10577,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,Autocuration
1804,,,,,,,1,,12092,H,10577,,8,,B,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,Autocuration
1805,,,,,,,1,,16700,H,10577,,8,,B,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,Autocuration
1806,Rattus norvegicus,,,10116.0,,,1,,403,D,10577,,9,,B,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,Expert
1807,Rattus norvegicus,,,10116.0,,,1,,12771,D,10577,,9,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Expert
1808,,,,,,,1,,11642,H,10577,,8,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,Autocuration
1809,,,,,,,1,,12953,H,10577,,8,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,Autocuration
1810,,,,,,,1,,12953,H,10577,,8,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,Autocuration
1811,,,2435.0,,,,1,,12953,H,10577,,8,Striatum,B,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,Expert
1812,,,,,,,1,,12953,H,10577,,8,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,Autocuration
1813,,,955.0,,,,1,,9737,H,10577,,8,Brain,B,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,Autocuration
1814,,,,,,,1,,9737,H,10577,,8,,B,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,Autocuration
1815,,,955.0,,,,1,,9737,H,10577,,8,Brain,B,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,Autocuration
1816,,,,,,,1,,12827,H,10577,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,Autocuration
1817,,,,,,,1,,5033,H,10577,,8,,B,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,Autocuration
1818,Rattus norvegicus,,,10116.0,,,1,,9786,D,10577,,9,,B,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,Expert
1819,,,,,,,1,,13116,H,10577,,8,,B,Binding affinity at 5-hydroxytryptamine 1B receptor,,Expert
1820,,,,,,,1,,16429,H,10577,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,Autocuration
1821,Rattus norvegicus,,,10116.0,,,1,,12409,D,10577,,9,,B,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,Expert
1822,,,,,,,1,,15194,H,10577,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,Autocuration
1823,,,,,,,1,,15194,H,10577,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,Autocuration
1824,,,,,,,1,,5486,H,104686,,4,,B,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,Autocuration
1825,,,,,,,1,,4639,H,106,,8,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,Autocuration
1826,,,,,,,1,,386,H,106,,8,,B,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Brain membranes,Autocuration
1827,,,,,,,1,,2474,H,106,,8,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,Autocuration
1828,,,,,,,1,,6011,H,106,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,Autocuration
1829,,,,,,,1,,5014,H,106,,8,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,Autocuration
1830,,,,,,,1,,17515,H,106,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,Autocuration
1831,,,,,,,1,,4373,H,106,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,Autocuration
1832,,,,,,,1,,1633,H,106,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,Expert
1833,,,,,,,1,,1633,H,106,,8,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,Autocuration
1834,,,,,,,1,,4373,H,106,,8,,B,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,Autocuration
1835,,,,,,,1,,4687,H,106,,8,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,Autocuration
1836,,,,,,,1,,11574,H,106,,8,,B,Binding affinity against 5-hydroxytryptamine 1B receptor,,Autocuration
1837,,,,,,,1,,10321,H,106,,8,,B,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,Autocuration
1838,,,,,,,1,,15527,H,106,,8,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,Autocuration
1839,,,,,,,1,,17200,H,106,,8,,B,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,Autocuration
1840,,,,,,,1,,14423,H,104802,,4,,B,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,Autocuration
1841,Bos taurus,,,9913.0,,,1,,5834,H,108,,8,,B,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,Autocuration
1842,Sus scrofa,,,9823.0,,,1,,11473,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Autocuration
1843,Sus scrofa,,,9823.0,,,1,,11473,H,108,,8,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,Autocuration
1844,Sus scrofa,,,9823.0,,,1,,10639,H,108,,8,,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Autocuration
1845,Sus scrofa,,,9823.0,,,1,,10639,H,108,,8,,B,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Autocuration
1846,Sus scrofa,,,9823.0,,,1,,14331,H,108,,8,,B,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,Autocuration
1847,Sus scrofa,,,9823.0,,,1,,10796,H,108,,8,,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,Autocuration
1848,Sus scrofa,,,9823.0,,,1,,9098,H,108,,8,,B,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,Expert
1849,Sus scrofa,,,9823.0,,,1,,14331,H,108,,8,,B,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,Expert
1850,Sus scrofa,,,9823.0,,,1,,11828,H,108,,8,,B,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,Expert
1851,Sus scrofa,,,9823.0,,,1,,11866,H,108,,8,,B,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,Autocuration
1852,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,108,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Autocuration
1853,Rattus norvegicus,,,10116.0,,,1,,188,D,12689,,9,,B,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,Autocuration
1854,Rattus norvegicus,,,10116.0,,,1,,11825,D,12689,,9,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Autocuration
1855,Rattus norvegicus,,,10116.0,,,1,,11825,D,12689,,9,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Autocuration
1856,Rattus norvegicus,,,10116.0,,,1,,11624,D,12689,,9,,B,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,Expert
1857,Rattus norvegicus,,,10116.0,,,1,,11139,D,12689,,9,,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,Autocuration
1858,Rattus norvegicus,,,10116.0,,,1,,11147,D,12689,,9,,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Autocuration
1859,Rattus norvegicus,,,10116.0,,,1,,10444,D,12689,,9,,B,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,Autocuration
1860,Rattus norvegicus,,,10116.0,,,1,,11624,D,12689,,9,,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,Expert
1861,Rattus norvegicus,,,10116.0,,,1,,11662,D,12689,,9,,B,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Autocuration
1862,Rattus norvegicus,,,10116.0,,,1,,11662,D,12689,,9,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Autocuration
1863,Rattus norvegicus,,,10116.0,,,1,,11662,D,12689,,9,,B,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Expert
1864,Rattus norvegicus,,,10116.0,,,1,,11662,D,12689,,9,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Autocuration
1865,Rattus norvegicus,,,10116.0,,,1,,9098,D,12689,,9,,B,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,Autocuration
1866,Rattus norvegicus,,,10116.0,,,1,,10394,D,12689,,9,,B,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,Autocuration
1867,,,,,,,1,,11933,H,12689,,8,,B,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,Expert
1868,Rattus norvegicus,,,10116.0,,,1,,12092,D,12689,,9,,B,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,Autocuration
1869,Rattus norvegicus,,,10116.0,,,1,,12253,D,12689,,9,,B,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,Autocuration
1870,Rattus norvegicus,,,10116.0,,,1,,12253,D,12689,HEK293,9,,B,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,Autocuration
1871,,,,,,,1,,1558,H,108,,8,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,Autocuration
1872,,,,,,,1,,2474,H,108,,8,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,Autocuration
1873,,,,,,,1,,2474,H,108,,8,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,Autocuration
1874,,,,,,,1,,11574,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,Autocuration
1875,,,,,,,1,,1558,H,12689,,8,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,Autocuration
1876,,,,,,,1,,13944,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,Autocuration
1877,,,,,,,1,,13033,H,12689,,8,,B,Binding affinity against serotonergic 5-HT1c receptor,,Autocuration
1878,,,,,,,1,,10321,H,12689,,8,,B,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,Autocuration
1879,,,,,,,1,,11866,H,12689,,8,,B,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,Autocuration
1880,Oryctolagus cuniculus,,,9986.0,,,1,,14454,H,105,,8,,B,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Autocuration
1881,,,,,,,1,,11574,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,Autocuration
1882,,,,,,,1,,11574,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,Autocuration
1883,,,,,,,1,,13631,H,104686,,4,,B,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,Autocuration
1884,Rattus norvegicus,,,10116.0,,,1,,9630,D,104686,,5,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,Autocuration
1885,Rattus norvegicus,,,10116.0,,,1,,8822,D,104686,,5,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,Autocuration
1886,Rattus norvegicus,,955.0,10116.0,,,1,,9064,D,104686,,5,Brain,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,Autocuration
1887,,,,,,,1,,8868,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,Autocuration
1888,,,,,,,1,,9064,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,Autocuration
1889,,,,,,,1,,9806,H,104686,,4,,B,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,Autocuration
1890,,,,,,,1,,9098,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,Autocuration
1891,,,,,,,1,,8868,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,Autocuration
1892,,,,,,,1,,12765,H,104686,,4,,B,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,Autocuration
1893,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration
1894,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration
1895,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,Autocuration
1896,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,Autocuration
1897,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration
1898,,,,,,,1,,11473,H,104686,,4,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,Autocuration
1899,,,,,,,1,,11473,H,104686,,4,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,Autocuration
1900,,,,,,,1,,3086,H,104686,,4,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,Autocuration
1901,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration
1902,,,,,,,1,,11049,H,104686,,4,,B,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration
1903,,,,,,,1,,10639,H,104686,,4,,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,Autocuration
1904,,,,,,,1,,10922,H,104686,,4,,B,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,Autocuration
1905,Rattus norvegicus,,955.0,10116.0,,,1,,9064,D,104686,,5,Brain,B,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,Autocuration
1906,,,955.0,,,,1,,10748,H,104686,,4,Brain,B,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,Autocuration
1907,,,,,,,1,,11614,H,104686,,4,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,Autocuration
1908,,,,,,,1,,11615,H,104686,,4,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,Autocuration
1909,,,,,,,1,,11615,H,104686,,4,,B,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,Autocuration
1910,,,,,,,1,,11614,H,104686,,4,,B,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,Autocuration
1911,,,,,,,1,,11702,H,104686,,4,,B,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,Autocuration
1912,,,,,,,1,,11702,H,104686,,4,,B,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,Autocuration
1913,Rattus norvegicus,,,10116.0,,,1,,11702,D,104686,,5,,B,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,Autocuration
1914,,,,,,,1,,11702,H,104686,,4,,B,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,Autocuration
1915,,,,,,,1,,13346,H,104686,,4,,B,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,Autocuration
1916,,,,,,,1,,10025,H,104686,,4,,B,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,Autocuration
1917,,,,,,,1,,10025,H,104686,,4,,B,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,Autocuration
1918,,,,,,,1,,10025,H,104686,,4,,B,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,Autocuration
1919,,,,,,,1,,9036,H,104686,,4,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,Autocuration
1920,,,,,,,1,,9036,H,104686,,4,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,Autocuration
1921,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,Autocuration
1922,,,,,,,1,,12304,H,104686,,4,,B,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,Autocuration
1923,,,,,,,1,,13276,H,104686,,4,,B,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,Autocuration
1924,,,,,,,1,,11825,H,104686,,4,,B,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,Autocuration
1925,,,,,,,1,,12443,H,104686,,4,,B,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,Autocuration
1926,,,,,,,1,,13830,H,104686,,4,,B,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,Autocuration
1927,,,,,,,1,,9592,H,104686,,4,,B,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Membranes,Autocuration
1928,,,,,,,1,,9592,H,104686,,4,,B,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Membranes,Autocuration
1929,,,,,,,1,,10881,H,104686,,4,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,Autocuration
1930,,,,,,,1,,13605,H,104686,,4,,B,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,Autocuration
1931,Rattus norvegicus,,,10116.0,,,1,,11624,D,104686,,5,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,Autocuration
1932,,,,,,,1,,4101,H,104686,,4,,B,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,Autocuration
1933,,,,,,,1,,4101,H,104686,,4,,B,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,Autocuration
1934,,,,,,,1,,15360,H,104686,,4,,B,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,Autocuration
1935,,,,,,,1,,11576,H,104686,,4,,B,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,Autocuration
1936,,,,,,,1,,5834,H,104686,,4,,B,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,Autocuration
1937,Rattus norvegicus,,,10116.0,,,1,,2395,D,104686,CHO-K1,5,,B,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Autocuration
1938,,,,,,,1,,11965,H,104686,,4,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,Autocuration
1939,,,,,,,1,,3967,H,104686,,4,,B,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,Autocuration
1940,,,,,,,1,,11130,H,104686,,4,,B,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Brain membranes,Autocuration
1941,,,,,In vitro,,1,,13427,H,104686,,4,,B,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,Autocuration
1942,,,,,,,1,,9443,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
1943,,,,,,,1,,9443,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,Autocuration
1944,,,,,,,1,,11825,H,104686,,4,,B,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,Autocuration
1945,,,,,,,1,,12120,H,104686,,4,,B,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Membranes,Autocuration
1946,,,,,,,1,,12120,H,104686,,4,,B,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Membranes,Autocuration
1947,,,1515.0,,,,1,,11963,H,104686,,4,Thoracic aorta,F,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,Autocuration
1948,,,,,,,1,,9069,H,104686,,4,,B,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,Autocuration
1949,,,,,,,1,,8868,H,104686,,4,,B,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,Autocuration
1950,,,,,,,1,,17200,H,10624,,8,,B,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,Autocuration
1951,,,,,,,1,,17200,H,10624,,8,,B,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,Autocuration
1952,,,,,,,1,,13969,H,17106,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,Expert
1953,,,,,,,1,,13392,D,17106,,9,,B,Binding affinity for 5-hydroxytryptamine 1D receptor,,Expert
1954,,,,,,,1,,1742,H,17106,,8,,B,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,Autocuration
1955,,,,,,,1,,1742,H,17106,,8,,B,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,Autocuration
1956,,,2435.0,,,,1,,14331,H,17106,,8,Striatum,B,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,Autocuration
1957,,,,,,,1,,12861,H,17106,,8,,F,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,Autocuration
1958,,,,,,,1,,12861,H,17106,,8,,B,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,Expert
1959,,,,,,,1,,12861,H,17106,,8,,B,Binding activity radioligand.,,Autocuration
1960,,,,,,,1,,12861,H,17106,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,Autocuration
1961,,,,,,,1,,12861,H,17106,,8,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Expert
1962,,,,,,,1,,12861,H,17106,,8,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,Autocuration
1963,,,,,,,1,,675,H,17106,,8,,B,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,Autocuration
1964,,,,,,,1,,12490,H,17106,,8,,B,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,Expert
1965,,,,,,,1,,11828,H,17106,,8,,B,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,Expert
1966,,,,,,,1,,11866,H,17106,,8,,B,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,Autocuration
1967,Sus scrofa,,,9823.0,,,1,,773,H,105,,8,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,Autocuration
1968,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,105,,8,,B,The compound was tested for intrinsic activity against 5-HT1D receptor,,Expert
1969,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,105,,8,,B,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Autocuration
1970,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,105,,8,,B,The compound was tested for binding affinity against 5-HT1D receptor,,Expert
1971,,,,,,,1,,188,H,10578,,8,,B,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,Autocuration
1972,,,,,,,1,,10639,H,10578,,8,,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,Autocuration
1973,,,,,,,1,,12438,H,10578,,8,,F,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,Autocuration
1974,,,,,,,1,,12438,H,10578,,8,,B,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,Autocuration
1975,,,,,,,1,,15854,H,10578,,8,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,Expert
1976,,,,,,,1,,10394,H,10578,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,Autocuration
1977,,,,,,,1,,12092,H,10578,,8,,B,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,Autocuration
1978,,,,,,,1,,3389,H,10578,,8,,B,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,Expert
1979,,,,,,,1,,6011,H,105,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,Autocuration
1980,,,,,,,1,,4639,H,105,,8,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration
1981,,,,,,,1,,2474,H,105,,8,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,Autocuration
1982,,,,,,,1,,5014,H,105,,8,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,Autocuration
1983,,,,,,,1,,17515,H,105,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,Autocuration
1984,,,,,,,1,,11866,H,105,,8,,B,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,Autocuration
1985,,,,,,,1,,4687,H,105,,8,,B,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration
1986,,,,,,,1,,12146,H,105,,8,,B,Tested against 5-hydroxytryptamine 1D receptor,,Autocuration
1987,,,,,,,1,,10321,H,105,,8,,B,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,Autocuration
1988,,,,,,,1,,13267,H,105,HEK293,8,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,Autocuration
1989,Homo sapiens,,,9606.0,,,1,,1274,D,105,,9,,B,Binding affinity against 5-Hydroxytryptamine 1D receptor,,Expert
1990,,,,,,,1,,15250,H,105,,8,,B,,,Autocuration
1991,,,,,,,1,,13706,H,106,CHO-K1,8,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,Autocuration
1992,,,,,,,1,,13706,H,105,CHO-K1,8,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,Autocuration
1993,,,,,,,1,,13706,H,105,HEK293,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,Autocuration
1994,,,,,,,1,,13706,H,105,HEK293,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,Autocuration
1995,,,,,,,1,,13047,H,105,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,Autocuration
1996,,,,,,,1,,13366,H,105,,8,,B,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,Autocuration
1997,,,,,,,1,,13366,H,105,,8,,B,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,Expert
1998,,,,,,,1,,1558,H,105,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,Autocuration
1999,,,,,,,1,,12902,H,105,CHO-K1,8,,B,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,Expert
2000,,,,,,,1,,13706,H,105,CHO-K1,8,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,Autocuration
2001,,,,,,,1,,13706,H,105,,8,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,Autocuration
2002,,,,,,,1,,13706,H,105,,8,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,Autocuration
2003,,,,,,,1,,14251,H,105,,8,,F,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,Autocuration
2004,,,,,,,1,,14251,H,105,,8,,F,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,Autocuration
2005,,,,,,,1,,14251,H,105,,8,,F,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,Autocuration
2006,,,,,,,1,,13313,H,105,,8,,B,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,Autocuration
2007,,,,,,,1,,13313,H,105,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,Autocuration
2008,,,,,,,1,,13366,H,105,,8,,B,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,Autocuration
2009,,,,,,,1,,13051,H,105,,8,,B,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,Expert
2010,,,,,,,1,,12903,H,105,CHO,8,,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,Expert
2011,Homo sapiens,,,9606.0,,,1,,12469,D,105,,9,,B,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,Autocuration
2012,,,,,,,1,,5619,H,17106,,8,,B,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,Autocuration
2013,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,105,,8,,B,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Autocuration
2014,,,,,,,1,,16633,H,105,,8,,B,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,Autocuration
2015,,,,,,,1,,16633,H,105,,8,,B,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,Autocuration
2016,,,,,,,1,,16633,H,105,,8,,B,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,Autocuration
2017,,,,,,,1,,16633,H,105,,8,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,Autocuration
2018,,,,,,,1,,3269,H,105,,8,,B,Affinity against 5-hydroxytryptamine 1D receptor alpha,,Autocuration
2019,,,,,,,1,,12409,H,105,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,Expert
2020,,,,,,,1,,13706,H,106,,8,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,Autocuration
2021,,,,,,,1,,13706,H,106,HEK293,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,Autocuration
2022,,,,,,,1,,13706,H,106,HEK293,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,Autocuration
2023,,,,,,,1,,12903,H,106,CHO,8,,B,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,Autocuration
2024,,,,,,,1,,13047,H,106,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,Autocuration
2025,,,,,,,1,,13366,D,106,,9,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,Expert
2026,,,,,,,1,,13366,D,106,,9,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,Expert
2027,,,,,,,1,,13366,D,106,,9,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,Expert
2028,,,,,,,1,,13366,H,106,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,Autocuration
2029,,,,,,,1,,13366,H,106,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration
2030,,,,,,,1,,12469,H,106,CHO,8,,B,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,Autocuration
2031,,,,,,,1,,13706,H,106,CHO-K1,8,,B,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,Autocuration
2032,,,,,,,1,,13706,H,106,CHO-K1,8,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,Autocuration
2033,,,,,,,1,,13706,H,106,,8,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,Autocuration
2034,,,,,,,1,,12902,H,106,CHO-K1,8,,B,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,Expert
2035,,,,,,,1,,13051,H,105,,8,,B,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,Expert
2036,,,,,,,1,,12903,H,106,CHO,8,,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,Expert
2037,,,,,,,1,,1558,H,105,CHO-K1,8,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,Autocuration
2038,,,,,,,1,,1558,H,105,CHO-K1,8,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,Autocuration
2039,,,,,,,1,,1558,H,105,CHO-K1,8,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,Autocuration
2040,,,,,,,1,,1558,H,105,CHO-K1,8,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,Autocuration
2041,,,,,,,1,,1558,H,105,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,Autocuration
2042,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,106,,8,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,Autocuration
2043,,,,,,,1,,13313,H,105,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,Autocuration
2044,,,,,,,1,,13313,H,105,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,Autocuration
2045,,,,,,,1,,12409,H,105,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,Expert
2046,,,,,,,1,,15250,H,10618,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,Autocuration
2047,Homo sapiens,,,9606.0,,,1,,1348,D,10618,,9,,B,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,Expert
2048,,,,,,,1,,1348,H,10618,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,Autocuration
2049,Homo sapiens,,,9606.0,,,1,,4234,D,10618,,9,,B,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,Expert
2050,,,,,,,1,,16209,H,10618,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,Autocuration
2051,,,,,,,1,,10444,H,10618,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,Autocuration
2052,,,,,,,1,,3935,H,10618,,8,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,Autocuration
2053,,,,,,,1,,15818,H,10618,,8,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,Autocuration
2054,,,,,,,1,,17085,H,10618,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,Autocuration
2055,Homo sapiens,,,9606.0,,,1,,12936,D,10618,CHO,9,,B,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,Expert
2056,,,,,,,1,,6166,H,10618,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,Autocuration
2057,,,,,,,1,,15779,H,10618,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration
2058,,,,,,,1,,15779,H,10618,CHO,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,Autocuration
2059,,,,,,,1,,15779,H,10618,CHO,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,Autocuration
2060,,,,,,,1,,13181,H,10618,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,Autocuration
2061,,,,,,,1,,4199,H,10618,CHO,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,Autocuration
2062,,,,,,,1,,14875,H,10618,,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,Autocuration
2063,,,,,,,1,,15146,H,10618,CHO,8,,B,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,Autocuration
2064,,,,,,,1,,5213,H,10618,,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,Autocuration
2065,,,,,,,1,,12146,H,10618,,8,,B,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,Autocuration
2066,,,,,,,1,,13267,H,10618,CHO,8,,B,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,Autocuration
2067,,,,,,,1,,14818,H,10618,CHO,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,Autocuration
2068,,,,,,,1,,4829,H,10618,CHO,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration
2069,,,,,,,1,,4373,H,10618,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,Autocuration
2070,,,,,,,1,,4373,H,10618,,8,,B,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,Autocuration
2071,,,,,,,1,,14159,H,10618,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,Autocuration
2072,,,,,,,1,,16633,H,10618,,8,,B,Binding affinity towards 5-hydroxytryptamine 1E receptor,,Autocuration
2073,,,,,,,1,,17085,H,279,,8,,F,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,Autocuration
2074,,,,,,,1,,17085,H,279,,8,,F,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,Expert
2075,,,,,,,1,,16209,H,279,,8,,F,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,Autocuration
2076,,,,,,,1,,16209,H,279,,8,,F,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,Autocuration
2077,,,,,,,1,,17085,H,279,,8,,F,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,Expert
2078,,,,,,,1,,14159,H,279,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,Autocuration
2079,,,,,,,1,,15250,H,279,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,Autocuration
2080,,,,,,,1,,3805,H,279,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,Autocuration
2081,,,,,,,1,,16190,H,279,CHO,8,,B,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,Autocuration
2082,,,,,,,1,,16190,H,279,,8,,B,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,Autocuration
2083,,,,,,,1,,16209,H,279,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,Autocuration
2084,,,,,,,1,,16209,H,279,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,Autocuration
2085,,,,,,,1,,16209,H,279,,8,,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,Autocuration
2086,,,,,,,1,,6866,H,279,,8,,B,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,Autocuration
2087,,,,,,,1,,17085,H,279,,8,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,Expert
2088,,,,,,,1,,16312,H,279,,8,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,Autocuration
2089,,,,,,,1,,6166,H,279,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,Autocuration
2090,,,,,,,1,,15779,H,279,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration
2091,,,,,,,1,,4199,H,279,CHO,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,Autocuration
2092,,,,,,,1,,14875,H,279,,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,Autocuration
2093,,,,,,,1,,15146,H,279,CHO,8,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,Autocuration
2094,,,,,,,1,,5213,H,279,,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,Autocuration
2095,,,,,,,1,,14818,H,279,CHO,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,Autocuration
2096,,,,,,,1,,4829,H,279,CHO,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration
2097,,,,,,,1,,4829,H,279,CHO,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration
2098,,,,,,,1,,4373,H,279,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,Autocuration
2099,,,,,,,1,,4373,H,279,,8,,B,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,Autocuration
2100,,,,,,,1,,5014,H,279,,8,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,Autocuration
2101,,,,,,,1,,11662,H,104686,,4,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,Autocuration
2102,,,,,,,1,,11662,H,104686,,4,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,Autocuration
2103,,,,,,,1,,11662,H,104686,,4,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,Autocuration
2104,,,,,,,1,,14093,H,12687,,8,,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,Autocuration
2105,,,,,In vivo,,1,,11200,H,104686,,4,,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,Autocuration
2106,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration
2107,,,,,,,1,,12352,H,17005,,8,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,Intermediate
2108,Bos taurus,,,9913.0,,,1,,13657,U,22226,,0,,B,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,Autocuration
2109,Bos taurus,,,9913.0,,,1,,14331,U,22226,,0,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,Autocuration
2110,Bos taurus,,,9913.0,,,1,,14331,U,22226,,0,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,Autocuration
2111,,,,,,,1,,14331,U,22226,,0,,B,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,Autocuration
2112,Cavia porcellus,,,10141.0,,,1,,12685,H,104784,,4,,B,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,Autocuration
2113,Cavia porcellus,,,10141.0,,,1,,14389,H,104784,,4,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,Autocuration
2114,Cavia porcellus,,,10141.0,,,1,,14386,H,104784,,4,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,Autocuration
2115,,,,,,,1,,5732,H,104784,,4,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,Autocuration
2116,,,,,,,1,,16293,H,104784,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,Autocuration
2117,,,,,,,1,,2078,H,104784,,4,,B,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,Autocuration
2118,,,,,,,1,,5486,H,10209,,8,,B,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,Autocuration
2119,,,,,In vivo,,1,,11820,H,104826,,4,,B,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,Autocuration
2120,,,,,,,1,,10297,H,104826,,4,,B,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Autocuration
2121,,,,,,,1,,13704,H,104826,,4,,B,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,Autocuration
2122,Mus musculus,,,10090.0,,,1,,10297,D,104826,,5,,B,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,Autocuration
2123,,,,,In vivo,,1,,11820,H,104826,,4,,B,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,Autocuration
2124,Mus musculus,,,10090.0,,,1,,10297,D,104826,,5,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,Autocuration
2125,,,,,,,1,,11555,H,104826,,4,,B,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
2126,,,,,,,1,,11555,H,104826,,4,,B,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,Autocuration
2127,,,,,,,1,,11555,H,104826,,4,,B,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,Autocuration
2128,Mus musculus,,,10090.0,,,1,,10297,D,104826,,5,,B,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Autocuration
2129,Sus scrofa,,,9823.0,,,1,,16688,H,104784,,4,,B,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,Autocuration
2130,Sus scrofa,,,9823.0,,,1,,16688,H,104784,,4,,B,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,Autocuration
2131,,,,,,,1,,5333,U,22226,,0,,B,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,Autocuration
2132,,,,,,,1,,4437,U,22226,,0,,B,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,Autocuration
2133,Sus scrofa,,,9823.0,,,1,,5033,H,17005,,8,,B,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,Autocuration
2134,,,,,,,1,,15267,H,104686,,4,,B,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,Autocuration
2135,,,,,,,1,,15267,H,104686,,4,,B,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,Autocuration
2136,,,,,,,1,,11820,H,104826,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,Autocuration
2137,,,,,,,1,,9069,H,104686,,4,,B,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,Autocuration
2138,Rattus norvegicus,,,10116.0,,,1,,9162,D,104686,,5,,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,Autocuration
2139,,,,,,,1,,9162,H,104686,,4,,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,Autocuration
2140,,,,,,,1,,9162,H,104686,,4,,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,Autocuration
2141,,,,,,,1,,10428,H,104686,,4,,F,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,Autocuration
2142,,,,,,,1,,9628,H,104686,,4,,B,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,Autocuration
2143,,,,,,,1,,12704,H,104686,,4,,B,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,Autocuration
2144,Rattus norvegicus,,,10116.0,,,1,,15453,D,104686,,5,,B,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Autocuration
2145,,,,,,,1,,188,H,104686,,4,,B,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,Autocuration
2146,,,,,,,1,,10349,H,104686,,4,,B,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,Autocuration
2147,,,,,,,1,,10349,H,104686,,4,,B,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,Autocuration
2148,,,,,,,1,,8868,H,104686,,4,,B,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,Autocuration
2149,,,,,,,1,,10025,H,104686,,4,,B,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,Autocuration
2150,,,,,,,1,,10025,H,104686,,4,,B,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,Autocuration
2151,,,,,,,1,,11702,H,104686,,4,,B,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,Autocuration
2152,,,,,,,1,,11702,H,104686,,4,,B,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,Autocuration
2153,,,,,,,1,,11702,H,104686,,4,,B,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,Autocuration
2154,,,,,,,1,,11702,H,104686,,4,,F,Compound was tested for the inhibition of quipazine induced head twitches in rats,,Autocuration
2155,,,,,,,1,,11702,H,104686,,4,,F,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,Autocuration
2156,,,10000000.0,,,,1,,10085,H,104686,,4,Hippocampus,B,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,Autocuration
2157,,,10000000.0,,,,1,,10085,H,104686,,4,Hippocampus,B,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,Autocuration
2158,Rattus norvegicus,,955.0,10116.0,,,1,,9630,D,104686,,5,Brain,B,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,Autocuration
2159,,,,,,,1,,11070,H,104686,,4,,B,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,Autocuration
2160,,,,,,,1,,9841,H,104686,,4,,B,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,Autocuration
2161,,,,,,,1,,9841,H,104686,,4,,B,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,Autocuration
2162,,,,,,,1,,13291,H,104686,,4,,B,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,Autocuration
2163,,,,,,,1,,10590,H,104686,,4,,F,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,Autocuration
2164,Rattus norvegicus,,955.0,10116.0,,,1,,9064,D,104686,,5,Brain,B,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,Autocuration
2165,Rattus norvegicus,,,10116.0,,,1,,12268,D,104686,,5,,B,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Membranes,Autocuration
2166,,,955.0,,,,1,,13508,H,104686,,4,Brain,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,Autocuration
2167,,,,,,,1,,11279,H,104686,,4,,F,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,Autocuration
2168,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,Autocuration
2169,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration
2170,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,Autocuration
2171,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,Autocuration
2172,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration
2173,,,955.0,,,,1,,9231,H,104686,,4,Brain,B,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,Autocuration
2174,,,,,,,1,,9737,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,Autocuration
2175,,,955.0,,,,1,,9737,H,104686,,4,Brain,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,Autocuration
2176,,,,,,,1,,9737,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,Autocuration
2177,,,,,,,1,,9737,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,Autocuration
2178,Rattus norvegicus,,,10116.0,,,1,,11828,D,104686,,5,,B,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,Autocuration
2179,,,,,,,1,,12253,H,104686,,4,,B,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,Autocuration
2180,,,,,,,1,,12253,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,Autocuration
2181,,,,,,,1,,11279,H,104686,,4,,F,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,Autocuration
2182,,,,,,,1,,11866,H,104686,,4,,B,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,Autocuration
2183,Rattus norvegicus,,,10116.0,,,1,,14424,D,104686,,5,,B,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,Autocuration
2184,Rattus norvegicus,,,10116.0,,,1,,15180,D,104686,,5,,B,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Autocuration
2185,Rattus norvegicus,,,10116.0,,,1,,15180,D,104686,,5,,B,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Autocuration
2186,Rattus norvegicus,,,10116.0,,,1,,9786,D,104686,,5,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,Autocuration
2187,,,,,,,1,,12132,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,Autocuration
2188,,,,,,,1,,5486,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,Autocuration
2189,,,,,,,1,,15316,H,104686,,4,,B,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,Autocuration
2190,,,,,,,1,,16429,H,104686,,4,,B,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,Autocuration
2191,,,,,,,1,,14617,H,104686,,4,,B,pKi value for 5-hydroxytryptamine 2 receptor binding site,,Autocuration
2192,,,955.0,,,,1,,11351,H,104686,,4,Brain,B,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,Autocuration
2193,,,,,,,1,,11279,H,104686,,4,,F,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,Autocuration
2194,,,,,,,1,,9523,H,105075,,4,,B,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration
2195,,,,,,,1,,9523,H,105075,,4,,B,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration
2196,,,,,,,1,,9523,H,105075,,4,,B,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration
2197,,,,,,,1,,9523,H,105075,,4,,B,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration
2198,,,,,,,1,,9523,H,105075,,4,,B,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration
2199,,,,,,,1,,9523,H,105075,,4,,B,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration
2200,,,,,,,1,,9523,H,105075,,4,,B,Hill coefficient of compound was determined,,Autocuration
2201,,,,,,,1,,4771,U,22226,,0,,B,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,Autocuration
2202,Rattus norvegicus,,,10116.0,,,1,,5033,D,104686,,5,,B,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,Autocuration
2203,,,,,,,1,,10845,H,12687,,8,,B,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,Expert
2204,,,,,,,1,,10845,H,12687,,8,,B,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,Expert
2205,,,,,,,1,,16288,H,12687,,8,,B,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,Autocuration
2206,,,,,,,1,,16288,H,12687,,8,,B,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,Autocuration
2207,,,,,,,1,,16190,H,12687,,8,,B,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,Autocuration
2208,Rattus norvegicus,,,10116.0,,,1,,12463,D,104686,,5,,B,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,Autocuration
2209,,,,,,,1,,9699,H,104686,,4,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,Autocuration
2210,,,,,,,1,,9699,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,Autocuration
2211,,,,,,,1,,11662,H,104686,,4,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,Autocuration
2212,,,,,,,1,,1205,H,104784,,4,,B,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,Autocuration
2213,,,,,,,1,,11376,U,22226,,0,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,Autocuration
2214,,,,,,,1,,11376,H,104784,,4,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,Autocuration
2215,,,,,,,1,,4639,H,104784,,4,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,Autocuration
2216,,,,,,,1,,2222,H,104784,,4,,B,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,Autocuration
2217,,,,,,,1,,1558,H,104784,,4,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
2218,,,,,,,1,,1089,H,104784,,4,,B,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration
2219,,,,,,,1,,386,H,104784,,4,,B,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Brain membranes,Autocuration
2220,,,,,,,1,,2474,H,104784,,4,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,Autocuration
2221,,,,,,,1,,17066,H,104784,,4,,B,Binding affinity towards 5-HT2 receptor,,Autocuration
2222,,,,,,,1,,959,H,104784,,4,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration
2223,,,,,,,1,,6398,H,104784,,4,,B,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,Autocuration
2224,,,,,,,1,,11889,H,104686,,4,,B,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,Autocuration
2225,,,,,,,1,,4221,H,104784,,4,,B,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration
2226,,,,,,,1,,11026,H,104784,,4,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,Autocuration
2227,,,,,,,1,,11866,H,104784,,4,,B,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,Autocuration
2228,,,,,,,1,,4221,H,104784,,4,,B,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration
2229,,,,,,,1,,13950,U,22226,,0,,B,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration
2230,,,,,,,1,,1263,H,104784,,4,,B,5-hydroxytryptamine 2 receptor binding affinity,,Autocuration
2231,,,,,,,1,,13291,H,17005,,8,,B,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,Autocuration
2232,,,,,,,1,,10812,H,17005,,8,,B,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,Autocuration
2233,,,,,,,1,,13020,H,104784,,4,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,Autocuration
2234,,,,,,,1,,13021,H,104784,,4,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,Autocuration
2235,,,,,,,1,,13020,H,104784,,4,,B,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,Autocuration
2236,,,,,,,1,,14532,H,17005,,8,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,Autocuration
2237,,,,,,,1,,13944,H,17005,,8,,B,Binding affinity against 5-hydroxytryptamine 2 receptor,,Autocuration
2238,,,,,,,1,,14331,H,17005,,8,,B,Binding affinity against 5-hydroxytryptamine 2 receptor,,Autocuration
2239,,,,,,,1,,14118,H,17005,,8,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,Autocuration
2240,,,,,,,1,,13033,H,17005,,8,,B,Binding affinity against serotonergic 5-HT2 receptor,,Autocuration
2241,,,,,,,1,,10321,H,17005,,8,,B,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,Autocuration
2242,,,,,,,1,,12918,H,17005,,8,,B,Compound was evaluated for the binding affinity at 5- HT2 receptor,,Autocuration
2243,,,,,,,1,,15120,H,17005,,8,,B,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,Autocuration
2244,,,,,,,1,,2613,H,17005,,8,,B,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,Autocuration
2245,Homo sapiens,,,9606.0,,,1,,13378,D,104784,,5,,B,Inhibitory activity against cloned human 5-HT2 receptor,,Autocuration
2246,Homo sapiens,,,9606.0,,,1,,2331,D,104784,CHO,5,,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,Autocuration
2247,Homo sapiens,,,9606.0,,,1,,2331,D,104784,CHO,5,,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,Autocuration
2248,Homo sapiens,,,9606.0,,,1,,2331,D,104784,CHO,5,,B,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,Autocuration
2249,Homo sapiens,,,9606.0,,,1,,2331,D,104784,CHO,5,,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,Autocuration
2250,,,,,,,1,,4170,H,104784,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
2251,,,,,,,1,,15453,H,104784,,4,,B,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Autocuration
2252,,,,,,,1,,1479,H,17005,,8,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
2253,,,,,,,1,,11139,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,Autocuration
2254,,,,,,,1,,13969,H,17005,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,Expert
2255,,,,,,,1,,13392,H,17005,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Expert
2256,,,,,,,1,,14430,H,17005,,8,,B,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,Expert
2257,Cavia porcellus,,,10141.0,,,1,,13181,H,107,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Autocuration
2258,,,,,,,1,,17200,H,51,,8,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration
2259,,,,,,,1,,17200,H,107,,8,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration
2260,,,,,,,1,,17200,H,51,,8,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration
2261,,,,,,,1,,13463,H,107,,8,,B,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,Autocuration
2262,,,,,,,1,,6347,H,107,CHO,8,,B,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,Autocuration
2263,Homo sapiens,,,9606.0,,,1,,6857,D,107,CHO,9,,F,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,Expert
2264,,,,,,,1,,4176,H,107,,8,,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,Autocuration
2265,,,,,,,1,,4176,H,107,,8,,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,Autocuration
2266,,,,,,,1,,4176,H,107,,8,,F,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,Autocuration
2267,,,,,,,1,,6347,H,107,CHO,8,,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,Autocuration
2268,,,,,,,1,,6347,H,107,CHO,8,,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,Autocuration
2269,,,,,,,1,,15331,H,107,,8,,B,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,Autocuration
2270,Homo sapiens,,,9606.0,,,1,,16146,D,107,,9,,B,Inhibition of human 5-hydroxytryptamine 2A receptor,,Expert
2271,,,,,,,1,,15250,H,107,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Autocuration
2272,,,,,,,1,,13631,H,107,,8,,B,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,Expert
2273,,,,,,,1,,3805,H,107,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,Autocuration
2274,,,,,,,1,,4011,H,107,CHO,8,,B,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,Autocuration
2275,,,,,,,1,,4012,H,107,CHO,8,,B,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,Expert
2276,,,,,,,1,,6366,H,107,L929,8,,B,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,Expert
2277,,,,,,,1,,15949,H,107,CHO,8,,B,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Expert
2278,,,,,,,1,,14093,H,107,,8,,F,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,Autocuration
2279,,,,,,,1,,13481,H,107,,8,,F,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration
2280,,,,,,,1,,6347,H,107,CHO,8,,B,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,Autocuration
2281,,,,,,,1,,6347,H,107,CHO,8,,B,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,Autocuration
2282,,,,,,,1,,14093,H,107,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,Autocuration
2283,,,,,,,1,,14093,H,107,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,Autocuration
2284,,,,,,,1,,13481,H,107,,8,,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration
2285,,,,,,,1,,14442,H,107,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,Autocuration
2286,,,,,,,1,,14442,H,107,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration
2287,,,,,,,1,,14755,H,107,,8,,B,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,Autocuration
2288,,,,,,,1,,16441,H,107,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,Autocuration
2289,,,,,,,1,,14744,H,107,,8,,B,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,Autocuration
2290,,,,,,,1,,16659,H,107,CHO,8,,B,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Expert
2291,,,,,,,1,,3307,H,107,,8,,B,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,Autocuration
2292,Homo sapiens,,,9606.0,,,1,,6857,D,107,,9,,B,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,Expert
2293,,,,,,,1,,5635,H,107,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,Expert
2294,Homo sapiens,,,9606.0,,,1,,4234,D,107,,9,,B,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,Expert
2295,,,,,,,1,,15527,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,Autocuration
2296,,,,,,,1,,6588,H,107,CHO,8,,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,Expert
2297,,,,,,,1,,13631,H,107,,8,,B,Binding affinity towards human 5-HT2A receptor in BEK cells,,Expert
2298,,,,,,,1,,17723,H,107,,8,,B,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,Autocuration
2299,,,,,,,1,,14770,H,107,,8,,B,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,Autocuration
2300,Homo sapiens,,,9606.0,,,1,,16293,D,107,,9,,B,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Expert
2301,,,,,,,1,,16209,H,107,,8,,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration
2302,,,,,,,1,,12469,H,107,,8,,B,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,Autocuration
2303,,,,,,,1,,15363,H,107,,8,,B,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,Autocuration
2304,,,,,,,1,,15363,H,107,,8,,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,Autocuration
2305,,,,,,,1,,16441,H,107,,8,,B,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,Expert
2306,,,,,,,1,,8,H,107,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,Autocuration
2307,,,,,,,1,,4176,H,107,HEK293,8,,B,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,Autocuration
2308,,,,,,,1,,17085,H,107,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,Autocuration
2309,,,,,,,1,,17200,H,107,,8,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration
2310,Homo sapiens,,,9606.0,,,1,,17200,D,107,,9,,B,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Expert
2311,Homo sapiens,,,9606.0,,,1,,4013,D,107,CHO,9,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,Expert
2312,,,,,,,1,,5088,H,107,,8,,B,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration
2313,Homo sapiens,,,9606.0,,,1,,5088,D,107,,9,,B,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,Expert
2314,,,,,,,1,,5088,H,107,,8,,B,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,Autocuration
2315,Homo sapiens,,,9606.0,,,1,,5088,D,107,,9,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,Expert
2316,,,,,,,1,,5088,H,107,,8,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,Autocuration
2317,,,,,,,1,,5088,H,107,,8,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Autocuration
2318,,,,,,,1,,9786,H,104686,,4,,B,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,Autocuration
2319,Rattus norvegicus,,,10116.0,,,1,,9205,D,104686,,5,,B,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,Autocuration
2320,,,,,,,1,,11257,H,104686,,4,,B,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,Autocuration
2321,,,,,,,1,,9362,H,104686,,4,,B,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,Autocuration
2322,,,,,,,1,,9362,H,104686,,4,,B,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,Autocuration
2323,,,,,,,1,,10590,H,104686,,4,,B,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,Autocuration
2324,,,,,,,1,,10468,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,Autocuration
2325,,,,,,,1,,13050,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,Autocuration
2326,,,,,,,1,,11624,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,Autocuration
2327,,,,,,,1,,10468,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,Autocuration
2328,,,,,,,1,,10330,H,104686,,4,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,Autocuration
2329,,,,,,,1,,10062,H,104686,,4,,B,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,Autocuration
2330,,,,,,,1,,11642,H,104686,,4,,B,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,Autocuration
2331,,,,,,,1,,10062,H,104686,,4,,B,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,Autocuration
2332,,,,,In vitro,,1,,13427,H,104686,,4,,B,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,Autocuration
2333,Rattus norvegicus,,,10116.0,,,1,,12280,D,104686,,5,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration
2334,Rattus norvegicus,,,10116.0,,,1,,4101,D,104686,,5,,B,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,Autocuration
2335,,,,,,,1,,10062,H,104686,,4,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,Autocuration
2336,,,,,,,1,,11147,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,Autocuration
2337,Rattus norvegicus,,,10116.0,,,1,,2395,D,104686,CHO-K1,5,,B,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Autocuration
2338,Rattus norvegicus,,,10116.0,,,1,,2395,D,104686,CHO-K1,5,,B,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Autocuration
2339,Rattus norvegicus,,,10116.0,,,1,,9098,D,104686,,5,,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,Autocuration
2340,,,,,,,1,,9098,H,104686,,4,,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,Autocuration
2341,Rattus norvegicus,,,10116.0,,,1,,9098,D,104686,,5,,B,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,Autocuration
2342,,,,,,,1,,9443,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
2343,,,,,,,1,,9443,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,Autocuration
2344,,,,,,,1,,9699,H,104686,,4,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,Autocuration
2345,,,,,,,1,,9699,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,Autocuration
2346,,,,,,,1,,9098,H,104686,,4,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,Autocuration
2347,Rattus norvegicus,,,10116.0,,,1,,3070,D,104686,,5,,B,Affinity for 5-hydroxytryptamine 2 receptor,,Autocuration
2348,,,,,,,1,,9547,H,104686,,4,,B,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,Autocuration
2349,,,,,,,1,,10444,H,104686,,4,,B,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,Autocuration
2350,,,,,,,1,,14617,H,104686,,4,,B,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,Autocuration
2351,,,,,,,1,,14617,H,104686,,4,,B,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,Autocuration
2352,,,,,,,1,,11130,H,104686,,4,,B,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,Autocuration
2353,,,,,In vivo,,1,,11130,H,104686,,4,,B,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,Autocuration
2354,,,955.0,,,,1,,14542,H,104686,,4,Brain,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,Autocuration
2355,,,,,,,1,,2797,H,104686,,4,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,Autocuration
2356,,,,,,,1,,11332,H,104686,,4,,B,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,Autocuration
2357,,,,,,,1,,11332,H,104686,,4,,B,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,Autocuration
2358,,,1870.0,,,,1,,10752,H,104686,,4,Frontal cortex,B,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,Autocuration
2359,,,,,,,1,,1185,H,104686,,4,,B,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,Autocuration
2360,,,,,,,1,,1185,H,104686,,4,,B,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,Autocuration
2361,Rattus norvegicus,,,10116.0,,,1,,11624,D,104686,,5,,B,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,Autocuration
2362,,,,,,,1,,1344,H,104686,,4,,B,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,Autocuration
2363,Rattus norvegicus,,2435.0,10116.0,,,1,,15453,D,104686,,5,Striatum,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,Autocuration
2364,,,,,,,1,,11662,H,104686,,4,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,Autocuration
2365,,,,,,,1,,11662,H,104686,,4,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,Autocuration
2366,,,,,,,1,,10796,H,104686,,4,,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration
2367,,,,,,,1,,9069,H,104686,,4,,B,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,Autocuration
2368,Rattus norvegicus,,,10116.0,,,1,,8814,D,104686,,5,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,Autocuration
2369,Rattus norvegicus,,,10116.0,,,1,,8908,D,104686,,5,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,Autocuration
2370,,,,,,,1,,9098,H,104686,,4,,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,Autocuration
2371,,,,,,,1,,9098,H,104686,,4,,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,Autocuration
2372,,,,,,,1,,9098,H,104686,,4,,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,Autocuration
2373,,,,,,,1,,9098,H,104686,,4,,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,Autocuration
2374,,,,,,,1,,9098,H,104686,,4,,B,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,Autocuration
2375,,,,,,,1,,9098,H,104686,,4,,B,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,Autocuration
2376,,,,,,,1,,9098,H,104686,,4,,B,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,Autocuration
2377,,,,,,,1,,9161,H,104686,,4,,B,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,Autocuration
2378,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,Autocuration
2379,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,Autocuration
2380,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,Autocuration
2381,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,Autocuration
2382,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,Autocuration
2383,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,Autocuration
2384,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,Autocuration
2385,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,Autocuration
2386,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,Autocuration
2387,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,Autocuration
2388,,,,,,,1,,9161,H,104686,,4,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,Autocuration
2389,,,,,,,1,,12094,H,104686,,4,,B,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,Autocuration
2390,,,,,,,1,,12018,H,104686,,4,,B,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,Autocuration
2391,,,,,,,1,,10394,H,104686,,4,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,Autocuration
2392,,,,,,,1,,15260,H,104686,,4,,B,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,Autocuration
2393,Rattus norvegicus,,,10116.0,,,1,,11624,D,104686,,5,,B,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,Autocuration
2394,,,,,,,1,,13654,H,104686,,4,,B,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration
2395,,,,,,,1,,9541,H,104686,,4,,B,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,Autocuration
2396,,,,,,,1,,11933,H,104686,,4,,B,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,Autocuration
2397,,,,,,,1,,15538,H,104686,,4,,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,Autocuration
2398,,,,,,,1,,15538,H,104686,,4,,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,Autocuration
2399,,,,,,,1,,15538,H,104686,,4,,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,Autocuration
2400,,,,,,,1,,8841,D,104686,,5,,B,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,Autocuration
2401,,,,,,,1,,1455,H,104686,,4,,B,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,Autocuration
2402,,,,,,,1,,1455,H,104686,,4,,B,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,Autocuration
2403,,,,,,,1,,11752,H,104686,,4,,B,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,Autocuration
2404,,,955.0,,,,1,,11642,H,104686,,4,Brain,B,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,Autocuration
2405,,,,,,,1,,12092,H,104686,,4,,B,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,Autocuration
2406,,,,,,,1,,3967,H,104686,,4,,B,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,Autocuration
2407,Rattus norvegicus,,,10116.0,,,1,,12771,D,104686,,5,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration
2408,,,,,,,1,,11642,H,104686,,4,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,Autocuration
2409,,,,,,,1,,11628,H,104686,,4,,B,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,Autocuration
2410,,,,,,,1,,13654,H,104686,,4,,B,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration
2411,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration
2412,,,,,,,1,,11200,H,104686,,4,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration
2413,,,,,In vivo,,1,,11200,H,104686,,4,,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,Autocuration
2414,,,,,In vivo,,1,,11200,H,104686,,4,,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,Autocuration
2415,,,,,In vivo,,1,,11200,H,104686,,4,,F,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,Autocuration
2416,,,,,In vivo,,1,,11200,H,104686,,4,,F,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,Autocuration
2417,,,955.0,,,,1,,15436,H,12687,,8,Brain,B,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,Expert
2418,Rattus norvegicus,,,10116.0,,,1,,15436,D,12687,,9,,B,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Expert
2419,,,,,,,1,,14025,H,12687,,8,,B,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,Autocuration
2420,,,,,,,1,,4342,H,12687,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,Autocuration
2421,Rattus norvegicus,,,10116.0,,,1,,13735,D,12687,,9,,B,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,Expert
2422,Rattus norvegicus,,,10116.0,,,1,,5816,D,12687,,9,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Expert
2423,,,,,,,1,,14287,H,12687,,8,,B,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,Expert
2424,,,,,,,1,,15738,H,12687,,8,,B,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,Autocuration
2425,Rattus norvegicus,,,10116.0,,,1,,15738,D,12687,,9,,B,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,Expert
2426,,,,,,,1,,15026,H,12687,,8,,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,Autocuration
2427,,,,,,,1,,16647,H,12687,,8,,B,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,Expert
2428,,,,,,,1,,16647,H,12687,,8,,B,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,Autocuration
2429,Rattus norvegicus,,,10116.0,,,1,,13345,D,12687,,9,,B,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,Expert
2430,,,,,,,1,,1543,H,12687,,8,,B,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Membranes,Autocuration
2431,,,,,,,1,,12444,H,12687,,8,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,Autocuration
2432,,,,,,,1,,16404,H,12687,,8,,B,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,Expert
2433,,,,,,,1,,16404,H,12687,CHO,8,,B,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Autocuration
2434,,,,,,,1,,15577,H,12687,,8,,B,Kinetic inhibition constant evaluated by measuring serotonergic activity,,Expert
2435,,,,,,,1,,15577,H,12687,,8,,B,Serotonergic activity of the compound.,,Autocuration
2436,,,,,,,1,,2495,H,12687,,8,,B,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,Autocuration
2437,Rattus norvegicus,,,10116.0,,,1,,15042,D,12687,,9,,B,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,Expert
2438,,,,,,,1,,15026,H,12687,,8,,B,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,Expert
2439,Rattus norvegicus,,,10116.0,,,1,,12919,D,12687,,9,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert
2440,Rattus norvegicus,,,10116.0,,,1,,12919,D,12687,,9,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert
2441,Rattus norvegicus,,,10116.0,,,1,,12919,D,12687,,9,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert
2442,,,,,,,1,,15194,H,12687,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration
2443,,,,,,,1,,15194,H,12687,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,Autocuration
2444,,,,,,,1,,4820,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Expert
2445,,,,,,,1,,6736,H,107,,8,,B,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,Autocuration
2446,,,,,,,1,,5163,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,Autocuration
2447,,,,,,,1,,5163,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,Autocuration
2448,,,,,,,1,,6011,H,107,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,Autocuration
2449,Homo sapiens,,,9606.0,,,1,,14294,D,107,,9,,B,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,Expert
2450,,,,,,,1,,5014,H,107,,8,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,Autocuration
2451,,,,,,,1,,17066,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Expert
2452,,,,,,,1,,17515,H,107,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,Autocuration
2453,,,,,,,1,,6736,H,107,,8,,B,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,Expert
2454,,,,,,,1,,5163,H,107,,8,,B,Affinity for 5-hydroxytryptamine 2A receptor,,Expert
2455,,,,,,,1,,16911,H,107,NIH3T3,8,,B,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,Expert
2456,,,,,,,1,,6841,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Expert
2457,,,,,,,1,,6119,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,Expert
2458,,,,,,,1,,3962,H,107,,8,,B,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,Autocuration
2459,,,,,,,1,,4373,H,107,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,Autocuration
2460,,,,,,,1,,4373,H,107,,8,,B,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,Autocuration
2461,,,,,,,1,,3962,H,107,,8,,F,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,Autocuration
2462,,,,,,,1,,1633,H,107,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,Expert
2463,,,,,,,1,,4373,H,107,,8,,B,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,Autocuration
2464,,,,,,,1,,6576,H,107,,8,,B,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,Expert
2465,,,,,,,1,,4687,H,107,,8,,B,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration
2466,,,,,,,1,,16946,H,107,,8,,B,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,Autocuration
2467,,,,,,,1,,14159,H,107,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,Autocuration
2468,Mus musculus,,,10090.0,,,1,,3032,H,107,CHO,8,,B,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,Expert
2469,,,,,,,1,,16655,H,107,,8,,B,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,Autocuration
2470,,,,,,,1,,13964,H,107,,8,,B,Binding affinity at 5-hydroxytryptamine 2A receptor,,Autocuration
2471,,,,,,,1,,16989,H,107,,8,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,Expert
2472,,,,,,,1,,16117,H,107,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,Autocuration
2473,,,,,,,1,,16700,H,107,,8,,B,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,Autocuration
2474,,,,,,,1,,3269,H,107,,8,,B,Affinity against 5-hydroxytryptamine 2A receptor,,Autocuration
2475,Homo sapiens,,,9606.0,,,1,,1274,D,107,,9,,B,Binding affinity against 5-Hydroxytryptamine 2A receptor,,Expert
2476,,,,,,,1,,1317,H,107,,8,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,Autocuration
2477,,,,,,,1,,12146,H,107,,8,,B,Tested against 5-hydroxytryptamine 2A receptor,,Autocuration
2478,,,,,,,1,,12652,H,105075,,4,,B,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,Autocuration
2479,,,,,,,1,,12652,H,105075,,4,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,Autocuration
2480,,,,,,,1,,12652,H,105075,,4,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,Autocuration
2481,,,,,,,1,,12652,H,105075,,4,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,Autocuration
2482,,,,,,,1,,16647,H,107,,8,,B,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,Autocuration
2483,Homo sapiens,,,9606.0,,,1,,15851,D,227,HEK293,9,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,Expert
2484,Homo sapiens,,,9606.0,,,1,,6857,D,227,CHO,9,,F,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,Expert
2485,,,,,,,1,,3805,H,227,,8,,B,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,Autocuration
2486,Homo sapiens,,,9606.0,,,1,,6491,D,227,,9,,B,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,Expert
2487,,,,,,,1,,14093,H,227,,8,,F,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,Autocuration
2488,,,,,,,1,,13481,H,227,,8,,F,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,Autocuration
2489,,,,,,,1,,14093,H,227,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,Autocuration
2490,,,,,,,1,,14093,H,227,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,Autocuration
2491,,,,,,,1,,14093,H,227,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,Autocuration
2492,,,,,,,1,,13481,H,227,,8,,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,Autocuration
2493,,,,,,,1,,14442,H,227,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,Autocuration
2494,,,,,,,1,,14442,H,227,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,Autocuration
2495,,,,,,,1,,14442,H,227,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,Autocuration
2496,,,,,,,1,,12369,H,107,,8,,B,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,Autocuration
2497,,,,,,,1,,12369,H,107,,8,,B,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,Expert
2498,,,,,,,1,,12369,H,107,,8,,B,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,Expert
2499,,,,,,,1,,14447,H,107,,8,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,Autocuration
2500,,,,,,,1,,14447,H,107,,8,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,Autocuration
2501,,,,,,,1,,17451,H,107,NIH3T3,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration
2502,,,,,,,1,,6857,H,107,CHO,8,,F,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Autocuration
2503,Homo sapiens,,,9606.0,,,1,,6857,D,107,CHO,9,,F,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert
2504,,,,,,,1,,5635,H,104817,,4,,B,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,Autocuration
2505,,,,,,,1,,12861,H,107,,8,,B,Binding activity radioligand.,,Autocuration
2506,,,,,,,1,,12861,H,107,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,Autocuration
2507,,,,,,,1,,5105,H,107,L929,8,,B,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,Autocuration
2508,,,,,,,1,,5104,H,107,L929,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,Expert
2509,,,,,,,1,,5105,H,107,L929,8,,B,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,Expert
2510,,,,,,,1,,5105,H,107,L929,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,Autocuration
2511,,,,,,,1,,5254,H,107,,8,,B,Binding affinity against 5-HT2A receptor,,Autocuration
2512,,,,,,,1,,5254,H,107,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor,,Autocuration
2513,,,,,,,1,,13267,H,107,HEK293,8,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,Autocuration
2514,,,,,,,1,,13267,H,107,HEK293,8,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,Autocuration
2515,Homo sapiens,,,9606.0,,,1,,14157,D,107,HEK293,9,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,Expert
2516,Homo sapiens,,,9606.0,,,1,,12936,D,107,HEK293,9,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert
2517,,,,,,,1,,14068,H,107,,8,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,Expert
2518,Homo sapiens,,,9606.0,,,1,,12936,D,107,HEK293,9,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert
2519,Homo sapiens,,,9606.0,,,1,,12936,D,107,HEK293,9,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert
2520,Homo sapiens,,,9606.0,,,1,,4540,D,107,HEK293,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,Expert
2521,,,,,,,1,,6166,H,107,,8,,B,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,Expert
2522,,,,,,,1,,17296,H,107,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,Autocuration
2523,,,,,,,1,,17296,H,107,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,Autocuration
2524,,,,,,,1,,17296,H,107,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,Autocuration
2525,Homo sapiens,,,9606.0,,,1,,15779,D,107,HEK293,9,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,Expert
2526,,,,,,,1,,14391,H,107,HEK293,8,,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,Expert
2527,,,,,,,1,,15851,H,107,HEK293,8,,B,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,Expert
2528,Homo sapiens,,,9606.0,,,1,,15851,D,107,HEK293,9,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,Expert
2529,,,,,,,1,,3832,H,107,HEK293,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,Expert
2530,,,,,,,1,,3833,H,107,HEK293,8,,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,Expert
2531,Homo sapiens,,,9606.0,,,1,,12936,D,107,HEK293,9,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert
2532,,,,,,,1,,17451,H,107,NIH3T3,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,Autocuration
2533,,,,,,,1,,17451,H,107,NIH3T3,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration
2534,,,,,,,1,,17451,H,107,NIH3T3,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration
2535,,,,,,,1,,4199,H,107,HEK293,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,Autocuration
2536,,,,,,,1,,1883,H,107,CHO-K1,8,,B,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,Autocuration
2537,,,,,,,1,,1883,H,107,CHO-K1,8,,B,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,Expert
2538,Homo sapiens,,,9606.0,,,1,,14875,D,107,,9,,B,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Expert
2539,,,,,,,1,,15146,H,107,HEK293,8,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,Autocuration
2540,,,,,,,1,,5213,H,107,HEK293,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,Autocuration
2541,Homo sapiens,,,9606.0,,,1,,16404,D,107,CHO,9,,B,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Expert
2542,,,,,,,1,,14818,H,107,HEK293,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,Autocuration
2543,,,,,,,1,,4829,H,107,HEK293,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,Autocuration
2544,,,,,,,1,,12652,H,10620,NIH3T3,8,,F,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,Autocuration
2545,,,,,,,1,,4682,H,107,NIH3T3,8,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,Expert
2546,,,,,,,1,,12652,H,10620,,8,,F,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,Autocuration
2547,,,,,,,1,,4921,H,10621,,8,,B,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,Autocuration
2548,,,,,,,1,,4921,H,10621,,8,,B,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,Autocuration
2549,Oryctolagus cuniculus,,,9986.0,,,1,,16312,H,107,,8,,B,Binding affinity against rabbit aorta 5-HT2A receptor,,Autocuration
2550,Oryctolagus cuniculus,,,9986.0,,,1,,14998,H,107,,8,,B,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,Expert
2551,Oryctolagus cuniculus,,,9986.0,,,1,,14025,H,107,,8,,B,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,Expert
2552,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,107,,8,,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Autocuration
2553,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,107,,8,,B,The compound was tested for binding affinity against 5-HT2A receptor,,Expert
2554,,,,,,,1,,1883,H,10576,CHO-K1,8,,B,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,Autocuration
2555,,,,,,,1,,13463,H,12687,,8,,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,Autocuration
2556,,,,,,,1,,13463,H,12687,,8,,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,Autocuration
2557,,,945.0,,,,1,,13463,H,12687,,8,Stomach,B,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,Autocuration
2558,Rattus norvegicus,,945.0,10116.0,,,1,,13463,D,12687,,9,Stomach,B,Binding affinity for 5-HT 2A in rat stomach fundus,,Expert
2559,,,,,,,1,,13463,H,12687,,8,,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,Autocuration
2560,,,,,,,1,,16326,H,12687,NIH3T3,8,,B,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,Expert
2561,,,,,,,1,,14093,H,12687,,8,,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,Autocuration
2562,,,,,,,1,,14093,H,12687,,8,,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,Autocuration
2563,,,,,,,1,,15740,H,12687,,8,,B,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,Autocuration
2564,,,,,,,1,,16633,H,12687,,8,,B,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,Autocuration
2565,Rattus norvegicus,,,10116.0,,,1,,17200,D,12687,,9,,F,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,Expert
2566,,,,,,,1,,17133,H,12687,,8,,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,Autocuration
2567,,,,,,,1,,17133,H,12687,,8,,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,Autocuration
2568,,,,,,,1,,17133,H,12687,,8,,B,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,Autocuration
2569,,,,,,,1,,17200,H,12687,,8,,F,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Autocuration
2570,,,,,,,1,,15363,H,12687,,8,,F,Efficacy at 5-hydroxytryptamine 2A receptor,,Autocuration
2571,,,,,,,1,,17200,H,12687,,8,,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Autocuration
2572,Rattus norvegicus,,,10116.0,,,1,,17200,D,12687,,9,,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Expert
2573,Rattus norvegicus,,,10116.0,,,1,,17200,D,12687,,9,,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,Expert
2574,Rattus norvegicus,,,10116.0,,,1,,17200,D,12687,,9,,F,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Expert
2575,,,,,,,1,,17200,H,12687,,8,,F,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Autocuration
2576,,,,,,,1,,17211,H,12687,,8,,B,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,Autocuration
2577,,,,,,,1,,17331,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,Expert
2578,,,,,,,1,,13565,H,12687,,8,,B,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,Expert
2579,,,,,,,1,,13730,H,12687,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,Expert
2580,,,,,,,1,,12416,H,12687,,8,,B,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,Expert
2581,,,,,,,1,,15295,H,12687,,8,,B,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration
2582,,,,,,,1,,1742,H,12687,,8,,B,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,Autocuration
2583,,,,,,,1,,15295,H,12687,,8,,B,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,Autocuration
2584,,,,,,,1,,14970,H,12687,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,Expert
2585,,,,,,,1,,16693,H,12687,,8,,B,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,Expert
2586,Rattus norvegicus,,,10116.0,,,1,,14776,D,12687,,9,,B,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,Expert
2587,,,,,,,1,,14286,H,12687,,8,,B,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration
2588,Rattus norvegicus,,,10116.0,,,1,,17200,D,12687,,9,,B,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Expert
2589,,,,,,,1,,15306,H,12687,,8,,B,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,Expert
2590,Rattus norvegicus,,,10116.0,,,1,,14178,D,12687,,9,,B,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,Expert
2591,Rattus norvegicus,,,10116.0,,,1,,14229,D,12687,,9,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,Expert
2592,,,,,,,1,,12884,H,12687,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,Expert
2593,,,,,,,1,,13149,H,12687,,8,,B,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,Expert
2594,Rattus norvegicus,,,10116.0,,,1,,15295,D,12687,,9,,B,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,Expert
2595,,,,,,,1,,15740,H,12687,,8,,B,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,Autocuration
2596,,,,,,,1,,15185,H,12687,,8,,B,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,Autocuration
2597,,,,,,,1,,15185,H,12687,,8,,B,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,Autocuration
2598,,,,,,,1,,17529,H,12687,,8,,B,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,Expert
2599,,,,,,,1,,14826,H,12687,,8,,B,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,Autocuration
2600,,,,,,,1,,17211,H,12687,,8,,B,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,Expert
2601,,,,,,,1,,14826,H,12687,,8,,B,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,Autocuration
2602,,,,,,,1,,14093,H,12687,,8,,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,Autocuration
2603,,,,,,,1,,14093,H,12687,,8,,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,Autocuration
2604,,,,,,,1,,13246,H,12687,NIH3T3,8,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,Expert
2605,,,,,,,1,,13246,H,12687,,8,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,Expert
2606,Rattus norvegicus,,,10116.0,,,1,,15436,D,12687,,9,,B,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Expert
2607,Rattus norvegicus,,,10116.0,,,1,,15436,D,12687,,9,,B,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Expert
2608,,,955.0,,,,1,,14442,H,12687,,8,Brain,B,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,Autocuration
2609,,,,,,,1,,12457,H,12687,,8,,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,Expert
2610,,,,,,,1,,12457,H,12687,NIH3T3,8,,B,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,Expert
2611,,,,,,,1,,14755,H,12687,,8,,F,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,Autocuration
2612,,,,,,,1,,4707,H,12687,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,Autocuration
2613,,,,,,,1,,13297,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor,,Expert
2614,,,,,,,1,,17331,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,Expert
2615,,,,,,,1,,4664,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,Autocuration
2616,,,,,,,1,,16633,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration
2617,Rattus norvegicus,,,10116.0,,,1,,4664,D,12687,NIH3T3,9,,B,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,Expert
2618,,,,,,,1,,16133,H,12687,,8,,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Expert
2619,,,,,,,1,,16133,H,12687,,8,,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Expert
2620,Rattus norvegicus,,,10116.0,,,1,,14060,D,12687,,9,,B,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,Expert
2621,,,,,,,1,,16326,H,12687,,8,,B,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Expert
2622,,,,,,,1,,16659,H,12687,CHO,8,,B,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Expert
2623,,,,,,,1,,14776,H,12687,,8,,B,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,Autocuration
2624,,,,,,,1,,13481,H,12687,,8,,B,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,Autocuration
2625,,,,,,,1,,17386,H,12687,,8,,B,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,Autocuration
2626,Rattus norvegicus,,,10116.0,,,1,,6611,D,12687,,9,,B,Binding affinity for 5-hydroxytryptamine 2A receptor,,Expert
2627,,,,,,,1,,14423,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,Autocuration
2628,,,,,,,1,,15412,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,Autocuration
2629,,,,,,,1,,15412,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,Autocuration
2630,,,,,,,1,,6238,H,12687,,8,,B,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,Autocuration
2631,,,,,,,1,,6648,H,12687,,8,,B,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,Expert
2632,,,,,,,1,,5667,H,12687,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,Expert
2633,Rattus norvegicus,,,10116.0,,,1,,6611,D,12687,,9,,B,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,Expert
2634,,,,,,,1,,13481,H,12687,,8,,B,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration
2635,,,,,,,1,,13481,H,12687,,8,,B,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,Autocuration
2636,,,,,,,1,,15558,H,12687,NIH3T3,8,,B,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,Expert
2637,,,,,,,1,,6013,H,12687,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration
2638,,,,,,,1,,16633,H,12687,,8,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration
2639,,,,,,,1,,6013,H,12687,,8,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,Autocuration
2640,Rattus norvegicus,,,10116.0,,,1,,6013,D,12687,,9,,B,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,Expert
2641,,,,,,,1,,6013,H,12687,,8,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,Autocuration
2642,,,,,,,1,,6013,H,12687,,8,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,Expert
2643,,,,,,,1,,6013,H,12687,,8,,B,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,Autocuration
2644,,,,,,,1,,6013,H,12687,,8,,B,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,Autocuration
2645,,,,,,,1,,16293,H,12687,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,Autocuration
2646,,,,,,,1,,17175,H,12687,NIH3T3,8,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,Expert
2647,Rattus norvegicus,,,10116.0,,,1,,13278,D,12687,,9,,B,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Expert
2648,,,5383.0,,,,1,,3682,H,12687,,8,Caudate-putamen,B,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,Autocuration
2649,,,,,,,1,,2014,H,12687,,8,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,Autocuration
2650,,,,,,,1,,2014,H,12687,,8,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,Autocuration
2651,,,,,,,1,,4932,H,12687,,8,,B,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,Autocuration
2652,,,,,,,1,,4932,H,12687,,8,,B,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,Autocuration
2653,,,,,,,1,,3935,H,12687,,8,,B,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,Autocuration
2654,Rattus norvegicus,,10000000.0,10116.0,,,1,,5432,D,12687,,9,Hippocampus,B,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,Expert
2655,,,,,,,1,,15818,H,12687,,8,,B,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,Autocuration
2656,,,,,,,1,,13672,H,12687,,8,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,Autocuration
2657,,,,,,,1,,13672,H,12687,,8,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,Autocuration
2658,,,,,,,1,,14749,H,12687,NIH3T3,8,,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,Expert
2659,,,,,,,1,,13462,H,12687,,8,,B,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,Autocuration
2660,,,,,,,1,,15740,H,12687,,8,,B,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,Autocuration
2661,,,,,,,1,,16647,H,12687,,8,,B,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,Expert
2662,,,955.0,,,,1,,13345,H,12687,,8,Brain,B,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,Autocuration
2663,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration
2664,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration
2665,Rattus norvegicus,,,10116.0,,,1,,15535,D,12687,,9,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,Expert
2666,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Expert
2667,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration
2668,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration
2669,Rattus norvegicus,,,10116.0,,,1,,4795,D,12687,,9,,B,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,Expert
2670,,,,,,,1,,8,H,12687,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,Expert
2671,,,,,,,1,,8,H,12687,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,Autocuration
2672,Rattus norvegicus,,,10116.0,,,1,,17200,D,12687,,9,,B,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Expert
2673,Rattus norvegicus,,,10116.0,,,1,,2148,D,12687,,9,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,Expert
2674,Rattus norvegicus,,,10116.0,,,1,,13345,D,105102,,5,,B,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,Expert
2675,,,,,,,1,,5088,H,12687,,8,,B,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Autocuration
2676,,,,,,,1,,5088,H,12687,,8,,B,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration
2677,,,,,,,1,,17133,H,12687,,8,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,Autocuration
2678,Rattus norvegicus,,,10116.0,,,1,,17133,D,12687,,9,,B,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,Expert
2679,,,,,,,1,,16532,H,12687,,8,,B,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,Autocuration
2680,,,,,,,1,,15086,H,12687,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,Autocuration
2681,Rattus norvegicus,,,10116.0,,,1,,2309,D,12687,,9,,B,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert
2682,,,,,,,1,,12953,H,12687,,8,,B,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,Expert
2683,,,,,,,1,,12953,H,12687,,8,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,Autocuration
2684,,,,,,,1,,12953,H,12687,,8,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,Autocuration
2685,,,,,,,1,,16659,H,12687,CHO,8,,B,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,Autocuration
2686,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,Autocuration
2687,,,,,,,1,,16740,H,12687,,8,,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,Autocuration
2688,,,,,,,1,,17133,H,12687,,8,,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,Autocuration
2689,,,,,,,1,,17211,H,12687,,8,,B,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,Autocuration
2690,,,,,,,1,,17331,H,12687,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,Autocuration
2691,,,,,,,1,,16633,H,12687,,8,,B,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,Autocuration
2692,,,,,,,1,,16633,H,12687,,8,,B,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,Autocuration
2693,,,,,,,1,,16633,H,12687,,8,,B,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,Autocuration
2694,,,,,,,1,,15026,H,12687,,8,,B,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,Expert
2695,,,,,,,1,,15026,H,12687,,8,,B,Ratio of pKi of 5-HT2A to that of D2 receptor,,Expert
2696,,,,,,,1,,16404,H,105093,,4,,B,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,Expert
2697,,,,,,,1,,16404,H,105093,,4,,B,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,Expert
2698,,,,,,,1,,16404,H,105075,,4,,B,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,Expert
2699,,,,,,,1,,16404,H,12687,,8,,B,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,Autocuration
2700,,,,,,,1,,16326,H,12687,,8,,B,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,Expert
2701,,,,,,,1,,15847,H,12687,,8,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,Autocuration
2702,,,,,,,1,,15847,H,12687,,8,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,Autocuration
2703,,,,,,,1,,15329,H,12687,,8,,F,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,Autocuration
2704,,,1515.0,,,,1,,16404,H,12687,,8,Thoracic aorta,F,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,Expert
2705,,,1515.0,,,,1,,16404,H,12687,,8,Thoracic aorta,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,Expert
2706,,,1515.0,,,,1,,16404,H,12687,,8,Thoracic aorta,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,Autocuration
2707,,,,,,,1,,12861,H,12687,,8,,B,Binding activity radioligand.,,Autocuration
2708,,,,,,,1,,12861,H,12687,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,Expert
2709,,,,,,,1,,12861,H,12687,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,Autocuration
2710,,,,,,,1,,12490,H,12687,,8,,B,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,Expert
2711,,,,,,,1,,12827,H,12687,N1E-115,8,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,Autocuration
2712,,,,,,,1,,12827,H,12687,N1E-115,8,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,Autocuration
2713,,,,,,,1,,12918,H,12687,,8,,B,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,Autocuration
2714,Rattus norvegicus,,,10116.0,,,1,,12919,D,12687,,9,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,Expert
2715,,,,,,,1,,17723,H,108,,8,,B,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,Autocuration
2716,,,,,,,1,,6013,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,Autocuration
2717,,,,,,,1,,16293,H,108,,8,,B,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,Autocuration
2718,,,,,,,1,,3857,H,108,,8,,B,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,Expert
2719,,,,,,,1,,3857,H,108,,8,,B,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,Expert
2720,,,,,,,1,,3857,H,108,,8,,B,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,Expert
2721,,,,,,,1,,15363,H,108,,8,,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,Autocuration
2722,,,,,,,1,,15363,H,108,,8,,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,Autocuration
2723,,,,,,,1,,16441,H,108,,8,,B,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,Expert
2724,,,,,,,1,,16441,H,108,,8,,B,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,Expert
2725,,,,,,,1,,4176,H,108,HEK293,8,,B,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,Autocuration
2726,,,,,,,1,,17085,H,108,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,Autocuration
2727,Homo sapiens,,,9606.0,,,1,,17200,D,108,,9,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,Expert
2728,,,,,,,1,,5088,H,108,,8,,B,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,Expert
2729,,,,,,,1,,5088,H,108,,8,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,Autocuration
2730,,,,,,,1,,5088,H,108,,8,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration
2731,,,,,,,1,,5088,H,108,,8,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,Autocuration
2732,,,,,,,1,,16659,H,108,CHO,8,,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,Autocuration
2733,,,,,,,1,,16659,H,108,CHO,8,,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,Autocuration
2734,,,,,,,1,,17451,H,108,NIH3T3,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration
2735,Homo sapiens,,,9606.0,,,1,,6857,D,108,CHO,9,,F,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert
2736,,,,,,,1,,3857,H,108,,8,,B,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,Expert
2737,,,,,,,1,,12861,H,108,,8,,B,Binding activity radioligand.,,Autocuration
2738,,,,,,,1,,12861,H,108,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,Autocuration
2739,,,,,,,1,,5104,H,108,CHO,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,Expert
2740,,,,,,,1,,5105,H,108,CHO,8,,B,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,Expert
2741,,,,,,,1,,5105,H,108,CHO,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,Autocuration
2742,,,,,,,1,,5254,H,108,,8,,B,Binding affinity against 5-HT2C receptor,,Autocuration
2743,,,,,,,1,,13267,H,108,HEK293,8,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,Autocuration
2744,Homo sapiens,,,9606.0,,,1,,14157,D,108,HEK293,9,,B,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,Expert
2745,Homo sapiens,,,9606.0,,,1,,12936,D,108,HEK293,9,,B,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Expert
2746,,,,,,,1,,14068,H,108,,8,,B,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,Expert
2747,Homo sapiens,,,9606.0,,,1,,12936,D,108,HEK293,9,,B,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Expert
2748,Homo sapiens,,,9606.0,,,1,,4540,D,108,HEK293,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,Expert
2749,Homo sapiens,,,9606.0,,,1,,4540,D,108,HEK293,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,Expert
2750,,,,,,,1,,6166,H,108,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,Autocuration
2751,,,,,,,1,,17296,H,108,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,Autocuration
2752,,,,,,,1,,17296,H,108,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,Autocuration
2753,,,,,,,1,,15779,H,108,HEK293,8,,B,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration
2754,,,,,,,1,,15779,H,108,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration
2755,,,,,,,1,,14391,H,108,HEK293,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,Expert
2756,,,,,,,1,,15779,H,108,HEK293,8,,B,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,Autocuration
2757,,,,,,,1,,15851,H,108,HEK293,8,,B,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,Expert
2758,Homo sapiens,,,9606.0,,,1,,15851,D,108,HEK293,9,,B,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,Expert
2759,,,,,,,1,,15779,H,108,HEK293,8,,B,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,Autocuration
2760,,,,,,,1,,3832,H,108,HEK293,8,,B,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,Expert
2761,,,,,,,1,,3833,H,108,HEK293,8,,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,Expert
2762,,,,,,,1,,17451,H,108,NIH3T3,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,Autocuration
2763,,,,,,,1,,4199,H,108,HEK293,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,Autocuration
2764,,,,,,,1,,1883,H,108,CHO-K1,8,,B,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,Expert
2765,Homo sapiens,,,9606.0,,,1,,4321,D,108,,9,,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,Expert
2766,,,,,,,1,,14875,H,108,,8,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,Autocuration
2767,,,,,,,1,,15146,H,108,HEK293,8,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,Autocuration
2768,,,,,,,1,,5213,H,108,HEK293,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,Autocuration
2769,,,,,,,1,,16404,H,108,HeLa,8,,B,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,Autocuration
2770,,,,,,,1,,13267,H,108,,8,,F,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,Autocuration
2771,,,10000000.0,,,,1,,13267,H,108,,8,Hippocampus,F,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,Autocuration
2772,,,,,,,1,,14818,H,108,HEK293,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,Autocuration
2773,,,,,,,1,,4829,H,108,HEK293,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,Autocuration
2774,,,,,,,1,,13463,H,11864,,8,,B,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,Autocuration
2775,,,945.0,,,,1,,13463,H,11864,,8,Stomach,B,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,Autocuration
2776,,,945.0,,,,1,,13463,H,11864,,8,Stomach,B,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,Autocuration
2777,,,,,,,1,,12652,H,11864,A9,8,,F,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,Autocuration
2778,,,,,,,1,,4682,H,11864,NIH3T3,8,,B,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,Autocuration
2779,,,,,,,1,,4682,H,11864,NIH3T3,8,,B,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,Autocuration
2780,,,,,,,1,,4682,H,11864,NIH3T3,8,,B,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,Autocuration
2781,,,,,,,1,,12652,H,11864,,8,,F,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,Autocuration
2782,Mus musculus,,945.0,10090.0,,,1,,13463,H,12689,,8,Stomach,B,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,Autocuration
2783,Rattus norvegicus,,945.0,10116.0,,,1,,13463,D,12689,,9,Stomach,B,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,Expert
2784,,,,,,,1,,13969,H,108,,8,,B,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,Expert
2785,Sus scrofa,,,9823.0,,,1,,13392,H,108,,8,,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,Expert
2786,,,,,,,1,,13392,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,Expert
2787,,,,,,,1,,14430,H,108,,8,,B,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,Expert
2788,,,,,,,1,,1742,H,108,,8,,B,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,Autocuration
2789,,,,,,,1,,14286,H,108,,8,,B,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,Autocuration
2790,,,,,,,1,,5619,H,108,,8,,B,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,Autocuration
2791,,,,,,,1,,15086,H,108,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,Autocuration
2792,,,,,,,1,,12861,H,108,,8,,B,Binding activity radioligand.,,Autocuration
2793,,,,,,,1,,12861,H,108,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,Expert
2794,,,,,,,1,,12861,H,108,,8,,B,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,Autocuration
2795,,,,,,,1,,12827,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,Autocuration
2796,,,,,,,1,,12827,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,Autocuration
2797,Sus scrofa,,,9823.0,,,1,,12919,H,108,,8,,F,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Expert
2798,Sus scrofa,,,9823.0,,,1,,12919,H,108,,8,,F,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Expert
2799,Sus scrofa,,,9823.0,,,1,,16429,H,108,,8,,B,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,Autocuration
2800,Sus scrofa,,,9823.0,,,1,,773,H,108,,8,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,Autocuration
2801,Sus scrofa,,,9823.0,,,1,,5033,H,108,,8,,B,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,Autocuration
2802,,,,,,,1,,12861,H,12687,,8,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,Autocuration
2803,,,,,,,1,,14093,H,12689,,8,,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,Autocuration
2804,,,,,,,1,,14970,H,12689,,8,,B,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,Expert
2805,,,,,,,1,,14970,H,12689,,8,,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,Autocuration
2806,,,,,,,1,,14970,H,12689,,8,,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,Autocuration
2807,Rattus norvegicus,,,10116.0,,,1,,14178,D,12689,,9,,B,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,Expert
2808,Rattus norvegicus,,,10116.0,,,1,,14178,D,12689,,9,,B,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,Expert
2809,Rattus norvegicus,,,10116.0,,,1,,14229,D,12689,,9,,B,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Brain membranes,Expert
2810,,,,,,,1,,16532,H,12689,,8,,B,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,Autocuration
2811,,,,,,,1,,14826,H,12689,,8,,B,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,Autocuration
2812,,,,,,,1,,17211,H,12689,,8,,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,Autocuration
2813,,,,,In vitro,,1,,17211,H,12689,,8,,B,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,Expert
2814,,,,,,,1,,13246,H,12689,NIH3T3,8,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,Expert
2815,,,,,,,1,,13246,H,12689,,8,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,Expert
2816,,,,,,,1,,12457,H,12689,,8,,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,Expert
2817,,,,,,,1,,12457,H,12689,NIH3T3,8,,B,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,Expert
2818,,,,,,,1,,4707,H,12689,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,Autocuration
2819,,,,,,,1,,13297,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,Expert
2820,,,,,,,1,,16633,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,Autocuration
2821,,,,,,,1,,16133,H,12689,,8,,B,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Expert
2822,,,,,,,1,,16326,H,12689,,8,,B,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,Expert
2823,,,,,,,1,,14423,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,Autocuration
2824,,,,,,,1,,15412,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,Autocuration
2825,,,,,,,1,,15412,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,Autocuration
2826,,,,,,,1,,15558,H,12689,A9,8,,B,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,Expert
2827,,,,,,,1,,16633,H,12689,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,Autocuration
2828,,,,,,,1,,6013,H,12689,,8,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,Expert
2829,,,,,In vitro,,1,,17175,H,12689,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,Expert
2830,,,,,,,1,,12469,H,12689,,8,,B,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,Autocuration
2831,,,5383.0,,,,1,,3682,H,12689,,8,Caudate-putamen,B,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,Autocuration
2832,,,,,,,1,,4932,H,12689,,8,,B,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,Autocuration
2833,,,,,,,1,,4932,H,12689,,8,,B,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,Autocuration
2834,,,,,,,1,,3935,H,12689,,8,,B,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,Autocuration
2835,,,,,,,1,,15818,H,12689,,8,,B,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,Autocuration
2836,,,,,,,1,,15818,H,12689,,8,,B,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,Autocuration
2837,,,,,,,1,,14749,H,12689,,8,,B,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,Expert
2838,,,,,,,1,,15740,H,12689,,8,,B,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,Autocuration
2839,Rattus norvegicus,,,10116.0,,,1,,17133,D,12689,,9,,B,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,Expert
2840,,,,,,,1,,16532,H,12689,,8,,B,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,Autocuration
2841,,,,,,,1,,12369,H,12689,,8,,B,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,Autocuration
2842,,,,,,,1,,12369,H,12689,,8,,B,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,Expert
2843,Rattus norvegicus,,,10116.0,,,1,,2309,D,12689,,9,,B,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,Expert
2844,,,,,,,1,,12953,H,12689,,8,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,Autocuration
2845,,,,,,,1,,12953,H,12689,,8,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,Autocuration
2846,,,,,,,1,,12953,H,12689,,8,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,Autocuration
2847,,,,,,,1,,12953,H,12689,,8,,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,Expert
2848,,,,,,,1,,17133,H,12689,,8,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,Autocuration
2849,,,,,,,1,,17211,H,12689,,8,,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,Autocuration
2850,,,,,,,1,,17211,H,12689,,8,,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,Autocuration
2851,,,,,,,1,,14025,H,12689,,8,,B,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,Autocuration
2852,,,,,,,1,,14998,H,12689,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,Autocuration
2853,,,,,,,1,,4342,H,12689,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,Autocuration
2854,Rattus norvegicus,,,10116.0,,,1,,13735,D,12689,,9,,B,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,Expert
2855,,,,,,,1,,13181,H,12689,,8,,B,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,Autocuration
2856,,,,,,,1,,1883,H,12689,CHO-K1,8,,B,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,Autocuration
2857,,,,,,,1,,15194,H,12689,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration
2858,,,,,,,1,,15194,H,12689,,8,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,Autocuration
2859,,,,,,,1,,14579,H,12689,,8,,F,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,Autocuration
2860,,,,,,,1,,4639,H,108,,8,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,Autocuration
2861,,,,,,,1,,4820,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,Expert
2862,,,,,,,1,,14442,H,227,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,Autocuration
2863,,,,,,,1,,14755,H,227,,8,,B,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,Autocuration
2864,,,,,,,1,,14744,H,227,,8,,B,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,Autocuration
2865,Homo sapiens,,,9606.0,,,1,,6857,D,227,,9,,B,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,Expert
2866,,,,,,,1,,16209,H,227,,8,,B,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,Autocuration
2867,,,,,,,1,,15363,H,227,,8,,B,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,Autocuration
2868,,,,,,,1,,15363,H,227,,8,,B,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,Autocuration
2869,,,,,,,1,,15363,H,227,,8,,B,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,Autocuration
2870,,,,,,,1,,17085,H,227,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,Autocuration
2871,Homo sapiens,,,9606.0,,,1,,17200,D,227,,9,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,Expert
2872,Homo sapiens,,,9606.0,,,1,,15851,D,227,HEK293,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Expert
2873,Homo sapiens,,,9606.0,,,1,,15851,D,227,HEK293,9,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Expert
2874,Homo sapiens,,,9606.0,,,1,,6857,D,227,CHO,9,,F,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert
2875,Homo sapiens,,,9606.0,,,1,,6857,D,227,CHO,9,,F,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert
2876,,,,,,,1,,15779,H,227,HEK293,8,,B,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,Autocuration
2877,,,,,,,1,,15851,H,227,HEK293,8,,B,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,Expert
2878,,,,,,,1,,15779,H,227,HEK293,8,,B,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,Autocuration
2879,Homo sapiens,,,9606.0,,,1,,14157,D,227,HEK293,9,,B,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,Expert
2880,Homo sapiens,,,9606.0,,,1,,4540,D,227,HEK293,9,,B,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,Expert
2881,,,,,,,1,,6166,H,227,,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,Autocuration
2882,,,,,,,1,,15779,H,227,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,Autocuration
2883,,,,,,,1,,14391,H,227,HEK293,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,Expert
2884,,,,,,,1,,3832,H,227,HEK293,8,,B,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,Expert
2885,,,,,,,1,,3833,H,227,HEK293,8,,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,Expert
2886,Homo sapiens,,,9606.0,,,1,,15851,D,227,HEK293,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,Expert
2887,Homo sapiens,,,9606.0,,,1,,15851,D,227,HEK293,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,Expert
2888,,,,,,,1,,4199,H,227,HEK293,8,,B,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,Autocuration
2889,,,,,,,1,,1883,H,227,CHO-K1,8,,B,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,Expert
2890,,,,,,,1,,4321,H,227,,8,,B,Binding affinity against 5-hydroxytryptamine 2B receptor,,Expert
2891,,,,,,,1,,15146,H,227,HEK293,8,,B,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,Autocuration
2892,,,,,,,1,,5213,H,227,HEK293,8,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,Autocuration
2893,,,,,,,1,,14818,H,227,HEK293,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,Autocuration
2894,,,,,,,1,,4829,H,227,HEK293,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,Autocuration
2895,,,,,,,1,,4829,H,227,HEK293,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,Autocuration
2896,Oryctolagus cuniculus,,,9986.0,,,1,,14025,H,227,,8,,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,Autocuration
2897,,,945.0,,,,1,,13463,H,12688,,8,Stomach,B,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,Expert
2898,,,945.0,,,,1,,7259,H,12688,,8,Stomach,B,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,Expert
2899,,,945.0,,,,1,,7259,H,12688,,8,Stomach,B,Affinity against serotonergic receptor in the isolated rat stomach fundus,,Autocuration
2900,Rattus norvegicus,,945.0,10116.0,,,1,,7185,D,12688,,9,Stomach,F,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,Expert
2901,Rattus norvegicus,,,10116.0,,,1,,7185,D,12688,,9,,F,Antagonistic against 5-hydroxytryptamine 2B receptor,,Expert
2902,,,945.0,,,,1,,13267,H,12688,,8,Stomach,F,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,Autocuration
2903,Rattus norvegicus,,945.0,10116.0,,,1,,13735,D,12688,,9,Stomach,B,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,Expert
2904,,,,,,,1,,15738,H,12688,,8,,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,Autocuration
2905,,,,,,,1,,15738,H,12688,,8,,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,Autocuration
2906,,,,,,,1,,15738,H,12688,,8,,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,Autocuration
2907,Rattus norvegicus,,945.0,10116.0,,,1,,12936,D,12688,,9,Stomach,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Expert
2908,Rattus norvegicus,,945.0,10116.0,,,1,,12936,D,12688,,9,Stomach,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Expert
2909,Rattus norvegicus,,945.0,10116.0,,,1,,12936,D,12688,,9,Stomach,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Expert
2910,Rattus norvegicus,,945.0,10116.0,,,1,,12936,D,12688,,9,Stomach,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Expert
2911,,,945.0,,,,1,,16404,H,12688,,8,Stomach,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,Autocuration
2912,,,945.0,,,,1,,16404,H,12688,,8,Stomach,F,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,Expert
2913,,,945.0,,,,1,,16404,H,12688,,8,Stomach,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,Autocuration
2914,,,945.0,,,,1,,16404,H,12688,,8,Stomach,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,Autocuration
2915,Rattus norvegicus,,945.0,10116.0,,,1,,16404,D,12688,,9,Stomach,F,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,Expert
2916,,,1515.0,,,,1,,16404,H,12688,,8,Thoracic aorta,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,Autocuration
2917,,,,,,,1,,7483,H,12688,,8,,B,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,Autocuration
2918,,,,,,,1,,7483,H,12688,,8,,B,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,Expert
2919,,,,,,,1,,7483,H,12688,,8,,B,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,Autocuration
2920,,,,,,,1,,7483,H,12688,,8,,B,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,Autocuration
2922,Rattus norvegicus,,945.0,10116.0,,,1,,16404,D,12688,,9,Stomach,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,Autocuration
2923,,,,,,,1,,6347,H,227,,8,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration
2924,,,,,,,1,,4373,H,227,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,Autocuration
2925,,,,,,,1,,4373,H,227,,8,,B,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,Autocuration
2926,,,,,,,1,,4687,H,227,,8,,B,Evaluated for the binding affinity to 5-HT 2B receptor,,Autocuration
2927,,,,,,,1,,16946,H,227,,8,,B,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,Autocuration
2928,,,,,,,1,,16633,H,227,,8,,B,Binding affinities against 5-hydroxytryptamine 2B receptor,,Autocuration
2929,,,,,,,1,,16633,H,227,,8,,B,Binding affinities towards 5-hydroxytryptamine 2B receptor,,Autocuration
2930,,,,,,,1,,16633,H,227,,8,,B,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,Autocuration
2931,,,,,,,1,,15026,H,108,,8,,B,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Expert
2932,Bos taurus,,,9913.0,,,1,,15738,H,108,,8,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Autocuration
2933,Bos taurus,,,9913.0,,,1,,15738,H,108,,8,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,Autocuration
2934,Bos taurus,,,9913.0,,,1,,15738,H,108,,8,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,Autocuration
2935,Bos taurus,,,9913.0,,,1,,15738,H,108,,8,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,Autocuration
2936,Bos taurus,,,9913.0,,,1,,16404,H,108,,8,,B,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,Expert
2937,Bos taurus,,,9913.0,,,1,,15026,H,108,,8,,B,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Expert
2938,Bos taurus,,,9913.0,,,1,,15738,H,108,,8,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Autocuration
2939,Cavia porcellus,,,10141.0,,,1,,16312,H,108,,8,,B,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,Autocuration
2940,Cavia porcellus,,2435.0,10141.0,,,1,,5486,D,20033,,9,Striatum,B,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,Intermediate
2941,,,,,,,1,,5254,H,51,,8,,B,Binding affinity against 5-HT1A receptor,,Autocuration
2942,,,,,,,1,,3857,H,108,CHO,8,,F,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,Expert
2943,Homo sapiens,,,9606.0,,,1,,6857,D,108,CHO,9,,F,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,Expert
2944,,,,,,,1,,4176,H,108,,8,,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,Autocuration
2945,,,,,,,1,,6347,H,108,CHO,8,,B,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,Autocuration
2946,,,,,,,1,,6347,H,108,CHO,8,,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,Autocuration
2947,Homo sapiens,,,9606.0,,,1,,16146,D,108,,9,,B,Inhibition of human 5-hydroxytryptamine 2C receptor,,Expert
2948,,,,,,,1,,3805,H,108,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,Autocuration
2949,,,,,,,1,,3857,H,108,,8,,B,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,Autocuration
2950,,,,,,,1,,5635,H,108,,8,,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,Autocuration
2951,,,,,,,1,,5635,H,108,,8,,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,Autocuration
2952,,,,,,,1,,5635,H,108,,8,,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,Autocuration
2953,,,,,,,1,,4012,H,108,CHO,8,,B,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,Expert
2954,,,,,,,1,,6366,H,108,CHO,8,,B,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,Expert
2955,,,,,,,1,,15949,H,108,CHO,8,,B,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,Expert
2956,,,,,,,1,,17211,H,108,CHO,8,,B,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,Autocuration
2957,Homo sapiens,,,9606.0,,,1,,6491,D,108,,9,,B,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,Expert
2958,,,,,,,1,,14093,H,108,,8,,F,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,Autocuration
2959,,,,,,,1,,13481,H,108,,8,,F,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,Autocuration
2960,Rattus norvegicus,,,10116.0,,,1,,6347,H,108,CHO,8,,B,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,Expert
2961,,,,,,,1,,14093,H,108,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,Autocuration
2962,,,,,,,1,,14093,H,108,,8,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,Autocuration
2963,,,,,,,1,,13481,H,108,,8,,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration
2964,,,,,,,1,,14442,H,108,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,Autocuration
2965,,,,,,,1,,14442,H,108,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,Autocuration
2966,,,,,,,1,,14442,H,108,,8,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,Autocuration
2967,,,,,,,1,,14755,H,108,,8,,B,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,Autocuration
2968,,,,,,,1,,14744,H,108,,8,,B,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,Autocuration
2969,,,,,,,1,,16659,H,108,CHO,8,,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,Expert
2970,Homo sapiens,,,9606.0,,,1,,6857,D,108,,9,,B,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,Expert
2971,,,,,,,1,,5635,H,108,,8,,B,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,Expert
2972,Homo sapiens,,,9606.0,,,1,,4234,D,108,,9,,B,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,Expert
2973,,,,,,,1,,16209,H,108,,8,,B,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,Autocuration
2974,Rattus norvegicus,,,10116.0,,,1,,5778,D,104698,,7,,B,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Membranes,Autocuration
2975,,,,,,,1,,5094,H,104698,,6,,B,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,Autocuration
2976,Rattus norvegicus,,,10116.0,,,1,,809,D,104698,,7,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,Autocuration
2977,,,,,,,1,,1578,H,104698,,6,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,Autocuration
2978,,,,,,,1,,809,H,104698,,6,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,Autocuration
2979,,,,,,,1,,12469,H,104698,,6,,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,Autocuration
2980,,,,,,,1,,14290,H,104698,,6,,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,Autocuration
2981,,,,,,,1,,14290,H,104698,,6,,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,Autocuration
2982,,,,,,,1,,10609,H,104698,,6,,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,Autocuration
2983,,,,,,,1,,10609,H,104698,,6,,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,Autocuration
2984,,,,,,,1,,10609,H,104698,,6,,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,Autocuration
2985,,,,,,,1,,15253,H,104698,,6,,B,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,Autocuration
2986,,,,,,,1,,15253,H,104698,,6,,B,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,Autocuration
2987,,,,,,,1,,11683,H,104698,,6,,B,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Membranes,Autocuration
2988,,,,,,,1,,12092,H,104698,,6,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,Autocuration
2989,,,,,,,1,,1946,H,104698,,6,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,Autocuration
2990,,,,,,,1,,11623,H,104698,,6,,B,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,Autocuration
2991,,,,,,,1,,11623,H,104698,,6,,B,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,Autocuration
2992,,,,,,,1,,14788,H,104698,,6,,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,Autocuration
2993,Rattus norvegicus,,,10116.0,,,1,,5432,D,104698,,7,,B,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,Autocuration
2994,,,,,,,1,,14826,H,104698,,6,,B,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,Autocuration
2995,,,,,,,1,,2222,H,104698,,6,,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,Autocuration
2996,,,,,,,1,,11963,H,104698,,6,,B,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,Autocuration
2997,,,,,,,1,,14145,H,104698,,6,,B,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,Autocuration
2998,,,,,,,1,,17819,H,104698,,6,,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,Autocuration
2999,,,,,,,1,,10394,H,104698,,6,,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,Autocuration
3000,,,,,,,1,,10394,H,104698,,6,,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,Autocuration
3001,,,,,,,1,,15034,H,104698,,6,,B,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,Autocuration
3002,,,,,,,1,,691,H,104698,,6,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,Autocuration
3003,,,,,,,1,,12092,H,104698,,6,,B,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Membranes,Autocuration
3004,Rattus norvegicus,,,10116.0,,,1,,11752,D,104698,,7,,B,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Autocuration
3005,,,955.0,,,,1,,11752,H,104698,,6,Brain,B,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,Autocuration
3006,,,,,,,1,,301,H,104698,,6,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,Autocuration
3007,,,,,,,1,,16532,H,104698,,6,,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,Autocuration
3008,,,,,,,1,,16532,H,104698,,6,,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,Autocuration
3009,,,,,,,1,,12092,H,104698,,6,,B,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,Autocuration
3010,,,,,,,1,,11684,H,104698,,6,,B,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,Autocuration
3011,,,,,,,1,,11684,H,104698,,6,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,Autocuration
3012,,,,,,,1,,12953,H,104698,,6,,B,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,Autocuration
3013,,,,,,,1,,12953,H,104698,,6,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,Autocuration
3014,,,,,,,1,,12953,H,104698,,6,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,Autocuration
3015,,,,,,,1,,12861,H,104698,,6,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,Autocuration
3016,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration
3017,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration
3018,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration
3019,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,Autocuration
3020,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration
3021,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration
3022,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,Autocuration
3023,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration
3024,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,Autocuration
3025,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration
3026,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration
3027,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration
3028,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,Autocuration
3029,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration
3030,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration
3031,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration
3032,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration
3033,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration
3034,,,,,,,1,,10609,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,Autocuration
3035,,,,,,,1,,12861,H,104698,,6,,B,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,Autocuration
3036,Rattus norvegicus,,,10116.0,,,1,,12861,D,104698,,7,,B,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Autocuration
3037,,,,,,,1,,12861,H,104698,,6,,B,Binding activity radioligand.,,Autocuration
3038,,,,,,,1,,10728,H,104698,,6,,B,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Brain membranes,Autocuration
3039,,,,,,,1,,10728,H,104698,,6,,B,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Brain membranes,Autocuration
3040,,,,,,,1,,5163,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,Autocuration
3041,,,,,,,1,,5163,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,Autocuration
3042,,,,,,,1,,6011,H,108,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,Autocuration
3043,,,,,,,1,,5014,H,108,,8,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,Autocuration
3044,,,,,,,1,,5635,H,108,,8,,B,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,Autocuration
3045,,,,,,,1,,5163,H,108,,8,,B,Affinity for 5-hydroxytryptamine 2C receptor,,Expert
3046,,,,,,,1,,6841,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration
3047,,,,,,,1,,6119,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,Expert
3048,,,,,,,1,,4373,H,108,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,Autocuration
3049,,,,,,,1,,1633,H,108,,8,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,Autocuration
3050,,,,,,,1,,1633,H,108,,8,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,Expert
3051,,,,,,,1,,4373,H,108,,8,,B,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,Autocuration
3052,,,,,,,1,,6576,H,108,,8,,B,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,Expert
3053,,,,,,,1,,4687,H,108,,8,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,Autocuration
3054,,,,,,,1,,12146,H,108,,8,,B,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,Autocuration
3055,,,,,,,1,,12146,H,108,,8,,B,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,Autocuration
3056,,,,,,,1,,16946,H,108,,8,,B,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,Autocuration
3057,,,,,,,1,,14159,H,108,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,Autocuration
3058,,,,,,,1,,16700,H,108,,8,,B,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,Autocuration
3059,,,,,,,1,,3269,H,108,,8,,B,Affinity against 5-hydroxytryptamine 2C receptor,,Autocuration
3060,Homo sapiens,,,9606.0,,,1,,1274,D,108,,9,,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,Expert
3061,,,,,,,1,,1317,H,108,,8,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,Autocuration
3062,Bos taurus,,,9913.0,,,1,,5834,H,144,,8,,B,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,Autocuration
3063,Bos taurus,,,9913.0,,,1,,11147,H,144,,8,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,Autocuration
3064,Cavia porcellus,,,10141.0,,,1,,14145,H,104714,,4,,F,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,Expert
3065,Cavia porcellus,,2116.0,10141.0,,,1,,10561,H,104714,,4,Ileum,B,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,Autocuration
3066,Cavia porcellus,,,10141.0,,,1,,15847,H,104714,,4,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,Autocuration
3067,Cavia porcellus,,,10141.0,,,1,,15847,H,104714,,4,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,Autocuration
3068,Cavia porcellus,,2116.0,10141.0,,,1,,10561,H,104714,,4,Ileum,B,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,Autocuration
3069,Cavia porcellus,,2116.0,10141.0,,,1,,11454,H,104714,,4,Ileum,B,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,Autocuration
3070,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,Autocuration
3071,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,Autocuration
3072,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,Autocuration
3073,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,Autocuration
3074,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,Autocuration
3075,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,Autocuration
3076,Cavia porcellus,,2116.0,10141.0,,,1,,15253,H,104714,,4,Ileum,F,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,Autocuration
3077,Cavia porcellus,,2116.0,10141.0,,,1,,15253,H,104714,,4,Ileum,F,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,Autocuration
3078,Cavia porcellus,,2116.0,10141.0,,,1,,11963,H,104714,,4,Ileum,F,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,Autocuration
3079,Cavia porcellus,,2116.0,10141.0,,,1,,1946,H,104714,,4,Ileum,B,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,Autocuration
3080,Cavia porcellus,,2116.0,10141.0,,,1,,1946,H,104714,,4,Ileum,B,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,Autocuration
3081,Cavia porcellus,,,10141.0,,,1,,12045,H,104714,,4,,B,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,Autocuration
3082,Cavia porcellus,,2116.0,10141.0,,,1,,1559,H,104714,,4,Ileum,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Autocuration
3083,Cavia porcellus,,2116.0,10141.0,,,1,,273,H,104714,,4,Ileum,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Autocuration
3084,Cavia porcellus,,2116.0,10141.0,,,1,,273,H,104714,,4,Ileum,F,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,Autocuration
3085,Cavia porcellus,,2116.0,10141.0,,,1,,188,H,104714,,4,Ileum,F,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,Autocuration
3086,Cavia porcellus,,2116.0,10141.0,,,1,,12919,H,104714,,4,Ileum,F,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,Autocuration
3087,Cavia porcellus,,2116.0,10141.0,,,1,,12918,H,104714,,4,Ileum,F,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,Autocuration
3088,Cavia porcellus,,2116.0,10141.0,,,1,,1559,H,104714,,4,Ileum,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Autocuration
3089,Cavia porcellus,,2116.0,10141.0,,,1,,273,H,104714,,4,Ileum,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Autocuration
3090,Cavia porcellus,,2116.0,10141.0,,,1,,1559,H,104714,,4,Ileum,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Autocuration
3091,Cavia porcellus,,2116.0,10141.0,,,1,,1559,H,104714,,4,Ileum,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,Autocuration
3092,Cavia porcellus,,2116.0,10141.0,,,1,,1559,H,104714,,4,Ileum,B,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,Autocuration
3093,Cavia porcellus,,2116.0,10141.0,,,1,,14424,H,104714,,4,Ileum,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,Autocuration
3094,Cavia porcellus,,,10141.0,,,1,,13181,U,22226,,0,,B,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Autocuration
3095,,,,,,,1,,5486,H,51,,8,,B,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,Autocuration
3096,Homo sapiens,,,9606.0,,,1,,6491,D,104714,,5,,B,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,Expert
3097,,,,,,,1,,6013,H,104714,,4,,B,Binding affinity towards 5-HT3 receptor,,Autocuration
3098,,,,,,,1,,12861,H,104714,,4,,B,Binding activity radioligand.,,Autocuration
3099,,,,,,,1,,12861,H,104714,,4,,B,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,Autocuration
3100,,,,,,,1,,5104,H,104714,,4,,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,Autocuration
3101,,,,,,,1,,5105,H,104714,,4,,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,Autocuration
3102,,,,,,,1,,5104,H,104714,,4,,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,Autocuration
3103,,,,,,,1,,3935,U,22226,,0,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,Autocuration
3104,,,,,,,1,,13657,H,105030,NG108-15,4,,B,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,Expert
3105,,,,,In vivo,,1,,10369,H,105030,,4,,B,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,Autocuration
3106,,,,,,,1,,10369,H,105030,,4,,B,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,Autocuration
3107,,,,,,,1,,12918,H,105030,,4,,B,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,Autocuration
3108,,,,,,,1,,12918,H,105030,,4,,B,Compound was evaluated for the binding affinity at 5- HT3 receptor,,Autocuration
3109,,,,,,,1,,10369,H,105030,,4,,B,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,Autocuration
3110,,,,,,,1,,773,H,105030,,4,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,Autocuration
3111,,,,,,,1,,12918,H,105030,,4,,F,5-hydroxytryptamine 3 receptor agonism in mouse,,Autocuration
3112,,,,,,,1,,10561,H,105030,,4,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,Autocuration
3113,,,,,,,1,,12827,H,105030,,4,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,Autocuration
3114,,,,,,,1,,12827,H,105030,,4,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,Autocuration
3115,,,,,,,1,,12918,H,105030,,4,,B,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,Autocuration
3116,,,,,,,1,,273,H,105030,,4,,B,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,Autocuration
3117,,,,,,,1,,273,H,105030,,4,,B,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,Autocuration
3118,,,,,,,1,,10561,H,105030,,4,,B,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Autocuration
3119,,,,,In vitro,,1,,5033,H,105030,,4,,B,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,Autocuration
3120,,,,,,,1,,16429,H,105030,N1E-115,4,,B,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,Autocuration
3121,,,,,,,1,,10322,H,11765,,8,,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,Autocuration
3122,,,,,,,1,,14331,H,11765,,8,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,Autocuration
3123,Mus musculus,,,10090.0,,,1,,13462,D,10630,,9,,B,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,Autocuration
3124,,,,,,,1,,12861,H,17106,,8,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Autocuration
3125,Sus scrofa,,,9823.0,,,1,,15086,H,144,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,Autocuration
3126,Sus scrofa,,,9823.0,,,1,,12861,H,144,,8,,B,Binding activity radioligand.,,Autocuration
3127,Oryctolagus cuniculus,,,9986.0,,,1,,10561,H,104714,,4,,B,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,Autocuration
3128,Oryctolagus cuniculus,,,9986.0,,,1,,10561,H,104714,,4,,B,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Autocuration
3129,Oryctolagus cuniculus,,,9986.0,,,1,,10561,H,104714,,4,,B,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,Autocuration
3130,Oryctolagus cuniculus,,,9986.0,,,1,,10561,H,104714,,4,,B,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Autocuration
3131,Oryctolagus cuniculus,,,9986.0,,,1,,273,H,104714,,4,,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Autocuration
3132,Oryctolagus cuniculus,,,9986.0,,,1,,273,H,104714,,4,,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Autocuration
3133,Oryctolagus cuniculus,,2116.0,9986.0,,,1,,273,H,104714,,4,Ileum,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Autocuration
3134,Oryctolagus cuniculus,,,9986.0,,,1,,273,H,104714,,4,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Autocuration
3135,Oryctolagus cuniculus,,,9986.0,,,1,,273,H,104714,,4,,F,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Autocuration
3136,Oryctolagus cuniculus,,,9986.0,,,1,,273,H,104714,,4,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Autocuration
3137,Oryctolagus cuniculus,,,9986.0,,,1,,273,H,104714,,4,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Autocuration
3138,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,104714,CHO,4,,B,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,Autocuration
3139,Rattus norvegicus,,,10116.0,,,1,,1650,D,104698,,7,,B,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,Autocuration
3140,,,,,,,1,,16288,H,12020,,8,,B,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,Autocuration
3141,,,,,,,1,,16288,H,12020,,8,,B,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,Autocuration
3142,Rattus norvegicus,,,10116.0,,,1,,10254,D,104698,,7,,B,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,Autocuration
3143,,,,,,,1,,14532,H,104698,,6,,B,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,Autocuration
3144,,,948.0,,In vivo,,1,,13392,H,104698,,6,Heart,F,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,Autocuration
3145,,,948.0,,,,1,,13392,H,104698,,6,Heart,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,Autocuration
3146,,,948.0,,,,1,,13392,H,104698,,6,Heart,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,Autocuration
3147,,,948.0,,,,1,,13392,H,104698,,6,Heart,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,Autocuration
3148,,,948.0,,,,1,,13392,H,104698,,6,Heart,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,Autocuration
3149,,,,,,,1,,13392,H,104698,,6,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration
3150,,,,,,,1,,13392,H,104698,,6,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration
3151,,,,,,,1,,13392,H,104698,,6,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration
3152,,,,,,,1,,13392,H,104698,,6,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration
3153,Rattus norvegicus,,,10116.0,In vivo,,1,,1089,D,104698,,7,,F,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,Autocuration
3154,,,,,In vivo,,1,,1089,H,104698,,6,,F,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,Autocuration
3155,Rattus norvegicus,,,10116.0,In vivo,,1,,11454,D,104698,,7,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration
3156,Rattus norvegicus,,,10116.0,,,1,,11454,D,104698,,7,,F,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,Autocuration
3157,Rattus norvegicus,,,10116.0,In vivo,,1,,12205,D,104698,,7,,F,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,Autocuration
3158,Rattus norvegicus,,,10116.0,,,1,,1089,D,104698,,7,,F,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,Autocuration
3159,,,,,,,1,,5094,H,104698,,6,,B,Binding affinity towards 5-HT3 receptor in rat was evaluated,,Autocuration
3160,Rattus norvegicus,,,10116.0,,,1,,2622,D,104698,,7,,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,Autocuration
3161,,,,,,,1,,245,H,104698,,6,,B,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,Autocuration
3162,,,,,,,1,,14788,H,104698,,6,,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,Autocuration
3163,,,,,,,1,,14788,H,104698,,6,,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,Autocuration
3164,,,,,,,1,,3020,H,104698,,6,,B,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,Autocuration
3165,,,,,,,1,,1742,H,104698,,6,,B,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,Autocuration
3166,,,955.0,,,,1,,17394,H,104698,,6,Brain,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,Autocuration
3167,,,955.0,,,,1,,17394,H,104698,,6,Brain,B,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,Autocuration
3168,,,,,,,1,,17394,H,104698,,6,,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,Autocuration
3169,,,,,,,1,,14286,H,104698,,6,,B,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,Autocuration
3170,,,,,,,1,,14178,H,104698,,6,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,Autocuration
3171,Rattus norvegicus,,,10116.0,,,1,,14178,D,104698,,7,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,Autocuration
3172,Rattus norvegicus,,,10116.0,,,1,,14178,D,104698,,7,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,Autocuration
3173,Rattus norvegicus,,,10116.0,,,1,,14178,D,104698,,7,,B,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,Autocuration
3174,,,,,,,1,,15034,H,104698,,6,,B,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,Autocuration
3175,,,,,,,1,,1089,H,104698,,6,,B,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Membranes,Autocuration
3176,Rattus norvegicus,,,10116.0,,,1,,1089,D,104698,,7,,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,Autocuration
3177,,,,,,,1,,16532,H,104698,,6,,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,Autocuration
3178,Rattus norvegicus,,,10116.0,,,1,,12801,D,104698,,7,,B,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,Autocuration
3179,,,,,,,1,,15194,H,104698,NG108-15,6,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,Autocuration
3180,,,,,,,1,,15194,H,104698,NG108-15,6,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,Autocuration
3181,,,,,,,1,,15194,H,104698,,6,,B,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,Autocuration
3182,,,,,,,1,,15194,H,104698,,6,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,Autocuration
3183,,,,,,,1,,15194,H,104698,,6,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,Autocuration
3184,,,,,,,1,,15194,H,104698,,6,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,Autocuration
3185,,,,,,,1,,10610,H,104698,,6,,F,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,Autocuration
3186,Rattus norvegicus,,,10116.0,,,1,,10355,D,104698,,7,,F,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,Autocuration
3187,,,,,,,1,,691,H,104698,,6,,F,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,Autocuration
3188,,,,,,,1,,10611,H,104698,,6,,F,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,Autocuration
3189,,,,,In vivo,,1,,12801,H,104698,,6,,F,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,Autocuration
3190,,,,,,,1,,10609,H,104698,,6,,F,Inhibition of 5-HT evoked reflex bradycardia in rat.,,Autocuration
3191,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration
3192,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,Autocuration
3193,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,Autocuration
3194,Rattus norvegicus,,,10116.0,In vivo,,1,,11454,D,104698,,7,,F,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,Autocuration
3195,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration
3196,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,Autocuration
3197,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,Autocuration
3198,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,Autocuration
3199,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,Autocuration
3200,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration
3201,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,Autocuration
3202,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,Autocuration
3203,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,Autocuration
3204,,,,,In vivo,,1,,11454,H,104698,,6,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration
3205,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,Autocuration
3206,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,Autocuration
3207,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,Autocuration
3208,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,Autocuration
3209,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,Autocuration
3210,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,Autocuration
3211,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,Autocuration
3212,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,Autocuration
3213,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,Autocuration
3214,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,Autocuration
3215,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration
3216,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,Autocuration
3217,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,Autocuration
3218,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,Autocuration
3219,,,,,In vivo,,1,,11454,H,104698,,6,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,Autocuration
3220,,,,,,,1,,670,H,104698,,6,,F,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,Autocuration
3221,,,,,,,1,,670,H,104698,,6,,F,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,Autocuration
3222,,,,,In vivo,,1,,10321,H,104698,,6,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,Autocuration
3223,,,,,In vivo,,1,,10321,H,104698,,6,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,Autocuration
3224,,,,,In vivo,,1,,10321,H,104698,,6,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,Autocuration
3225,,,,,In vivo,,1,,10321,H,104698,,6,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,Autocuration
3226,,,,,In vivo,,1,,10321,H,104698,,6,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,Autocuration
3227,,,,,In vivo,,1,,10322,H,104698,,6,,F,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,Autocuration
3228,,,,,,,1,,15412,H,104698,,6,,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,Autocuration
3229,,,,,,,1,,15412,H,104698,,6,,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,Autocuration
3230,Rattus norvegicus,,,10116.0,,,1,,15412,D,104698,,7,,B,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,Autocuration
3231,,,,,,,1,,15412,H,104698,,6,,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,Autocuration
3232,,,10000000.0,,,,1,,15412,D,104698,,7,Hippocampus,B,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,Intermediate
3233,Rattus norvegicus,,,10116.0,,,1,,15412,D,104698,,7,,B,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,Autocuration
3234,Rattus norvegicus,,,10116.0,,,1,,17394,D,104698,,7,,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,Autocuration
3235,,,,,,,1,,12457,H,104698,,6,,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,Autocuration
3236,,,,,,,1,,12457,H,104698,,6,,B,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,Autocuration
3237,,,,,,,1,,12205,H,104698,,6,,B,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,Autocuration
3238,,,,,,,1,,14532,H,104698,,6,,B,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,Autocuration
3239,,,,,,,1,,1122,H,104698,,6,,B,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,Autocuration
3240,,,,,,,1,,5094,H,104698,,6,,B,Binding affinity towards 5-HT3 receptor in rat was evaluated,,Autocuration
3241,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,Intermediate
3242,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,Intermediate
3243,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,Intermediate
3244,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,Intermediate
3245,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,Intermediate
3246,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,Intermediate
3247,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,Intermediate
3248,Cavia porcellus,,2116.0,10141.0,,,1,,13961,D,20033,,9,Ileum,F,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,Intermediate
3249,Cavia porcellus,,2116.0,10141.0,,,1,,13961,D,20033,,9,Ileum,F,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,Intermediate
3250,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,Intermediate
3251,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,Intermediate
3252,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,Intermediate
3253,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,Intermediate
3254,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,Intermediate
3255,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,Intermediate
3256,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,Intermediate
3257,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,Intermediate
3258,Cavia porcellus,,2116.0,10141.0,,,1,,14290,D,20033,,9,Ileum,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,Intermediate
3259,Cavia porcellus,,,10141.0,,,1,,15034,D,20033,,9,,B,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Intermediate
3260,Cavia porcellus,,2435.0,10141.0,,,1,,5094,D,20033,,9,Striatum,B,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,Intermediate
3261,Cavia porcellus,,2435.0,10141.0,,,1,,5094,D,20033,,9,Striatum,B,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,Intermediate
3262,Cavia porcellus,,2435.0,10141.0,,,1,,5399,D,20033,,9,Striatum,B,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,Intermediate
3263,Cavia porcellus,,2435.0,10141.0,,,1,,17394,D,20033,,9,Striatum,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Intermediate
3264,Cavia porcellus,,2435.0,10141.0,,,1,,17394,D,20033,,9,Striatum,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,Intermediate
3265,Cavia porcellus,,2435.0,10141.0,,,1,,17394,D,20033,,9,Striatum,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,Intermediate
3266,Cavia porcellus,,2116.0,10141.0,,,1,,13961,D,20033,,9,Ileum,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,Intermediate
3267,Cavia porcellus,,2116.0,10141.0,,,1,,13961,D,20033,,9,Ileum,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,Intermediate
3268,Cavia porcellus,,2116.0,10141.0,,,1,,13961,D,20033,,9,Ileum,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,Intermediate
3269,Cavia porcellus,,,10141.0,,,1,,16946,D,20033,,9,,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,Intermediate
3270,Cavia porcellus,,,10141.0,,,1,,16946,D,20033,,9,,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,Intermediate
3271,Cavia porcellus,,,10141.0,,,1,,15034,D,20033,,9,,F,Agonistic activity against 5-hydroxytryptamine 4 receptor,,Intermediate
3272,Cavia porcellus,,,10141.0,,,1,,15034,D,20033,,9,,F,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,Intermediate
3273,Cavia porcellus,,,10141.0,,,1,,12918,D,20033,,9,,F,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,Intermediate
3274,Cavia porcellus,,,10141.0,,,1,,16946,D,20033,,9,,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,Intermediate
3275,Cavia porcellus,,2435.0,10141.0,,,1,,17394,D,20033,,9,Striatum,B,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,Intermediate
3276,Cavia porcellus,,2435.0,10141.0,,,1,,15034,D,20033,,9,Striatum,B,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,Intermediate
3277,Cavia porcellus,,2435.0,10141.0,,,1,,5094,D,20033,,9,Striatum,B,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,Intermediate
3278,Cavia porcellus,,2435.0,10141.0,,,1,,5094,D,20033,,9,Striatum,B,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,Intermediate
3279,Cavia porcellus,,2116.0,10141.0,,,1,,17358,D,20033,,9,Ileum,B,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,Intermediate
3280,Cavia porcellus,,,10141.0,,,1,,12953,D,20033,,9,,B,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,Expert
3281,Cavia porcellus,,,10141.0,,,1,,12953,D,20033,,9,,B,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Intermediate
3282,Cavia porcellus,,,10141.0,,,1,,12953,D,20033,,9,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,Intermediate
3283,Cavia porcellus,,,10141.0,,,1,,12953,D,20033,,9,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Intermediate
3284,Cavia porcellus,,2116.0,10141.0,,,1,,273,D,20033,,9,Ileum,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,Intermediate
3285,Cavia porcellus,,2116.0,10141.0,,,1,,12918,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,Intermediate
3286,Cavia porcellus,,2116.0,10141.0,,,1,,12919,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,Intermediate
3287,Cavia porcellus,,2116.0,10141.0,,,1,,273,D,20033,,9,Ileum,F,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,Intermediate
3288,Cavia porcellus,,2116.0,10141.0,,,1,,273,D,20033,,9,Ileum,F,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,Intermediate
3289,Cavia porcellus,,,10141.0,,,1,,13181,D,20033,,9,,B,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,Intermediate
3290,Cavia porcellus,,,10141.0,,,1,,13181,H,168,,8,,B,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,Autocuration
3291,Cavia porcellus,,,10141.0,,,1,,15034,D,20033,,9,,F,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,Intermediate
3292,Cavia porcellus,,,10141.0,,,1,,5033,D,20033,,9,,B,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,Intermediate
3293,Cavia porcellus,,,10141.0,,,1,,1980,D,20033,,9,,B,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,Intermediate
3294,Cavia porcellus,,,10141.0,,,1,,13181,H,168,HEK293,8,,B,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,Autocuration
3295,Cavia porcellus,,,10141.0,,,1,,14287,D,20033,,9,,B,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,Intermediate
3296,Cavia porcellus,,,10141.0,,,1,,1317,D,20033,,9,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,Intermediate
3297,Cavia porcellus,,,10141.0,,,1,,15316,D,20033,,9,,B,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,Intermediate
3298,Cavia porcellus,,2435.0,10141.0,,,1,,16429,D,20033,,9,Striatum,B,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,Intermediate
3299,Cavia porcellus,,10000000.0,10141.0,,,1,,14818,D,20033,,9,Hippocampus,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,Intermediate
3300,Cavia porcellus,,,10141.0,,,1,,15194,D,20033,,9,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,Intermediate
3301,Cavia porcellus,,,10141.0,,,1,,15194,D,20033,,9,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,Intermediate
3302,Cavia porcellus,,2116.0,10141.0,,,1,,13961,D,20033,,9,Ileum,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,Intermediate
3303,,,,,,,1,,5486,H,108,,8,,B,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,Autocuration
3304,,,,,,,1,,16209,H,168,,8,,B,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,Autocuration
3305,,,,,,,1,,17085,H,168,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,Autocuration
3306,,,,,,,1,,4199,H,168,HeLa,8,,B,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,Autocuration
3307,,,,,,,1,,15146,H,168,,8,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,Autocuration
3308,,,,,,,1,,5213,H,168,,8,,B,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,Autocuration
3309,,,,,,,1,,4829,H,168,HeLa,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,Autocuration
3310,,,,,,,1,,17358,H,10622,,8,,B,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,Autocuration
3311,,,,,,,1,,17358,H,10622,,8,,B,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,Autocuration
3312,,,,,,,1,,16946,H,10622,,8,,B,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,Autocuration
3313,,,,,,,1,,17358,H,10622,,8,,B,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,Autocuration
3314,,,2081.0,,,,1,,268,H,11249,,8,Cardiac atrium,F,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,Autocuration
3315,,,2081.0,,,,1,,268,H,11249,,8,Cardiac atrium,F,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,Autocuration
3316,,,,,,,1,,15086,H,11249,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,Autocuration
3317,,,10000000.0,,,,1,,14875,H,11249,,8,Hippocampus,B,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,Autocuration
3318,Sus scrofa,,10000000.0,9823.0,,,1,,13267,H,168,,8,Hippocampus,B,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,Autocuration
3319,Oryctolagus cuniculus,,,9986.0,,,1,,13047,H,168,,8,,B,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,Autocuration
3320,Rattus norvegicus,,,10116.0,,,1,,1650,D,10623,,9,,B,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,Expert
3321,,,,,,,1,,567,H,10623,,8,,F,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,Autocuration
3322,,,,,,,1,,17358,H,10623,,8,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,Autocuration
3323,,,,,,,1,,188,H,10623,,8,,B,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,Autocuration
3324,,,,,,,1,,670,H,10623,,8,,F,lntrinsic activity relative to 5-HT receptor,,Autocuration
3325,,,,,,,1,,204,H,10623,,8,,F,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,Autocuration
3326,,,,,,,1,,1946,H,10623,,8,,F,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,Expert
3327,,,,,,,1,,6398,H,10623,,8,,F,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,Autocuration
3328,,,,,,,1,,6398,H,10623,,8,,F,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,Autocuration
3329,,,,,,,1,,17358,H,10623,,8,,F,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,Autocuration
3330,,,,,,,1,,6398,H,10623,,8,,F,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,Autocuration
3331,,,,,,,1,,11752,H,10623,,8,,B,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,Expert
3332,,,,,,,1,,809,H,10623,,8,,F,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,Autocuration
3333,Rattus norvegicus,,,10116.0,,,1,,14178,D,10623,,9,,B,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,Expert
3334,,,,,,,1,,567,H,10623,,8,,B,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,Autocuration
3335,,,,,,,1,,1946,H,10623,,8,,B,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,Autocuration
3336,,,,,,,1,,1946,H,10623,,8,,B,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,Autocuration
3337,Rattus norvegicus,,,10116.0,,,1,,13961,D,10623,,9,,B,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,Expert
3338,,,2435.0,,,,1,,6238,H,10623,,8,Striatum,B,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,Autocuration
3339,,,,,,,1,,14290,H,10623,,8,,B,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,Autocuration
3340,,,,,,,1,,14290,H,10623,,8,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,Expert
3341,Rattus norvegicus,,2435.0,10116.0,,,1,,809,D,10623,,9,Striatum,B,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,Expert
3342,,,2435.0,,,,1,,1578,H,10623,,8,Striatum,B,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,Autocuration
3343,,,2435.0,,,,1,,16709,H,10623,,8,Striatum,B,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,Expert
3344,,,2435.0,,,,1,,1946,H,10623,,8,Striatum,B,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,Expert
3345,,,2435.0,,,,1,,15253,H,10623,,8,Striatum,B,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,Expert
3346,,,2435.0,,,,1,,4535,H,10623,,8,Striatum,B,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,Expert
3347,,,,,,,1,,13961,H,10623,,8,,B,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,Expert
3348,,,955.0,,,,1,,17358,H,10623,,8,Brain,F,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,Autocuration
3349,,,,,,,1,,15847,H,10623,,8,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,Autocuration
3350,,,,,,,1,,15847,H,10623,,8,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,Autocuration
3351,,,,,,,1,,670,H,10623,,8,,F,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,Autocuration
3352,,,,,,,1,,670,H,10623,,8,,F,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,Autocuration
3353,,,,,,,1,,1317,H,10623,,8,,F,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Autocuration
3354,Rattus norvegicus,,,10116.0,,,1,,12936,D,10623,,9,,B,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,Expert
3355,,,2435.0,,,,1,,4535,H,10623,,8,Striatum,B,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,Expert
3356,Rattus norvegicus,,,10116.0,,,1,,14424,D,10623,,9,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,Expert
3357,,,,,,,1,,14424,H,10623,,8,,F,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,Expert
3358,,,,,,,1,,14424,H,10623,,8,,F,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,Expert
3359,Rattus norvegicus,,,10116.0,,,1,,14424,D,10623,,9,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,Expert
3360,,,,,,,1,,14424,H,10623,,8,,F,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,Autocuration
3361,,,,,,,1,,14424,H,10623,,8,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,Expert
3362,,,,,,,1,,14424,H,10623,,8,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,Expert
3363,,,,,,,1,,14424,H,10623,,8,,F,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,Autocuration
3364,Rattus norvegicus,,,10116.0,,,1,,1980,H,168,,8,,F,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,Autocuration
3365,,,,,,,1,,4639,H,168,,8,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,Autocuration
3366,,,,,,,1,,17358,H,168,,8,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,Autocuration
3367,,,,,,,1,,17358,H,168,,8,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,Autocuration
3368,,,,,,,1,,17358,H,168,,8,,B,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,Autocuration
3369,,,,,,,1,,1558,H,168,,8,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,Autocuration
3370,,,,,,,1,,17358,H,168,,8,,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,Autocuration
3371,,,,,,,1,,16117,H,168,,8,,B,In vitro binding affinity towards 5-HT4 receptor was determined,,Autocuration
3372,,,,,,,1,,17358,H,168,,8,,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,Autocuration
3373,,,,,,,1,,17358,H,168,,8,,F,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,Autocuration
3374,,,,,,,1,,17358,H,168,,8,,B,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,Autocuration
3375,,,,,,,1,,17358,H,168,,8,,B,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,Autocuration
3376,,,,,,,1,,17358,H,168,,8,,B,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,Autocuration
3377,,,,,,,1,,17358,H,168,,8,,B,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,Autocuration
3378,,,,,,,1,,1274,H,168,,8,,B,Binding affinity against 5-Hydroxytryptamine 4 receptor,,Expert
3379,,,,,,,1,,10728,H,104698,,6,,B,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Brain membranes,Autocuration
3380,,,,,,,1,,11695,H,104698,,6,,B,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Brain membranes,Autocuration
3381,,,,,,,1,,11695,H,104698,,6,,B,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Brain membranes,Autocuration
3382,,,,,,,1,,12490,H,104698,,6,,B,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,Autocuration
3383,Rattus norvegicus,,,10116.0,,,1,,11828,D,104698,,7,,B,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Autocuration
3384,,,10000000.0,,,,1,,12253,H,104698,,6,Hippocampus,B,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,Autocuration
3385,,,,,,,1,,10561,H,104698,,6,,B,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Autocuration
3386,,,,,,,1,,10561,H,104698,,6,,B,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,Autocuration
3387,,,,,,,1,,14432,H,104698,,6,,F,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,Autocuration
3388,Rattus norvegicus,,,10116.0,,,1,,12936,D,104698,,7,,B,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,Autocuration
3389,Rattus norvegicus,,,10116.0,,,1,,1274,D,104698,,7,,B,Binding affinity against 5-Hydroxytryptamine 3 receptor,,Autocuration
3390,,,,,,,1,,1980,H,104698,,6,,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,Autocuration
3391,,,,,,,1,,670,H,104698,,6,,B,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,Autocuration
3392,Rattus norvegicus,,,10116.0,,,1,,968,D,104698,,7,,B,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,Autocuration
3393,,,,,,,1,,14287,H,104698,,6,,B,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,Autocuration
3394,,,,,,,1,,567,H,104698,,6,,B,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,Autocuration
3395,,,,,,,1,,13267,H,104698,,6,,B,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,Autocuration
3396,,,,,,,1,,14826,H,104698,,6,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,Autocuration
3397,,,,,,,1,,15194,H,104698,,6,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,Autocuration
3398,,,,,,,1,,15194,H,104698,,6,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,Autocuration
3399,Rattus norvegicus,,,10116.0,,,1,,10394,D,104698,,7,,B,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,Autocuration
3400,,,,,,,1,,13657,D,10576,,9,,B,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,Expert
3401,,,955.0,,,,1,,1879,H,12020,,8,Brain,F,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,Autocuration
3402,,,,,,,1,,1879,H,12020,,8,,F,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,Autocuration
3403,,,,,,,1,,1879,H,12020,,8,,F,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,Autocuration
3404,,,,,In vivo,,1,,204,H,12020,,8,,F,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3405,,,,,,,1,,1879,H,12020,,8,,B,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,Autocuration
3406,,,,,,,1,,1879,H,12020,,8,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3407,,,,,,,1,,1879,H,12020,,8,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,Autocuration
3408,,,,,,,1,,1879,H,12020,,8,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,Autocuration
3409,,,,,,,1,,10641,H,104698,,6,,B,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,Autocuration
3410,,,,,,,1,,773,H,12020,,8,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,Autocuration
3411,,,,,,,1,,11952,H,104698,,6,,B,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,Autocuration
3412,Rattus norvegicus,,,10116.0,,,1,,14145,D,12020,,9,,F,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,Autocuration
3413,,,,,,,1,,17066,H,144,,8,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Expert
3414,,,,,,,1,,6398,H,104714,,4,,B,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,Autocuration
3415,,,,,,,1,,10321,U,22226,,0,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,Autocuration
3416,,,,,,,1,,511,H,104714,,4,,F,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,Autocuration
3417,,,,,,,1,,4639,H,104714,,4,,B,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3418,,,,,,,1,,4639,H,104714,,4,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3419,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,Autocuration
3420,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Autocuration
3421,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,Autocuration
3422,,,,,,,1,,1558,H,104714,,4,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3423,,,,,,,1,,268,H,104714,,4,,F,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,Autocuration
3424,,,,,,,1,,2474,H,104714,,4,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,Autocuration
3425,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,Autocuration
3426,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,Autocuration
3427,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,Autocuration
3428,,,,,,,1,,5067,H,104714,,4,,B,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,Autocuration
3429,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,Autocuration
3430,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,Autocuration
3431,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,Autocuration
3432,,,,,,,1,,5067,H,104714,,4,,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,Autocuration
3433,,,,,,,1,,5067,H,104714,,4,,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,Autocuration
3434,,,,,,,1,,5067,H,104714,,4,,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,Autocuration
3435,,,,,,,1,,5067,H,104714,,4,,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,Autocuration
3436,,,,,,,1,,5067,H,104714,,4,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3437,,,,,,,1,,14331,H,104714,,4,,B,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,Autocuration
3438,,,,,,,1,,5067,H,104714,,4,,B,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,Autocuration
3439,,,,,,,1,,6179,H,104714,NG108-15,4,,B,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,Autocuration
3440,,,,,,,1,,4265,H,104714,,4,,B,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,Autocuration
3441,,,,,,,1,,4265,H,104714,NG108-15,4,,B,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,Autocuration
3442,,,,,,,1,,17358,H,104714,,4,,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,Autocuration
3443,,,,,,,1,,17358,H,104714,,4,,B,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,Autocuration
3444,,,,,In vitro,,1,,13628,H,104714,,4,,B,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,Autocuration
3445,,,,,,,1,,4612,H,104714,,4,,B,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,Autocuration
3446,,,,,,,1,,17358,H,104714,,4,,F,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,Autocuration
3447,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,Autocuration
3448,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,Autocuration
3449,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,Autocuration
3450,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Autocuration
3451,,,,,,,1,,511,H,104714,,4,,B,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,Autocuration
3452,,,,,,,1,,1479,H,104714,,4,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3453,,,,,,,1,,1317,H,104714,,4,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,Autocuration
3454,,,,,,,1,,12146,H,104714,,4,,B,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,Autocuration
3455,,,,,,,1,,12146,H,104714,,4,,B,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,Autocuration
3456,,,,,,,1,,13969,H,104714,,4,,B,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,Autocuration
3457,,,,,,,1,,13392,H,108,,8,,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,Expert
3458,,,,,,,1,,13392,H,104698,,6,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3459,,,,,,,1,,14159,H,144,,8,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,Autocuration
3460,,,,,,,1,,1558,H,144,,8,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3461,,,,,,,1,,16655,H,144,,8,,B,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Autocuration
3462,,,,,,,1,,13020,H,104714,,4,,B,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,Autocuration
3463,,,,,,,1,,13021,H,104714,,4,,B,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,Autocuration
3464,,,,,,,1,,13020,H,104714,,4,,B,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,Autocuration
3465,,,,,,,1,,10321,H,144,,8,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,Autocuration
3466,,,,,,,1,,15818,H,144,,8,,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3467,,,,,,,1,,15818,H,144,,8,,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration
3468,,,,,,,1,,17358,H,144,,8,,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,Autocuration
3469,,,,,,,1,,2222,H,144,,8,,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,Autocuration
3470,,,,,,,1,,10322,H,144,,8,,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,Autocuration
3471,,,,,,,1,,16117,H,144,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,Autocuration
3472,,,,,,,1,,17200,H,144,,8,,B,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,Autocuration
3473,,,,,,,1,,17358,H,144,,8,,F,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,Autocuration
3474,,,,,,,1,,16700,H,144,,8,,B,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,Autocuration
3475,,,,,,,1,,1980,H,144,,8,,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,Autocuration
3476,,,,,,,1,,1980,H,144,,8,,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,Autocuration
3477,,,,,,,1,,12409,H,104714,,4,,B,Binding affinity against the 5-hydroxytryptamine 3 receptor,,Autocuration
3478,,,,,,,1,,4365,H,144,,8,,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,,Autocuration
3479,,,,,,,1,,4365,H,144,,8,,F,Percent efficacy against 5-hydroxytryptamine 3A receptor,,Autocuration
3480,,,,,,,1,,4365,H,144,,8,,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,,Autocuration
3481,Rattus norvegicus,,,10116.0,,,1,,6769,D,12020,Oocytes,9,,F,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Expert
3482,Rattus norvegicus,,,10116.0,,,1,,6769,D,12020,Oocytes,9,,F,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Expert
3483,Rattus norvegicus,,,10116.0,,,1,,6769,D,12020,Oocytes,9,,F,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Expert
3484,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,Intermediate
3485,Cavia porcellus,,2116.0,10141.0,,,1,,809,D,20033,,9,Ileum,F,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,Intermediate
3486,Cavia porcellus,,,10141.0,,,1,,14290,D,20033,,9,,F,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,Intermediate
3487,Cavia porcellus,,2116.0,10141.0,,,1,,17358,D,20033,,9,Ileum,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,Intermediate
3488,Cavia porcellus,,,10141.0,,,1,,17358,D,20033,,9,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,Intermediate
3489,Cavia porcellus,,2116.0,10141.0,,,1,,17358,D,20033,,9,Ileum,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,Intermediate
3490,,,2116.0,,,,1,,17386,H,10209,,8,Ileum,B,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,Autocuration
3491,,,,,,,1,,3269,H,10209,,8,,B,Affinity against 5-hydroxytryptamine 7 receptor,,Autocuration
3492,Cavia porcellus,,,10141.0,,,1,,7721,H,104841,,4,,B,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Autocuration
3493,Cavia porcellus,,,10141.0,,,1,,7721,H,104841,,4,,B,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Autocuration
3494,Cavia porcellus,,2116.0,10141.0,,,1,,9117,H,104841,,4,Ileum,B,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,Autocuration
3495,Cavia porcellus,,,10141.0,,,1,,7721,H,104841,,4,,B,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Autocuration
3496,Cavia porcellus,,,10141.0,,,1,,7721,H,104841,,4,,B,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Autocuration
3497,Cavia porcellus,,,10141.0,,,1,,15796,H,104841,,4,,F,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Autocuration
3498,Cavia porcellus,,,10141.0,,,1,,15796,H,104841,,4,,F,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Autocuration
3499,Homo sapiens,,2081.0,9606.0,,,1,,15650,D,168,,9,Cardiac atrium,B,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,Expert
3500,Homo sapiens,,2081.0,9606.0,,,1,,15650,D,168,,9,Cardiac atrium,B,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,Expert
3501,Homo sapiens,,,9606.0,,,1,,6866,D,104841,,5,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,Autocuration
3502,Homo sapiens,,2081.0,9606.0,,,1,,15650,D,168,,9,Cardiac atrium,F,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,Expert
3503,Mus musculus,,,10090.0,,,1,,10063,U,22226,,0,,B,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,Autocuration
3504,Mus musculus,,,10090.0,,,1,,12665,U,22226,,0,,B,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,Autocuration
3505,,,,,,,1,,7504,H,104705,,4,,B,5-hydroxytryptamine receptor binding affinity was determined in rats,,Autocuration
3506,,,,,,,1,,7504,H,104705,,4,,B,Binding affinity at rat 5-hydroxytryptamine receptor.,,Autocuration
3507,,,,,,,1,,7038,H,104705,,4,,B,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,Autocuration
3508,,,,,,,1,,7626,H,104705,,4,,B,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,Autocuration
3509,,,,,,,1,,7626,H,104705,,4,,B,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,Autocuration
3510,,,945.0,,,,1,,7185,H,104705,,4,Stomach,F,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,Autocuration
3511,,,945.0,,,,1,,7185,H,104705,,4,Stomach,F,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,Autocuration
3512,,,,,,,1,,7185,H,104705,,4,,F,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,Autocuration
3513,,,,,,,1,,6960,H,104705,,4,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,Autocuration
3514,,,,,,,1,,6960,H,104705,,4,,B,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,Autocuration
3515,,,10000000.0,,,,1,,12416,H,10576,,8,Hippocampus,B,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,Autocuration
3516,,,,,,,1,,15753,H,12198,,8,,B,Binding affinity for rat 5-hydroxytryptamine transporter.,,Expert
3517,,,,,,,1,,8062,H,104705,,4,,B,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,Autocuration
3518,Rattus norvegicus,,,10116.0,,,1,,9036,D,104705,,5,,B,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,Autocuration
3519,Rattus norvegicus,,,10116.0,,,1,,15067,D,104705,,5,,B,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,Autocuration
3520,Rattus norvegicus,,955.0,10116.0,,,1,,15753,D,12198,,9,Brain,F,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,Expert
3521,Rattus norvegicus,,2037.0,10116.0,,,1,,15753,D,12198,,9,Cerebellum,F,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,Expert
3522,Rattus norvegicus,,,10116.0,,,1,,15295,D,104705,,5,,B,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,Autocuration
3523,Rattus norvegicus,,,10116.0,,,1,,6347,D,104705,,5,,B,Percent binding affinity against 5-hydroxytryptamine receptor,,Autocuration
3524,,,,,,,1,,6763,U,22226,,0,,B,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,Autocuration
3525,Rattus norvegicus,,,10116.0,,,1,,12092,D,104705,,5,,B,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,Autocuration
3526,Rattus norvegicus,,,10116.0,,,1,,1579,D,104705,,5,,B,Affinity against 5-hydroxytryptamine receptor was determined,,Autocuration
3527,Rattus norvegicus,,945.0,10116.0,,,1,,1579,D,104705,,5,Stomach,B,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,Autocuration
3528,Homo sapiens,,,9606.0,In vitro,,1,,5963,D,121,,9,,B,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Expert
3529,Homo sapiens,,,9606.0,In vitro,,1,,5963,D,121,,9,,B,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Expert
3530,,,,,,,1,,5030,H,18065,,8,,B,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,Autocuration
3531,,,,,,,1,,15796,H,121,,8,,B,Inhibition of 5-hydroxytryptamine reuptake,,Expert
3532,,,,,,,1,,15413,H,18065,,8,,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,Autocuration
3533,,,,,,,1,,15413,H,18065,,8,,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,Autocuration
3534,,,,,,,1,,15413,H,18065,,8,,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,Autocuration
3535,,,,,,,1,,12409,H,18065,,8,,F,Tested for 5-hydroxytryptamine receptor uptake,,Autocuration
3536,Homo sapiens,,,9606.0,,,1,,16909,D,51,CHO,9,,B,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Expert
3537,Homo sapiens,,,9606.0,,,1,,16909,D,51,,9,,F,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,Expert
3538,Homo sapiens,,,9606.0,,,1,,15629,H,10576,,8,,B,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,Autocuration
3539,,,,,,,1,,15629,H,10576,,8,,B,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,Autocuration
3540,,,,,,,1,,15629,H,10576,,8,,B,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,Expert
3541,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,Autocuration
3542,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,Autocuration
3543,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,Autocuration
3544,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,Autocuration
3545,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,Autocuration
3546,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,Autocuration
3547,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,Autocuration
3548,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,Autocuration
3549,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,Autocuration
3550,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,Autocuration
3551,,,2435.0,,,,1,,10034,H,10825,,8,Striatum,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,Autocuration
3552,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,Autocuration
3553,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,Autocuration
3554,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,Autocuration
3555,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,Autocuration
3556,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,Autocuration
3557,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,Autocuration
3558,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,Autocuration
3559,,,,,,,1,,1274,H,168,,8,,B,Binding affinity against 5-hydroxytryptamine 4 receptor,,Expert
3560,,,,,,,1,,17358,H,168,,8,,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,Autocuration
3561,,,,,,,1,,14532,H,168,,8,,B,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,Autocuration
3562,,,,,,,1,,16989,H,168,,8,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,Expert
3563,,,,,,,1,,17200,H,168,,8,,B,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,Autocuration
3564,,,,,,,1,,15779,H,168,,8,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor,,Autocuration
3565,,,,,,,1,,15779,H,168,,8,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,Autocuration
3566,,,,,,,1,,15779,H,168,,8,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,Autocuration
3567,,,,,,,1,,15650,H,168,COS-7,8,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,Autocuration
3568,,,,,,,1,,15650,H,168,COS-7,8,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,Autocuration
3569,,,,,,,1,,15650,H,168,COS-7,8,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,Autocuration
3570,,,,,,,1,,15650,H,168,COS-7,8,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,Autocuration
3571,,,,,,,1,,17046,H,168,C6,8,,B,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,Autocuration
3572,,,,,,,1,,17046,H,168,C6,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,Expert
3573,,,,,,,1,,15650,H,168,C6,8,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,Expert
3574,,,,,,,1,,17046,H,168,C6,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,Expert
3575,,,,,,,1,,17066,H,10624,,8,,B,Binding affinity towards 5-hydroxytryptamine 5 receptor,,Expert
3576,,,,,,,1,,17200,H,105,,8,,B,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,Autocuration
3577,Homo sapiens,,,9606.0,,,1,,16146,D,10624,,9,,B,Binding affinity against 5-hydroxytryptamine 5A receptor,,Expert
3578,,,,,,,1,,15250,H,10624,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,Autocuration
3579,Homo sapiens,,,9606.0,,,1,,6491,D,10624,,9,,B,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,Expert
3580,Homo sapiens,,,9606.0,,,1,,17066,D,10624,,9,,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,Expert
3581,Homo sapiens,,,9606.0,,,1,,17066,D,10624,,9,,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,Expert
3582,Homo sapiens,,,9606.0,,,1,,4234,D,10624,,9,,B,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,Expert
3583,,,,,,,1,,6013,H,10624,,8,,B,Binding affinity towards 5-HT5A receptor,,Autocuration
3584,,,,,,,1,,17175,H,10624,,8,,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,Expert
3585,,,,,,,1,,15818,H,10624,,8,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,Autocuration
3586,,,,,,,1,,6166,H,10624,,8,,B,Binding affinity towards cloned human 5-HT5A receptor was determined,,Autocuration
3587,,,,,,,1,,15779,H,10624,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration
3588,,,,,,,1,,15779,H,10624,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,Autocuration
3589,,,,,,,1,,5213,H,10624,HEK293,8,,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,Autocuration
3590,Mus musculus,,,10090.0,,,1,,17066,D,10625,,9,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,Expert
3591,Mus musculus,,,10090.0,,,1,,17066,D,10625,,9,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Expert
3592,Mus musculus,,,10090.0,,,1,,17066,D,10625,,9,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,Expert
3593,Mus musculus,,,10090.0,,,1,,17066,D,10625,,9,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,Expert
3594,Mus musculus,,,10090.0,,,1,,17066,D,10625,,9,,B,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,Expert
3595,,,,,,,1,,17175,H,10625,,8,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,Expert
3596,,,,,,,1,,16190,H,10576,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,Autocuration
3597,,,,,,,1,,16190,H,10626,HEK293,8,,B,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,Autocuration
3598,,,,,,,1,,4820,H,10624,,8,,B,Binding affinity towards 5-HT5a receptor,,Expert
3599,Homo sapiens,,,9606.0,,,1,,17066,D,10624,,9,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor,,Expert
3600,,,,,,,1,,17066,H,10624,,8,,B,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,Expert
3601,,,,,,,1,,17175,H,10624,,8,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,Expert
3602,,,,,,,1,,16633,H,10624,,8,,B,Binding affinities against 5-hydroxytryptamine 5A receptor,,Autocuration
3603,,,,,,,1,,16633,H,10624,,8,,B,Binding affinities towards 5-hydroxytryptamine 5A receptor,,Autocuration
3604,,,,,,,1,,16700,H,10624,,8,,B,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,Autocuration
3605,Cavia porcellus,,,10141.0,,,1,,4639,H,104714,,4,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,Autocuration
3606,,,,,,,1,,5486,H,104714,,4,,B,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,Autocuration
3607,Homo sapiens,,,9606.0,,,1,,16146,D,10627,,9,,B,Inhibition of human 5-hydroxytryptamine 6 receptor,,Expert
3608,Homo sapiens,,,9606.0,,,1,,17273,D,10627,,9,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,Expert
3609,,,,,,,1,,17687,H,10627,,8,,B,Inhibition against human 5-hydroxytryptamine 6 receptor,,Autocuration
3610,Homo sapiens,,,9606.0,,,1,,6491,D,10627,,9,,B,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,Expert
3611,,,,,,,1,,16190,H,10627,HeLa,8,,B,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,Expert
3612,Homo sapiens,,,9606.0,,,1,,17066,D,10627,,9,,B,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,Expert
3613,Homo sapiens,,,9606.0,,,1,,17066,D,10627,,9,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert
3614,Homo sapiens,,,9606.0,,,1,,17066,D,10627,,9,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Expert
3615,Homo sapiens,,,9606.0,,,1,,17066,D,10627,,9,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,Expert
3616,Homo sapiens,,,9606.0,,,1,,3555,D,10627,,9,,B,Binding affinity against 5-hydroxytryptamine 6 receptor,,Expert
3617,,,,,,,1,,5808,H,10627,,8,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert
3618,,,,,,,1,,6013,H,10627,,8,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Autocuration
3619,,,,,,,1,,15818,H,10627,HEK293,8,,B,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,Expert
3620,,,,,,,1,,16209,H,10627,,8,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,Autocuration
3621,,,,,,,1,,3935,H,10627,HEK293,8,,B,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,Expert
3622,,,,,,,1,,15818,H,10627,,8,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,Autocuration
3623,Homo sapiens,,,9606.0,,,1,,3805,D,10627,HEK293,9,,B,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Expert
3624,,,,,,,1,,16441,H,10627,,8,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,Expert
3625,,,,,,,1,,16441,H,10627,,8,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,Expert
3626,,,,,,,1,,6786,H,10627,COS-7,8,,B,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,Expert
3627,Homo sapiens,,,9606.0,,,1,,4234,D,10627,,9,,B,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,Expert
3628,,,,,,,1,,17085,H,10627,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,Autocuration
3629,,,,,,,1,,17200,H,10627,,8,,B,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,Autocuration
3630,,,,,,,1,,17451,H,10627,HEK293,8,,B,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Autocuration
3631,,,,,,,1,,3935,H,10627,,8,,F,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,Autocuration
3632,,,,,,,1,,5033,H,10627,,8,,B,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,Autocuration
3633,,,,,,,1,,4540,H,10627,,8,,B,Binding affinity against human 5-hydroxytryptamine 6 receptor,,Expert
3634,Homo sapiens,,,9606.0,,,1,,4540,D,10627,HeLa,9,,B,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,Expert
3635,Homo sapiens,,,9606.0,,,1,,4540,D,10627,HeLa,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,Expert
3636,,,,,,,1,,17296,H,10627,HeLa,8,,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,Autocuration
3637,,,,,,,1,,17296,H,10627,HeLa,8,,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,Autocuration
3638,,,,,,,1,,17296,H,10627,HeLa,8,,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,Autocuration
3639,,,,,,,1,,15779,H,10627,CHO,8,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,Autocuration
3640,,,,,,,1,,15779,H,10627,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration
3641,,,,,,,1,,15779,H,10627,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,Autocuration
3642,,,,,,,1,,15779,H,10627,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,Autocuration
3643,,,,,,,1,,15779,H,10627,HeLa,8,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,Autocuration
3644,,,,,,,1,,6166,H,10627,,8,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Autocuration
3645,,,,,,,1,,17451,H,10627,HeLa,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,Autocuration
3646,,,,,,,1,,15316,H,10627,,8,,B,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,Autocuration
3647,,,,,,,1,,4199,H,10627,,8,,B,Binding affinity against human 5-hydroxytryptamine 6 receptor,,Expert
3648,,,,,,,1,,15146,H,10627,HeLa,8,,B,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,Expert
3649,,,,,,,1,,5213,H,10627,,8,,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,Autocuration
3650,,,,,,,1,,16429,H,10627,,8,,B,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,Autocuration
3651,,,,,,,1,,14818,H,10627,HeLa,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,Autocuration
3652,,,,,,,1,,4829,H,10627,HeLa,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,Autocuration
3653,,,,,,,1,,4829,H,10627,HeLa,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,Autocuration
3654,,,,,,,1,,4829,H,10627,HeLa,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,Autocuration
3655,,,,,,,1,,15250,H,10628,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,Autocuration
3656,,,,,,,1,,14423,H,10628,,8,,B,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,Autocuration
3657,,,,,,,1,,15086,H,10628,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,Autocuration
3658,,,,,,,1,,4342,H,10628,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,Autocuration
3659,Homo sapiens,,,9606.0,,,1,,16190,D,10627,HeLa,9,,B,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,Autocuration
3660,,,,,,,1,,4820,H,10627,,8,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert
3661,,,,,,,1,,4639,H,10627,,8,,B,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,Autocuration
3662,Homo sapiens,,,9606.0,,,1,,17066,D,10627,,9,,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Expert
3663,,,,,,,1,,6011,H,10627,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,Autocuration
3664,,,,,,,1,,17066,H,10627,,8,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert
3665,,,,,,,1,,17515,H,10627,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,Autocuration
3666,,,,,,,1,,5014,H,10627,,8,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,Autocuration
3667,,,,,,,1,,4373,H,10627,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,Autocuration
3668,,,,,,,1,,17066,H,10627,,8,,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,Expert
3669,,,,,,,1,,17066,H,10627,,8,,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Expert
3670,,,,,,,1,,4373,H,10627,,8,,B,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,Autocuration
3671,,,,,,,1,,4687,H,10627,,8,,B,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,Autocuration
3672,,,,,,,1,,16946,H,10627,,8,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,Autocuration
3673,,,,,,,1,,16946,H,10627,,8,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,Autocuration
3674,,,,,,,1,,16633,H,10627,,8,,B,Binding affinities against 5-hydroxytryptamine 6 receptor,,Autocuration
3675,,,,,,,1,,16633,H,10627,,8,,B,Binding affinities towards 5-hydroxytryptamine 6 receptor,,Autocuration
3676,Homo sapiens,,,9606.0,,,1,,17066,D,10627,,9,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor,,Expert
3677,,,,,,,1,,16700,H,10627,,8,,B,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,Autocuration
3678,,,,,,,1,,3269,H,10627,,8,,B,Affinity against 5-hydroxytryptamine 6 receptor,,Autocuration
3679,,,,,,,1,,5486,H,10627,,8,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,Autocuration
3680,Homo sapiens,,,9606.0,,,1,,16146,D,10209,,9,,B,Inhibition of human 5-hydroxytryptamine 7 receptor,,Expert
3681,,,,,,,1,,5014,H,10209,HEK293,8,,B,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,Autocuration
3682,,,,,,,1,,15463,H,10209,,8,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,Autocuration
3683,,,,,,,1,,3805,H,10209,,8,,B,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,Autocuration
3684,,,,,,,1,,5014,H,10209,HEK293,8,,B,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,Expert
3685,Homo sapiens,,,9606.0,,,1,,6491,D,10209,,9,,B,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,Expert
3686,,,,,,,1,,16190,H,10209,CHO,8,,B,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,Autocuration
3687,Homo sapiens,,,9606.0,,,1,,17066,D,10209,,9,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Expert
3688,Homo sapiens,,,9606.0,,,1,,17066,D,10209,,9,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,Expert
3689,Homo sapiens,,,9606.0,,,1,,3555,D,10209,,9,,B,Binding affinity against 5-hydroxytryptamine 7 receptor,,Expert
3690,,,,,,,1,,6588,H,10209,CHO,8,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,Expert
3691,,,,,,,1,,15463,H,10209,,8,,B,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,Autocuration
3692,,,,,,,1,,6013,H,10209,,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,Autocuration
3693,,,,,,,1,,16209,H,10209,,8,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,Autocuration
3694,,,,,,,1,,3935,H,10209,,8,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,Autocuration
3695,,,,,,,1,,15818,H,10209,,8,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,Autocuration
3696,,,,,,,1,,5014,H,10209,HEK293,8,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,Expert
3697,,,,,,,1,,16441,H,10209,,8,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,Expert
3698,,,,,,,1,,16441,H,10209,,8,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,Expert
3699,Homo sapiens,,,9606.0,,,1,,4234,D,10209,,9,,B,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,Expert
3700,,,,,,,1,,17085,H,10209,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,Autocuration
3701,,,,,,,1,,17200,H,10209,,8,,B,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,Autocuration
3702,,,,,,,1,,17451,H,10209,CHO,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,Autocuration
3703,,,,,,,1,,17085,H,10209,,8,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,Autocuration
3704,,,,,,,1,,5104,H,10209,,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,Autocuration
3705,,,,,,,1,,5104,H,10209,,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,Autocuration
3706,Homo sapiens,,,9606.0,,,1,,5033,D,10209,COS-7,9,,B,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Expert
3707,,,,,,,1,,5486,H,10209,COS-7,8,,B,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Autocuration
3708,Homo sapiens,,,9606.0,,,1,,4540,D,10209,HEK293,9,,B,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,Expert
3709,,,,,,,1,,6166,H,10209,,8,,B,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,Expert
3710,,,,,,,1,,17342,H,10209,HEK293,8,,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,Expert
3711,,,,,,,1,,17342,H,10209,,8,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,Expert
3712,,,,,,,1,,17296,H,10209,,8,,B,Binding affinity against 5-hydroxytryptamine 7 human receptors,,Autocuration
3713,,,,,,,1,,16429,H,10209,,8,,B,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,Expert
3714,,,,,,,1,,15779,H,10209,HEK293,8,,B,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,Autocuration
3715,,,,,,,1,,15779,H,10209,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration
3716,,,,,,,1,,15779,H,10209,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration
3717,,,,,,,1,,15779,H,10209,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration
3718,,,,,,,1,,15779,H,10209,HEK293,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration
3719,,,,,,,1,,17451,H,10209,CHO,8,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,Autocuration
3720,,,,,,,1,,4199,H,10209,HEK293,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,Autocuration
3721,,,,,,,1,,4199,D,10209,HEK293,9,,B,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,Expert
3722,,,,,,,1,,4199,H,10209,HEK293,8,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,Autocuration
3723,,,,,,,1,,3680,D,10209,HEK293,9,,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,Intermediate
3724,,,,,,,1,,3680,D,10209,,9,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,Intermediate
3725,,,,,,,1,,15316,H,10209,COS-7,8,,B,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,Autocuration
3726,,,,,,,1,,15146,H,10209,HEK293,8,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,Autocuration
3727,,,,,,,1,,5213,H,10209,HEK293,8,,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,Expert
3728,,,,,,,1,,5213,H,10209,HEK293,8,,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,Autocuration
3729,Homo sapiens,,,9606.0,,,1,,14818,D,10209,HEK293,9,,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,Expert
3730,,,,,,,1,,14818,H,10209,HEK293,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,Autocuration
3731,,,,,,,1,,14818,H,10209,HEK293,8,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,Autocuration
3732,,,,,,,1,,4829,H,10209,HEK293,8,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,Autocuration
3733,Homo sapiens,,,9606.0,,,1,,17200,D,10209,,9,,B,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,Autocuration
3734,Mus musculus,,,10090.0,,,1,,17066,D,10022,,9,,B,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Expert
3735,Oryctolagus cuniculus,,,9986.0,,,1,,14025,H,10209,,8,,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,Autocuration
3736,,,,,,,1,,15250,H,11923,CHO,8,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,Autocuration
3737,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,Autocuration
3738,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,Autocuration
3739,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,Autocuration
3740,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,Autocuration
3741,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,Autocuration
3742,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,Autocuration
3743,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,Autocuration
3744,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,Autocuration
3745,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,Autocuration
3746,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,Autocuration
3747,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,Autocuration
3748,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,Autocuration
3749,,,,,,,1,,17066,H,11923,,8,,B,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,Expert
3750,Rattus norvegicus,,,10116.0,,,1,,17066,D,11923,,9,,B,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Expert
3751,,,,,,,1,,17386,H,11923,,8,,B,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,Expert
3752,,,,,,,1,,14423,H,11923,,8,,B,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,Autocuration
3753,Rattus norvegicus,,,10116.0,,,1,,15874,D,11923,,9,,B,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,Expert
3754,Rattus norvegicus,,,10116.0,,,1,,15874,D,11923,,9,,B,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,Expert
3755,Rattus norvegicus,,,10116.0,,,1,,16372,D,11923,CHO,9,,B,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,Expert
3756,,,,,,,1,,4622,H,11923,,8,,B,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,Autocuration
3757,,,,,,,1,,15086,H,11923,,8,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,Autocuration
3758,,,,,,,1,,16372,H,11923,CHO,8,,B,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,Autocuration
3759,,,,,,,1,,16372,H,11923,CHO,8,,B,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,Autocuration
3760,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,Autocuration
3761,,,,,,,1,,16372,H,11923,CHO,8,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,Autocuration
3762,,,2116.0,,,,1,,17386,H,11923,,8,Ileum,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,Autocuration
3763,,,2116.0,,,,1,,17386,H,11923,,8,Ileum,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,Autocuration
3764,,,2116.0,,,,1,,17386,H,11923,,8,Ileum,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,Autocuration
3765,Rattus norvegicus,,,10116.0,,,1,,5831,D,11923,,9,,B,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Membranes,Expert
3766,,,,,,,1,,4342,H,11923,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,Autocuration
3767,,,,,,,1,,17319,H,11923,,8,,B,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,Expert
3768,,,1898.0,,,,1,,17342,H,11923,,8,Hypothalamus,B,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,Expert
3769,,,,,,,1,,17342,H,11923,,8,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,Autocuration
3770,,,1898.0,,,,1,,3680,H,11923,,8,Hypothalamus,B,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,Expert
3771,,,,,,,1,,3680,H,11923,,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,Expert
3772,Rattus norvegicus,,,10116.0,,,1,,17319,D,11923,HEK293,9,,F,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,Expert
3773,Rattus norvegicus,,,10116.0,,,1,,17319,D,11923,HEK293,9,,F,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,Expert
3774,Rattus norvegicus,,,10116.0,,,1,,17319,D,11923,HEK293,9,,F,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,Autocuration
3775,,,,,,,1,,4820,H,10209,,8,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,Expert
3776,,,,,,,1,,4639,H,10209,,8,,B,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,Autocuration
3777,,,,,,,1,,6011,H,10209,,8,,B,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,Autocuration
3778,Homo sapiens,,,9606.0,,,1,,17066,D,10209,,9,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Expert
3779,,,,,,,1,,17066,H,10209,,8,,B,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,Expert
3780,,,,,,,1,,17515,H,10209,,8,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,Autocuration
3781,,,,,,,1,,4373,H,10209,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,Autocuration
3782,,,,,,,1,,17066,H,10209,,8,,F,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,Expert
3783,,,,,,,1,,4373,H,10209,,8,,B,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,Autocuration
3784,,,,,,,1,,4373,H,10209,,8,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,Autocuration
3785,,,,,,,1,,4687,H,10209,,8,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,Autocuration
3786,,,,,,,1,,17342,H,10209,,8,,B,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,Expert
3787,,,,,,,1,,16946,H,10209,,8,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,Autocuration
3788,,,,,,,1,,16946,H,10209,,8,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,Autocuration
3789,,,,,,,1,,16633,H,10209,,8,,B,Binding affinities against 5-hydroxytryptamine 7 receptor,,Autocuration
3790,,,,,,,1,,16633,H,10209,,8,,B,Binding affinities towards 5-hydroxytryptamine 7 receptor,,Autocuration
3791,,,,,,,1,,17066,H,10209,,8,,B,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,Expert
3792,,,,,,,1,,16700,H,10209,,8,,B,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,Autocuration
3793,,,2116.0,,,,1,,17386,H,10209,,8,Ileum,B,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,Autocuration
3794,,,,,,,1,,14080,H,55,,8,,F,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,Autocuration
3795,Homo sapiens,,,9606.0,,,1,,14080,D,55,,9,,F,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,Expert
3796,,,,,,,1,,409,H,55,,8,,B,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,Autocuration
3797,,,,,,,1,,409,H,55,,8,,B,In vitro inhibition of human recombinant lipoxygenase enzyme,,Autocuration
3798,,,,,,,1,,409,H,55,,8,,B,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,Autocuration
3799,,,178.0,,,,1,,11090,H,55,,8,Blood,B,Inhibition of 5-lipoxygenase in human whole blood.,,Expert
3800,,,178.0,,,,1,,11090,H,55,,8,Blood,B,Inhibition of 5-lipoxygenase in human whole blood.,,Expert
3801,,,,,,,1,,948,H,55,,8,,B,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,Autocuration
3802,,,,,,,1,,948,H,55,,8,,B,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,Autocuration
3803,,,,,,,1,,13622,H,55,,8,,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,Expert
3804,,,178.0,,,,1,,13622,H,55,,8,Blood,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,Autocuration
3805,,,,,,,1,,9637,H,55,,8,,B,In vitro inhibition of 5-lipoxygenase from human polymorphs,,Autocuration
3806,,,,,,,1,,11320,H,55,,8,,B,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,Autocuration
3807,,,,,,,1,,11320,H,55,,8,,B,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,Expert
3808,,,,,,,1,,6838,H,55,,8,,B,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,Autocuration
3809,Homo sapiens,,178.0,9606.0,,,1,,17667,D,55,,9,Blood,B,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,Expert
3810,,,,,,,1,,12703,H,55,,8,,B,In vitro potency against human 5-Lipoxygenase,,Autocuration
3811,Homo sapiens,,,9606.0,,,1,,14312,D,55,,9,,F,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,Expert
3812,,,178.0,,,,1,,14312,H,55,,8,Blood,F,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,Autocuration
3813,,,,,,,1,,5364,H,55,,8,,F,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,Autocuration
3814,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,Autocuration
3815,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,Autocuration
3816,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,Autocuration
3817,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,Autocuration
3818,,,,,,,1,,12365,H,55,,8,,B,Inhibition of human 5-lipoxygenase in human cells,,Autocuration
3819,,,,,,,1,,10603,H,55,,8,,B,Inhibition of human neutrophil 5-lipoxygenase,,Expert
3820,,,,,,,1,,10501,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,Autocuration
3821,,,178.0,,,,1,,12281,H,55,,8,Blood,B,Inhibition of 5-lipoxygenase from human whole blood,,Expert
3822,,,,,,,1,,2567,H,55,,8,,B,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,Autocuration
3823,,,,,,,1,,2567,H,55,,8,,B,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,Autocuration
3824,,,,,,,1,,10193,H,55,,8,,B,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,Expert
3825,,,,,,,1,,10193,H,55,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,Autocuration
3826,,,,,,,1,,13623,H,55,,8,,B,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,Expert
3827,,,,,,,1,,12780,H,55,,8,,B,Tested against 5-lipoxygenase,,Autocuration
3828,,,,,,,1,,12780,H,55,,8,,B,Tested for activity against 5-Lipoxygenase (5-LO),,Autocuration
3829,,,,,,,1,,12780,H,55,,8,,B,Tested for activity against 5-lipoxygenase,,Autocuration
3830,,,,,,,1,,11966,H,55,,8,,B,Tested for inhibition of 5-HPETE production by human 5-LO,,Autocuration
3831,,,,,,,1,,5364,H,55,,8,,F,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,Autocuration
3832,,,,,,,1,,13165,H,55,,8,,B,Inhibition of Human 5-lipoxygenase,,Expert
3833,,,,,,,1,,5364,H,55,,8,,B,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,Autocuration
3834,,,,,,,1,,11311,H,55,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,Autocuration
3835,,,,,,,1,,11311,H,55,,8,,B,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,Autocuration
3836,,,,,,,1,,14863,H,55,,8,,B,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,Autocuration
3837,,,,,,,1,,14863,H,55,,8,,B,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,Autocuration
3838,,,178.0,,,,1,,11087,H,55,,8,Blood,B,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,Autocuration
3839,,,,,,,1,,455,H,55,,8,,B,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,Autocuration
3840,,,,,,,1,,13183,H,55,,8,,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,Autocuration
3841,,,,,,,1,,10319,H,55,,8,,B,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,Expert
3842,,,,,,,1,,10193,H,55,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,Autocuration
3843,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,Autocuration
3844,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,Autocuration
3845,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,Autocuration
3846,,,,,,,1,,951,H,55,,8,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,Autocuration
3847,,,,,,,1,,9859,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,Expert
3848,,,,,,,1,,9859,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,Expert
3849,,,,,,,1,,9859,H,55,,8,,B,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,Autocuration
3850,,,,,,,1,,2567,H,55,,8,,B,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,Autocuration
3851,,,,,,,1,,10193,H,55,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,Autocuration
3852,,,,,,,1,,10193,H,55,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,Autocuration
3853,,,,,,,1,,949,H,55,,8,,B,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,Autocuration
3854,,,,,,,1,,949,H,55,,8,,B,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,Autocuration
3855,,,,,,,1,,10603,H,55,,8,,B,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,Expert
3856,,,,,,,1,,10603,H,55,,8,,B,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,Expert
3857,,,,,,,1,,10603,H,55,,8,,F,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,Autocuration
3858,,,,,,,1,,10603,H,55,,8,,B,Inhibition of lipoxygenase at the concentration of 0.1 uM,,Expert
3859,,,,,,,1,,10603,H,55,,8,,B,Inhibition of lipoxygenase at the concentration of 1 uM,,Expert
3860,,,,,,,1,,10193,H,55,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,Autocuration
3861,Homo sapiens,,,9606.0,,,1,,14580,D,55,,9,,B,Inhibition of 5-Lipoxygenase (5-LOX),,Expert
3862,,,,,,,1,,11090,H,17087,,8,,B,Inhibition of 5-lipoxygenase in mouse macrophages.,,Expert
3863,,,,,,,1,,11090,H,17087,,8,,B,Inhibition of 5-lipoxygenase in mouse macrophages.,,Expert
3864,,,,,,,1,,6339,H,17087,,8,,B,Inhibitory activity against lipoxygenase-2 in mice,,Autocuration
3865,,,,,,,1,,6339,H,17087,,8,,B,Inhibitory activity against murine lipoxygenase-2.,,Expert
3866,Mus musculus,,,10090.0,,,1,,12281,D,17087,,9,,B,Inhibition of 5-lipoxygenase from mouse macrophage,,Expert
3867,,,,,,,1,,11311,H,17087,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,Autocuration
3868,Sus scrofa,,,9823.0,,,1,,11089,H,55,,8,,B,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Autocuration
3869,Sus scrofa,,,9823.0,,,1,,10091,H,55,,8,,B,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,Autocuration
3870,Oryctolagus cuniculus,,,9986.0,,,1,,14352,H,55,,8,,B,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,Autocuration
3871,Rattus norvegicus,,,10116.0,,,1,,13329,D,12166,,9,,B,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,Expert
3872,,,,,,,1,,13329,H,12166,,8,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,Autocuration
3873,,,,,,,1,,13329,H,12166,,8,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,Autocuration
3874,,,,,,,1,,13329,H,12166,,8,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,Autocuration
3875,,,,,,,1,,13329,H,12166,,8,,B,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,Expert
3876,,,,,,,1,,13329,H,12166,,8,,B,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,Expert
3877,,,,,,,1,,13329,H,12166,,8,,B,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,Autocuration
3878,,,,,,,1,,11311,H,12166,,8,,B,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,Autocuration
3879,,,,,,,1,,11311,H,12166,,8,,B,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,Autocuration
3880,,,,,,,1,,105,H,12166,RBL-1,8,,B,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,Autocuration
3881,,,,,,,1,,105,H,12166,RBL-1,8,,B,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,Autocuration
3882,,,,,,,1,,9138,H,12166,,8,,B,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,Autocuration
3883,,,,,,,1,,9138,H,12166,,8,,B,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,Autocuration
3884,,,,,,,1,,9138,H,12166,,8,,B,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,Autocuration
3885,,,,,,,1,,14427,H,12166,,8,,B,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,Autocuration
3886,,,,,,,1,,13329,H,12166,,8,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,Autocuration
3887,,,,,,,1,,13329,H,12166,,8,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,Autocuration
3888,Rattus norvegicus,,,10116.0,,,1,,14427,D,12166,RBL-2H3,9,,B,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,Expert
3889,,,,,,,1,,14427,H,12166,,8,,B,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,Autocuration
3890,,,,,,,1,,14427,H,12166,,8,,B,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,Autocuration
3891,,,,,,,1,,10293,H,12166,RBL-1,8,,B,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,Expert
3892,Rattus norvegicus,,,10116.0,,,1,,338,D,12166,RBL-1,9,,B,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,Expert
3893,,,,,,,1,,303,H,12166,,8,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,Autocuration
3894,,,,,,,1,,303,H,12166,RBL-1,8,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,Autocuration
3895,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,Expert
3896,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,Autocuration
3897,,,,,,,1,,137,H,12166,RBL-1,8,,B,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,Autocuration
3898,,,,,,,1,,11481,H,12166,,8,,B,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,Expert
3899,,,,,,,1,,11481,H,12166,,8,,B,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,Expert
3900,,,,,,,1,,9029,H,12166,,8,,B,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,Expert
3901,,,,,,,1,,1701,H,12166,,8,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,Autocuration
3902,,,,,,,1,,1701,H,12166,,8,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,Autocuration
3903,,,,,,,1,,1701,H,12166,,8,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,Autocuration
3904,,,,,,,1,,1701,H,12166,,8,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,Autocuration
3905,,,,,,,1,,13358,H,12166,RBL-1,8,,F,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,Expert
3906,,,,,,,1,,1175,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,Expert
3907,,,,,,,1,,8797,H,12166,RBL-1,8,,B,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,Expert
3908,,,,,,,1,,8797,H,12166,,8,,B,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,Autocuration
3909,Rattus norvegicus,,,10116.0,,,1,,577,D,12166,,9,,B,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,Expert
3910,,,,,,,1,,9295,H,12166,RBL-1,8,,B,In vitro inhibitory activity against RBL-1 5-LO,,Expert
3911,,,,,,,1,,9295,H,12166,RBL-1,8,,B,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,Autocuration
3912,,,,,,,1,,9295,H,12166,RBL-1,8,,B,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,Autocuration
3913,,,,,,,1,,9295,H,12166,,8,,B,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,Autocuration
3914,,,,,,,1,,9295,H,12166,,8,,B,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,Autocuration
3915,,,,,,,1,,216,H,12166,,8,,B,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,Autocuration
3916,,,,,,,1,,11090,H,12166,RBL-1,8,,B,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,Autocuration
3917,,,178.0,,,,1,,11090,H,12166,,8,Blood,B,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,Autocuration
3918,,,,,,,1,,10091,H,12166,,8,,B,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,Expert
3919,,,,,,,1,,10274,H,12166,,8,,F,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,Autocuration
3920,,,,,,,1,,13622,H,12166,,8,,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,Autocuration
3921,,,,,,,1,,12118,H,12166,RBL-1,8,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,Expert
3922,,,,,,,1,,12576,H,12166,,8,,B,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,Expert
3923,,,,,,,1,,9546,H,12166,RBL-1,8,,B,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,Expert
3924,,,,,,,1,,9521,H,12166,RBL-1,8,,B,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,Autocuration
3925,,,,,,,1,,10626,H,12166,RBL-1,8,,B,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,Expert
3926,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase,,Autocuration
3927,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,Autocuration
3928,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,Autocuration
3929,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,Autocuration
3930,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,Autocuration
3931,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,Autocuration
3932,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,Autocuration
3933,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,Autocuration
3934,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,Autocuration
3935,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,Autocuration
3936,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,Autocuration
3937,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,Autocuration
3938,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,Autocuration
3939,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,Autocuration
3940,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,Autocuration
3941,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,Autocuration
3942,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,Autocuration
3943,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,Autocuration
3944,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,Autocuration
3945,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,Autocuration
3946,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,Autocuration
3947,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,Autocuration
3948,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,Autocuration
3949,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,Autocuration
3950,,,,,,,1,,9401,H,12166,,8,,B,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,Expert
3951,,,,,,,1,,10325,H,12166,,8,,B,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,Autocuration
3952,,,,,,,1,,1556,H,12166,RBL-2H3,8,,F,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,Expert
3953,,,,,,,1,,1556,H,12166,RBL-2H3,8,,F,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,Expert
3954,Rattus norvegicus,,,10116.0,,,1,,961,D,12166,RBL-1,9,,B,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,Expert
3955,,,,,,,1,,6838,H,12166,,8,,B,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,Autocuration
3956,,,,,,,1,,10325,H,12166,,8,,B,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,Expert
3957,Rattus norvegicus,,,10116.0,,,1,,9209,D,12166,RBL-1,9,,B,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,Expert
3958,,,,,,,1,,11520,H,12166,RBL-1,8,,B,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,Expert
3959,,,,,,,1,,137,H,12166,,8,,B,In vitro inhibitory activity against 5-lipoxygenase was determined,,Autocuration
3960,,,,,,,1,,4717,H,12166,RBL-1,8,,B,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,Autocuration
3961,,,,,,,1,,10636,H,12166,RBL-1,8,,B,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,Expert
3962,Rattus norvegicus,,,10116.0,,,1,,14312,D,12166,,9,,F,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,Expert
3963,,,,,,,1,,1203,H,12166,RBL-1,8,,B,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,Autocuration
3964,,,,,,,1,,1203,H,12166,,8,,B,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,Autocuration
3965,,,,,,,1,,13622,H,12166,RBL-1,8,,B,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,Expert
3966,,,,,,,1,,9793,H,12166,,8,,B,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,Autocuration
3967,Rattus norvegicus,,,10116.0,,,1,,1143,D,12166,RBL-1,9,,B,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,Expert
3968,Rattus norvegicus,,,10116.0,,,1,,11854,D,12166,RBL-1,9,,B,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,Expert
3969,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,Autocuration
3970,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,Autocuration
3971,Rattus norvegicus,,,10116.0,,,1,,10501,D,12166,RBL-1,9,,B,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,Expert
3972,,,,,,,1,,12526,H,12166,RBL-1,8,,B,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Expert
3973,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,Autocuration
3974,,,349.0,,,,1,,10034,H,10825,,8,Limbic system,F,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,Autocuration
3975,,,,,,,1,,10034,H,10825,,8,,F,Approximate dose levels for a half maximal reduction of 5-HTP levels,,Autocuration
3976,,,10000000.0,,,,1,,10046,H,10576,,8,Hippocampus,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,Autocuration
3977,,,10000000.0,,,,1,,10046,H,10576,,8,Hippocampus,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,Autocuration
3978,,,,,,,1,,10046,H,10577,,8,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,Autocuration
3979,Canis lupus familiaris,,178.0,9615.0,,,1,,12079,H,55,,8,Blood,F,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,Autocuration
3980,,,178.0,,,,1,,12079,H,55,,8,Blood,F,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,Autocuration
3981,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,Autocuration
3982,,,,,,,1,,12338,H,17140,,8,,B,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,Expert
3983,,,,,,,1,,12143,H,17140,,8,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,Expert
3984,,,,,,,1,,12143,H,17140,,8,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,Autocuration
3985,,,,,,,1,,12143,H,17140,,8,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,Expert
3986,,,,,,,1,,12143,H,17140,,8,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,Autocuration
3987,,,,,,,1,,12365,H,17140,,8,,B,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,Expert
3988,,,,,,,1,,13500,H,17140,,8,,B,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,Expert
3989,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3990,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3991,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3992,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3993,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3994,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3995,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3996,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3997,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3998,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
3999,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4000,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4001,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4002,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4003,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4004,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4005,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4006,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4007,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4008,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4009,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4010,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4011,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4012,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4013,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4014,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4015,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4016,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4017,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4018,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4019,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4020,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4021,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4022,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4023,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,Autocuration
4024,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4025,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,Autocuration
4026,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4027,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4028,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4029,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4030,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4031,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,Autocuration
4032,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4033,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4034,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,12832,H,55,,8,Blood,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4035,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,Autocuration
4036,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,Autocuration
4037,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,Autocuration
4038,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,Autocuration
4039,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,Autocuration
4040,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,Autocuration
4041,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,Autocuration
4042,Canis lupus familiaris,,,9615.0,,,1,,3595,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,Autocuration
4043,Cavia porcellus,,,10141.0,,,1,,9203,H,55,,8,,B,Ability to inhibit 5-lipoxygenase in guinea pig,,Autocuration
4044,Cavia porcellus,,,10141.0,,,1,,82,H,55,,8,,B,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,Expert
4045,Cavia porcellus,,,10141.0,,,1,,11090,H,55,,8,,B,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,Autocuration
4046,Cavia porcellus,,178.0,10141.0,,,1,,12832,H,55,,8,Blood,B,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,Autocuration
4047,Cavia porcellus,,,10141.0,,,1,,1065,H,55,,8,,B,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,Autocuration
4048,Cavia porcellus,,,10141.0,,,1,,1065,H,55,,8,,B,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,Autocuration
4049,Cavia porcellus,,,10141.0,,,1,,12832,H,55,,8,,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,Expert
4050,Cavia porcellus,,,10141.0,,,1,,12832,H,55,,8,,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Expert
4051,Cavia porcellus,,,10141.0,,,1,,12832,H,55,,8,,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Autocuration
4052,Cavia porcellus,,,10141.0,,,1,,10504,H,55,,8,,B,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Autocuration
4053,Cavia porcellus,,,10141.0,,,1,,7788,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase,,Autocuration
4054,Cavia porcellus,,,10141.0,,,1,,10001,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,Autocuration
4055,Cavia porcellus,,,10141.0,,,1,,10193,H,55,,8,,B,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,Autocuration
4056,Cavia porcellus,,,10141.0,,,1,,13243,H,55,,8,,B,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,Autocuration
4057,Cavia porcellus,,,10141.0,,,1,,13243,H,55,,8,,B,Inhibitory activity uM,,Autocuration
4058,Cavia porcellus,,,10141.0,,,1,,969,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,Autocuration
4059,Cavia porcellus,,,10141.0,,,1,,10001,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase at 10 uM,,Autocuration
4060,Cavia porcellus,,,10141.0,,,1,,7788,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Autocuration
4061,Cavia porcellus,,,10141.0,,,1,,10001,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,Autocuration
4062,Cavia porcellus,,,10141.0,,,1,,10193,H,55,,8,,B,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Autocuration
4063,Cavia porcellus,,,10141.0,,,1,,13243,H,55,,8,,B,Inhibitory activity uM,,Autocuration
4064,Cavia porcellus,,,10141.0,,,1,,13243,H,55,,8,,B,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,Autocuration
4065,Cavia porcellus,,,10141.0,,,1,,13243,H,55,,8,,B,Inhibitory activity uM,,Expert
4066,Cavia porcellus,,,10141.0,,,1,,13243,H,55,,8,,F,Inhibitory activity uM,,Autocuration
4067,Cavia porcellus,,,10141.0,,,1,,10504,H,55,,8,,B,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Autocuration
4068,Cavia porcellus,,,10141.0,,,1,,7788,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Autocuration
4069,Cavia porcellus,,2116.0,10141.0,,,1,,10546,H,55,,8,Ileum,F,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,Expert
4070,,,,,,,1,,13183,H,55,,8,,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,Autocuration
4071,,,,,,,1,,13183,H,55,,8,,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,Autocuration
4072,,,,,,,1,,2578,H,55,,8,,B,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,Autocuration
4073,,,,,,,1,,12780,H,55,,8,,B,In vitro inhibition of human 5-Lipoxygenase.,,Expert
4074,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,Autocuration
4075,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,Autocuration
4076,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,Autocuration
4077,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Microsomes,Autocuration
4078,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,Autocuration
4079,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,Autocuration
4080,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,Autocuration
4081,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,Autocuration
4082,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,Autocuration
4083,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,Autocuration
4084,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,Autocuration
4085,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Microsomes,Autocuration
4086,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,Autocuration
4087,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,Autocuration
4088,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,Autocuration
4089,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,Autocuration
4090,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,Autocuration
4091,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,Autocuration
4092,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Microsomes,Autocuration
4093,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Microsomes,Autocuration
4094,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Microsomes,Autocuration
4095,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Microsomes,Autocuration
4096,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Microsomes,Autocuration
4097,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,Autocuration
4098,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,Autocuration
4099,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Microsomes,Autocuration
4100,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Microsomes,Autocuration
4101,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,Autocuration
4102,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,Autocuration
4103,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,Autocuration
4104,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,Autocuration
4105,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,Autocuration
4106,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,Autocuration
4107,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,Autocuration
4108,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,Autocuration
4109,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,Autocuration
4110,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,Autocuration
4111,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,Autocuration
4112,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,Autocuration
4113,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,Autocuration
4114,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,Autocuration
4115,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,Autocuration
4116,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Microsomes,Autocuration
4117,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Microsomes,Autocuration
4118,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Microsomes,Autocuration
4119,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Microsomes,Autocuration
4120,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,Autocuration
4121,Rattus norvegicus,,,10116.0,,,1,,7411,U,22226,,0,,B,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,Autocuration
4122,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,Autocuration
4123,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,Autocuration
4124,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Microsomes,Autocuration
4125,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,Autocuration
4126,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,Autocuration
4127,Homo sapiens,,,9606.0,,,1,,10797,N,80433,RPMI-8226,1,,F,In vitro inhibition of 7226/S myeloma cancer cell line,,Intermediate
4128,Homo sapiens,,,9606.0,,,1,,6881,N,80698,BEL-7404 tumor cell line,1,,F,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,Intermediate
4129,Homo sapiens,,,9606.0,,,1,,3838,N,80640,786-0,1,,F,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Intermediate
4130,Homo sapiens,,,9606.0,,,1,,3838,N,80640,786-0,1,,F,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Intermediate
4131,Cricetulus griseus,,,10029.0,,,1,,12981,N,81264,V79,1,,F,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,Expert
4132,Cricetulus griseus,,,10029.0,,,1,,12981,N,81264,V79,1,,F,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,Expert
4133,Rattus norvegicus,,,10116.0,,,1,,7653,N,80635,7800C1 cell line,1,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,Intermediate
4134,Rattus norvegicus,,,10116.0,,,1,,7653,N,80635,7800C1 cell line,1,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,Intermediate
4135,Rattus norvegicus,,,10116.0,,,1,,7653,N,80635,7800C1 cell line,1,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,Intermediate
4136,Rattus norvegicus,,,10116.0,,,1,,7653,N,80635,7800C1 cell line,1,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,Intermediate
4137,Rattus norvegicus,,,10116.0,,,1,,7653,N,80635,7800C1 cell line,1,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,Intermediate
4138,Rattus norvegicus,,,10116.0,,,1,,7653,N,80635,7800C1 cell line,1,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,Intermediate
4139,Homo sapiens,,,9606.0,,,1,,17229,N,80640,786-0,1,,F,In vitro antitumor activity against renal 786-0 tumor cell lines,,Intermediate
4140,Homo sapiens,,,9606.0,,,1,,12858,N,80640,786-0,1,,F,Cytotoxic activity against 786-0 Renal cancer cell line,,Intermediate
4141,Homo sapiens,,,9606.0,,,1,,16325,N,80640,786-0,1,,F,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,Intermediate
4142,Homo sapiens,,,9606.0,,,1,,16325,N,80640,786-0,1,,F,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,Intermediate
4143,Homo sapiens,,,9606.0,,,1,,5858,N,80640,786-0,1,,F,In vitro antitumor activity against human renal 786-0 cell line,,Intermediate
4144,Homo sapiens,,,9606.0,,,1,,16325,N,80640,786-0,1,,F,Inhibition of Renal cancer in 786-0 cancer cell lines,,Intermediate
4145,Homo sapiens,,,9606.0,,,1,,14696,N,80640,786-0,1,,F,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,Intermediate
4146,Homo sapiens,,,9606.0,,,1,,3786,N,80640,786-0,1,,F,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,Intermediate
4147,Homo sapiens,,,9606.0,,,1,,14696,N,80640,786-0,1,,F,inhibition of the growth of renal cancer(786-0) cell line,,Intermediate
4148,Homo sapiens,,,9606.0,,,1,,14769,N,80640,786-0,1,,F,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Intermediate
4149,Homo sapiens,,,9606.0,,,1,,15354,N,80640,786-0,1,,F,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,Intermediate
4150,Homo sapiens,,,9606.0,,,1,,14255,N,80640,786-0,1,,F,The IC50 value was measured on 786-0 cell line in ovarian tumor,,Intermediate
4151,Homo sapiens,,,9606.0,,,1,,14255,N,80640,786-0,1,,F,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,Intermediate
4152,Homo sapiens,,,9606.0,,,1,,14255,N,80640,786-0,1,,F,The IC50 value was measured on 786-0 cell line in renal tumor type.,,Intermediate
4153,Homo sapiens,,,9606.0,,,1,,14696,N,80640,786-0,1,,F,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,Intermediate
4154,Homo sapiens,,,9606.0,,,1,,12016,N,80640,786-0,1,,F,Tested for cytotoxic activity against renal cancer 786-0 cell line,,Intermediate
4155,Homo sapiens,,,9606.0,,,1,,2597,N,80640,786-0,1,,F,Compound was tested for growth inhibitory activity against 786-0 cell line,,Intermediate
4156,,,,,,,1,,12526,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,Autocuration
4157,,,,,,,1,,12526,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,Autocuration
4158,,,,,,,1,,14799,H,12166,,8,,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,Autocuration
4159,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,Expert
4160,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,Expert
4161,,,,,,,1,,12767,H,12166,,8,,B,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,Autocuration
4162,,,,,,,1,,10997,H,12166,,8,,B,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,Autocuration
4163,,,,,,,1,,11388,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,Autocuration
4164,,,,,,,1,,167,H,12166,,8,,B,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,Autocuration
4165,,,,,,,1,,167,H,12166,,8,,B,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,Autocuration
4166,,,,,,,1,,13744,H,12166,,8,,B,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,Expert
4167,,,,,,,1,,1630,H,12166,,8,,B,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,Autocuration
4168,,,,,,,1,,1630,H,12166,,8,,B,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,Autocuration
4169,Rattus norvegicus,,,10116.0,,,1,,969,D,12166,,9,,B,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,Expert
4170,,,,,,,1,,13621,H,12166,RBL-1,8,,B,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,Autocuration
4171,,,,,,,1,,10089,H,12166,,8,,B,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,Autocuration
4172,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,Expert
4173,,,,,,,1,,11966,H,12166,,8,,B,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,Autocuration
4174,,,,,,,1,,12251,H,12166,,8,,B,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,Autocuration
4175,,,,,,,1,,211,H,12166,RBL-1,8,,B,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,Autocuration
4176,,,,,,,1,,12251,H,12166,,8,,F,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,Expert
4177,,,,,,,1,,12495,H,12166,RBL-1,8,,B,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,Autocuration
4178,,,,,,,1,,414,H,12166,,8,,B,Tested for its inhibitory activity against 5-lipoxygenase,,Autocuration
4179,,,,,,,1,,414,H,12166,,8,,B,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,Autocuration
4180,,,,,,,1,,10325,H,12166,,8,,B,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,Expert
4181,,,,,,,1,,11966,H,12166,,8,,B,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,Expert
4182,,,,,,,1,,165,H,12166,RBL-1,8,,B,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,Expert
4183,,,,,,,1,,165,H,12166,RBL-1,8,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,Autocuration
4184,,,,,,,1,,165,H,12166,RBL-1,8,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,Autocuration
4185,,,,,,,1,,165,H,12166,RBL-1,8,,B,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,Expert
4186,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,Autocuration
4187,,,,,,,1,,11311,H,12166,RBL-1,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,Autocuration
4188,,,,,,,1,,11311,H,12166,RBL-1,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,Autocuration
4189,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,Autocuration
4190,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,Autocuration
4191,,,,,In vivo,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,Autocuration
4192,,,,,,,1,,11311,H,12166,RBL-2H3,8,,F,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,Autocuration
4193,,,,,,,1,,11311,H,12166,RBL-2H3,8,,F,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,Autocuration
4194,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,Autocuration
4195,,,,,,,1,,11732,H,12166,,8,,B,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,Autocuration
4196,,,,,,,1,,11732,H,12166,,8,,B,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,Expert
4197,,,,,,,1,,11087,H,12166,,8,,B,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,Expert
4198,,,,,,,1,,11087,H,12166,,8,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,Autocuration
4199,,,,,,,1,,11087,H,12166,RBL-1,8,,B,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,Autocuration
4200,Rattus norvegicus,,,10116.0,,,1,,11087,D,12166,,9,,B,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,Expert
4201,,,,,,,1,,496,H,12166,RBL-1,8,,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,Autocuration
4202,,,,,,,1,,13986,H,12166,RBL-1,8,,F,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,Expert
4203,,,,,,,1,,11520,H,12166,,8,,B,Compound was evaluated for the inhibition of 5-lipoxygenase,,Autocuration
4204,,,,,,,1,,10293,H,12166,RBL-1,8,,B,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,Autocuration
4205,,,,,,,1,,303,H,12166,RBL-1,8,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,Autocuration
4206,,,,,,,1,,303,H,12166,RBL-1,8,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,Autocuration
4207,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,Autocuration
4208,Rattus norvegicus,,,10116.0,,,1,,9247,D,12166,RBL-1,9,,B,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,Expert
4209,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,Autocuration
4210,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,Autocuration
4211,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,Autocuration
4212,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,Autocuration
4213,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,Autocuration
4214,,,,,,,1,,9247,H,12166,RBL-1,8,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,Autocuration
4215,Rattus norvegicus,,,10116.0,,,1,,11481,D,12166,,9,,B,Inhibitory activity against 5-lipoxygenase at 10 uM,,Expert
4216,,,,,,,1,,105,H,12166,,8,,B,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,Autocuration
4217,,,,,,,1,,9029,H,12166,,8,,B,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,Expert
4218,,,,,,,1,,1175,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,Expert
4219,,,,,,,1,,12118,H,12166,RBL-1,8,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,Autocuration
4220,,,,,,,1,,12118,H,12166,RBL-1,8,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,Autocuration
4221,,,,,,,1,,12118,H,12166,RBL-1,8,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,Autocuration
4222,,,,,,,1,,9225,H,12166,RBL-1,8,,B,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,Autocuration
4223,,,,,,,1,,9401,H,12166,,8,,B,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,Autocuration
4224,,,,,,,1,,137,H,12166,,8,,B,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,Autocuration
4225,,,,,,,1,,137,H,12166,,8,,B,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,Autocuration
4226,,,,,,,1,,4717,H,12166,RBL-1,8,,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,Autocuration
4227,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,Autocuration
4228,,,,,,,1,,10501,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,Autocuration
4229,,,,,,,1,,10501,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,Autocuration
4230,,,,,,,1,,10501,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,Autocuration
4231,,,,,,,1,,12526,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Autocuration
4232,Rattus norvegicus,,,10116.0,,,1,,14799,D,12166,RBL-1,9,,B,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,Expert
4233,,,,,,,1,,14799,H,12166,,8,,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,Autocuration
4234,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,Autocuration
4235,,,,,,,1,,3595,H,12166,RBL-1,8,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,Expert
4236,,,,,,,1,,12526,H,12166,RBL-1,8,,B,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Autocuration
4237,,,,,,,1,,12526,H,12166,RBL-1,8,,B,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Autocuration
4238,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,Autocuration
4239,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,Autocuration
4240,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,Autocuration
4241,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,Autocuration
4242,,,,,,,1,,9138,H,12166,,8,,B,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,Expert
4243,,,,,,,1,,9138,H,12166,,8,,B,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,Autocuration
4244,,,,,,,1,,11966,H,12166,,8,,B,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,Autocuration
4245,,,,,,,1,,165,H,12166,RBL-1,8,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,Autocuration
4246,,,,,,,1,,165,H,12166,RBL-1,8,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,Autocuration
4247,,,,,,,1,,11311,H,12166,RBL-2H3,8,,B,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,Autocuration
4248,,,,,,,1,,11311,H,12166,RBL-2H3,8,,B,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,Autocuration
4249,,,,,,,1,,11311,H,12166,RBL-2H3,8,,F,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,Autocuration
4250,,,,,,,1,,11311,H,12166,,8,,F,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,Autocuration
4251,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibition of isolated 5-lipoxygenase,,Autocuration
4252,,,,,,,1,,11311,H,12166,RBL-2H3,8,,F,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,Autocuration
4253,,,,,,,1,,11087,H,12166,,8,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,Autocuration
4254,,,,,,,1,,11087,H,12166,,8,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,Autocuration
4255,,,,,,,1,,11087,H,12166,,8,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,Autocuration
4256,,,,,,,1,,11087,H,12166,,8,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,Autocuration
4257,,,,,,,1,,11087,H,12166,,8,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,Autocuration
4258,,,,,,,1,,496,H,12166,RBL-1,8,,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,Autocuration
4259,,,,,,,1,,496,H,12166,RBL-1,8,,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,Autocuration
4260,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,Autocuration
4261,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,Autocuration
4262,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,Autocuration
4263,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,Autocuration
4264,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,Autocuration
4265,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,Autocuration
4266,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,Autocuration
4267,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,Autocuration
4268,,,,,,,1,,13986,H,12166,RBL-1,8,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,Autocuration
4269,Rattus norvegicus,,,10116.0,,,1,,13986,D,12166,,9,,F,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,Expert
4270,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,Autocuration
4271,,,,,,,1,,9295,H,12166,,8,,B,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,Autocuration
4272,,,,,,,1,,4717,H,12166,RBL-1,8,,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,Autocuration
4273,,,,,,,1,,4717,H,12166,RBL-1,8,,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,Autocuration
4274,,,,,,,1,,11854,H,12166,RBL-1,8,,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,Autocuration
4275,,,,,,,1,,11854,H,12166,RBL-1,8,,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,Autocuration
4276,,,,,,,1,,11854,H,12166,RBL-1,8,,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,Autocuration
4277,,,,,,,1,,10193,H,12166,,8,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,Autocuration
4278,,,,,,,1,,9295,H,12166,RBL-1,8,,B,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,Autocuration
4279,,,,,,,1,,9295,H,12166,RBL-1,8,,B,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,Autocuration
4280,,,,,,,1,,9295,H,12166,RBL-1,8,,B,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,Autocuration
4281,,,,,,,1,,9295,H,12166,RBL-1,8,,B,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,Autocuration
4282,,,,,,,1,,165,H,12166,RBL-1,8,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,Autocuration
4283,,,,,,,1,,11311,H,12166,,8,,B,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,Autocuration
4284,Homo sapiens,,,9606.0,,,1,,10489,H,12166,RBL-1,8,,B,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Expert
4285,Rattus norvegicus,,,10116.0,,,1,,10489,D,12166,RBL-1,9,,B,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Expert
4286,Rattus norvegicus,,,10116.0,,,1,,10489,D,12166,RBL-1,9,,B,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,Expert
4287,Rattus norvegicus,,,10116.0,,,1,,14799,D,12166,,9,,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,Autocuration
4288,Glycine max,,,3847.0,,,1,,9295,H,12054,,8,,B,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,Autocuration
4289,,,,,,,1,,16811,U,22226,,0,,B,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,Autocuration
4290,,,,,,,1,,168,H,55,,8,,B,In vitro inhibition of 5-Lipoxygenase; Inactive.,,Expert
4291,,,,,,,1,,6309,H,55,,8,,B,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,Autocuration
4292,,,,,,,1,,6309,H,55,,8,,B,Inhibitory concentration against 5-lipoxygenase; No inhibition,,Autocuration
4293,,,,,,,1,,3092,H,55,RBL-1,8,,B,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,Autocuration
4294,,,,,,,1,,168,H,55,,8,,B,Inhibitory activity against 5-lipoxygenase.,,Expert
4295,,,,,,,1,,168,H,55,,8,,B,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,Autocuration
4296,,,,,,,1,,168,H,55,,8,,B,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,Autocuration
4297,,,,,,,1,,168,H,55,,8,,B,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,Autocuration
4298,,,,,,,1,,12338,H,55,,8,,F,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,Expert
4299,,,,,,,1,,4501,H,55,,8,,B,Tested for the inhibitory activity against 5-lipoxygenase,,Autocuration
4300,,,,,,,1,,1132,H,55,,8,,B,Compound was tested for its inhibitory activity against 5-lipoxygenase,,Autocuration
4301,,,,,,,1,,2117,H,55,,8,,B,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,Autocuration
4302,,,,,,,1,,168,H,55,,8,,B,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,Autocuration
4303,,,,,,,1,,168,H,55,,8,,B,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,Autocuration
4304,,,,,,,1,,13575,H,12166,RBL-1,8,,B,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,Autocuration
4305,,,,,,,1,,11089,H,12166,,8,,B,,,Autocuration
4306,,,,,,,1,,216,H,10102,,8,,B,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,Autocuration
4307,,,,,,,1,,13165,H,10102,,8,,B,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,Autocuration
4308,,,,,,,1,,3278,H,10102,,8,,B,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,Autocuration
4309,,,,,,,1,,3278,H,10102,,8,,B,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,Expert
4310,,,,,,,1,,11966,H,10102,,8,,B,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,Autocuration
4311,,,,,,,1,,175,H,10102,,8,,B,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,Autocuration
4312,,,,,,,1,,175,H,10102,,8,,B,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,Autocuration
4313,,,,,,,1,,13449,H,10102,,8,,B,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,Autocuration
4314,,,,,,,1,,12014,H,11238,,8,,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,Autocuration
4315,,,,,,,1,,12014,H,11238,,8,,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,Autocuration
4316,,,,,,,1,,12014,H,11238,,8,,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,Autocuration
4317,,,,,,,1,,99,S,100284,,2,,B,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,Intermediate
4318,Homo sapiens,,,9606.0,,,1,,4349,U,22226,,0,,F,The dark toxicity against 543 human galactophore carcinoma cells,,Autocuration
4319,Homo sapiens,,,9606.0,,,1,,4071,N,80623,Panel (56 tumour cell lines),1,,F,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,Expert
4320,Homo sapiens,,,9606.0,,,1,,17589,N,80008,5637,1,,F,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,Expert
4321,Homo sapiens,,,9606.0,,,1,,15002,N,80008,5637,1,,F,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,Intermediate
4322,Homo sapiens,,,9606.0,,,1,,13958,N,80008,5637,1,,F,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,Intermediate
4323,Homo sapiens,,,9606.0,,,1,,17589,N,80008,5637,1,,F,Growth inhibition against human 5637 cell lines,,Expert
4324,Homo sapiens,,,9606.0,,,1,,16748,N,80008,5637,1,,F,Antitumor activity against human bladder carcinoma 5637 cells.,,Expert
4325,Homo sapiens,,,9606.0,,,1,,16747,N,80008,5637,1,,F,Antitumor activity against human bladder carcinoma 5637 cells,,Intermediate
4326,Homo sapiens,,,9606.0,,,1,,16747,N,80008,5637,1,,F,Antitumor activity against human bladder carcinoma 5637 cells,,Intermediate
4327,Bos taurus,,,9913.0,,,1,,15285,D,10443,,9,,B,In vitro inhibition of bovine trypsin(Trp).,,Expert
4328,Cercopithecidae,,,9527.0,,,1,,3726,H,240,CV-1,8,,B,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,Expert
4329,,,,,,,1,,5033,H,10577,,8,,B,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,Autocuration
4330,,,,,,,1,,11756,H,104698,,6,,F,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,Autocuration
4331,,,,,In vivo,,1,,11953,U,22226,,0,,F,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,Autocuration
4332,Cavia porcellus,,,10141.0,,,1,,5033,D,20033,,9,,B,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,Intermediate
4333,Rattus norvegicus,,,10116.0,,,1,,11347,H,17045,,8,,A,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,Expert
4334,Rattus norvegicus,,,10116.0,,,1,,11347,H,17045,,8,,A,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,Expert
4335,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,Intermediate
4336,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,Intermediate
4337,Trypanosoma brucei,,,5691.0,,,1,,17588,H,11938,,8,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,Expert
4338,Trypanosoma brucei,,,5691.0,,,1,,17588,H,11938,,8,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,Autocuration
4339,Ovis aries,,,9940.0,,,1,,17588,H,11938,,8,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,Expert
4340,Ovis aries,,,9940.0,,,1,,17588,H,11938,,8,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,Autocuration
4341,,,,,,,1,,16485,H,11938,,8,,B,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,Autocuration
4342,Homo sapiens,,,9606.0,,,1,,4337,U,22226,,0,,F,Average inhibitory concentration against 60 human cell lines was reported,,Intermediate
4343,Homo sapiens,,,9606.0,,,1,,4112,U,22226,,0,,F,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,Expert
4344,Homo sapiens,,,9606.0,,,1,,16160,N,80315,Panel NCI-60 (60 carcinoma cell lines),1,,F,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,Intermediate
4345,Homo sapiens,,,9606.0,,,1,,16160,N,80315,Panel NCI-60 (60 carcinoma cell lines),1,,F,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,Intermediate
4346,,,,,,,1,,17376,N,80315,Panel NCI-60 (60 carcinoma cell lines),1,,F,In vitro mean growth inhibitory activity against 60-cell panel,,Expert
4347,,,,,,,1,,17376,N,80315,Panel NCI-60 (60 carcinoma cell lines),1,,F,In vitro mean growth lethal concentration against 60-cell panel,,Expert
4348,,,,,,,1,,17376,N,80315,Panel NCI-60 (60 carcinoma cell lines),1,,F,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,Expert
4349,,,,,,,1,,17376,N,80315,Panel NCI-60 (60 carcinoma cell lines),1,,F,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,Expert
4350,,,,,,,1,,3241,H,104775,,4,,F,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,Autocuration
4351,,,,,,,1,,3241,H,104775,,4,,F,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,Autocuration
4352,,,,,,,1,,3725,H,275,,8,,B,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,Expert
4353,Plasmodium falciparum,,,5833.0,,,1,,10805,N,50425,,1,,F,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,Expert
4354,Plasmodium falciparum,,,5833.0,,,1,,10805,N,50425,,1,,F,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,Expert
4355,Plasmodium falciparum,,,5833.0,,,1,,10805,N,50425,,1,,F,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,Expert
4356,Plasmodium falciparum,,,5833.0,,,1,,10805,N,50425,,1,,F,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,Expert
4357,Plasmodium falciparum,,,5833.0,,,1,,10805,N,50425,,1,,F,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,Intermediate
4358,Mus musculus,,,10090.0,,,1,,10144,N,80628,6C3HED,1,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Intermediate
4359,Mus musculus,,,10090.0,,,1,,10144,N,80628,6C3HED,1,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Intermediate
4360,Mus musculus,,,10090.0,,,1,,10144,N,80628,6C3HED,1,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,Intermediate
4361,Mus musculus,,,10090.0,,,1,,10144,N,80628,6C3HED,1,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Intermediate
4362,Mus musculus,,,10090.0,,,1,,10144,N,80628,6C3HED,1,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Intermediate
4363,Mus musculus,,,10090.0,,,1,,10144,N,80628,6C3HED,1,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,Intermediate
4364,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,Autocuration
4365,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,Autocuration
4366,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,Autocuration
4367,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,Autocuration
4368,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,Autocuration
4369,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,Autocuration
4370,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,Autocuration
4371,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,Autocuration
4372,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,Autocuration
4373,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,Autocuration
4374,Mus musculus,,,10090.0,In vivo,,1,,10685,U,22224,,0,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,Autocuration
4375,Mus musculus,,,10090.0,,,1,,10144,U,22224,,0,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Autocuration
4376,Mus musculus,,,10090.0,,,1,,10144,U,22224,,0,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Autocuration
4377,Mus musculus,,,10090.0,,,1,,10144,U,22224,,0,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Autocuration
4378,Mus musculus,,,10090.0,,,1,,10144,U,22224,,0,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Autocuration
4379,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,Autocuration
4380,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,Autocuration
4381,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,Autocuration
4382,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,Autocuration
4383,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,Autocuration
4384,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,Autocuration
4385,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,Autocuration
4386,Mus musculus,,,10090.0,,,1,,10685,U,22224,,0,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,Autocuration
4387,Mus musculus,,,10090.0,,,1,,8831,N,80628,6C3HED,1,,F,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,Intermediate
4388,,,,,In vivo,,1,,11704,U,22224,,0,,F,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,Autocuration
4389,Mus musculus,,,10090.0,,,1,,11704,N,50594,,1,,A,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,Intermediate
4390,Mus musculus,,,10090.0,In vivo,,1,,10685,N,80628,6C3HED,1,,F,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,Intermediate
4391,Mus musculus,,,10090.0,In vivo,,1,,10685,N,80628,6C3HED,1,,F,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,Intermediate
4392,Mus musculus,,,10090.0,,,1,,11368,N,80628,6C3HED,1,,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,Expert
4393,Mus musculus,,,10090.0,,,1,,11368,N,80628,6C3HED,1,,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,Intermediate
4394,Mus musculus,,,10090.0,,,1,,11368,N,80628,6C3HED,1,,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,Expert
4395,Staphylococcus aureus,,,1280.0,,,1,,17763,U,22226,,0,,B,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,Autocuration
4396,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Microsomes,Autocuration
4397,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,Autocuration
4398,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Microsomes,Autocuration
4399,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Microsomes,Autocuration
4400,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Microsomes,Autocuration
4401,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Microsomes,Autocuration
4402,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Microsomes,Autocuration
4403,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,Autocuration
4404,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,Autocuration
4405,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,Autocuration
4406,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,Autocuration
4407,Rattus norvegicus,,2107.0,10116.0,,,1,,7411,U,22226,,0,Liver,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,Autocuration
4408,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,347,U,22224,,0,Plasma,A,The apparent total plasma clearance in monkey,,Autocuration
4409,Cercopithecidae,,,9527.0,In vivo,,1,,3341,U,22224,,0,,A,Compound was evaluated for Hepatic clearance in monkey,,Autocuration
4410,Cercopithecidae,,,9527.0,In vivo,,1,,17853,U,22224,,0,,A,Lower clearance in monkey (i.v.) at 0.5 mpk,,Autocuration
4411,Cercopithecidae,,,9527.0,In vivo,,1,,4514,U,22224,,0,,A,Plasma clearance in rhesus monkey,,Autocuration
4412,Cercopithecidae,,,9527.0,In vivo,,1,,6062,U,22224,,0,,A,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,Autocuration
4413,Cercopithecidae,,,9527.0,In vivo,,1,,6821,U,22224,,0,,A,Plasma clearance of compound was determined in monkey,,Autocuration
4414,Cercopithecidae,,,9527.0,In vivo,,1,,6057,U,22224,,0,,A,Plasma clearance was calculated in rhesus monkey,,Autocuration
4415,Cercopithecidae,,,9527.0,In vivo,,1,,5145,U,22224,,0,,A,Plasma clearance in rhesus monkey,,Autocuration
4416,Cercopithecidae,,,9527.0,In vivo,,1,,6641,U,22224,,0,,A,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration
4417,Cercopithecidae,,,9527.0,In vivo,,1,,5472,U,22224,,0,,A,Plasma clearance was evaluated in rhesus,,Autocuration
4418,Cercopithecidae,,,9527.0,In vivo,,1,,4257,U,22224,,0,,A,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,Autocuration
4419,Cercopithecidae,,,9527.0,In vivo,,1,,5546,U,22224,,0,,A,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Autocuration
4420,Cercopithecidae,,,9527.0,In vivo,,1,,5334,U,22224,,0,,A,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration
4421,Cercopithecidae,,,9527.0,In vivo,,1,,5334,U,22224,,0,,A,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration
4422,Cercopithecidae,,,9527.0,In vivo,,1,,17509,U,22224,,0,,A,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,Autocuration
4423,Cercopithecidae,,,9527.0,In vivo,,1,,6535,U,22224,,0,,A,Cmax in monkey after administration of 1 mg/kg iv,,Autocuration
4424,Cercopithecidae,,,9527.0,In vivo,,1,,5668,U,22224,,0,,A,Cmax was determine after peroral administration at 10 mpk in Rhesus,,Autocuration
4425,Cercopithecidae,,,9527.0,In vivo,,1,,5922,U,22224,,0,,A,Cmax in cynomolgus monkey by iv administration,,Autocuration
4426,Cercopithecidae,,,9527.0,In vivo,,1,,5922,U,22224,,0,,A,Cmax in cynomolgus monkey by po administration,,Autocuration
4427,Cercopithecidae,,,9527.0,In vivo,,1,,6078,U,22224,,0,,A,Cmax value evaluated in monkey,,Autocuration
4428,Cercopithecidae,,,9527.0,In vivo,,1,,2661,U,22224,,0,,A,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration
4429,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,3249,U,22224,,0,Plasma,A,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,Autocuration
4430,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,3249,U,22224,,0,Plasma,A,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,Autocuration
4431,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,5553,U,22224,,0,Plasma,A,Maximal plasma concentration in squirrel monkeys,,Autocuration
4432,Cercopithecidae,,,9527.0,In vivo,,1,,1916,U,22224,,0,,A,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration
4433,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,6227,U,22224,,0,Plasma,A,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,Autocuration
4434,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration
4435,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,Autocuration
4436,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,Autocuration
4437,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,Autocuration
4438,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,Autocuration
4439,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,6221,U,22224,,0,Plasma,A,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,Autocuration
4440,Cercopithecidae,,,9527.0,,,1,,167,U,22224,,0,,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,Autocuration
4441,Cercopithecidae,,,9527.0,,,1,,167,U,22224,,0,,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,Autocuration
4442,monkey,,,9443.0,In vivo,,1,,4257,U,22224,,0,,A,Absolute bioavailability was evaluated in monkey,,Autocuration
4443,monkey,,,9443.0,In vivo,,1,,6221,U,22224,,0,,A,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration
4444,monkey,,,9443.0,In vivo,,1,,17667,U,22224,,0,,A,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,Autocuration
4445,Macaca mulatta,,,9544.0,In vivo,,1,,17267,U,22224,,0,,A,Bioavailability of compound was determined in rhesus monkey,,Autocuration
4446,marmosets,,,38020.0,In vivo,,1,,4256,U,22224,,0,,A,Bioavailability determined after oral administration in marmoset,,Autocuration
4447,Macaca fascicularis,,,9541.0,In vivo,,1,,4256,U,22224,,0,,A,Oral bioavailability in cynomolgus monkey,,Autocuration
4448,monkey,,,9443.0,In vivo,,1,,17853,U,22224,,0,,A,Bioavailability in monkey (p.o.) at 2.0 mpk,,Autocuration
4449,monkey,,,9443.0,In vivo,,1,,16365,U,22224,,0,,A,Bioavailability was evaluated after oral administration in monkey,,Autocuration
4450,Macaca fascicularis,,,9541.0,In vivo,,1,,1916,U,22224,,0,,A,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration
4451,Macaca mulatta,,,9544.0,In vivo,,1,,5334,U,22224,,0,,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration
4452,Macaca mulatta,,,9544.0,In vivo,,1,,5334,U,22224,,0,,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration
4453,monkey,,,9443.0,In vivo,,1,,17592,U,22224,,0,,A,Bioavailability of the compound was determined in monkey,,Autocuration
4454,Saimiri sciureus,,,9521.0,In vivo,,1,,1399,U,22224,,0,,A,Bioavailability in squirrel monkey (dose 5 mg/kg),,Autocuration
4455,monkey,,,9443.0,In vivo,,1,,4809,U,22224,,0,,A,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration
4456,monkey,,,9443.0,In vivo,,1,,3341,U,22224,,0,,A,Oral bioavailability in monkey,,Autocuration
4457,Saimiri sciureus,,,9521.0,In vivo,,1,,64,U,22224,,0,,A,Compound was tested for bioavailability in squirrel monkey,,Autocuration
4458,Macaca mulatta,,,9544.0,In vivo,,1,,5005,U,22224,,0,,A,Oral bioavailability in Rhesus monkey,,Autocuration
4459,Macaca mulatta,,,9544.0,In vivo,,1,,5005,U,22224,,0,,A,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,Autocuration
4460,Macaca fascicularis,,,9541.0,In vivo,,1,,5237,U,22224,,0,,A,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,Autocuration
4461,Macaca fascicularis,,,9541.0,In vivo,,1,,5237,U,22224,,0,,A,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,Autocuration
4462,monkey,,,9443.0,In vivo,,1,,5302,U,22224,,0,,A,Oral bioavailability in monkey (dose 5 mg/kg),,Autocuration
4463,monkey,,,9443.0,In vivo,,1,,17667,U,22224,,0,,A,Oral bioavailability of compound at 5 mg/kg in monkey,,Autocuration
4464,Canis lupus familiaris,,,9615.0,In vivo,,1,,6161,N,50588,,1,,A,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,Intermediate
4465,Canis lupus familiaris,,,9615.0,In vivo,,1,,6161,N,50588,,1,,A,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,Intermediate
4466,Canis lupus familiaris,,1969.0,9615.0,,,1,,3854,N,50588,,1,Plasma,A,Plasma half life determined,,Intermediate
4467,Canis lupus familiaris,,1969.0,9615.0,,,1,,993,N,50588,,1,Plasma,A,Plasma half life in dog,,Intermediate
4468,Canis lupus familiaris,,1969.0,9615.0,,,1,,4514,N,50588,,1,Plasma,A,Plasma half-life in Beagle dogs,,Intermediate
4469,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5334,N,50588,,1,Plasma,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Intermediate
4470,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5334,N,50588,,1,Plasma,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,Intermediate
4471,Canis lupus familiaris,,,9615.0,In vivo,,1,,1466,N,50588,,1,,A,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,Intermediate
4472,Canis lupus familiaris,,,9615.0,In vivo,,1,,1466,N,50588,,1,,A,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,Intermediate
4473,Canis lupus familiaris,,,9615.0,,,1,,5313,N,50588,,1,,A,Tested for the half life period in dog,,Intermediate
4474,Canis lupus familiaris,,,9615.0,In vivo,,1,,5313,N,50588,,1,,A,Tested for the half life period in dog at dosage of 10 mpk,,Intermediate
4475,Canis lupus familiaris,,,9615.0,,,1,,3880,N,50588,,1,,A,The compound was tested for half life in dog,,Intermediate
4476,Canis lupus familiaris,,1969.0,9615.0,,,1,,3639,N,50588,,1,Plasma,A,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,Intermediate
4477,Canis lupus familiaris,,,9615.0,,,1,,3880,N,50588,,1,,A,The half life was determined,,Intermediate
4478,Canis lupus familiaris,,1969.0,9615.0,,,1,,3918,N,50588,,1,Plasma,A,The plasma half-life in dogs,,Intermediate
4479,Canis lupus familiaris,,1969.0,9615.0,,,1,,16452,N,50588,,1,Plasma,A,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,Intermediate
4480,Canis lupus familiaris,,,9615.0,,,1,,17796,N,50588,,1,,A,Half life in dog,,Intermediate
4481,Canis lupus familiaris,,,9615.0,In vivo,,1,,5983,N,50588,,1,,A,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,Intermediate
4482,Canis lupus familiaris,,,9615.0,In vivo,,1,,1466,N,50588,,1,,A,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,Intermediate
4483,Canis lupus familiaris,,,9615.0,In vivo,,1,,16456,N,50588,,1,,A,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate
4484,Mustela putorius furo,,,9669.0,In vivo,,1,,6113,N,50506,,1,,A,Cmax in ferrets after 30 mg/kg oral dose,,Expert
4485,Mustela putorius furo,,,9669.0,In vivo,,1,,6113,N,50506,,1,,F,Emesis in ferrets at 30 mg/kg oral dose,,Expert
4486,Macaca fascicularis,,,9541.0,In vivo,,1,,17796,U,22224,,0,,A,Bioavailability in cynomolgus monkey,,Autocuration
4487,Macaca fascicularis,,,9541.0,In vivo,,1,,17796,N,100710,,1,,A,Volume of distribution in cynomolgus,,Intermediate
4488,Cavia porcellus,,1969.0,10141.0,,,1,,5308,U,22224,,0,Plasma,A,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,Autocuration
4489,Cavia porcellus,,,10141.0,,,1,,4877,U,22224,,0,,A,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,Autocuration
4490,Cavia porcellus,,,10141.0,,,1,,4876,U,22224,,0,,A,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,Autocuration
4491,Cavia porcellus,,1969.0,10141.0,In vivo,,1,,4878,U,22224,,0,Plasma,A,AUC in guinea pig after 3mg/kg oral dose,,Autocuration
4492,Cavia porcellus,,,10141.0,In vivo,,1,,5308,U,22224,,0,,A,Bioavailability in guinea pig was tested,,Autocuration
4493,Cavia porcellus,,,10141.0,In vivo,,1,,4877,U,22224,,0,,A,Tested for oral bioavailability in guinea pig at 5 mg/kg,,Autocuration
4494,Cavia porcellus,,,10141.0,In vivo,,1,,4876,U,22224,,0,,A,Tested for the oral bioavailability of the compound,,Autocuration
4495,Cavia porcellus,,,10141.0,In vivo,,1,,4876,U,22224,,0,,A,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,Autocuration
4496,Cavia porcellus,,,10141.0,In vivo,,1,,5308,U,22224,,0,,A,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,Autocuration
4497,Cavia porcellus,,2048.0,10141.0,In vivo,,1,,4877,U,22224,,0,Lung,A,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,Autocuration
4498,Cavia porcellus,,,10141.0,In vivo,,1,,4878,U,22224,,0,,A,Cmax in guinea pig after 3mg/kg oral dose,,Autocuration
4499,Cavia porcellus,,178.0,10141.0,,,1,,5689,U,22224,,0,Blood,A,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4500,Cavia porcellus,,955.0,10141.0,,,1,,5689,U,22224,,0,Brain,A,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4501,Cavia porcellus,,,10141.0,,,1,,5689,U,22224,,0,,A,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4502,Cavia porcellus,,160.0,10141.0,,,1,,5689,U,22224,,0,Intestine,A,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4503,Cavia porcellus,,2113.0,10141.0,,,1,,5689,U,22224,,0,Kidney,A,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4504,Cavia porcellus,,2107.0,10141.0,,,1,,5689,U,22224,,0,Liver,A,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4505,Cavia porcellus,,,10141.0,,,1,,5689,U,22224,,0,,A,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4506,Cavia porcellus,,2106.0,10141.0,,,1,,5689,U,22224,,0,Spleen,A,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration
4507,Cavia porcellus,,,10141.0,In vivo,,1,,14465,U,22224,,0,,A,Elimination T1/2 in Guinea pig (PO dose),,Autocuration
4508,Cavia porcellus,,,10141.0,,,1,,5689,U,22224,,0,,A,Partition coefficient was measured as -log (counts per min ),,Autocuration
4509,Cavia porcellus,,,10141.0,In vivo,,1,,611,U,22224,,0,,A,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,Autocuration
4510,Cavia porcellus,,,10141.0,In vivo,,1,,611,U,22224,,0,,A,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,Autocuration
4511,Cavia porcellus,,,10141.0,In vivo,,1,,14465,U,22224,,0,,A,Elimination T1/2 in Guinea pig (PO dose),,Autocuration
4512,Cavia porcellus,,,10141.0,In vivo,,1,,4876,U,22224,,0,,A,"Tested for the half life period of the compound, intravenously",,Autocuration
4513,Cavia porcellus,,,10141.0,,,1,,5689,U,22224,,0,,A,Half-life was measured,,Autocuration
4514,Cavia porcellus,,,10141.0,,,1,,7515,U,22224,,0,,A,The time required for onset of inotropy after addition of a single dose of delta F75,,Autocuration
4515,Cavia porcellus,,,10141.0,In vivo,,1,,17667,U,22224,,0,,A,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,Autocuration
4516,Cavia porcellus,,,10141.0,In vivo,,1,,17667,U,22224,,0,,A,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,Autocuration
4517,Cricetulus griseus,,,10029.0,In vivo,,1,,4727,U,22224,,0,,A,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,Autocuration
4518,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
4519,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
4520,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
4521,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
4522,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,Intermediate
4523,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
4524,Mus musculus,,,10090.0,In vivo,,1,,10107,N,50594,,1,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
4525,Mus musculus,,178.0,10090.0,In vivo,,1,,3655,N,50594,,1,Blood,A,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,Intermediate
4526,Mus musculus,,178.0,10090.0,In vivo,,1,,3655,N,50594,,1,Blood,A,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,Intermediate
4527,Mus musculus,,178.0,10090.0,In vivo,,1,,3655,N,50594,,1,Blood,A,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,Intermediate
4528,Mus musculus,,10000001.0,10090.0,In vivo,,1,,3655,N,50594,,1,Bone,A,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,Intermediate
4529,Mus musculus,,10000001.0,10090.0,In vivo,,1,,3655,N,50594,,1,Bone,A,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,Intermediate
4530,Mus musculus,,10000001.0,10090.0,In vivo,,1,,3655,N,50594,,1,Bone,A,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,Intermediate
4531,Mus musculus,,955.0,10090.0,In vivo,,1,,3655,N,50594,,1,Brain,A,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,Intermediate
4532,Mus musculus,,955.0,10090.0,In vivo,,1,,3655,N,50594,,1,Brain,A,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,Intermediate
4533,Mus musculus,,955.0,10090.0,In vivo,,1,,3655,N,50594,,1,Brain,A,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,Intermediate
4534,Mus musculus,,948.0,10090.0,In vivo,,1,,3655,N,50594,,1,Heart,A,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,Intermediate
4535,Mus musculus,,948.0,10090.0,In vivo,,1,,3655,N,50594,,1,Heart,A,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,Intermediate
4536,Mus musculus,,948.0,10090.0,In vivo,,1,,3655,N,50594,,1,Heart,A,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,Intermediate
4537,Mus musculus,,160.0,10090.0,In vivo,,1,,3655,N,50594,,1,Intestine,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,Intermediate
4538,Mus musculus,,160.0,10090.0,In vivo,,1,,3655,N,50594,,1,Intestine,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,Intermediate
4539,Mus musculus,,160.0,10090.0,In vivo,,1,,3655,N,50594,,1,Intestine,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,Intermediate
4540,Mus musculus,,2113.0,10090.0,In vivo,,1,,3655,N,50594,,1,Kidney,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,Intermediate
4541,Mus musculus,,2113.0,10090.0,In vivo,,1,,3655,N,50594,,1,Kidney,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,Intermediate
4542,Mus musculus,,2113.0,10090.0,In vivo,,1,,3655,N,50594,,1,Kidney,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,Intermediate
4543,Mus musculus,,2107.0,10090.0,In vivo,,1,,3655,N,50594,,1,Liver,A,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,Intermediate
4544,Mus musculus,,2107.0,10090.0,In vivo,,1,,3655,N,50594,,1,Liver,A,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,Intermediate
4545,Mus musculus,,2107.0,10090.0,In vivo,,1,,3655,N,50594,,1,Liver,A,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,Intermediate
4546,Mus musculus,,2048.0,10090.0,In vivo,,1,,3655,N,50594,,1,Lung,A,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,Intermediate
4547,Mus musculus,,2048.0,10090.0,In vivo,,1,,3655,N,50594,,1,Lung,A,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,Intermediate
4548,Mus musculus,,2048.0,10090.0,In vivo,,1,,3655,N,50594,,1,Lung,A,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,Intermediate
4549,Mus musculus,,2385.0,10090.0,In vivo,,1,,3655,N,50594,,1,Muscle tissue,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,Intermediate
4550,Mus musculus,,2385.0,10090.0,In vivo,,1,,3655,N,50594,,1,Muscle tissue,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,Intermediate
4551,Mus musculus,,2385.0,10090.0,In vivo,,1,,3655,N,50594,,1,Muscle tissue,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,Intermediate
4552,Mus musculus,,2106.0,10090.0,In vivo,,1,,3655,N,50594,,1,Spleen,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,Intermediate
4553,Mus musculus,,2106.0,10090.0,In vivo,,1,,3655,N,50594,,1,Spleen,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,Intermediate
4554,Mus musculus,,2106.0,10090.0,In vivo,,1,,3655,N,50594,,1,Spleen,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,Intermediate
4555,Mus musculus,,945.0,10090.0,In vivo,,1,,3655,N,50594,,1,Stomach,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,Intermediate
4556,Mus musculus,,945.0,10090.0,In vivo,,1,,3655,N,50594,,1,Stomach,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,Intermediate
4557,Mus musculus,,945.0,10090.0,In vivo,,1,,3655,N,50594,,1,Stomach,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,Intermediate
4558,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,Intermediate
4559,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,F,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,Intermediate
4560,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
4561,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,MRT value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate
4562,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,Intermediate
4563,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Intermediate
4564,Homo sapiens,,,9606.0,,,1,,3830,N,81034,A2780,1,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,Intermediate
4565,Homo sapiens,,,9606.0,,,1,,3829,N,81034,A2780,1,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,Intermediate
4566,Homo sapiens,,,9606.0,,,1,,2040,N,81034,A2780,1,,F,Compound was evaluated for cytotoxicity against A2780 cell lines.,,Intermediate
4567,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,Intermediate
4568,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Intermediate
4569,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Intermediate
4570,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Intermediate
4571,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Intermediate
4572,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Intermediate
4573,Homo sapiens,,,9606.0,,,1,,2859,N,81034,A2780,1,,F,Compound was evaluated for cytotoxicity against A2780 cell line,,Intermediate
4574,Homo sapiens,,,9606.0,,,1,,5618,N,81034,A2780,1,,F,In vitro inhibitory activity against human tumor cell line A2780,,Intermediate
4575,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,Intermediate
4576,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Intermediate
4577,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Intermediate
4578,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Intermediate
4579,Homo sapiens,,,9606.0,,,1,,2113,N,81034,A2780,1,,F,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,Intermediate
4580,Homo sapiens,,,9606.0,,,1,,2113,N,81034,A2780,1,,F,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,Intermediate
4581,Homo sapiens,,,9606.0,,,1,,16745,N,81034,A2780,1,,F,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,Intermediate
4582,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Expert
4583,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Intermediate
4584,Homo sapiens,,,9606.0,,,1,,15684,N,81034,A2780,1,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Intermediate
4585,Homo sapiens,,,9606.0,,,1,,2040,N,81034,A2780,1,,F,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,Intermediate
4586,Homo sapiens,,,9606.0,,,1,,2040,N,81034,A2780,1,,F,Relative resistance factor in A2780 cisplatin-resistant line,,Intermediate
4587,Homo sapiens,,,9606.0,,,1,,16165,N,81034,A2780,1,,F,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,Intermediate
4588,Homo sapiens,,,9606.0,,,1,,16165,N,81034,A2780,1,,F,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,Intermediate
4589,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Expert
4590,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Expert
4591,Homo sapiens,,,9606.0,,,1,,3992,N,81034,A2780,1,,F,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,Intermediate
4592,Homo sapiens,,,9606.0,,,1,,10553,N,81034,A2780,1,,F,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,Intermediate
4593,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,Intermediate
4594,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,Intermediate
4595,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,Intermediate
4596,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,Intermediate
4597,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,Intermediate
4598,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,Intermediate
4599,Homo sapiens,,,9606.0,,,1,,15569,N,81034,A2780,1,,F,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,Intermediate
4600,Homo sapiens,,,9606.0,,,1,,17420,N,81034,A2780,1,,F,Antiproliferative effect of compound on A2780/DX cell line,,Intermediate
4601,Homo sapiens,,,9606.0,,,1,,17420,N,81034,A2780,1,,F,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,Intermediate
4602,Homo sapiens,,,9606.0,,,1,,15099,N,81034,A2780,1,,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,Intermediate
4603,Homo sapiens,,,9606.0,,,1,,15099,N,81034,A2780,1,,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,Intermediate
4604,Homo sapiens,,,9606.0,,,1,,17672,N,81034,A2780,1,,F,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,Intermediate
4605,Homo sapiens,,,9606.0,,,1,,17672,N,81034,A2780,1,,F,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,Intermediate
4606,Homo sapiens,,,9606.0,,,1,,17270,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780ADR cell line,,Intermediate
4607,Homo sapiens,,,9606.0,,,1,,17270,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780CIS cell line,,Intermediate
4608,Homo sapiens,,,9606.0,,,1,,5574,N,81034,A2780,1,,F,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,Intermediate
4609,Homo sapiens,,,9606.0,,,1,,2113,N,81034,A2780,1,,F,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,Intermediate
4610,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate
4611,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate
4612,Macaca mulatta,,,9544.0,In vivo,,1,,17839,U,22224,,0,,A,Oral bioavailability of compound in rhesus macaques,,Autocuration
4613,monkey,,,9443.0,In vivo,,1,,6821,U,22224,,0,,A,Oral bioavailability in monkey,,Autocuration
4614,monkey,,,9443.0,In vivo,,1,,6078,U,22224,,0,,A,Oral bioavailability evaluated in monkey,,Autocuration
4615,monkey,,,9443.0,In vivo,,1,,6535,U,22224,,0,,A,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,Autocuration
4616,Macaca mulatta,,,9544.0,In vivo,,1,,4449,U,22224,,0,,A,Oral bioavailability in Rhesus monkey,,Autocuration
4617,Macaca mulatta,,,9544.0,In vivo,,1,,6057,U,22224,,0,,A,Oral bioavailability was calculated in rhesus monkey,,Autocuration
4618,Macaca fascicularis,,,9541.0,In vivo,,1,,5922,U,22224,,0,,A,Oral bioavailability in cynomolgus monkey,,Autocuration
4619,monkey,,,9443.0,In vivo,,1,,5940,U,22224,,0,,A,Oral bioavailability in monkey,,Autocuration
4620,monkey,,,9443.0,In vivo,,1,,6265,U,22224,,0,,A,Oral bioavailability in monkey,,Autocuration
4621,monkey,,,9443.0,In vivo,,1,,6265,U,22224,,0,,A,Oral bioavailability in monkey (dose 1 mg/kg),,Autocuration
4622,monkey,,,9443.0,In vivo,,1,,6265,U,22224,,0,,A,Oral bioavailability in monkey (dose 5 mg/kg),,Autocuration
4623,monkey,,,9443.0,In vivo,,1,,5940,U,22224,,0,,A,Oral bioavailability in monkey,,Autocuration
4624,monkey,,,9443.0,In vivo,,1,,5940,U,22224,,0,,A,Oral bioavailability in monkey,,Autocuration
4625,Macaca mulatta,,,9544.0,In vivo,,1,,4514,U,22224,,0,,A,Oral bioavailability in rhesus monkey,,Autocuration
4626,Macaca mulatta,,,9544.0,In vivo,,1,,5546,U,22224,,0,,A,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,Autocuration
4627,Saimiri sciureus,,,9521.0,In vivo,,1,,5553,U,22224,,0,,A,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,Autocuration
4628,monkey,,,9443.0,In vivo,,1,,6641,U,22224,,0,,A,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration
4629,Macaca mulatta,,,9544.0,In vivo,,1,,5472,U,22224,,0,,A,Oral bioavailability in Rhesus monkey,,Autocuration
4630,Macaca mulatta,,,9544.0,In vivo,,1,,5668,U,22224,,0,,A,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,Autocuration
4631,monkey,,,9443.0,In vivo,,1,,5711,U,22224,,0,,A,Oral bioavailability in monkey at 10 mg/kg of the compound,,Autocuration
4632,Macaca mulatta,,,9544.0,In vivo,,1,,5145,U,22224,,0,,A,Bioavailability in Rhesus monkey,,Autocuration
4633,Cercopithecidae,,,9527.0,,,1,,3443,U,22224,,0,,A,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4634,Cercopithecidae,,,9527.0,,,1,,3443,U,22224,,0,,A,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4635,Cercopithecidae,,,9527.0,In vivo,,1,,3249,U,22224,,0,,A,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,Autocuration
4636,Cercopithecidae,,,9527.0,In vivo,,1,,3249,U,22224,,0,,A,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,Autocuration
4637,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,Autocuration
4638,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,Autocuration
4639,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,Autocuration
4640,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration
4641,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration
4642,Cercopithecidae,,,9527.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,Autocuration
4643,Cercopithecidae,,,9527.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Microsomes,Autocuration
4644,Cercopithecidae,,,9527.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Microsomes,Autocuration
4645,Cercopithecidae,,,9527.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Microsomes,Autocuration
4646,Cercopithecidae,,,9527.0,In vivo,,1,,3443,U,22224,,0,,A,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4647,Cercopithecidae,,,9527.0,In vivo,,1,,3443,U,22224,,0,,A,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4648,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,Autocuration
4649,Cercopithecidae,,,9527.0,,,1,,3443,U,22224,,0,,A,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4650,Cercopithecidae,,,9527.0,,,1,,3443,U,22224,,0,,A,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4651,Cercopithecidae,,,9527.0,,,1,,6821,U,22224,,0,,A,Elimination Half-life of compound was determined in monkey,,Autocuration
4652,Cercopithecidae,,,9527.0,,,1,,17267,U,22224,,0,,A,Half life of compound was determined in rhesus monkey,,Autocuration
4653,Cercopithecidae,,1969.0,9527.0,,,1,,5819,U,22224,,0,Plasma,A,Half life in monkey plasma,,Autocuration
4654,Cercopithecidae,,1969.0,9527.0,,,1,,5819,U,22224,,0,Plasma,A,Half life in monkey plasma; Not detected,,Autocuration
4655,Cercopithecidae,,,9527.0,In vivo,,1,,1916,U,22224,,0,,A,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration
4656,Cercopithecidae,,,9527.0,In vivo,,1,,17509,U,22224,,0,,A,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,Autocuration
4657,Cercopithecidae,,,9527.0,,,1,,1399,U,22224,,0,,A,Terminal half life of the compound.,,Autocuration
4658,Cercopithecidae,,,9527.0,In vivo,,1,,1916,U,22224,,0,,A,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration
4659,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration
4660,Cercopithecidae,,,9527.0,,,1,,5546,U,22224,,0,,A,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Autocuration
4661,Cercopithecidae,,1088.0,9527.0,,,1,,3443,U,22224,,0,Urine,A,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4662,Cercopithecidae,,1088.0,9527.0,,,1,,3443,U,22224,,0,Urine,A,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4663,Cercopithecidae,,,9527.0,In vivo,,1,,4257,U,22224,,0,,A,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,Autocuration
4664,Cercopithecidae,,,9527.0,In vivo,,1,,6221,U,22224,,0,,A,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration
4665,Cercopithecidae,,,9527.0,In vivo,,1,,5472,U,22224,,0,,A,Volume of distribution was evaluated in rhesus,,Autocuration
4666,Cricetulus griseus,,,10029.0,In vivo,,1,,4727,U,22224,,0,,A,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,Autocuration
4667,Cricetulus griseus,,,10029.0,In vivo,,1,,4727,U,22224,,0,,A,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,Autocuration
4668,Cricetulus griseus,,,10029.0,In vivo,,1,,4727,U,22224,,0,,A,Bioavailability in hamster was determined,,Autocuration
4669,Cricetulus griseus,,,10029.0,In vivo,,1,,4727,U,22224,,0,,A,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,Autocuration
4670,Cricetulus griseus,,,10029.0,In vivo,,1,,4727,U,22224,,0,,A,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,Autocuration
4671,Cricetulus griseus,,178.0,10029.0,,,1,,4727,U,22224,,0,Blood,A,Half life of compound was determined in hamster blood,,Autocuration
4672,Sus scrofa,,,9823.0,,,1,,1452,U,22224,,0,,A,Michaelis-Menten constant of the compound.,,Autocuration
4673,Sus scrofa,,,9823.0,,,1,,1452,U,22224,,0,,A,Vmax value was measured at 0 uM concentration of silyl ether.,,Autocuration
4674,Sus scrofa,,,9823.0,,,1,,1452,U,22224,,0,,A,Vmax value was measured at 10 uM concentration of silyl ether.,,Autocuration
4675,Sus scrofa,,,9823.0,,,1,,1452,U,22224,,0,,A,Vmax value was measured at 5 uM concentration of silyl ether.,,Autocuration
4676,Homo sapiens,,,9606.0,,,1,,11706,D,235,,9,,B,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,Expert
4677,Homo sapiens,,,9606.0,,,1,,1916,U,22224,,0,,A,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration
4678,Homo sapiens,,,9606.0,,,1,,17791,U,22224,,0,,A,Compound was evaluated for area under the curve expressed as (h*ug/ml),,Autocuration
4679,Homo sapiens,,,9606.0,,,1,,7766,U,22224,,0,,A,Active metabolite of ifosfamide determined in humans; A-Active,,Autocuration
4680,Homo sapiens,,,9606.0,,,1,,6567,U,22224,,0,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,Autocuration
4681,Homo sapiens,,,9606.0,,,1,,6567,U,22224,,0,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,Autocuration
4682,Homo sapiens,,,9606.0,,,1,,6567,U,22224,,0,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,Autocuration
4683,Homo sapiens,,,9606.0,,,1,,6567,U,22224,,0,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,Autocuration
4684,Homo sapiens,,,9606.0,,,1,,17791,U,22224,,0,,A,Compound was evaluated for oral bioavailability in human,,Autocuration
4685,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Metabolite of ifosfamide determined in urine; NF-Not found,,Autocuration
4686,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,Autocuration
4687,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,Autocuration
4688,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,Autocuration
4689,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,Autocuration
4690,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,Autocuration
4691,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,Autocuration
4692,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent of compound in healthy individuals (Group D),,Autocuration
4693,Homo sapiens,,2107.0,9606.0,,,1,,4397,U,22224,,0,Liver,A,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,Autocuration
4694,Homo sapiens,,,9606.0,,,1,,17409,U,22224,,0,,A,Binding towards human plasma protein at 10 uM,,Autocuration
4695,Homo sapiens,,,9606.0,,,1,,17409,U,22224,,0,,A,Binding towards human plasma protein at 100 uM,,Autocuration
4696,Homo sapiens,,,9606.0,,,1,,17176,U,22224,,0,,A,Human plasma protein binding activity was determined,,Autocuration
4697,Homo sapiens,,,9606.0,,,1,,15444,U,22224,,0,,A,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,Autocuration
4698,Homo sapiens,,,9606.0,,,1,,17267,U,22224,,0,,A,Percent binding of compound towards human plasma protein was determined,,Autocuration
4699,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5944,U,22224,,0,Liver,A,Plasma clearance in human liver microsomes,Microsomes,Autocuration
4700,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5668,U,22224,,0,Liver,A,In vitro intrinsic clearance in human liver microsome,Microsomes,Autocuration
4701,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5669,U,22224,,0,Liver,A,In vitro intrinsic clearance in human liver microsome,Microsomes,Autocuration
4702,Homo sapiens,,,9606.0,In vitro,,1,,5041,U,22224,,0,,A,In vitro microsome metabolism clearance in human was determined,Microsomes,Autocuration
4703,Homo sapiens,,,9606.0,In vitro,,1,,5041,U,22224,,0,,A,In vitro microsome metabolism clearance in human was determined; High,Microsomes,Autocuration
4704,Homo sapiens,,,9606.0,In vitro,,1,,5041,U,22224,,0,,A,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Microsomes,Autocuration
4705,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5676,U,22224,,0,Liver,A,Pharmacokinetic property (clearance) in human liver microsome,Microsomes,Autocuration
4706,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5944,U,22224,,0,Liver,A,Plasma clearance in human liver microsomes,Microsomes,Autocuration
4707,Homo sapiens,,2107.0,9606.0,In vitro,,1,,17538,U,22224,,0,Liver,A,In vitro clearance in human liver microsomes,Microsomes,Autocuration
4708,Homo sapiens,,2107.0,9606.0,In vitro,,1,,6331,U,22224,,0,Liver,A,Intrinsic clearance in human liver microsomes was determined,Microsomes,Autocuration
4709,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5948,U,22224,,0,Liver,A,Intrinsic clearance in human liver microsomes was determined,Microsomes,Autocuration
4710,Homo sapiens,,,9606.0,In vivo,,1,,5965,U,22224,,0,,A,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,Autocuration
4711,Homo sapiens,,,9606.0,In vivo,,1,,1916,U,22224,,0,,A,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration
4712,Homo sapiens,,,9606.0,,,1,,5965,U,22224,,0,,A,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,Autocuration
4713,Homo sapiens,,,9606.0,,,1,,1299,U,22224,,0,,A,Stability in human plasma 2 hr after incubation expressed as percent concentration,,Autocuration
4714,Homo sapiens,,,9606.0,,,1,,1299,U,22224,,0,,A,Stability in human plasma 4 hr after incubation expressed as percent concentration,,Autocuration
4715,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4716,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4717,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4718,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4719,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Intermediate
4720,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Intermediate
4721,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Intermediate
4722,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,Intermediate
4723,Mus musculus,,,10090.0,,,1,,14294,N,50594,,1,,A,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,Intermediate
4724,Mus musculus,,,10090.0,,,1,,14294,N,50594,,1,,A,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,Intermediate
4725,Mus musculus,,,10090.0,,,1,,14294,N,50594,,1,,A,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,Intermediate
4726,Mus musculus,,2107.0,10090.0,,,1,,6251,N,50594,,1,Liver,A,In vitro metabolic potential in mouse liver microsomes,,Intermediate
4727,Mus musculus,,,10090.0,,,1,,17582,N,50594,,1,,A,Ability of compound to bind to plasma protein was evaluated in HSA cells,,Intermediate
4728,Mus musculus,,2369.0,10090.0,,,1,,17811,N,50594,,1,Adrenal gland,A,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,Intermediate
4729,Mus musculus,,955.0,10090.0,,,1,,17811,N,50594,,1,Brain,A,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,Intermediate
4730,Mus musculus,,955.0,10090.0,,,1,,17811,N,50594,,1,Brain,A,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,Intermediate
4731,Mus musculus,,,10090.0,,,1,,17811,N,50594,,1,,A,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,Intermediate
4732,Mus musculus,,2113.0,10090.0,,,1,,17811,N,50594,,1,Kidney,A,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,Intermediate
4733,Mus musculus,,,10090.0,,,1,,17811,N,50594,,1,,A,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,Intermediate
4734,Mus musculus,,,10090.0,,,1,,5288,N,50594,,1,,A,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,Intermediate
4735,Mus musculus,,1977.0,10090.0,,,1,,2717,N,50594,,1,Serum,A,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,Intermediate
4736,Mus musculus,,1977.0,10090.0,,,1,,2717,N,50594,,1,Serum,A,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,Intermediate
4737,Mus musculus,,1977.0,10090.0,,,1,,2717,N,50594,,1,Serum,A,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,Intermediate
4738,Mus musculus,,1969.0,10090.0,In vivo,,1,,17753,N,50594,,1,Plasma,A,Half life of compound was determined in plasma of mice at 24 mg/Kg,,Intermediate
4739,Mus musculus,,1969.0,10090.0,In vivo,,1,,17753,N,50594,,1,Plasma,A,Half life of compound was determined in plasma of mice at 40 mg/Kg,,Intermediate
4740,Mus musculus,,1969.0,10090.0,In vivo,,1,,17753,N,50594,,1,Plasma,A,Half life of compound was determined in plasma of mice at 5 mg/Kg,,Intermediate
4741,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Half life after intraperitoneal administration in mice at 18 uM/kg,,Intermediate
4742,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Half life after intraperitoneal administration in mice at 23 uM/kg,,Intermediate
4743,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Half life after intraperitoneal administration in mice at 25 uM/kg,,Intermediate
4744,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Half life after intraperitoneal administration in mice at 26 uM/kg,,Intermediate
4745,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Half life after intravenous administration in mice at 23 uM/kg,,Intermediate
4746,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Half life after intravenous administration in mice at 24 uM/kg,,Intermediate
4747,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,Intermediate
4748,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,Intermediate
4749,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Maximum time required to reach Cp max was evaluated in mice after oral administration,,Intermediate
4750,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,Intermediate
4751,Mus musculus,,,10090.0,In vivo,,1,,4890,N,50594,,1,,A,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,Intermediate
4752,Mus musculus,,,10090.0,In vivo,,1,,429,N,50594,,1,,A,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,Intermediate
4753,Mus musculus,,178.0,10090.0,In vivo,,1,,17837,N,50594,,1,Blood,A,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,Intermediate
4754,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Half life at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
4755,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Half life at a dose of 10 mg/kg peroral administration in mice.,,Intermediate
4756,Mus musculus,,,10090.0,,,1,,6619,N,50594,,1,,A,Half life in ob/ob mice,,Intermediate
4757,Mus musculus,,,10090.0,In vivo,,1,,4066,N,50594,,1,,A,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate
4758,Mus musculus,,,10090.0,,,1,,4239,N,50594,,1,,A,Half-life was measured in mouse,,Intermediate
4759,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,Intermediate
4760,Mus musculus,,,10090.0,,,1,,8999,N,50594,,1,,A,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,Intermediate
4761,Mus musculus,,,10090.0,,,1,,8999,N,50594,,1,,A,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,Intermediate
4762,Mus musculus,,955.0,10090.0,,,1,,17641,N,50594,,1,Brain,A,T2 in brain of mice at the oral dose of 50 mg/kg,,Intermediate
4763,Mus musculus,,2113.0,10090.0,,,1,,17641,N,50594,,1,Kidney,A,T2 in kidney of mice at the oral dose of 50 mg/kg,,Intermediate
4764,Mus musculus,,2107.0,10090.0,,,1,,17641,N,50594,,1,Liver,A,T2 in liver of mice at the oral dose of 50 mg/kg,,Intermediate
4765,Mus musculus,,2048.0,10090.0,,,1,,17641,N,50594,,1,Lung,A,T2 in lungs of mice at the oral dose of 50 mg/kg,,Intermediate
4766,Mus musculus,,2106.0,10090.0,,,1,,17641,N,50594,,1,Spleen,A,T2 in spleen of mice at the oral dose of 50 mg/kg,,Intermediate
4767,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,Intermediate
4768,Mus musculus,,,10090.0,In vivo,,1,,4890,N,50594,,1,,A,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,Intermediate
4769,Mus musculus,,,10090.0,In vivo,,1,,429,N,50594,,1,,A,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,Intermediate
4770,Mus musculus,,,10090.0,In vivo,,1,,429,N,50594,,1,,A,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,Intermediate
4771,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,Intermediate
4772,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate
4773,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate
4774,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate
4775,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate
4776,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate
4777,Homo sapiens,,,9606.0,,,1,,16913,N,81034,A2780,1,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate
4778,Homo sapiens,,,9606.0,,,1,,17270,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780TAX cell line,,Intermediate
4779,Homo sapiens,,,9606.0,,,1,,5618,N,80017,A2780cisR,1,,F,In vitro inhibitory activity against human tumor cell line A2780cis,,Intermediate
4780,Homo sapiens,,,9606.0,,,1,,17777,N,81034,A2780,1,,F,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,Expert
4781,Homo sapiens,,,9606.0,,,1,,16112,N,80017,A2780cisR,1,,F,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,Intermediate
4782,Homo sapiens,,,9606.0,,,1,,15748,N,80017,A2780cisR,1,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,Intermediate
4783,Homo sapiens,,,9606.0,,,1,,6633,N,81034,A2780,1,,F,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,Intermediate
4784,Homo sapiens,,,9606.0,,,1,,16930,N,81034,A2780,1,,F,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,Intermediate
4785,Homo sapiens,,,9606.0,,,1,,17496,N,81034,A2780,1,,F,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,Intermediate
4786,Homo sapiens,,,9606.0,,,1,,12989,N,81034,A2780,1,,F,In vitro antitumor activity against A2780cisR cell line.,,Expert
4787,Homo sapiens,,,9606.0,,,1,,4840,N,81034,A2780,1,,F,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,Intermediate
4788,Homo sapiens,,,9606.0,,,1,,12989,N,81034,A2780,1,,F,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,Expert
4789,Homo sapiens,,,9606.0,,,1,,16745,N,80017,A2780cisR,1,,F,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,Intermediate
4790,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,Expert
4791,Rattus norvegicus,,,10116.0,,,1,,16547,D,11736,,9,,B,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,Expert
4792,,,,,,,1,,16547,H,11736,,8,,F,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,Expert
4793,Rattus norvegicus,,,10116.0,,,1,,16547,D,11736,,9,,F,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,Expert
4794,Homo sapiens,,,9606.0,,,1,,15856,D,278,HEK293,9,,F,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,Expert
4795,Homo sapiens,,,9606.0,,,1,,15856,D,278,HEK293,9,,F,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,Expert
4796,Mus musculus,,,10090.0,,,1,,16547,D,11831,,9,,B,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,Expert
4797,,,,,,,1,,16547,H,11831,,8,,F,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,Expert
4798,Mus musculus,,,10090.0,,,1,,16547,D,11831,,9,,F,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,Expert
4799,,,,,,,1,,17402,H,280,,8,,B,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,Expert
4800,Homo sapiens,,,9606.0,,,1,,11746,U,22226,T-cells,0,,F,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,Autocuration
4801,Homo sapiens,,,9606.0,,,1,,11746,U,22226,T-cells,0,,F,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,Autocuration
4802,Homo sapiens,,,9606.0,,,1,,5455,N,80018,A-375,1,,F,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,Intermediate
4803,Homo sapiens,,,9606.0,,,1,,2068,N,80018,A-375,1,,F,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,Intermediate
4804,Homo sapiens,,,9606.0,,,1,,2683,N,80018,A-375,1,,F,In vitro antitumor activity against A375cell line extracted form melanoma,,Intermediate
4805,Homo sapiens,,,9606.0,,,1,,15313,N,80018,A-375,1,,F,Inhibition of cell growth in (A375) melan cell line,,Expert
4806,Homo sapiens,,,9606.0,,,1,,13739,N,80018,A-375,1,,F,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,Intermediate
4807,Homo sapiens,,,9606.0,,,1,,13739,N,80018,A-375,1,,F,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,Intermediate
4808,Homo sapiens,,,9606.0,,,1,,14750,N,80018,A-375,1,,F,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,Intermediate
4809,Homo sapiens,,,9606.0,,,1,,14777,N,80019,A-427,1,,F,Antiproliferative activity measured against A427 human lung carcinoma,,Intermediate
4810,Homo sapiens,,,9606.0,,,1,,14777,N,80019,A-427,1,,F,Antiproliferative activity measured against A427 human lung carcinoma,,Intermediate
4811,Homo sapiens,,,9606.0,,,1,,17672,N,80019,A-427,1,,F,Cytotoxicity against lung carcinoma A427 tumor cell lines,,Intermediate
4812,Homo sapiens,,,9606.0,,,1,,14368,N,80019,A-427,1,,F,Inhibition of large cell lung carcinoma (A427),,Intermediate
4813,Homo sapiens,,,9606.0,,,1,,14368,N,80019,A-427,1,,F,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,Intermediate
4814,Homo sapiens,,,9606.0,,,1,,13866,N,80019,A-427,1,,F,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Intermediate
4815,Homo sapiens,,,9606.0,,,1,,2545,N,80019,A-427,1,,F,Inhibitory concentration in human lung carcinoma A427 cell line,,Intermediate
4816,Homo sapiens,,,9606.0,,,1,,2545,N,80019,A-427,1,,F,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,Intermediate
4817,Cercopithecidae,,,9527.0,In vivo,,1,,6062,U,22224,,0,,A,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,Autocuration
4818,Cercopithecidae,,,9527.0,In vivo,,1,,4578,U,22224,,0,,A,Tested for volume of distribution upon iv administration to african green monkey,,Autocuration
4819,Cercopithecidae,,,9527.0,In vivo,,1,,17592,U,22224,,0,,A,Volume of distribution in monkey,,Autocuration
4820,Macaca mulatta,,,9544.0,In vivo,,1,,5005,U,22224,,0,,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Autocuration
4821,Macaca mulatta,,,9544.0,In vivo,,1,,5005,U,22224,,0,,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,Autocuration
4822,Cercopithecidae,,,9527.0,In vivo,,1,,5922,U,22224,,0,,A,Pharmacokinetic property(Vdss) in cynomolgus monkey,,Autocuration
4823,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The distribution volume after intravenous administration in cynomolgus monkeys,,Autocuration
4824,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,Autocuration
4825,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,Autocuration
4826,Cercopithecidae,,,9527.0,In vivo,,1,,6057,U,22224,,0,,A,Volume displacement was calculated in rhesus monkey,,Autocuration
4827,Cercopithecidae,,,9527.0,In vivo,,1,,5145,U,22224,,0,,A,Volume of distribution in steady state was determined in rhesus monkey,,Autocuration
4828,Cercopithecidae,,,9527.0,In vivo,,1,,6821,U,22224,,0,,A,Volume of distribution of compound was determined in monkey,,Autocuration
4829,Cercopithecidae,,,9527.0,In vivo,,1,,5334,U,22224,,0,,A,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration
4830,Cercopithecidae,,,9527.0,In vivo,,1,,5334,U,22224,,0,,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration
4831,Cercopithecidae,,,9527.0,In vivo,,1,,6641,U,22224,,0,,A,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration
4832,Cercopithecidae,,,9527.0,In vivo,,1,,2661,U,22224,,0,,A,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration
4833,Cercopithecidae,,,9527.0,In vivo,,1,,6535,U,22224,,0,,A,Volume distribution in monkey after administration of 1 mg/kg iv,,Autocuration
4834,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration
4835,Cercopithecidae,,,9527.0,In vivo,,1,,6062,U,22224,,0,,A,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,Autocuration
4836,Cercopithecidae,,,9527.0,In vivo,,1,,3443,U,22224,,0,,A,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
4837,Cercopithecidae,,,9527.0,In vivo,,1,,4578,U,22224,,0,,A,Oral systemic bioavailability upon iv administration to african green monkey,,Autocuration
4838,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration
4839,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Baboon plasma free fraction. ,,Autocuration
4840,Cercopithecidae,,,9527.0,,,1,,6057,U,22224,,0,,A,Area under the curve was calculated in rhesus monkey after iv administration,,Autocuration
4841,Cercopithecidae,,,9527.0,,,1,,6057,U,22224,,0,,A,Area under the curve was calculated in rhesus monkey after peroral administration,,Autocuration
4842,Cercopithecidae,,,9527.0,,,1,,17853,U,22224,,0,,A,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,Autocuration
4843,Cercopithecidae,,,9527.0,In vivo,,1,,5302,U,22224,,0,,A,Half life period in monkey after 5 mg/kg dose,,Autocuration
4844,Cercopithecidae,,,9527.0,In vivo,,1,,4257,U,22224,,0,,A,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,Autocuration
4845,Cercopithecidae,,,9527.0,In vivo,,1,,4257,U,22224,,0,,A,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,Autocuration
4846,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,13501,U,22224,,0,Plasma,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,Autocuration
4847,Cercopithecidae,,,9527.0,In vivo,,1,,5394,U,22224,,0,,A,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,Autocuration
4848,Cercopithecidae,,,9527.0,In vivo,,1,,2661,U,22224,,0,,A,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration
4849,Cercopithecidae,,,9527.0,,,1,,3341,U,22224,,0,,A,Compound was evaluated for terminal half life in monkey,,Autocuration
4850,Cercopithecidae,,,9527.0,In vivo,,1,,3045,U,22224,,0,,A,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,Autocuration
4851,Macaca mulatta,,1969.0,9544.0,In vivo,,1,,5005,U,22224,,0,Plasma,A,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Autocuration
4852,Cercopithecidae,,,9527.0,,,1,,4847,U,22224,,0,,A,Half life of compound was determined in squirrel monkey,,Autocuration
4853,Macaca fascicularis,,,9541.0,In vivo,,1,,4256,U,22224,,0,,A,Half life after iv administration in cynomolgus monkey,,Autocuration
4854,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,6535,U,22224,,0,Plasma,A,Half life in monkey plasma after administration of 1 mg/kg iv,,Autocuration
4855,Cercopithecidae,,,9527.0,,,1,,6057,U,22224,,0,,A,Half life was calculated in rhesus monkey,,Autocuration
4856,Cercopithecidae,,,9527.0,,,1,,17592,U,22224,,0,,A,Half life in monkey,,Autocuration
4857,Cercopithecidae,,,9527.0,In vivo,,1,,6641,U,22224,,0,,A,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration
4858,Cercopithecidae,,,9527.0,,,1,,5472,U,22224,,0,,A,Half life was evaluated in rhesus,,Autocuration
4859,Cercopithecidae,,,9527.0,In vivo,,1,,6221,U,22224,,0,,A,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration
4860,Cercopithecidae,,,9527.0,In vivo,,1,,5668,U,22224,,0,,A,Half life period was determine after peroral administration at 10 mpk in Rhesus,,Autocuration
4861,Cercopithecidae,,,9527.0,In vivo,,1,,4809,U,22224,,0,,A,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration
4862,Cercopithecidae,,,9527.0,In vivo,,1,,5546,U,22224,,0,,A,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Autocuration
4863,Cercopithecidae,,,9527.0,In vivo,,1,,5553,U,22224,,0,,A,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,Autocuration
4864,Cercopithecidae,,,9527.0,,,1,,6078,U,22224,,0,,A,Half-life was calculated in monkey,,Autocuration
4865,Cercopithecidae,,,9527.0,,,1,,5147,U,22224,,0,,A,Half-life in Squirrel monkey,,Autocuration
4866,Cercopithecidae,,,9527.0,,,1,,5145,U,22224,,0,,A,Half-life in rhesus monkey,,Autocuration
4867,Cercopithecidae,,,9527.0,In vivo,,1,,6062,U,22224,,0,,A,Half-life was measured in monkey after an iv dose of 1 mg/kg,,Autocuration
4868,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,Half-life period after intravenous administration in cynomolgus monkeys,,Autocuration
4869,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,Half-life period after oral administration in cynomolgus monkeys,,Autocuration
4870,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,Autocuration
4871,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4872,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4873,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4874,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Autocuration
4875,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,Autocuration
4876,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,Autocuration
4877,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,Autocuration
4878,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,Autocuration
4879,Homo sapiens,,,9606.0,In vivo,,1,,1916,U,22224,,0,,A,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,Autocuration
4880,Homo sapiens,,,9606.0,In vivo,,1,,16643,U,22224,,0,,A,Oral bioavailability in human,,Autocuration
4881,Homo sapiens,,,9606.0,,,1,,17248,U,22224,,0,,A,Compound was tested for human plasma protein binding,,Autocuration
4882,Homo sapiens,,,9606.0,,,1,,17248,U,22224,,0,,A,Compound was tested for human plasma protein binding; Not determined,,Autocuration
4883,Homo sapiens,,,9606.0,,,1,,6241,U,22224,,0,,A,Protein binding activity of compound in human plasma; % Free,,Autocuration
4884,Homo sapiens,,,9606.0,,,1,,17716,U,22224,,0,,A,Unbound fraction (plasma),,Autocuration
4885,Homo sapiens,,1969.0,9606.0,,,1,,17605,U,22224,,0,Plasma,A,Half life for the hydrolysis of compound in human blood serum,,Autocuration
4886,Homo sapiens,,1969.0,9606.0,,,1,,17625,U,22224,,0,Plasma,A,Half life period in human plasma using phosphate buffer (0.08 M),,Autocuration
4887,Homo sapiens,,1969.0,9606.0,,,1,,17625,U,22224,,0,Plasma,A,Half life period in human plasma using phosphate buffer (0.1 M),,Autocuration
4888,Homo sapiens,,1969.0,9606.0,,,1,,17747,U,22224,,0,Plasma,A,Half-life in human plasma was determined,,Autocuration
4889,Homo sapiens,,,9606.0,,,1,,15613,U,22224,,0,,A,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,Autocuration
4890,Homo sapiens,,,9606.0,,,1,,354,U,22224,,0,,A,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,Autocuration
4891,Homo sapiens,,,9606.0,,,1,,3741,U,22224,,0,,A,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,Autocuration
4892,Homo sapiens,,,9606.0,,,1,,3741,U,22224,,0,,A,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,Autocuration
4893,Homo sapiens,,,9606.0,,,1,,3741,U,22224,,0,,A,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,Autocuration
4894,Homo sapiens,,,9606.0,,,1,,17599,U,22224,,0,,A,Partition coefficient (logP),,Autocuration
4895,Homo sapiens,,,9606.0,,,1,,5486,U,22224,,0,,A,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,Autocuration
4896,Homo sapiens,,,9606.0,,,1,,5600,U,22224,,0,,A,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Microsomes,Autocuration
4897,Homo sapiens,,,9606.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,Autocuration
4898,Homo sapiens,,,9606.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,Autocuration
4899,Homo sapiens,,,9606.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,Autocuration
4900,Homo sapiens,,,9606.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Microsomes,Autocuration
4901,Homo sapiens,,,9606.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Microsomes,Autocuration
4902,Homo sapiens,,,9606.0,,,1,,14294,U,22224,,0,,A,Metabolism of compound in human microsomes; Trace,Microsomes,Autocuration
4903,Homo sapiens,,2107.0,9606.0,,,1,,6260,U,22224,,0,Liver,A,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Microsomes,Autocuration
4904,Homo sapiens,,,9606.0,,,1,,6187,U,22224,,0,,A,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Microsomes,Autocuration
4905,Homo sapiens,,2107.0,9606.0,,,1,,6251,U,22224,,0,Liver,A,In vitro metabolic potential in human liver microsomes,Microsomes,Autocuration
4906,Homo sapiens,,,9606.0,,,1,,3246,U,22224,,0,,A,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,Autocuration
4907,Homo sapiens,,,9606.0,,,1,,17313,U,22224,,0,,A,Tested for human plasma protein binding of the compound; Not tested,,Autocuration
4908,Homo sapiens,,,9606.0,,,1,,6227,U,22224,,0,,A,Compound was tested for percent protein binding (PB) in human,,Autocuration
4909,Homo sapiens,,1969.0,9606.0,,,1,,5530,U,22224,,0,Plasma,A,Protein binding in human plasma,,Autocuration
4910,Homo sapiens,,,9606.0,,,1,,6108,U,22224,,0,,A,Permeability coefficient (B to A) in Caco-2 cell,,Autocuration
4911,Homo sapiens,,,9606.0,,,1,,6108,U,22224,,0,,A,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,Autocuration
4912,Homo sapiens,,,9606.0,,,1,,2774,U,22224,,0,,A,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,Autocuration
4913,Homo sapiens,,,9606.0,,,1,,16643,U,22224,,0,,A,In vitro rate of absorption observed as Caco-2 permeability in humans,,Autocuration
4914,Homo sapiens,,,9606.0,,,1,,17582,U,22224,Caco-2,0,,A,Cellular permeability of compound was determined in Caco-2 cells; High,,Autocuration
4915,Homo sapiens,,,9606.0,,,1,,6838,U,22224,Caco-2,0,,A,Permeability in Caco-2 cells of compound,,Autocuration
4916,Homo sapiens,,,9606.0,,,1,,6108,U,22224,,0,,A,Permeability coefficient (A to B) in Caco-2 cell,,Autocuration
4917,Homo sapiens,,,9606.0,,,1,,6108,U,22224,,0,,A,Permeability coefficient (B to A) in Caco-2 cell,,Autocuration
4918,Homo sapiens,,,9606.0,,,1,,6108,U,22224,,0,,A,Permeability coefficient (Papp) (Caco-2 cell monolayer),,Autocuration
4919,Homo sapiens,,,9606.0,,,1,,2146,U,22224,,0,,A,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,Autocuration
4920,Homo sapiens,,,9606.0,,,1,,4514,U,22224,,0,,A,Compound was tested for protein binding in human plasma,,Autocuration
4921,Homo sapiens,,,9606.0,,,1,,6108,U,22224,,0,,A,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,Autocuration
4922,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,Autocuration
4923,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,Intermediate
4924,Mus musculus,,,10090.0,In vivo,,1,,3277,N,50594,,1,,A,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Intermediate
4925,Mus musculus,,,10090.0,In vivo,,1,,3802,N,50594,,1,,A,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,Intermediate
4926,Mus musculus,,1969.0,10090.0,In vivo,,1,,2862,N,50594,,1,Plasma,A,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,Intermediate
4927,Mus musculus,,1969.0,10090.0,In vivo,,1,,6348,N,50594,,1,Plasma,A,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate
4928,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Tmax after intraperitoneal administration in mice at 23 uM/kg,,Intermediate
4929,Mus musculus,,,10090.0,In vivo,,1,,5781,N,50594,,1,,A,Tmax after oral administration at 30 mg/kg in ICR mouse,,Intermediate
4930,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Tmax after peroral administration in mice at 2.4 uM/kg,,Intermediate
4931,Mus musculus,,,10090.0,In vivo,,1,,4066,N,50594,,1,,A,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate
4932,Mus musculus,,955.0,10090.0,In vivo,,1,,17641,N,50594,,1,Brain,A,Tmax in brain of mice at the oral dose of 50 mg/kg,,Intermediate
4933,Mus musculus,,2113.0,10090.0,In vivo,,1,,17641,N,50594,,1,Kidney,A,Tmax in kidney of mice at the oral dose of 50 mg/kg,,Intermediate
4934,Mus musculus,,2107.0,10090.0,In vivo,,1,,17641,N,50594,,1,Liver,A,Tmax in liver of mice at the oral dose of 50 mg/kg,,Intermediate
4935,Mus musculus,,2048.0,10090.0,In vivo,,1,,17641,N,50594,,1,Lung,A,Tmax in lungs of mice at the oral dose of 50 mg/kg,,Intermediate
4936,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Tmax in mice at 18 uM/kg i.p. administration,,Intermediate
4937,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Tmax in mice at 23 uM/kg i.v. administration,,Intermediate
4938,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Tmax in mice at 25 uM/kg i.p. administration,,Intermediate
4939,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Tmax in mice at 26 uM/kg i.p. administration,,Intermediate
4940,Mus musculus,,2106.0,10090.0,In vivo,,1,,17641,N,50594,,1,Spleen,A,Tmax in spleen of mice at the oral dose of 50 mg/kg,,Intermediate
4941,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
4942,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate
4943,Mus musculus,,,10090.0,,,1,,5951,N,50594,,1,,A,Tmax value in IRC mice,,Intermediate
4944,Mus musculus,,,10090.0,In vivo,,1,,5506,N,50594,,1,,A,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,Intermediate
4945,Mus musculus,,,10090.0,In vivo,,1,,5506,N,50594,,1,,A,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,Intermediate
4946,Mus musculus,,1088.0,10090.0,,,1,,429,N,50594,,1,Urine,A,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,Intermediate
4947,Mus musculus,,1088.0,10090.0,,,1,,429,N,50594,,1,Urine,A,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,Intermediate
4948,Mus musculus,,1088.0,10090.0,,,1,,4066,N,50594,,1,Urine,A,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,Intermediate
4949,Mus musculus,,,10090.0,,,1,,17734,N,50594,,1,,A,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
4950,Mus musculus,,,10090.0,,,1,,17734,N,50594,,1,,A,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
4951,Mus musculus,,,10090.0,In vivo,,1,,6062,N,50594,,1,,A,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,Intermediate
4952,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,Intermediate
4953,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,Intermediate
4954,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Intermediate
4955,Mus musculus,,,10090.0,In vivo,,1,,5980,N,50594,,1,,A,Vd in mice,,Intermediate
4956,Mus musculus,,,10090.0,In vivo,,1,,17592,N,50594,,1,,A,Volume of distribution in mouse,,Intermediate
4957,Mus musculus,,,10090.0,In vivo,,1,,6348,N,50594,,1,,A,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate
4958,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,Intermediate
4959,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,Intermediate
4960,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,Intermediate
4961,Mus musculus,,,10090.0,In vivo,,1,,4239,N,50594,,1,,A,Pharmacokinetic property (vdss) was measured in mouse,,Intermediate
4962,Mus musculus,,,10090.0,In vivo,,1,,2862,N,50594,,1,,A,Value distribution upon iv administration in mouse,,Intermediate
4963,Mus musculus,,,10090.0,In vivo,,1,,17734,N,50594,,1,,A,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
4964,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Volume of distribution was evaluated in mice after intravenous administration,,Intermediate
4965,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Volume of distribution was evaluated in mice after oral administration,,Intermediate
4966,Mus musculus,,,10090.0,In vivo,,1,,17837,N,50594,,1,,A,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,Intermediate
4967,Mus musculus,,,10090.0,In vivo,,1,,5727,N,50594,,1,,A,Steady state volume of distribution was determined in mice,,Intermediate
4968,Mus musculus,,,10090.0,In vivo,,1,,17852,N,50594,,1,,A,Volume distribution (steady state) of compound was determined in mouse,,Intermediate
4969,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,Intermediate
4970,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
4971,Mus musculus,,,10090.0,In vivo,,1,,6062,N,50594,,1,,A,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,Intermediate
4972,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,Biodistribution of compound (oxidized form) in in kidney tissue,,Intermediate
4973,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,Intermediate
4974,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,Intermediate
4975,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
4976,Homo sapiens,,,9606.0,,,1,,10708,N,80019,A-427,1,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,Intermediate
4977,Homo sapiens,,,9606.0,,,1,,16597,N,80852,A-431,1,,F,Inhibition of A431 human squamous cell carcinoma cell proliferation,,Expert
4978,Homo sapiens,,,9606.0,,,1,,16062,N,80852,A-431,1,,F,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,Expert
4979,Homo sapiens,,,9606.0,,,1,,16062,N,80852,A-431,1,,F,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,Expert
4980,Homo sapiens,,,9606.0,,,1,,16958,N,80852,A-431,1,,F,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,Expert
4981,Homo sapiens,,,9606.0,,,1,,6700,N,80852,A-431,1,,F,Inhibition of A431 human carcinoma cell proliferation,,Expert
4982,Homo sapiens,,,9606.0,,,1,,17226,N,80852,A-431,1,,F,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,Expert
4983,Homo sapiens,,,9606.0,,,1,,6828,N,80852,A-431,1,,F,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,Intermediate
4984,Homo sapiens,,,9606.0,,,1,,12314,N,80852,A-431,1,,F,In vitro cytotoxicity against epidermoid carcinoma cell line,,Intermediate
4985,Homo sapiens,,,9606.0,,,1,,13412,D,9,A-431,9,,F,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,Expert
4986,Homo sapiens,,,9606.0,,,1,,13299,N,80852,A-431,1,,F,Antiproliferative activity of compound was measured on human tumor cell line A431.,,Intermediate
4987,Homo sapiens,,,9606.0,,,1,,17420,N,80852,A-431,1,,F,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,Intermediate
4988,Homo sapiens,,,9606.0,,,1,,13678,N,80852,A-431,1,,F,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,Intermediate
4989,,,,,,,1,,14171,H,9,A-431,8,,F,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,Expert
4990,Homo sapiens,,,9606.0,,,1,,6333,N,80852,A-431,1,,F,Tested for antiproliferative activity against human A431 cells,,Expert
4991,Homo sapiens,,,9606.0,,,1,,2356,D,9,A-431,9,,F,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,Expert
4992,Homo sapiens,,,9606.0,,,1,,15578,N,80852,A-431,1,,F,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,Expert
4993,Homo sapiens,,,9606.0,,,1,,5126,N,80852,A-431,1,,F,Inhibition of A431 cell proliferation,,Expert
4994,Homo sapiens,,,9606.0,,,1,,6844,N,80852,A-431,1,,F,Cytotoxic effect on A431 human epidermoid carcinoma cells,,Expert
4995,Homo sapiens,,,9606.0,,,1,,6844,N,80852,A-431,1,,F,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,Expert
4996,Homo sapiens,,,9606.0,,,1,,4925,N,80852,A-431,1,,F,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,Intermediate
4997,Homo sapiens,,,9606.0,,,1,,4925,N,80852,A-431,1,,F,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,Intermediate
4998,Homo sapiens,,,9606.0,,,1,,13978,N,80852,A-431,1,,F,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,Intermediate
4999,Homo sapiens,,,9606.0,,,1,,16786,N,80852,A-431,1,,F,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,Intermediate
5000,,,,,,,1,,13412,H,9,A-431,8,,F,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,Expert
5001,Homo sapiens,,,9606.0,,,1,,17824,N,80852,A-431,1,,F,In vivo antiproliferative activity against A431 cell line,,Intermediate
5002,Homo sapiens,,,9606.0,,,1,,12751,D,9,A-431,9,,F,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,Expert
5003,Homo sapiens,,,9606.0,,,1,,12380,N,80852,A-431,1,,F,Inhibition of A431 human epidermoid carcinoma cell proliferation,,Expert
5004,Homo sapiens,,,9606.0,,,1,,4959,D,9,A-431,9,,F,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,Expert
5005,Homo sapiens,,,9606.0,,,1,,6333,N,80852,A-431,1,,F,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,Intermediate
5006,Homo sapiens,,,9606.0,,,1,,6333,N,80852,A-431,1,,F,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,Intermediate
5007,Homo sapiens,,,9606.0,,,1,,6333,N,80852,A-431,1,,F,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,Intermediate
5008,Homo sapiens,,,9606.0,,,1,,5296,D,9,,9,,F,Inhibition of EGFR overexpressing A431 cell proliferation,,Expert
5009,Homo sapiens,,,9606.0,,,1,,12624,N,80852,A-431,1,,F,Inhibition of A431 cell proliferation,,Expert
5010,Homo sapiens,,,9606.0,,,1,,14926,D,9,A-431,9,,F,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,Expert
5011,Homo sapiens,,,9606.0,,,1,,14926,D,9,A-431,9,,F,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,Expert
5012,,,,,,,1,,14926,H,9,A-431,8,,F,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,Expert
5013,Homo sapiens,,,9606.0,,,1,,15144,N,80852,A-431,1,,F,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Intermediate
5014,Homo sapiens,,,9606.0,,,1,,15144,N,80852,A-431,1,,F,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Intermediate
5015,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,Intermediate
5016,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,Intermediate
5017,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Intermediate
5018,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,Intermediate
5019,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,Intermediate
5020,Cercopithecidae,,,9527.0,,,1,,5922,U,22224,,0,,A,Half-life period in cynomolgus monkey,,Autocuration
5021,Cercopithecidae,,1969.0,9527.0,In vitro,,1,,1116,U,22224,,0,Plasma,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,Autocuration
5022,Cercopithecidae,,,9527.0,In vivo,,1,,17853,U,22224,,0,,A,Longer half-life in monkey (i.v.) at 0.5 mpk,,Autocuration
5023,Cercopithecidae,,1969.0,9527.0,,,1,,993,U,22224,,0,Plasma,A,Plasma half life in monkey,,Autocuration
5024,Cercopithecidae,,1969.0,9527.0,,,1,,4514,U,22224,,0,Plasma,A,Plasma half-life in rhesus monkey,,Autocuration
5025,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,5334,U,22224,,0,Plasma,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration
5026,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,5334,U,22224,,0,Plasma,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration
5027,Cercopithecidae,,,9527.0,In vivo,,1,,4578,U,22224,,0,,A,Tested for half life upon iv administration to african green monkey,,Autocuration
5028,Cercopithecidae,,,9527.0,In vivo,,1,,2661,U,22224,,0,,A,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration
5029,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,Autocuration
5030,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,Autocuration
5031,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The time for peak concentration value after oral administration in cynomolgus monkeys,,Autocuration
5032,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,Autocuration
5033,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,Autocuration
5034,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,Autocuration
5035,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,Autocuration
5036,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,Autocuration
5037,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,Autocuration
5038,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,Autocuration
5039,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,Autocuration
5040,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,Autocuration
5041,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,Autocuration
5042,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,Autocuration
5043,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,Autocuration
5044,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,Autocuration
5045,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,Autocuration
5046,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,Autocuration
5047,Cercopithecidae,,,9527.0,,,1,,11271,U,22224,,0,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,Autocuration
5048,Rattus norvegicus,,,10116.0,In vivo,,1,,5809,N,50597,,1,,A,Bioavailability in rat (cannulated) (dose 2 mg/kg),,Intermediate
5049,Rattus norvegicus,,1969.0,10116.0,In vivo,,1,,17720,N,50597,,1,Plasma,A,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,Intermediate
5050,Rattus norvegicus,,1969.0,10116.0,,,1,,3546,N,50597,,1,Plasma,A,AUC value in rat after IV administration at a dose of 10 mg/kg,,Intermediate
5051,Rattus norvegicus,,1969.0,10116.0,,,1,,3546,N,50597,,1,Plasma,A,AUC value in rat after oral administration at a dose of 10 mg/kg,,Intermediate
5052,Rattus norvegicus,,,10116.0,In vivo,,1,,3546,N,50597,,1,,A,Cmax value in rat after oral administration at a dose of 10 mg/kg,,Intermediate
5053,Rattus norvegicus,,,10116.0,In vivo,,1,,3546,N,50597,,1,,A,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,Intermediate
5054,Rattus norvegicus,,,10116.0,In vivo,,1,,3546,N,50597,,1,,A,Tmax value in rat after oral administration at a dose of 10 mg/kg,,Intermediate
5055,Rattus norvegicus,,,10116.0,,,1,,3546,N,50597,,1,,A,Vc value in rat after IV administration at a dose of 10 mg/kg,,Intermediate
5056,Rattus norvegicus,,,10116.0,In vivo,,1,,3546,N,50597,,1,,A,Half life period in rat after IV administration at a dose of 10 mg/kg,,Intermediate
5057,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Autocuration
5058,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,Autocuration
5059,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,Autocuration
5060,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,Autocuration
5061,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,Autocuration
5062,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,Autocuration
5063,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,Autocuration
5064,Papio hamadryas,,,9557.0,,,1,,10625,U,22224,,0,,A,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Autocuration
5065,beagle,,,9615.0,,,1,,3510,U,22224,,0,,A,Area under curve after 1 mpk peroral administration to beagles,,Autocuration
5066,beagle,,,9615.0,,,1,,3510,U,22224,,0,,A,Area under curve after 2 mpk peroral administration to beagles,,Autocuration
5067,beagle,,,9615.0,In vivo,,1,,3510,U,22224,,0,,A,Cmax value after 1 mpk peroral administration to beagles,,Autocuration
5068,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,Autocuration
5069,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,Autocuration
5070,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,Autocuration
5071,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,Autocuration
5072,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,Autocuration
5073,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,Autocuration
5074,Homo sapiens,,1088.0,9606.0,,,1,,7766,U,22224,,0,Urine,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,Autocuration
5075,Homo sapiens,,2107.0,9606.0,,,1,,16643,U,22224,,0,Liver,A,Metabolic stability observed at 30 min after administration in human liver microsomes,Microsomes,Autocuration
5076,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,Autocuration
5077,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,Autocuration
5078,Homo sapiens,,,9606.0,,,1,,6852,U,22224,,0,,A,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,Autocuration
5079,Homo sapiens,,2107.0,9606.0,,,1,,6567,U,22224,,0,Liver,A,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Microsomes,Autocuration
5080,Homo sapiens,,,9606.0,,,1,,6570,U,22224,,0,,A,Metabolic stability (% remaining at 30 mins) in human S9.,,Autocuration
5081,Homo sapiens,,,9606.0,,,1,,6570,U,22224,,0,,A,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,Autocuration
5082,Homo sapiens,,2107.0,9606.0,,,1,,5237,U,22224,,0,Liver,A,Percent parent compound remaining after 20 min incubation with human liver microsomes,Microsomes,Autocuration
5083,Homo sapiens,,2107.0,9606.0,,,1,,5237,U,22224,,0,Liver,A,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Microsomes,Autocuration
5084,Homo sapiens,,2107.0,9606.0,,,1,,5237,U,22224,,0,Liver,A,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Microsomes,Autocuration
5085,Homo sapiens,,,9606.0,,,1,,5202,U,22224,,0,,A,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,Autocuration
5086,Homo sapiens,,,9606.0,,,1,,5481,U,22224,,0,,A,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,Autocuration
5087,Homo sapiens,,,9606.0,,,1,,5481,U,22224,,0,,A,Percent remaining in human plasma after incubation for 60 min at 37 C.,,Autocuration
5088,Homo sapiens,,,9606.0,,,1,,3956,U,22224,,0,,A,The percent remaining in human plasma after 30 min was determined,,Autocuration
5089,Homo sapiens,,1969.0,9606.0,,,1,,5074,U,22224,,0,Plasma,A,Conversion rate of the prodrug in human plasma,,Autocuration
5090,Homo sapiens,,1969.0,9606.0,,,1,,5074,U,22224,,0,Plasma,A,Conversion rate of the prodrug in human plasma; ND means no data,,Autocuration
5091,Homo sapiens,,178.0,9606.0,,,1,,4727,U,22224,,0,Blood,A,Half life of compound was determined in human blood,,Autocuration
5092,Homo sapiens,,,9606.0,,,1,,5965,U,22224,,0,,A,Half life of compound was determined in man with once daily dosing,,Autocuration
5093,Homo sapiens,,,9606.0,In vitro,,1,,5732,U,22224,,0,,A,Half life in human microsomes,Microsomes,Autocuration
5094,Homo sapiens,,1969.0,9606.0,,,1,,5819,U,22224,,0,Plasma,A,Half life in human plasma,,Autocuration
5095,Homo sapiens,,1969.0,9606.0,,,1,,5819,U,22224,,0,Plasma,A,Half life in human plasma; Not detected,,Autocuration
5096,Homo sapiens,,,9606.0,In vivo,,1,,1916,U,22224,,0,,A,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration
5097,Homo sapiens,,2107.0,9606.0,In vitro,,1,,6597,U,22224,,0,Liver,A,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Microsomes,Autocuration
5098,Homo sapiens,,1969.0,9606.0,,,1,,5229,U,22224,,0,Plasma,A,Half-life in human plasma,,Autocuration
5099,Homo sapiens,,1969.0,9606.0,,,1,,5229,U,22224,,0,Plasma,A,Half-life of the parent prodrug in plasma,,Autocuration
5100,Homo sapiens,,1969.0,9606.0,In vitro,,1,,2192,U,22224,,0,Plasma,A,In vitro half life in human plasma was determined,,Autocuration
5101,Homo sapiens,,2107.0,9606.0,In vitro,,1,,3032,U,22224,,0,Liver,A,The compound was tested In Vitro for half life in human liver microsomes.,Microsomes,Autocuration
5102,Homo sapiens,,,9606.0,In vivo,,1,,1916,U,22224,,0,,A,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration
5103,Homo sapiens,,,9606.0,In vivo,,1,,17716,U,22224,,0,,A,Observed volume of distribution,,Autocuration
5104,Homo sapiens,,,9606.0,In vivo,,1,,15778,U,22224,,0,,A,Oral bioavailability in human,,Autocuration
5105,Homo sapiens,,,9606.0,,,1,,17313,U,22224,,0,,A,Tested for human plasma protein binding of the compound,,Autocuration
5106,Homo sapiens,,,9606.0,,,1,,4231,U,22224,,0,,A,"First order rate constant, k was determined in human plasma",,Autocuration
5107,Homo sapiens,,,9606.0,,,1,,4755,U,22224,,0,,A,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Autocuration
5108,Homo sapiens,,,9606.0,,,1,,4755,U,22224,,0,,A,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Autocuration
5109,Homo sapiens,,2107.0,9606.0,,,1,,16907,U,22224,,0,Liver,A,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Microsomes,Autocuration
5110,Homo sapiens,,,9606.0,,,1,,10839,U,22224,,0,,A,The compound was tested for the plasma binding in human,,Autocuration
5111,Homo sapiens,,,9606.0,,,1,,10839,U,22224,,0,,A,Plasma protein binding (human),,Autocuration
5112,Homo sapiens,,2107.0,9606.0,In vitro,,1,,3199,U,22224,,0,Liver,A,Compound was evaluated for half-life in human liver microsomes,Microsomes,Autocuration
5113,Homo sapiens,,178.0,9606.0,In vitro,,1,,1345,U,22224,,0,Blood,A,Half life measured in vitro for its stability in human blood,,Autocuration
5114,Homo sapiens,,1977.0,9606.0,,,1,,4297,U,22224,,0,Serum,A,Half life in human serum,,Autocuration
5115,Homo sapiens,,1977.0,9606.0,,,1,,4297,U,22224,,0,Serum,A,Half life in human serum; ND=not determined,,Autocuration
5116,Homo sapiens,,,9606.0,,,1,,4297,U,22224,,0,,A,Half life were determined in CEM-SS cell extract in decomposition step 1,,Autocuration
5117,Homo sapiens,,,9606.0,,,1,,4297,U,22224,,0,,A,Half life were determined in CEM-SS cell extract in decomposition step 2,,Autocuration
5118,Homo sapiens,,1969.0,9606.0,,,1,,4231,U,22224,,0,Plasma,A,Half life of the in human plasma,,Autocuration
5119,Homo sapiens,,,9606.0,In vitro,,1,,5633,U,22224,,0,,A,Half life period in human hepatic S9 fraction was determined,S9,Autocuration
5120,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5633,U,22224,,0,Liver,A,Half life period in human liver microsome was determined,Microsomes,Autocuration
5121,Homo sapiens,,,9606.0,,,1,,17791,U,22224,,0,,A,Half life period was determined; 6-7,,Autocuration
5122,Homo sapiens,,,9606.0,,,1,,17791,U,22224,,0,,A,Half life period was evaluated in human,,Autocuration
5123,Homo sapiens,,1969.0,9606.0,,,1,,3160,U,22224,,0,Plasma,A,Half life time in human plasma,,Autocuration
5124,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5125,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5126,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5127,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5128,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,Intermediate
5129,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5130,Mus musculus,,2107.0,10090.0,In vivo,,1,,16438,N,50594,,1,Liver,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5131,Mus musculus,,2107.0,10090.0,In vivo,,1,,16438,N,50594,,1,Liver,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,Intermediate
5132,Mus musculus,,2107.0,10090.0,In vivo,,1,,16438,N,50594,,1,Liver,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5133,Mus musculus,,2106.0,10090.0,In vivo,,1,,16438,N,50594,,1,Spleen,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,Intermediate
5134,Mus musculus,,2106.0,10090.0,In vivo,,1,,16438,N,50594,,1,Spleen,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,Intermediate
5135,Mus musculus,,2106.0,10090.0,In vivo,,1,,16438,N,50594,,1,Spleen,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5136,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Intermediate
5137,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,Biodistribution of compound (oxidized form) in blood tissue,,Intermediate
5138,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5139,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,Intermediate
5140,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Intermediate
5141,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5142,Mus musculus,,178.0,10090.0,In vivo,,1,,16438,N,50594,,1,Blood,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,Intermediate
5143,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,Biodistribution of compound (oxidized form) in brain tissue of mice,,Intermediate
5144,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5145,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,Intermediate
5146,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5147,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,Intermediate
5148,Mus musculus,,955.0,10090.0,In vivo,,1,,16438,N,50594,,1,Brain,A,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,Intermediate
5149,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,Biodistribution of compound (oxidized form) in heart tissue of mice,,Intermediate
5150,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5151,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5152,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,Intermediate
5153,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5154,Mus musculus,,948.0,10090.0,In vivo,,1,,16438,N,50594,,1,Heart,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,Intermediate
5155,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5156,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,Intermediate
5157,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,Intermediate
5158,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,Intermediate
5159,Mus musculus,,2113.0,10090.0,In vivo,,1,,16438,N,50594,,1,Kidney,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,Intermediate
5160,Mus musculus,,2107.0,10090.0,In vivo,,1,,16438,N,50594,,1,Liver,A,Biodistribution of compound (oxidized form) in liver tissue,,Intermediate
5161,Mus musculus,,2107.0,10090.0,In vivo,,1,,16438,N,50594,,1,Liver,A,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,Intermediate
5162,Mus musculus,,2107.0,10090.0,In vivo,,1,,16438,N,50594,,1,Liver,A,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,Intermediate
5163,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,Intermediate
5164,Homo sapiens,,,9606.0,,,1,,5245,N,80852,A-431,1,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Intermediate
5165,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,Expert
5166,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,Expert
5167,Homo sapiens,,,9606.0,,,1,,16093,D,9,A-431,9,,F,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Expert
5168,Homo sapiens,,,9606.0,,,1,,16825,N,80852,A-431,1,,F,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,Intermediate
5169,Homo sapiens,,,9606.0,,,1,,4848,N,80852,A-431,1,,F,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,Intermediate
5170,Homo sapiens,,,9606.0,,,1,,14827,D,9,A-431,9,,F,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,Expert
5171,Homo sapiens,,,9606.0,,,1,,14827,D,9,A-431,9,,F,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,Expert
5172,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,Expert
5173,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,Expert
5174,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,Expert
5175,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,Expert
5176,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,Expert
5177,Homo sapiens,,,9606.0,,,1,,16289,D,9,A-431,9,,F,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,Expert
5178,,,,,,,1,,16289,H,9,A-431,8,,F,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,Expert
5179,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,Expert
5180,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,Expert
5181,,,,,,,1,,16289,N,80852,A-431,1,,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,Expert
5182,Mus musculus,,,10090.0,,,1,,14555,N,80852,A-431,1,,F,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert
5183,Mus musculus,,,10090.0,,,1,,14555,N,80852,A-431,1,,F,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert
5184,Mus musculus,,,10090.0,,,1,,14555,N,80852,A-431,1,,F,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert
5185,Mus musculus,,,10090.0,,,1,,14555,N,80852,A-431,1,,F,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert
5186,Homo sapiens,,,9606.0,,,1,,1937,N,80852,A-431,1,,F,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,Expert
5187,Homo sapiens,,,9606.0,,,1,,13739,N,80852,A-431,1,,F,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,Intermediate
5188,Homo sapiens,,,9606.0,,,1,,3558,N,80852,A-431,1,,F,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,Intermediate
5189,Homo sapiens,,,9606.0,,,1,,3558,N,80852,A-431,1,,F,Dose giving a 50% decrease in the living cell number (A437 cells),,Intermediate
5190,Homo sapiens,,,9606.0,,,1,,17686,N,80682,A549,1,,F,In vitro inhibitory concentration against proliferation of A459 cell line.,,Expert
5191,Homo sapiens,,,9606.0,,,1,,5305,N,80682,A549,1,,F,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,Intermediate
5192,Homo sapiens,,,9606.0,,,1,,3614,N,80682,A549,1,,F,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,Intermediate
5193,Homo sapiens,,,9606.0,,,1,,17229,N,80021,A498,1,,F,In vitro antitumor activity against renal A498 tumor cell lines,,Intermediate
5194,Homo sapiens,,,9606.0,,,1,,15935,N,80021,A498,1,,F,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,Intermediate
5195,Homo sapiens,,,9606.0,,,1,,15935,N,80021,A498,1,,F,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,Intermediate
5196,Homo sapiens,,,9606.0,,,1,,15560,N,80021,A498,1,,F,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,Intermediate
5197,Homo sapiens,,,9606.0,,,1,,13891,N,80021,A498,1,,F,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,Intermediate
5198,Homo sapiens,,,9606.0,,,1,,13891,N,80021,A498,1,,F,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,Intermediate
5199,Homo sapiens,,,9606.0,,,1,,13788,N,80021,A498,1,,F,Cytotoxicity on kidney carcinoma (A-498) cell line,,Intermediate
5200,Homo sapiens,,,9606.0,,,1,,15403,N,80021,A498,1,,F,Compound was evaluated against Human cell line renal A498,,Intermediate
5201,Homo sapiens,,,9606.0,,,1,,1009,N,80021,A498,1,,F,Compound was tested for inhibition of A498 human renal cancer cell line,,Intermediate
5202,Homo sapiens,,,9606.0,,,1,,1043,N,80021,A498,1,,F,Growth inhibitory activity against A498 human cancer cell line,,Intermediate
5203,Homo sapiens,,,9606.0,,,1,,5858,N,80021,A498,1,,F,In vitro antitumor activity against human renal A498 cell line,,Intermediate
5204,Homo sapiens,,,9606.0,,,1,,5958,N,80021,A498,1,,F,In vitro cytotoxic activity against renal (A498) cell line,,Intermediate
5205,Homo sapiens,,,9606.0,,,1,,5506,N,80021,A498,1,,F,In vitro cytotoxic activity against human renal cancer (A498) cell line,,Intermediate
5206,Homo sapiens,,,9606.0,,,1,,12781,N,80021,A498,1,,F,Tested for cytostatic activity against renal A498 cell line,,Intermediate
5207,Homo sapiens,,,9606.0,,,1,,14399,N,80021,A498,1,,F,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,Intermediate
5208,Homo sapiens,,,9606.0,,,1,,5958,N,80021,A498,1,,F,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,Expert
5209,beagle,,,9615.0,In vivo,,1,,3510,U,22224,,0,,A,Cmax value after 2 mpk peroral administration to beagles,,Autocuration
5210,Canis lupus familiaris,,,9615.0,In vivo,beagle,1,,3510,U,22224,,0,,A,Bioavailability,,Autocuration
5211,Canis lupus familiaris,,,9615.0,In vivo,beagle,1,,3510,U,22224,,0,,A,Bioavailability after 1 mpk peroral administration to beagles,,Autocuration
5212,Canis lupus familiaris,,,9615.0,In vivo,beagle,1,,3510,U,22224,,0,,A,Bioavailability after 2 mpk peroral administration to beagles,,Autocuration
5213,Bos taurus,,,9913.0,,,1,,3085,U,22224,,0,,A,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,Autocuration
5214,Bos taurus,,,9913.0,,,1,,3085,U,22224,,0,,A,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,Autocuration
5215,Bos taurus,,,9913.0,,,1,,3085,U,22224,,0,,A,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,Autocuration
5216,Bos taurus,,,9913.0,,,1,,9372,U,22224,,0,,A,Solubility against bovine alpha-chymotrypsin,,Autocuration
5217,Bos taurus,,,9913.0,,,1,,3085,U,22224,,0,,A,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Autocuration
5218,Bos taurus,,,9913.0,,,1,,3085,U,22224,,0,,A,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Autocuration
5219,Bos taurus,,2106.0,9913.0,,,1,,1469,U,22224,,0,Spleen,A,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,Autocuration
5220,Bos taurus,,,9913.0,,,1,,4297,U,22224,,0,,A,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,Autocuration
5221,Bos taurus,,,9913.0,,,1,,4297,U,22224,,0,,A,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,Autocuration
5222,Bos taurus,,,9913.0,,,1,,17585,U,22224,,0,,A,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,Autocuration
5223,Bos taurus,,2106.0,9913.0,,,1,,1336,U,22224,,0,Spleen,A,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,Autocuration
5224,Bos taurus,,,9913.0,,,1,,3085,U,22224,,0,,A,Half life in presence of 2 mg/mL BSA at pH 8.8,,Autocuration
5225,Bos taurus,,,9913.0,,,1,,2857,U,22224,,0,,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,Autocuration
5226,Bos taurus,,,9913.0,,,1,,2857,U,22224,,0,,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,Autocuration
5227,Bos taurus,,,9913.0,,,1,,2857,U,22224,,0,,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,Autocuration
5228,Bos taurus,,,9913.0,,,1,,1540,U,22224,,0,,A,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,Autocuration
5229,Canis lupus familiaris,,1969.0,9615.0,,,1,,6316,N,50588,,1,Plasma,A,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,Intermediate
5230,Canis lupus familiaris,,1969.0,9615.0,,,1,,17594,N,50588,,1,Plasma,A,AUC after administration at 100 mg/kg/day in dogs,,Intermediate
5231,Canis lupus familiaris,,1969.0,9615.0,,,1,,4953,N,50588,,1,Plasma,A,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,Intermediate
5232,Canis lupus familiaris,,1969.0,9615.0,,,1,,16907,N,50588,,1,Plasma,A,AUC value after 15 mg/kg iv dose in Dogs,,Intermediate
5233,Canis lupus familiaris,,1969.0,9615.0,,,1,,16907,N,50588,,1,Plasma,A,AUC value after 30 mg/kg po dose in Dogs,,Intermediate
5234,Canis lupus familiaris,,1969.0,9615.0,,,1,,2959,N,50588,,1,Plasma,A,AUC value after administration of 4 mg/Kg oral dose in dog,,Intermediate
5235,Canis lupus familiaris,,1969.0,9615.0,,,1,,17594,N,50588,,1,Plasma,A,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,Intermediate
5236,Canis lupus familiaris,,,9615.0,,,1,,5356,N,50588,,1,,A,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,Intermediate
5237,Canis lupus familiaris,,,9615.0,,,1,,16807,N,50588,,1,,A,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,Intermediate
5238,Canis lupus familiaris,,,9615.0,,,1,,4527,N,50588,,1,,A,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,Intermediate
5239,Canis lupus familiaris,,,9615.0,,,1,,4527,N,50588,,1,,A,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate
5240,Canis lupus familiaris,,,9615.0,,,1,,15660,N,50588,,1,,A,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,Intermediate
5241,Canis lupus familiaris,,,9615.0,,,1,,15660,N,50588,,1,,A,Area under curve determined in dogs after oral administration of 10 mg/kg,,Intermediate
5242,Canis lupus familiaris,,,9615.0,,,1,,5802,N,50588,,1,,A,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate
5243,Canis lupus familiaris,,,9615.0,,,1,,3598,N,50588,,1,,A,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert
5244,Canis lupus familiaris,,,9615.0,,,1,,3598,N,50588,,1,,A,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,Expert
5245,Canis lupus familiaris,,,9615.0,,,1,,5944,N,50588,,1,,A,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate
5246,Canis lupus familiaris,,,9615.0,,,1,,5944,N,50588,,1,,A,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,Intermediate
5247,Canis lupus familiaris,,,9615.0,,,1,,5944,N,50588,,1,,A,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate
5248,Canis lupus familiaris,,,9615.0,,,1,,5944,N,50588,,1,,A,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,Intermediate
5249,Canis lupus familiaris,,,9615.0,,,1,,4186,N,50588,,1,,A,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,Intermediate
5250,Canis lupus familiaris,,,9615.0,,,1,,5007,N,50588,,1,,A,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate
5251,Canis lupus familiaris,,,9615.0,,,1,,5668,N,50588,,1,,A,Area under curve was determine after peroral administration at 10 mpk in dog,,Intermediate
5252,Canis lupus familiaris,,,9615.0,,,1,,5668,N,50588,,1,,A,Area under curve was determine after peroral administration at 5 mpk in dog,,Intermediate
5253,Canis lupus familiaris,,,9615.0,,,1,,5006,N,50588,,1,,A,Area under curve was determined,,Intermediate
5254,Canis lupus familiaris,,,9615.0,,,1,,5006,N,50588,,1,,A,Area under curve in dogs,,Intermediate
5255,Canis lupus familiaris,,,9615.0,,,1,,3771,N,50588,,1,,A,Area under curve in dogs at 10 mg/kg dose fo oral administration,,Intermediate
5256,Canis lupus familiaris,,,9615.0,,,1,,3771,N,50588,,1,,A,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,Intermediate
5257,Canis lupus familiaris,,,9615.0,,,1,,3771,N,50588,,1,,A,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,Intermediate
5258,Canis lupus familiaris,,,9615.0,,,1,,1916,N,50588,,1,,A,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate
5259,Canis lupus familiaris,,,9615.0,,,1,,5302,N,50588,,1,,A,Area under curve value in dog at a dose of 5 mg/kg,,Intermediate
5260,Canis lupus familiaris,,,9615.0,,,1,,5600,N,50588,,1,,A,Area under curve was determined after 0.1 mg/kg iv administration in dog,,Intermediate
5261,Canis lupus familiaris,,,9615.0,,,1,,5600,N,50588,,1,,A,Area under curve was determined after 0.3 mg/kg po administration in dog,,Intermediate
5262,Canis lupus familiaris,,,9615.0,,,1,,17764,N,50588,,1,,A,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,Intermediate
5263,Canis lupus familiaris,,,9615.0,,,1,,4368,N,50588,,1,,A,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,Intermediate
5264,Homo sapiens,,,9606.0,,,1,,5318,U,22224,,0,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,Autocuration
5265,Homo sapiens,,,9606.0,,,1,,5318,U,22224,,0,,A,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Autocuration
5266,Homo sapiens,,,9606.0,,,1,,5318,U,22224,,0,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,Autocuration
5267,Homo sapiens,,,9606.0,,,1,,5318,U,22224,,0,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,Autocuration
5268,Homo sapiens,,178.0,9606.0,,,1,,14518,U,22224,,0,Blood,A,Time taken to reduce 50% of the concentration of compound in blood plasma,,Autocuration
5269,Homo sapiens,,1969.0,9606.0,,,1,,2209,U,22224,,0,Plasma,A,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,Autocuration
5270,Homo sapiens,,1969.0,9606.0,,,1,,6787,U,22224,,0,Plasma,A,Half life in human plasma,,Autocuration
5271,Homo sapiens,,1969.0,9606.0,,,1,,4898,U,22224,,0,Plasma,A,Half life in human plasma was reported,,Autocuration
5272,Homo sapiens,,1977.0,9606.0,,,1,,6072,U,22224,,0,Serum,A,Half life in human serum,,Autocuration
5273,Homo sapiens,,1969.0,9606.0,,,1,,16907,U,22224,,0,Plasma,A,Half life upon exposure to human plasma,,Autocuration
5274,Homo sapiens,,,9606.0,In vitro,,1,,5656,U,22224,,0,,A,t1/2 in human microsomes,Microsomes,Autocuration
5275,Homo sapiens,,1969.0,9606.0,,,1,,4755,U,22224,,0,Plasma,A,Half life period in 80% human plasma at 37 degree Centigrade,,Autocuration
5276,Homo sapiens,,14.0,9606.0,,,1,,17503,U,22224,,0,Zone of skin,A,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,Autocuration
5277,Homo sapiens,,1969.0,9606.0,In vitro,,1,,12357,U,22224,,0,Plasma,A,Half-life measured in in vitro Cathepsin B assay in human plasma,,Autocuration
5278,Homo sapiens,,,9606.0,,,1,,3076,U,22224,,0,,A,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,Autocuration
5279,Homo sapiens,,2107.0,9606.0,In vitro,,1,,6410,U,22224,,0,Liver,A,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Microsomes,Autocuration
5280,Homo sapiens,,1969.0,9606.0,,,1,,3741,U,22224,,0,Plasma,A,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,Autocuration
5281,Homo sapiens,,1969.0,9606.0,,,1,,3741,U,22224,,0,Plasma,A,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,Autocuration
5282,Homo sapiens,,1969.0,9606.0,,,1,,3741,U,22224,,0,Plasma,A,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,Autocuration
5283,Homo sapiens,,,9606.0,,,1,,1540,U,22224,,0,,A,Half-life in the CEM cell extracts,,Autocuration
5284,Homo sapiens,,1969.0,9606.0,,,1,,2905,U,22224,,0,Plasma,A,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,Autocuration
5285,Homo sapiens,,1969.0,9606.0,,,1,,2905,U,22224,,0,Plasma,A,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,Autocuration
5286,Homo sapiens,,,9606.0,,,1,,5523,U,22224,,0,,A,Half-life was determined,,Autocuration
5287,Homo sapiens,,178.0,9606.0,,,1,,1499,U,22224,,0,Blood,A,Half-life (human blood stability),,Autocuration
5288,Homo sapiens,,178.0,9606.0,,,1,,1499,U,22224,,0,Blood,A,Half-life (human blood stability); no data,,Autocuration
5289,Homo sapiens,,1969.0,9606.0,,,1,,17065,U,22224,,0,Plasma,A,Half-life in human plasma,,Autocuration
5290,Homo sapiens,,,9606.0,,,1,,6861,U,22224,,0,,A,CYP3A4 metabolism half-life (t1/2),,Autocuration
5291,Homo sapiens,,178.0,9606.0,,,1,,1499,U,22224,,0,Blood,A,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,Autocuration
5292,Homo sapiens,,1969.0,9606.0,In vitro,,1,,530,U,22224,,0,Plasma,A,In vitro half life in human plasma,,Autocuration
5293,Homo sapiens,,1969.0,9606.0,In vitro,,1,,1116,U,22224,,0,Plasma,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,Autocuration
5294,Homo sapiens,,1969.0,9606.0,In vitro,,1,,6695,U,22224,,0,Plasma,A,In vitro hydrolysis in human plasma,,Autocuration
5295,Homo sapiens,,1969.0,9606.0,In vitro,,1,,6695,U,22224,,0,Plasma,A,In vitro hydrolysis in human plasma; no data,,Autocuration
5296,Homo sapiens,,2107.0,9606.0,In vitro,,1,,10,U,22224,,0,Liver,A,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Microsomes,Autocuration
5297,Homo sapiens,,1969.0,9606.0,,,1,,993,U,22224,,0,Plasma,A,Plasma half life in human,,Autocuration
5298,Homo sapiens,,1969.0,9606.0,,,1,,15429,U,22224,,0,Plasma,A,Stability after incubation with human plasma (at 37 degree C),,Autocuration
5299,Homo sapiens,,1969.0,9606.0,,,1,,1675,U,22224,,0,Plasma,A,T1/2 was evaluated in human plasma,,Autocuration
5300,Homo sapiens,,1969.0,9606.0,,,1,,2209,U,22224,,0,Plasma,A,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,Autocuration
5301,Homo sapiens,,1969.0,9606.0,,,1,,2209,U,22224,,0,Plasma,A,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,Autocuration
5302,Homo sapiens,,,9606.0,,,1,,5318,U,22224,,0,,A,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Autocuration
5303,Homo sapiens,,,9606.0,In vitro,,1,,2412,U,22224,,0,,A,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,Autocuration
5304,Homo sapiens,,,9606.0,In vitro,,1,,2412,U,22224,,0,,A,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,Autocuration
5305,Homo sapiens,,1969.0,9606.0,,,1,,2906,U,22224,,0,Plasma,A,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,Autocuration
5306,Homo sapiens,,1969.0,9606.0,,,1,,2906,U,22224,,0,Plasma,A,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,Autocuration
5307,Homo sapiens,,,9606.0,,,1,,5495,U,22224,,0,,A,Time taken for 50% to be consumed by serum PON1 was determined,,Autocuration
5308,Homo sapiens,,,9606.0,,,1,,5495,U,22224,,0,,A,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,Autocuration
5309,Homo sapiens,,2107.0,9606.0,,,1,,4397,U,22224,,0,Liver,A,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,Autocuration
5310,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5311,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5312,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5313,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5314,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5315,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration
5316,Homo sapiens,,,9606.0,,,1,,6058,N,80640,786-0,1,,F,Compound tested for growth inhibition of renal cancer cell line 786-0,,Intermediate
5317,Homo sapiens,,,9606.0,,,1,,17708,N,80640,786-0,1,,F,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,Intermediate
5318,Homo sapiens,,,9606.0,,,1,,14017,N,80640,786-0,1,,F,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,Expert
5319,Homo sapiens,,,9606.0,,,1,,16818,N,80640,786-0,1,,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,Intermediate
5320,Homo sapiens,,,9606.0,,,1,,16818,N,80640,786-0,1,,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,Intermediate
5321,Homo sapiens,,,9606.0,,,1,,16818,N,80640,786-0,1,,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,Intermediate
5322,Homo sapiens,,,9606.0,,,1,,11970,N,80640,786-0,1,,F,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,Intermediate
5323,Homo sapiens,,,9606.0,,,1,,12400,N,80640,786-0,1,,F,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,Intermediate
5324,Homo sapiens,,,9606.0,,,1,,12888,N,80640,786-0,1,,F,Cytotoxic effect on renal cancer line 786-0,,Expert
5325,Homo sapiens,,,9606.0,,,1,,15300,N,80640,786-0,1,,F,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,Intermediate
5326,Homo sapiens,,,9606.0,,,1,,14769,N,80640,786-0,1,,F,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Intermediate
5327,Homo sapiens,,,9606.0,,,1,,15895,N,80640,786-0,1,,F,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,Intermediate
5328,Homo sapiens,,,9606.0,,,1,,17376,N,80640,786-0,1,,F,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,Intermediate
5329,Homo sapiens,,,9606.0,,,1,,14882,N,80640,786-0,1,,F,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Intermediate
5330,Homo sapiens,,,9606.0,,,1,,14882,N,80640,786-0,1,,F,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,Intermediate
5331,Homo sapiens,,,9606.0,,,1,,15176,N,80640,786-0,1,,F,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,Intermediate
5332,Homo sapiens,,,9606.0,,,1,,12696,N,80640,786-0,1,,F,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Intermediate
5333,Homo sapiens,,,9606.0,,,1,,2496,N,80640,786-0,1,,F,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,Intermediate
5334,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,Intermediate
5335,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,Intermediate
5336,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,Intermediate
5337,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,Intermediate
5338,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,Intermediate
5339,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,Intermediate
5340,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,Intermediate
5341,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,Intermediate
5342,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,Intermediate
5343,Homo sapiens,,,9606.0,,,1,,11831,N,80641,791T cell line,1,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,Intermediate
5344,Homo sapiens,,,9606.0,,,1,,12782,N,80640,786-0,1,,F,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,Intermediate
5345,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,Intermediate
5346,Homo sapiens,,,9606.0,,,1,,15313,N,80433,RPMI-8226,1,,F,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,Expert
5347,Homo sapiens,,,9606.0,,,1,,15313,N,80433,RPMI-8226,1,,F,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,Expert
5348,Homo sapiens,,,9606.0,,,1,,11544,N,80433,RPMI-8226,1,,F,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,Intermediate
5349,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Intermediate
5350,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Intermediate
5351,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Intermediate
5352,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Intermediate
5353,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Intermediate
5354,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate
5355,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate
5356,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Intermediate
5357,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Intermediate
5358,Homo sapiens,,,9606.0,,,1,,14769,N,80021,A498,1,,F,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Intermediate
5359,Homo sapiens,,,9606.0,,,1,,15354,N,80021,A498,1,,F,Compound was tested for the growth inhibition of A498 renal tumor cell line,,Intermediate
5360,Homo sapiens,,,9606.0,,,1,,17445,N,80021,A498,1,,F,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,Intermediate
5361,Homo sapiens,,,9606.0,,,1,,4337,N,80021,A498,1,,F,In vitro inhibitory concentration against renal cancer cell line A498,,Intermediate
5362,Homo sapiens,,,9606.0,,,1,,15277,N,80021,A498,1,,F,Cytotoxicity against A 498 tumor cell line,,Intermediate
5363,Homo sapiens,,,9606.0,,,1,,4812,N,80021,A498,1,,F,In vitro antitumor activity against A498 human cancer cell line,,Intermediate
5364,Homo sapiens,,,9606.0,,,1,,4812,N,80021,A498,1,,F,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,Intermediate
5365,Homo sapiens,,,9606.0,,,1,,4995,N,80021,A498,1,,F,Inhibitory dose required against A498 human tumor cell lines,,Intermediate
5366,Homo sapiens,,,9606.0,,,1,,5847,N,80021,A498,1,,F,Anticancer activity against one renal cancer (A498 cell line),,Intermediate
5367,Homo sapiens,,,9606.0,,,1,,6557,N,80021,A498,1,,F,In vitro cytotoxicity against melanoma A498 cell line,,Intermediate
5368,Homo sapiens,,,9606.0,,,1,,2597,N,80021,A498,1,,F,Compound was tested for growth inhibitory activity against A498 cell line,,Intermediate
5369,Homo sapiens,,,9606.0,,,1,,6058,N,80021,A498,1,,F,Compound tested for growth inhibition of renal cancer cell line A498,,Intermediate
5370,Homo sapiens,,,9606.0,,,1,,17708,N,80021,A498,1,,F,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,Intermediate
5371,Homo sapiens,,,9606.0,,,1,,15176,N,80021,A498,1,,F,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,Intermediate
5372,Homo sapiens,,,9606.0,,,1,,15300,N,80021,A498,1,,F,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,Intermediate
5373,Homo sapiens,,,9606.0,,,1,,11970,N,80021,A498,1,,F,Tested for cytotoxicity against A498 cell lines in renal cancer,,Intermediate
5374,Homo sapiens,,,9606.0,,,1,,12400,N,80021,A498,1,,F,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,Intermediate
5375,Homo sapiens,,,9606.0,,,1,,12888,N,80021,A498,1,,F,Cytotoxic effect on renal cancer lines A498,,Expert
5376,Homo sapiens,,,9606.0,,,1,,3030,N,80021,A498,1,,F,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,Intermediate
5377,Homo sapiens,,,9606.0,,,1,,14769,N,80021,A498,1,,F,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Intermediate
5378,Homo sapiens,,,9606.0,,,1,,17376,N,80021,A498,1,,F,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,Intermediate
5379,Homo sapiens,,,9606.0,,,1,,16558,N,80021,A498,1,,F,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,Intermediate
5380,Homo sapiens,,,9606.0,,,1,,5194,N,80021,A498,1,,F,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,Intermediate
5381,Homo sapiens,,,9606.0,,,1,,10708,N,80021,A498,1,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,Intermediate
5382,Homo sapiens,,,9606.0,,,1,,16880,N,80682,A549,1,,F,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,Expert
5383,Homo sapiens,,,9606.0,,,1,,10196,N,80682,A549,1,,F,Antitumor activity against A549 human lung carcinoma cell line,,Intermediate
5384,Homo sapiens,,,9606.0,,,1,,10196,N,80682,A549,1,,F,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,Intermediate
5385,Homo sapiens,,,9606.0,,,1,,10196,N,80682,A549,1,,F,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,Intermediate
5386,Homo sapiens,,,9606.0,,,1,,12083,N,80682,A549,1,,F,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,Intermediate
5387,Homo sapiens,,,9606.0,,,1,,16464,N,80682,A549,1,,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,Expert
5388,Homo sapiens,,,9606.0,,,1,,16464,N,80682,A549,1,,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate
5389,Homo sapiens,,,9606.0,,,1,,16470,N,80682,A549,1,,F,In vitro cytotoxic activity against human lung A549 cell line,,Expert
5390,Homo sapiens,,,9606.0,,,1,,16470,N,80682,A549,1,,F,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,Intermediate
5391,Homo sapiens,,,9606.0,,,1,,16470,N,80682,A549,1,,F,In vitro cytotoxic activity against human lung A549 cell line),,Intermediate
5392,Homo sapiens,,,9606.0,,,1,,16470,N,80682,A549,1,,F,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,Intermediate
5393,Homo sapiens,,,9606.0,,,1,,16582,N,80682,A549,1,,F,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,Expert
5394,Homo sapiens,,,9606.0,,,1,,15935,N,80682,A549,1,,F,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,Intermediate
5395,Homo sapiens,,,9606.0,,,1,,15935,N,80682,A549,1,,F,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,Intermediate
5396,Homo sapiens,,,9606.0,,,1,,16597,N,80682,A549,1,,F,Inhibition of A549 human lung carcinoma cell proliferation,,Expert
5397,Homo sapiens,,,9606.0,,,1,,17376,N,80682,A549,1,,F,Inhibitory activity against A549 lung adenocarcinoma cell line,,Intermediate
5398,Homo sapiens,,,9606.0,,,1,,16496,N,80682,A549,1,,F,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,Intermediate
5399,Homo sapiens,,,9606.0,,,1,,16152,N,80682,A549,1,,F,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,Intermediate
5400,Homo sapiens,,,9606.0,,,1,,16152,N,80682,A549,1,,F,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,Intermediate
5401,Homo sapiens,,,9606.0,,,1,,16464,N,80682,A549,1,,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate
5402,Homo sapiens,,,9606.0,,,1,,2288,N,80682,A549,1,,F,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,Intermediate
5403,Homo sapiens,,,9606.0,,,1,,17350,N,80682,A549,1,,F,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Intermediate
5404,Homo sapiens,,,9606.0,,,1,,4090,N,80682,A549,1,,F,Inhibition of A549 cancer cell proliferation,,Expert
5405,Homo sapiens,,,9606.0,,,1,,4090,N,80682,A549,1,,F,Inhibition of A549 cancer cell proliferation (Not tested),,Expert
5406,Homo sapiens,,,9606.0,,,1,,17350,N,80682,A549,1,,F,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Intermediate
5407,Homo sapiens,,,9606.0,,,1,,4197,N,80682,A549,1,,F,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,Intermediate
5408,Homo sapiens,,,9606.0,,,1,,17072,N,80682,A549,1,,F,Antiproliferative potency determined as inhibitory concentration against A549 cells,,Intermediate
5409,Homo sapiens,,,9606.0,,,1,,17072,N,80682,A549,1,,F,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,Intermediate
5410,Homo sapiens,,,9606.0,,,1,,5194,N,80682,A549,1,,F,Cytotoxicity against Renal cell lines A549 was determined,,Intermediate
5411,Canis lupus familiaris,,,9615.0,,,1,,4257,N,50588,,1,,A,Area under curve was determined in dog after a 3 mg/kg of oral dose,,Intermediate
5412,Canis lupus familiaris,,,9615.0,,,1,,6123,N,50588,,1,,A,Area under curve was determined in dog after oral administration at 1 mg/kg,,Intermediate
5413,Canis lupus familiaris,,,9615.0,,,1,,1337,N,50588,,1,,A,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
5414,Canis lupus familiaris,,,9615.0,,,1,,1337,N,50588,,1,,A,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
5415,Canis lupus familiaris,,,9615.0,,,1,,8833,N,50588,,1,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,Intermediate
5416,Canis lupus familiaris,,,9615.0,,,1,,8833,N,50588,,1,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,Intermediate
5417,Canis lupus familiaris,,,9615.0,,,1,,8833,N,50588,,1,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,Intermediate
5418,Canis lupus familiaris,,,9615.0,,,1,,8833,N,50588,,1,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,Intermediate
5419,Canis lupus familiaris,,1969.0,9615.0,,,1,,17657,N,50588,,1,Plasma,A,Area under plasma concentration time curve in dog upon oral administration,,Intermediate
5420,Canis lupus familiaris,,1969.0,9615.0,,,1,,17650,N,50588,,1,Plasma,A,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,Intermediate
5421,Canis lupus familiaris,,,9615.0,,,1,,1977,N,50588,,1,,A,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,Intermediate
5422,Canis lupus familiaris,,,9615.0,,,1,,1977,N,50588,,1,,A,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,Intermediate
5423,Canis lupus familiaris,,,9615.0,,,1,,3132,N,50588,,1,,A,Area under the curve for the compound was obtained when tested in dog,,Intermediate
5424,Canis lupus familiaris,,,9615.0,,,1,,5473,N,50588,,1,,A,Area under the curve at a dose of 1 mg/kg,,Intermediate
5425,Canis lupus familiaris,,,9615.0,,,1,,5474,N,50588,,1,,A,Area under the curve at a dose of 1 mg/kg (oral),,Intermediate
5426,Canis lupus familiaris,,,9615.0,,,1,,5474,N,50588,,1,,A,Area under the curve at i.v. dose of 0.2 mg/kg,,Intermediate
5427,Canis lupus familiaris,,,9615.0,,,1,,6062,N,50588,,1,,A,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,Intermediate
5428,Canis lupus familiaris,,,9615.0,,,1,,4709,N,50588,,1,,A,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,Intermediate
5429,Canis lupus familiaris,,,9615.0,,,1,,2652,N,50588,,1,,A,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,Intermediate
5430,Canis lupus familiaris,,,9615.0,,,1,,2652,N,50588,,1,,A,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,Intermediate
5431,Canis lupus familiaris,,,9615.0,,,1,,2877,N,50588,,1,,A,Compound was evaluated for area under the curve in dog blood.,,Intermediate
5432,Canis lupus familiaris,,,9615.0,,,1,,5444,N,50588,,1,,A,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,Intermediate
5433,Canis lupus familiaris,,1969.0,9615.0,,,1,,5130,N,50588,,1,Plasma,A,AUC in dog after oral dose (1 mg/kg),,Intermediate
5434,Canis lupus familiaris,,,9615.0,,,1,,6265,N,50588,,1,,A,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,Intermediate
5435,Canis lupus familiaris,,,9615.0,,,1,,4657,N,50588,,1,,A,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,Intermediate
5436,Canis lupus familiaris,,,9615.0,,,1,,16367,N,50588,,1,,A,Pharmacokinetic parameter AUC after intravenous administration to dogs,,Intermediate
5437,Canis lupus familiaris,,,9615.0,,,1,,16367,N,50588,,1,,A,Pharmacokinetic parameter AUC after oral administration to dogs,,Intermediate
5438,Canis lupus familiaris,,,9615.0,,,1,,9579,N,50588,,1,,A,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,Intermediate
5439,Canis lupus familiaris,,,9615.0,,,1,,9579,N,50588,,1,,A,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,Intermediate
5440,Canis lupus familiaris,,,9615.0,,,1,,5983,N,50588,,1,,A,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,Intermediate
5441,Canis lupus familiaris,,,9615.0,,,1,,6241,N,50588,,1,,A,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,Intermediate
5442,Canis lupus familiaris,,,9615.0,,,1,,5313,N,50588,,1,,A,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,Intermediate
5443,Canis lupus familiaris,,,9615.0,,,1,,5313,N,50588,,1,,A,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,Intermediate
5444,Canis lupus familiaris,,,9615.0,,,1,,6642,N,50588,,1,,A,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate
5445,Canis lupus familiaris,,,9615.0,,,1,,6642,N,50588,,1,,A,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate
5446,Canis lupus familiaris,,,9615.0,,,1,,6641,N,50588,,1,,A,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Intermediate
5447,Canis lupus familiaris,,,9615.0,,,1,,6642,N,50588,,1,,A,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Intermediate
5448,Canis lupus familiaris,,,9615.0,,,1,,17791,N,50588,,1,,A,Compound was evaluated for oral bioavailability in dog; 90-100,,Intermediate
5449,Canis lupus familiaris,,,9615.0,,,1,,17655,N,50588,,1,,A,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,Intermediate
5450,Canis lupus familiaris,,,9615.0,,,1,,17655,N,50588,,1,,A,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,Intermediate
5451,Canis lupus familiaris,,,9615.0,,,1,,6596,N,50588,,1,,A,PAPP (membrane permeability) in dog kidney cell monolayer assay,,Intermediate
5452,Canis lupus familiaris,,,9615.0,,,1,,3880,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5453,Canis lupus familiaris,,,9615.0,,,1,,16367,N,50588,,1,,A,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,Intermediate
5454,Canis lupus familiaris,,1969.0,9615.0,,,1,,17409,N,50588,,1,Plasma,A,Plasma protein binding towards dog plasma at 10 uM,,Intermediate
5455,Canis lupus familiaris,,1969.0,9615.0,,,1,,17409,N,50588,,1,Plasma,A,Plasma protein binding towards dog plasma at 100 uM,,Intermediate
5456,Canis lupus familiaris,,,9615.0,In vivo,,1,,2959,N,50588,,1,,A,Bioavailability in dog (dose 4 mg/kg p.o.),,Intermediate
5457,Canis lupus familiaris,,,9615.0,In vivo,,1,,13501,N,50588,,1,,A,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,Intermediate
5458,Canis lupus familiaris,,,9615.0,In vivo,,1,,4527,N,50588,,1,,A,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate
5459,Canis lupus familiaris,,,9615.0,In vivo,,1,,15145,N,50588,,1,,A,Bioavailability in dogs,,Intermediate
5460,Canis lupus familiaris,,,9615.0,In vivo,,1,,4219,N,50588,,1,,A,Bioavailability,,Intermediate
5461,Canis lupus familiaris,,,9615.0,In vivo,,1,,17538,N,50588,,1,,A,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate
5462,Canis lupus familiaris,,,9615.0,In vivo,,1,,17538,N,50588,,1,,A,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,Intermediate
5463,Canis lupus familiaris,,,9615.0,In vivo,,1,,1466,N,50588,,1,,A,Bioavailability in dog (dose 10.0 mg/kg p.o.),,Intermediate
5464,Canis lupus familiaris,,,9615.0,In vivo,,1,,17650,N,50588,,1,,A,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,Intermediate
5465,Canis lupus familiaris,,,9615.0,In vivo,,1,,3132,N,50588,,1,,A,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,Intermediate
5466,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5467,Mus sp.,,2107.0,10095.0,,,1,,2413,U,22224,,0,Liver,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5468,Mus sp.,,2107.0,10095.0,,,1,,2413,U,22224,,0,Liver,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration
5469,Mus sp.,,2107.0,10095.0,,,1,,2413,U,22224,,0,Liver,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5470,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5471,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5472,Mus sp.,,2385.0,10095.0,,,1,,2413,U,22224,,0,Muscle tissue,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5473,Mus sp.,,2385.0,10095.0,,,1,,2413,U,22224,,0,Muscle tissue,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration
5474,Mus sp.,,2385.0,10095.0,,,1,,2413,U,22224,,0,Muscle tissue,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5475,Mus sp.,,2106.0,10095.0,,,1,,2413,U,22224,,0,Spleen,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5476,Mus sp.,,2106.0,10095.0,,,1,,2413,U,22224,,0,Spleen,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5477,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration
5478,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration
5479,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5480,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration
5481,Mus sp.,,,10095.0,,,1,,2413,U,22224,,0,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration
5482,Cercopithecidae,,,9527.0,,,1,,17827,U,22224,,0,,A,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Autocuration
5483,Cercopithecidae,,2037.0,9527.0,,,1,,17827,U,22224,,0,Cerebellum,A,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,Autocuration
5484,Cercopithecidae,,1870.0,9527.0,,,1,,17827,U,22224,,0,Frontal cortex,A,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,Autocuration
5485,Cercopithecidae,,,9527.0,,,1,,17827,U,22224,,0,,A,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,Autocuration
5486,Cercopithecidae,,2435.0,9527.0,,,1,,17827,U,22224,,0,Striatum,A,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,Autocuration
5487,Cercopithecidae,,,9527.0,,,1,,17827,U,22224,,0,,A,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Autocuration
5488,Cercopithecidae,,2037.0,9527.0,,,1,,17827,U,22224,,0,Cerebellum,A,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,Autocuration
5489,Cercopithecidae,,1870.0,9527.0,,,1,,17827,U,22224,,0,Frontal cortex,A,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,Autocuration
5490,Cercopithecidae,,,9527.0,,,1,,17827,U,22224,,0,,A,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,Autocuration
5491,Cercopithecidae,,2435.0,9527.0,,,1,,17827,U,22224,,0,Striatum,A,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,Autocuration
5492,Cercopithecidae,,,9527.0,,,1,,17791,U,22224,,0,,A,Compound was evaluated for oral bioavailability in rats,,Autocuration
5493,Cercopithecidae,,1969.0,9527.0,In vivo,,1,,17667,U,22224,,0,Plasma,A,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,Autocuration
5494,Cercopithecidae,,,9527.0,,,1,,17791,U,22224,,0,,A,Half life period was evaluated in monkey,,Autocuration
5495,Cercopithecidae,,,9527.0,In vivo,,1,,110,U,22224,,0,,A,Half-life in rhesus monkeys by intravenous administration of dose,,Autocuration
5496,Mus musculus,,1969.0,10090.0,,,1,,5781,N,50594,,1,Plasma,A,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,Intermediate
5497,Mus musculus,,1969.0,10090.0,,,1,,17734,N,50594,,1,Plasma,A,AUC after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
5498,Mus musculus,,1969.0,10090.0,,,1,,17718,N,50594,,1,Plasma,A,AUC value was determined after oral administration,,Intermediate
5499,Mus musculus,,,10090.0,,,1,,4573,N,50594,,1,,A,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,Intermediate
5500,Mus musculus,,,10090.0,,,1,,3277,N,50594,,1,,A,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Intermediate
5501,Mus musculus,,,10090.0,,,1,,2862,N,50594,,1,,A,Area under curve by ioral administration in mouse,,Intermediate
5502,Mus musculus,,,10090.0,,,1,,2862,N,50594,,1,,A,Area under curve by iv administration in mouse,,Intermediate
5503,Mus musculus,,,10090.0,,,1,,5951,N,50594,,1,,A,Area under curve at 0-8 hr in IRC mice after peroral administration,,Intermediate
5504,Mus musculus,,,10090.0,,,1,,17729,N,50594,,1,,A,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,Intermediate
5505,Mus musculus,,,10090.0,,,1,,17728,N,50594,,1,,A,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,Intermediate
5506,Mus musculus,,,10090.0,,,1,,17728,N,50594,,1,,A,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,Intermediate
5507,Mus musculus,,,10090.0,,,1,,17729,N,50594,,1,,A,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,Intermediate
5508,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Intermediate
5509,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Intermediate
5510,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Intermediate
5511,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Intermediate
5512,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Intermediate
5513,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate
5514,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Intermediate
5515,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Intermediate
5516,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Intermediate
5517,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Intermediate
5518,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Intermediate
5519,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Intermediate
5520,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Intermediate
5521,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate
5522,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Intermediate
5523,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Intermediate
5524,Homo sapiens,,,9606.0,,,1,,9424,N,80433,RPMI-8226,1,,F,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,Expert
5525,Homo sapiens,,,9606.0,,,1,,11544,N,80433,RPMI-8226,1,,F,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,Intermediate
5526,Homo sapiens,,,9606.0,,,1,,17378,N,80433,RPMI-8226,1,,F,Cytotoxicity of compound against 8226/DOX1V cells,,Intermediate
5527,Homo sapiens,,,9606.0,,,1,,17378,N,80433,RPMI-8226,1,,F,Cytotoxicity of compound against 8226/S cells,,Intermediate
5528,Homo sapiens,,,9606.0,,,1,,17079,N,80433,RPMI-8226,1,,F,Inhibitory concentration against 8226 myeloma cancer cell line,,Intermediate
5529,Homo sapiens,,,9606.0,,,1,,17079,N,80433,RPMI-8226,1,,F,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,Intermediate
5530,Homo sapiens,,,9606.0,,,1,,13466,N,80647,833K,1,,F,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,Intermediate
5531,Homo sapiens,,,9606.0,,,1,,13466,N,80647,833K,1,,F,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,Intermediate
5532,Homo sapiens,,,9606.0,,,1,,2392,N,80647,833K,1,,F,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,Expert
5533,Homo sapiens,,,9606.0,,,1,,2392,N,80647,833K,1,,F,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,Intermediate
5534,,,,,,,1,,6608,U,22226,,0,,B,Inhibitory activity against caspase-1,,Autocuration
5535,Enterococcus faecalis,,,1351.0,,,1,,10199,H,45,,8,,B,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,Autocuration
5536,Homo sapiens,,,9606.0,,,1,,17749,N,80648,8701-BC,1,,F,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,Intermediate
5537,Homo sapiens,,,9606.0,,,1,,17749,N,80648,8701-BC,1,,F,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,Intermediate
5538,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,Intermediate
5539,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,Intermediate
5540,,,,,,,1,,1229,U,22226,,0,,F,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,Intermediate
5541,,,,,,,1,,6390,U,22226,,0,,B,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,Autocuration
5542,Streptococcus pyogenes,,,1314.0,,,1,,16219,U,22226,,0,,F,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Autocuration
5543,Streptococcus pyogenes,,,1314.0,,,1,,16219,U,22226,,0,,F,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Autocuration
5544,,,,,,,1,,17043,H,11922,,8,,B,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,Autocuration
5545,Homo sapiens,,,9606.0,,,1,,6929,N,81115,KB ,1,,F,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Intermediate
5546,Homo sapiens,,,9606.0,,,1,,6929,N,81115,KB ,1,,A,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Intermediate
5547,Homo sapiens,,,9606.0,,,1,,7083,U,22226,,0,,F,In vitro cytotoxicity of compound was tested against 9KB cells.,,Autocuration
5548,Rattus norvegicus,,,10116.0,,,1,,12446,N,80653,9L,1,,F,Cytotoxic concentration against 9L cells was determined on day 3,,Intermediate
5549,Rattus norvegicus,,,10116.0,,,1,,15345,N,80653,9L,1,,F,Tested in vitro for anticancer activity against 9L cells,,Expert
5550,Rattus norvegicus,,,10116.0,,,1,,15345,N,80653,9L,1,,F,Tested in vitro for anticancer activity against 9L cells; Not determined,,Expert
5551,Homo sapiens,,,9606.0,,,1,,6301,N,80682,A549,1,,F,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,Intermediate
5552,Homo sapiens,,,9606.0,,,1,,4833,N,80682,A549,1,,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,Intermediate
5553,Homo sapiens,,,9606.0,,,1,,4833,N,80682,A549,1,,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,Intermediate
5554,Homo sapiens,,,9606.0,,,1,,4833,N,80682,A549,1,,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,Intermediate
5555,Homo sapiens,,,9606.0,,,1,,13330,N,80682,A549,1,,F,Cytotoxicity against human lung carcinoma A549 cell line,,Expert
5556,Homo sapiens,,,9606.0,,,1,,17517,D,25,A549,9,,F,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,Expert
5557,Homo sapiens,,,9606.0,,,1,,17517,D,25,A549,9,,F,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,Expert
5558,Homo sapiens,,,9606.0,,,1,,14425,N,80682,A549,1,,F,"In vitro growth inhibition of A549, lung carcinoma",,Intermediate
5559,Homo sapiens,,,9606.0,,,1,,14425,N,80682,A549,1,,F,"In vitro growth inhibition of A549, lung carcinoma.",,Intermediate
5560,Homo sapiens,,,9606.0,,,1,,5228,N,80682,A549,1,,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Expert
5561,Homo sapiens,,,9606.0,,,1,,5351,N,80682,A549,1,,F,Cytotoxic activity against human lung cancer A549 cell line was determined,,Intermediate
5562,Homo sapiens,,,9606.0,,,1,,12198,N,80682,A549,1,,F,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,Expert
5563,Homo sapiens,,,9606.0,,,1,,13891,N,80682,A549,1,,F,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,Intermediate
5564,Homo sapiens,,,9606.0,,,1,,5677,N,80682,A549,1,,F,Cytotoxicity in A549 (human carcinoma) cell line.,,Expert
5565,Homo sapiens,,,9606.0,,,1,,13788,N,80682,A549,1,,F,Cytotoxicity on lung carcinoma (A-549) cell line,,Intermediate
5566,Homo sapiens,,,9606.0,,,1,,13384,N,80682,A549,1,,F,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,Expert
5567,Homo sapiens,,,9606.0,,,1,,6726,N,80682,A549,1,,F,Effective dose of compound against replication of A549 cell line was evaluated,,Intermediate
5568,Homo sapiens,,,9606.0,,,1,,3455,N,80682,A549,1,,F,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,Expert
5569,Homo sapiens,,,9606.0,,,1,,5726,N,80682,A549,1,,F,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,Intermediate
5570,Homo sapiens,,,9606.0,,,1,,5726,N,80682,A549,1,,F,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,Intermediate
5571,Homo sapiens,,,9606.0,,,1,,3936,N,80682,A549,1,,F,The compound was evaluated for antiproliferative activity against A549 cell line,,Intermediate
5572,Homo sapiens,,,9606.0,,,1,,14991,N,80682,A549,1,,F,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,Intermediate
5573,Homo sapiens,,,9606.0,,,1,,5243,N,80682,A549,1,,F,Concentration required for growth inhibition of human lung carcinoma cell line A549,,Intermediate
5574,Homo sapiens,,,9606.0,,,1,,12858,N,80682,A549,1,,F,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,Intermediate
5575,Homo sapiens,,,9606.0,,,1,,6776,N,80682,A549,1,,F,Growth inhibition against A549 cell line was evaluated,,Intermediate
5576,Homo sapiens,,,9606.0,,,1,,16558,N,80682,A549,1,,F,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,Intermediate
5577,Homo sapiens,,,9606.0,,,1,,4583,N,80682,A549,1,,F,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,Expert
5578,Homo sapiens,,,9606.0,,,1,,13514,N,80682,A549,1,,F,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,Intermediate
5579,Homo sapiens,,,9606.0,,,1,,15166,N,80682,A549,1,,F,Chemosensitivity against DT-diaphorase rich A549 cell lines,,Expert
5580,Homo sapiens,,,9606.0,,,1,,13873,N,80682,A549,1,,F,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,Intermediate
5581,Homo sapiens,,,9606.0,,,1,,6447,N,80682,A549,1,,F,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,Expert
5582,Homo sapiens,,,9606.0,,,1,,2068,N,80682,A549,1,,F,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,Intermediate
5583,Homo sapiens,,,9606.0,,,1,,1863,N,80682,A549,1,,F,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,Expert
5584,Homo sapiens,,,9606.0,,,1,,13873,N,80682,A549,1,,F,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,Intermediate
5585,Homo sapiens,,,9606.0,,,1,,13873,N,80682,A549,1,,F,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Intermediate
5586,Homo sapiens,,,9606.0,,,1,,13873,N,80682,A549,1,,F,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,Expert
5587,Homo sapiens,,,9606.0,,,1,,579,N,80682,A549,1,,F,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,Intermediate
5588,Homo sapiens,,,9606.0,,,1,,579,N,80682,A549,1,,F,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,Intermediate
5589,Homo sapiens,,,9606.0,,,1,,4584,N,80682,A549,1,,F,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,Intermediate
5590,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,Expert
5591,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Intermediate
5592,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Intermediate
5593,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,Intermediate
5594,Homo sapiens,,,9606.0,,,1,,14188,N,80682,A549,1,,F,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,Intermediate
5595,Homo sapiens,,,9606.0,,,1,,14188,N,80682,A549,1,,F,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,Intermediate
5596,Homo sapiens,,,9606.0,,,1,,15354,N,80682,A549,1,,F,Compound was tested for the growth inhibition of A549 lung tumor cell line,,Intermediate
5597,Homo sapiens,,,9606.0,,,1,,14253,N,80682,A549,1,,F,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,Expert
5598,Homo sapiens,,,9606.0,,,1,,13873,N,80682,A549,1,,F,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Intermediate
5599,Canis lupus familiaris,,,9615.0,In vivo,,1,,3043,N,50588,,1,,A,Oral bioavailability in dog (conscious),,Intermediate
5600,Canis lupus familiaris,,,9615.0,In vivo,,1,,3045,N,50588,,1,,A,Compound was evaluated for the oral bioavailability after oral administration in dog.,,Intermediate
5601,Canis lupus familiaris,,,9615.0,In vivo,,1,,3022,N,50588,,1,,A,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,Intermediate
5602,Canis lupus familiaris,,,9615.0,In vivo,,1,,4453,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5603,Canis lupus familiaris,,,9615.0,In vivo,,1,,1696,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5604,Canis lupus familiaris,,,9615.0,In vivo,,1,,5045,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5605,Canis lupus familiaris,,,9615.0,In vivo,,1,,5356,N,50588,,1,,A,Oral bioavailability in dog (fasted),,Intermediate
5606,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,Intermediate
5607,Canis lupus familiaris,,,9615.0,In vivo,,1,,6448,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5608,Canis lupus familiaris,,,9615.0,In vivo,,1,,1475,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5609,Canis lupus familiaris,,,9615.0,In vivo,,1,,3788,N,50588,,1,,A,Percent bioavailability in dog,,Intermediate
5610,Canis lupus familiaris,,,9615.0,In vivo,,1,,3639,N,50588,,1,,A,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,Intermediate
5611,Canis lupus familiaris,,,9615.0,In vivo,,1,,13397,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5612,Canis lupus familiaris,,,9615.0,In vivo,,1,,2137,N,50588,,1,,A,The compound was evaluated for bioavailability in dogs; 34-44,,Intermediate
5613,Canis lupus familiaris,,,9615.0,In vivo,,1,,2959,N,50588,,1,,A,Bioavailability in dog (dose 4 mg/kg p.o.),,Intermediate
5614,Canis lupus familiaris,,,9615.0,In vivo,,1,,6448,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
5615,Canis lupus familiaris,,,9615.0,,,1,,6084,N,50588,,1,,A,8 hour trough Blood level in dog was measured after administration of compound,,Intermediate
5616,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3639,N,50588,,1,Plasma,A,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,Intermediate
5617,Canis lupus familiaris,,,9615.0,,,1,,6316,N,50588,,1,,A,C24 after oral administration at 5 mg/kg,,Intermediate
5618,Canis lupus familiaris,,,9615.0,,,1,,5238,N,50588,,1,,A,Clearance after oral and iv dosing in dogs,,Intermediate
5619,Canis lupus familiaris,,1969.0,9615.0,,,1,,17796,N,50588,,1,Plasma,A,Clearance of the drug was measured in the plasma of dog,,Intermediate
5620,Canis lupus familiaris,,,9615.0,,,1,,2652,N,50588,,1,,A,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,Intermediate
5621,Canis lupus familiaris,,,9615.0,In vivo,,1,,5654,N,50588,,1,,A,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Intermediate
5622,Canis lupus familiaris,,,9615.0,In vivo,,1,,6621,N,50588,,1,,A,Clearance of compound was determined in dogs,,Intermediate
5623,Canis lupus familiaris,,,9615.0,In vivo,,1,,6505,N,50588,,1,,A,Clearance on i.v. administration of 2 mg/kg was measured in dog,,Intermediate
5624,Canis lupus familiaris,,,9615.0,In vivo,,1,,5802,N,50588,,1,,A,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate
5625,Canis lupus familiaris,,,9615.0,In vivo,,1,,17267,N,50588,,1,,A,Plasma clearance in dog was determined,,Intermediate
5626,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate
5627,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Plasma clearance in dog after administration of 0.25 mg/kg iv,,Intermediate
5628,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Plasma clearance in dog after administration of 1 mg/kg iv,,Intermediate
5629,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Plasma clearance in dogs,,Intermediate
5630,Canis lupus familiaris,,,9615.0,In vivo,,1,,5542,N,50588,,1,,A,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,Intermediate
5631,Canis lupus familiaris,,,9615.0,In vivo,,1,,5199,N,50588,,1,,A,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,Intermediate
5632,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Plasma clearance after 15 mg/kg iv dose in Dogs,,Intermediate
5633,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Plasma clearance after 30 mg/kg po dose in Dogs,,Intermediate
5634,Canis lupus familiaris,,,9615.0,In vivo,,1,,16367,N,50588,,1,,A,Plasma administration to dogs,,Intermediate
5635,Canis lupus familiaris,,,9615.0,In vivo,,1,,5505,N,50588,,1,,A,Plasma clearance was determined,,Intermediate
5636,Canis lupus familiaris,,,9615.0,In vivo,,1,,6215,N,50588,,1,,A,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,Intermediate
5637,Canis lupus familiaris,,,9615.0,In vivo,,1,,1466,N,50588,,1,,A,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,Intermediate
5638,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5007,S,102164,,2,Liver,A,Intrinsic clearance in human liver microsomes,Microsomes,Intermediate
5639,Homo sapiens,,2107.0,9606.0,In vitro,,1,,5007,S,102164,,2,Liver,A,Intrinsic clearance in human liver microsomes,Microsomes,Intermediate
5640,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Intermediate
5641,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Intermediate
5642,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Clearance in dog (dose 1 mg/kg i.v.),,Intermediate
5643,Canis lupus familiaris,,,9615.0,In vivo,,1,,6221,N,50588,,1,,A,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,Intermediate
5644,Canis lupus familiaris,,,9615.0,In vivo,,1,,5007,N,50588,,1,,A,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate
5645,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Plasma clearance after peroral administration at 10 mpk in dog,,Intermediate
5646,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Plasma clearance after peroral administration at 5 mpk in dog,,Intermediate
5647,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Plasma clearance after peroral administration at 5 mg/kg in dog,,Intermediate
5648,Canis lupus familiaris,,,9615.0,In vivo,,1,,15660,N,50588,,1,,A,Plasma clearance was measured in dog,,Intermediate
5649,Canis lupus familiaris,,,9615.0,In vivo,,1,,15660,N,50588,,1,,A,Plasma clearance was measured in dog,,Intermediate
5650,Canis lupus familiaris,,,9615.0,In vivo,,1,,5983,N,50588,,1,,A,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,Intermediate
5651,Canis lupus familiaris,,,9615.0,In vivo,,1,,5600,N,50588,,1,,A,Total clearance was determined after 0.1 mg/kg iv administration in dog,,Intermediate
5652,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,Intermediate
5653,Canis lupus familiaris,,,9615.0,In vivo,,1,,6039,N,50588,,1,,A,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,Intermediate
5654,Canis lupus familiaris,,,9615.0,In vivo,,1,,6039,N,50588,,1,,A,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,Intermediate
5655,Canis lupus familiaris,,,9615.0,In vivo,,1,,6039,N,50588,,1,,A,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,Intermediate
5656,Canis lupus familiaris,,,9615.0,In vivo,,1,,4368,N,50588,,1,,A,Clearance by intravenous administration of 1.2 mg/kg in dog,,Intermediate
5657,Canis lupus familiaris,,,9615.0,In vivo,,1,,4305,N,50588,,1,,A,Clearance by iv administration in dogs at a dose of 1 mg/kg,,Intermediate
5658,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1918,N,50588,,1,Plasma,A,Clearance value was evaluated in dog plasma,,Intermediate
5659,Canis lupus familiaris,,,9615.0,In vivo,,1,,6005,N,50588,,1,,A,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,Intermediate
5660,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,4839,N,50588,,1,Plasma,A,Compound was tested for plasma clearance in dog,,Intermediate
5661,Canis lupus familiaris,,,9615.0,In vivo,,1,,4239,N,50588,,1,,A,Pharmacokinetic property (Plasma clearance) was measured in dog,,Intermediate
5662,Mus musculus,,,10090.0,,,1,,17729,N,50594,,1,,A,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,Intermediate
5663,Mus musculus,,,10090.0,,,1,,17728,N,50594,,1,,A,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,Intermediate
5664,Mus musculus,,,10090.0,,,1,,5302,N,50594,,1,,A,Area under curve value in mouse at a dose of 10 mg/kg,,Intermediate
5665,Mus musculus,,,10090.0,,,1,,5506,N,50594,,1,,A,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,Intermediate
5666,Mus musculus,,,10090.0,,,1,,5506,N,50594,,1,,A,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,Intermediate
5667,Mus musculus,,,10090.0,,,1,,17764,N,50594,,1,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Intermediate
5668,Mus musculus,,,10090.0,,,1,,17764,N,50594,,1,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Intermediate
5669,Mus musculus,,,10090.0,,,1,,17764,N,50594,,1,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Intermediate
5670,Mus musculus,,,10090.0,,,1,,17764,N,50594,,1,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Intermediate
5671,Mus musculus,,,10090.0,,,1,,17764,N,50594,,1,,A,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,Intermediate
5672,Mus musculus,,,10090.0,,,1,,17753,N,50594,,1,,A,Area under curve was determined for the compound at 24 mg/Kg,,Intermediate
5673,Mus musculus,,,10090.0,,,1,,17753,N,50594,,1,,A,Area under curve was determined for the compound at 40 mg/Kg,,Intermediate
5674,Mus musculus,,,10090.0,,,1,,17753,N,50594,,1,,A,Area under curve was determined for the compound at 5 mg/Kg,,Intermediate
5675,Mus musculus,,,10090.0,,,1,,3132,N,50594,,1,,A,Area under the curve for the compound is obtained at dose 25 mg/kg,,Intermediate
5676,Mus musculus,,,10090.0,,,1,,3132,N,50594,,1,,A,Area under the curve for the compound was obtained when tested in mouse,,Intermediate
5677,Mus musculus,,,10090.0,,,1,,17837,N,50594,,1,,A,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,Intermediate
5678,Mus musculus,,,10090.0,,,1,,17837,N,50594,,1,,A,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,Intermediate
5679,Mus musculus,,,10090.0,,,1,,6062,N,50594,,1,,A,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,Intermediate
5680,Mus musculus,,,10090.0,,,1,,4066,N,50594,,1,,A,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate
5681,Mus musculus,,,10090.0,,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Intermediate
5682,Mus musculus,,,10090.0,,,1,,14239,N,50594,,1,,A,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,Intermediate
5683,Mus musculus,,,10090.0,,,1,,14239,N,50594,,1,,A,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,Intermediate
5684,Mus musculus,,,10090.0,,,1,,4890,N,50594,,1,,A,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,Intermediate
5685,Mus musculus,,,10090.0,,,1,,429,N,50594,,1,,A,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,Intermediate
5686,Mus musculus,,,10090.0,,,1,,429,N,50594,,1,,A,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,Intermediate
5687,Mus musculus,,,10090.0,,,1,,5969,N,50594,,1,,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,Intermediate
5688,Mus musculus,,,10090.0,,,1,,5969,N,50594,,1,,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,Intermediate
5689,Mus musculus,,,10090.0,,,1,,5969,N,50594,,1,,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Intermediate
5690,Mus musculus,,,10090.0,,,1,,6091,N,50594,,1,,A,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,Intermediate
5691,Mus musculus,,,10090.0,,,1,,6091,N,50594,,1,,A,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,Intermediate
5692,Mus musculus,,,10090.0,,,1,,6091,N,50594,,1,,A,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,Intermediate
5693,Mus musculus,,,10090.0,,,1,,6091,N,50594,,1,,A,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,Intermediate
5694,Mus musculus,,,10090.0,,,1,,6178,N,50594,,1,,A,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,Intermediate
5695,Mus musculus,,,10090.0,,,1,,6178,N,50594,,1,,A,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,Intermediate
5696,Mus musculus,,,10090.0,,,1,,6619,N,50594,,1,,A,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Intermediate
5697,Mus musculus,,,10090.0,,,1,,6619,N,50594,,1,,A,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Intermediate
5698,Mus musculus,,,10090.0,,,1,,3760,N,50594,,1,,A,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,Intermediate
5699,Mus musculus,,,10090.0,,,1,,3760,N,50594,,1,,A,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,Intermediate
5700,Mus musculus,,,10090.0,,,1,,3760,N,50594,,1,,A,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,Intermediate
5701,Mus musculus,,,10090.0,,,1,,3760,N,50594,,1,,A,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,Intermediate
5702,Mus musculus,,,10090.0,,,1,,3192,N,50594,,1,,A,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,Intermediate
5703,Mus musculus,,,10090.0,,,1,,3192,N,50594,,1,,A,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,Intermediate
5704,Mus musculus,,,10090.0,,,1,,2675,N,50594,,1,,A,Area under the curve was evaluated in mice after intravenous administration,,Intermediate
5705,Mus musculus,,,10090.0,,,1,,2675,N,50594,,1,,A,Area under the curve was evaluated in mice after oral administration,,Intermediate
5706,Mus musculus,,1969.0,10090.0,,,1,,16597,N,50594,,1,Plasma,A,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
5707,Mus musculus,,1969.0,10090.0,,,1,,16597,N,50594,,1,Plasma,A,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate
5708,Mus musculus,,,10090.0,,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Intermediate
5709,Mus musculus,,,10090.0,,,1,,17734,N,50594,,1,,A,AUMC after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
5710,Mus musculus,,178.0,10090.0,In vivo,,1,,7767,N,50594,,1,Blood,A,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,Intermediate
5711,,,,,,,1,,15345,N,80653,9L,1,,F,The compound was tested in vitro for anticancer activity against 9L cells,,Intermediate
5712,Rattus norvegicus,,,10116.0,,,1,,2181,U,22226,,0,,F,Anti proliferation activity determined; Weak effect,,Autocuration
5713,Rattus norvegicus,,,10116.0,,,1,,2181,U,22226,,0,,F,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,Autocuration
5714,Rattus norvegicus,,,10116.0,,,1,,2181,U,22226,,0,,F,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,Autocuration
5715,Rattus norvegicus,,,10116.0,,,1,,2181,U,22226,,0,,F,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,Autocuration
5716,Mus musculus,,,10090.0,,,1,,10486,U,22226,,0,,F,The cytotoxic activity was in vitro tested by 9PS assay method,,Autocuration
5717,Mus musculus,,,10090.0,,,1,,10486,U,22226,,0,,F,The cytotoxic activity was in vitro tested by 9PS assay method.,,Autocuration
5718,,,,,,,1,,15508,U,22224,,0,,A,Partition coefficient (logD6.5),,Autocuration
5719,Homo sapiens,,,9606.0,,,1,,5242,N,81034,A2780,1,,F,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,Expert
5720,Homo sapiens,,,9606.0,,,1,,16167,N,80018,A-375,1,,F,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,Intermediate
5721,Homo sapiens,,,9606.0,,,1,,4782,N,80852,A-431,1,,F,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,Expert
5722,Homo sapiens,,,9606.0,,,1,,16093,D,9,A-431,9,,F,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Expert
5723,Homo sapiens,,,9606.0,,,1,,2596,N,80021,A498,1,,F,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,Intermediate
5724,Homo sapiens,,,9606.0,,,1,,2596,N,80021,A498,1,,F,in vitro cytotoxicity against A 498 cancer cell line,,Intermediate
5725,Homo sapiens,,,9606.0,,,1,,3239,N,80021,A498,1,,F,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,Intermediate
5726,Homo sapiens,,,9606.0,,,1,,1847,N,80021,A498,1,,F,Cytotoxic activity against A 498 renal cancer cell lines.,,Intermediate
5727,Homo sapiens,,,9606.0,,,1,,10553,N,80021,A498,1,,F,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,Intermediate
5728,Staphylococcus aureus,,,1280.0,,,1,,16219,U,22226,,0,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Autocuration
5729,Staphylococcus aureus,,,1280.0,,,1,,16219,U,22226,,0,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Autocuration
5730,Staphylococcus aureus,,,1280.0,,,1,,16219,U,22226,,0,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Autocuration
5731,Staphylococcus aureus,,,1280.0,,,1,,16219,U,22226,,0,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Autocuration
5732,Homo sapiens,,,9606.0,,,1,,4782,N,80682,A549,1,,F,Inhibitory concentration required against A 549 lung cancer cell line,,Intermediate
5733,Homo sapiens,,,9606.0,,,1,,11805,N,80682,A549,1,,F,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,Intermediate
5734,Homo sapiens,,,9606.0,,,1,,11805,N,80682,A549,1,,F,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,Intermediate
5735,Homo sapiens,,,9606.0,,,1,,2007,N,80682,A549,1,,F,In vitro cytotoxicity against lung cancer A 549 cell lines,,Intermediate
5736,Homo sapiens,,,9606.0,,,1,,4594,N,80682,A549,1,,F,Compound was tested for its cytotoxicity against A 549 cell line,,Intermediate
5737,Homo sapiens,,,9606.0,,,1,,6018,N,80682,A549,1,,F,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,Expert
5738,Homo sapiens,,,9606.0,,,1,,6018,N,80682,A549,1,,F,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,Intermediate
5739,Homo sapiens,,,9606.0,,,1,,3599,N,80682,A549,1,,F,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,Expert
5740,Homo sapiens,,,9606.0,,,1,,2551,N,80682,A549,1,,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Intermediate
5741,Homo sapiens,,,9606.0,,,1,,16132,N,80682,A549,1,,F,In vitro inhibition of A549 (human lung cancer) cell growth.,,Expert
5742,Homo sapiens,,,9606.0,,,1,,16132,N,80682,A549,1,,F,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,Intermediate
5743,Homo sapiens,,,9606.0,,,1,,2551,N,80682,A549,1,,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Expert
5744,Homo sapiens,,,9606.0,,,1,,2551,N,80682,A549,1,,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,Expert
5745,,,,,,,1,,11913,U,22226,,0,,F,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,Autocuration
5746,,,,,In vivo,,1,,12621,H,104694,,4,,F,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,Autocuration
5747,,,,,In vivo,,1,,12621,H,104694,,4,,F,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,Autocuration
5748,,,,,In vivo,,1,,12621,H,104694,,4,,F,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,Autocuration
5749,,,,,In vivo,,1,,12621,H,104694,,4,,F,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,Autocuration
5750,,,,,In vivo,,1,,12621,H,104694,,4,,F,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,Autocuration
5751,Homo sapiens,,,9606.0,,,1,,3600,N,80021,A498,1,,F,Inhibition of A-498 human Renal cell proliferation,,Expert
5752,Rattus norvegicus,,,10116.0,,,1,,1796,U,22226,,0,,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,Autocuration
5753,Rattus norvegicus,,,10116.0,,,1,,1796,U,22226,,0,,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,Autocuration
5754,Rattus norvegicus,,,10116.0,,,1,,1796,U,22226,,0,,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,Autocuration
5755,Homo sapiens,,,9606.0,,,1,,16464,N,80012,A 172,1,,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,Expert
5756,Homo sapiens,,,9606.0,,,1,,16464,N,80012,A 172,1,,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate
5757,Homo sapiens,,,9606.0,,,1,,16464,N,80012,A 172,1,,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate
5758,Homo sapiens,,,9606.0,,,1,,13617,N,80682,A549,1,,F,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,Expert
5759,Homo sapiens,,,9606.0,,,1,,4584,N,80682,A549,1,,F,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,Intermediate
5760,Homo sapiens,,,9606.0,,,1,,13799,N,80682,A549,1,,F,Cytotoxic activity evaluated against A549 tumor cells,,Expert
5761,Homo sapiens,,,9606.0,,,1,,16726,N,80682,A549,1,,F,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,Intermediate
5762,Homo sapiens,,,9606.0,,,1,,16109,N,80682,A549,1,,F,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,Intermediate
5763,Homo sapiens,,,9606.0,,,1,,16109,N,80682,A549,1,,F,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,Intermediate
5764,Homo sapiens,,,9606.0,,,1,,15474,N,80682,A549,1,,F,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,Intermediate
5765,Homo sapiens,,,9606.0,,,1,,6851,N,80682,A549,1,,F,Cytotoxicity of compound against A549 cell line,,Intermediate
5766,Homo sapiens,,,9606.0,,,1,,17534,N,80682,A549,1,,F,Cytotoxicity against human lung cell carcinoma A549 cell line,,Expert
5767,Homo sapiens,,,9606.0,,,1,,2621,N,80682,A549,1,,F,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,Intermediate
5768,Homo sapiens,,,9606.0,,,1,,830,N,80682,A549,1,,F,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,Intermediate
5769,Homo sapiens,,,9606.0,,,1,,14255,N,80682,A549,1,,F,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,Intermediate
5770,Homo sapiens,,,9606.0,,,1,,14255,N,80682,A549,1,,F,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,Intermediate
5771,Homo sapiens,,,9606.0,,,1,,1590,N,80682,A549,1,,F,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,Intermediate
5772,Homo sapiens,,,9606.0,,,1,,6146,N,80682,A549,1,,F,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,Expert
5773,Homo sapiens,,,9606.0,,,1,,17427,N,80682,A549,1,,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Expert
5774,Homo sapiens,,,9606.0,,,1,,5280,N,80682,A549,1,,F,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,Intermediate
5775,Homo sapiens,,,9606.0,,,1,,16786,N,80682,A549,1,,F,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,Intermediate
5776,Homo sapiens,,,9606.0,,,1,,5895,N,80682,A549,1,,F,In vitro cytotoxicity against A549 (human lung cancer),,Intermediate
5777,Homo sapiens,,,9606.0,,,1,,14297,N,80682,A549,1,,F,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Expert
5778,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,In vivo antiproliferative activity against A549 cell line,,Intermediate
5779,Homo sapiens,,,9606.0,,,1,,14368,N,80682,A549,1,,F,Inhibition of non-small-cell lung adenocarcinoma (A549),,Intermediate
5780,Homo sapiens,,,9606.0,,,1,,14368,N,80682,A549,1,,F,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,Intermediate
5781,Homo sapiens,,,9606.0,,,1,,14254,N,80682,A549,1,,F,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,Intermediate
5782,Homo sapiens,,,9606.0,,,1,,15897,N,80682,A549,1,,F,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,Intermediate
5783,Homo sapiens,,,9606.0,,,1,,13866,N,80682,A549,1,,F,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Intermediate
5784,Homo sapiens,,,9606.0,,,1,,13370,N,80682,A549,1,,F,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,Intermediate
5785,Homo sapiens,,,9606.0,,,1,,4862,N,80682,A549,1,,F,Inhibitory activity against A549 lung cancer cell line,,Intermediate
5786,Homo sapiens,,,9606.0,,,1,,4862,N,80682,A549,1,,F,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,Intermediate
5787,Homo sapiens,,,9606.0,,,1,,4862,N,80682,A549,1,,F,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,Intermediate
5788,Homo sapiens,,,9606.0,,,1,,15970,N,80682,A549,1,,F,Inhibitory concentration against A549 (lung cancer) cell line,,Intermediate
5789,Homo sapiens,,,9606.0,,,1,,17713,N,80682,A549,1,,F,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Expert
5790,Homo sapiens,,,9606.0,,,1,,4833,N,80682,A549,1,,F,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,Intermediate
5791,Homo sapiens,,,9606.0,,,1,,13736,N,80682,A549,1,,F,Activity against A549 cancer cell line.,,Expert
5792,Homo sapiens,,,9606.0,,,1,,4312,N,80682,A549,1,,F,The compound was evaluated for cytotoxicity against A549 cell line,,Intermediate
5793,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,Intermediate
5794,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Intermediate
5795,Homo sapiens,,,9606.0,,,1,,14717,N,80682,A549,1,,F,Growth inhibitory activity was measured for human A549 tumor cell line.,,Intermediate
5796,Homo sapiens,,,9606.0,,,1,,4634,N,80682,A549,1,,F,Inhibitory activity against A549 lung cancer cell line,,Intermediate
5797,Homo sapiens,,,9606.0,,,1,,1149,N,80682,A549,1,,F,Inhibitory activity against A549 cell line; inactive,,Intermediate
5798,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Expert
5799,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Expert
5800,Homo sapiens,,,9606.0,,,1,,5421,N,80682,A549,1,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Intermediate
5801,Homo sapiens,,,9606.0,,,1,,3320,N,80682,A549,1,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,Intermediate
5802,Homo sapiens,,,9606.0,,,1,,3320,N,80682,A549,1,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,Intermediate
5803,Homo sapiens,,,9606.0,,,1,,3320,N,80682,A549,1,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,Intermediate
5804,Homo sapiens,,,9606.0,,,1,,3320,N,80682,A549,1,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,Intermediate
5805,Homo sapiens,,,9606.0,,,1,,3320,N,80682,A549,1,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,Intermediate
5806,Homo sapiens,,,9606.0,,,1,,5726,N,80682,A549,1,,F,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,Intermediate
5807,Canis lupus familiaris,,,9615.0,In vivo,,1,,17800,N,50588,,1,,A,Plasma clearance (in vivo) in mongrel dogs was determined,,Intermediate
5808,Canis lupus familiaris,,,9615.0,In vivo,,1,,5985,N,50588,,1,,A,Plasma clearance was measured in dog,,Intermediate
5809,Canis lupus familiaris,,,9615.0,In vivo,,1,,5530,N,50588,,1,,A,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,Intermediate
5810,Canis lupus familiaris,,,9615.0,In vivo,,1,,5530,N,50588,,1,,A,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,Intermediate
5811,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,4839,N,50588,,1,Plasma,A,Tested for plasma clearance in dog,,Intermediate
5812,Canis lupus familiaris,,,9615.0,In vivo,,1,,3639,N,50588,,1,,A,The compound was tested for clearance in dog plasma.,,Intermediate
5813,Canis lupus familiaris,,,9615.0,In vivo,,1,,4838,N,50588,,1,,A,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,Intermediate
5814,Canis lupus familiaris,,,9615.0,In vivo,,1,,4137,N,50588,,1,,A,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,Intermediate
5815,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5017,N,50588,,1,Plasma,A,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,Intermediate
5816,Canis lupus familiaris,,2107.0,9615.0,In vitro,,1,,17538,N,50588,,1,Liver,A,In vitro clearance in dog liver microsomes,Microsomes,Intermediate
5817,Canis lupus familiaris,,,9615.0,In vivo,,1,,6161,N,50588,,1,,A,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,Intermediate
5818,Canis lupus familiaris,,,9615.0,In vivo,,1,,6161,N,50588,,1,,A,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,Intermediate
5819,Canis lupus familiaris,,,9615.0,In vivo,,1,,1696,N,50588,,1,,A,Plasma clearance in dog,,Intermediate
5820,Canis lupus familiaris,,,9615.0,In vivo,,1,,6762,N,50588,,1,,A,Clearance rate in dog,,Intermediate
5821,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5932,N,50588,,1,Plasma,A,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,Intermediate
5822,Canis lupus familiaris,,,9615.0,In vivo,,1,,6305,N,50588,,1,,A,Clearance in dogs,,Intermediate
5823,Canis lupus familiaris,,,9615.0,In vivo,,1,,4942,N,50588,,1,,A,Plasma clearance in dogs,,Intermediate
5824,Canis lupus familiaris,,,9615.0,In vivo,,1,,4219,N,50588,,1,,A,Plasma clearance was determined,,Intermediate
5825,Canis lupus familiaris,,,9615.0,In vivo,,1,,17853,N,50588,,1,,A,Lower clearance in dog (i.v.) at 0.5 mpk,,Intermediate
5826,Canis lupus familiaris,,,9615.0,In vivo,,1,,4514,N,50588,,1,,A,Plasma clearance in Beagle dogs,,Intermediate
5827,Canis lupus familiaris,,,9615.0,In vivo,,1,,6448,N,50588,,1,,A,Plasma clearance (Clp) in dog,,Intermediate
5828,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,Intermediate
5829,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Plasma clearance (pharmacokinetic parameter) in dog was determined,,Intermediate
5830,Canis lupus familiaris,,,9615.0,In vivo,,1,,6062,N,50588,,1,,A,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,Intermediate
5831,Canis lupus familiaris,,,9615.0,In vivo,,1,,6821,N,50588,,1,,A,Plasma clearance of compound was determined in dog,,Intermediate
5832,Canis lupus familiaris,,,9615.0,In vivo,,1,,4709,N,50588,,1,,A,Plasma clearance after intravenous administration of 1 mg/kg in dog,,Intermediate
5833,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Intermediate
5834,Canis lupus familiaris,,,9615.0,In vivo,,1,,5374,N,50588,,1,,A,Plasma clearance in dog was determined,,Intermediate
5835,Canis lupus familiaris,,,9615.0,In vivo,,1,,6057,N,50588,,1,,A,Plasma clearance was calculated in dog,,Intermediate
5836,Canis lupus familiaris,,,9615.0,In vivo,,1,,4727,N,50588,,1,,A,Plasma clearance at the dose of 2 mg/kg in dog,,Intermediate
5837,Canis lupus familiaris,,,9615.0,In vivo,,1,,5145,N,50588,,1,,A,Plasma clearance in dog,,Intermediate
5838,Canis lupus familiaris,,,9615.0,In vivo,,1,,17657,N,50588,,1,,A,Plasma clearance in dog,,Intermediate
5839,Canis lupus familiaris,,,9615.0,In vivo,,1,,17657,N,50588,,1,,A,Plasma clearance in dog; Unable to calculate,,Intermediate
5840,Canis lupus familiaris,,,9615.0,In vivo,,1,,5145,N,50588,,1,,A,Plasma clearance in rhesus monkey,,Intermediate
5841,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate
5842,Canis lupus familiaris,,,9615.0,In vivo,,1,,6641,N,50588,,1,,A,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate
5843,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate
5844,Canis lupus familiaris,,,9615.0,In vivo,,1,,5472,N,50588,,1,,A,Plasma clearance was evaluated in dog,,Intermediate
5845,Canis lupus familiaris,,,9615.0,In vivo,,1,,5472,N,50588,,1,,A,Plasma clearance was evaluated in dog; Not tested,,Intermediate
5846,Canis lupus familiaris,,,9615.0,In vivo,,1,,5472,N,50588,,1,,A,Plasma clearance was evaluated in rhesus,,Intermediate
5847,Canis lupus familiaris,,,9615.0,In vivo,,1,,5472,N,50588,,1,,A,Plasma clearance was evaluated in rhesus; Not tested,,Intermediate
5848,Canis lupus familiaris,,,9615.0,In vivo,,1,,4257,N,50588,,1,,A,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,Intermediate
5849,Canis lupus familiaris,,,9615.0,In vivo,,1,,6679,N,50588,,1,,A,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate
5850,Canis lupus familiaris,,,9615.0,In vivo,,1,,5546,N,50588,,1,,A,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Intermediate
5851,Canis lupus familiaris,,,9615.0,In vivo,,1,,6348,N,50588,,1,,A,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate
5852,Canis lupus familiaris,,,9615.0,In vivo,,1,,5474,N,50588,,1,,A,Clearance value at a dose of 0.2 mg/kg i.v.,,Intermediate
5853,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6316,N,50588,,1,Plasma,A,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,Intermediate
5854,Canis lupus familiaris,,,9615.0,In vivo,,1,,17594,N,50588,,1,,A,Cmax after oral dose of compound at 3 mg/kg in dogs,,Intermediate
5855,Canis lupus familiaris,,,9615.0,In vivo,,1,,17594,N,50588,,1,,A,Cmax after single intravenous bolus of 1 mg/kg in dogs,,Intermediate
5856,Canis lupus familiaris,,,9615.0,In vivo,,1,,5802,N,50588,,1,,A,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate
5857,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,Intermediate
5858,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Cmax in dog after administration of 1 mg/kg iv,,Intermediate
5859,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1466,N,50588,,1,Plasma,A,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,Intermediate
5860,Canis lupus familiaris,,,9615.0,In vivo,,1,,6505,N,50588,,1,,A,Cmax on p.o. administration of 10 mg/kg was measured in dog,,Intermediate
5861,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Cmax was determine after peroral administration at 10 mpk in dog,,Intermediate
5862,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Cmax was determine after peroral administration at 5 mpk in dog,,Intermediate
5863,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Cmax was determine after peroral administration at 5 mg/kg in dog,,Intermediate
5864,Canis lupus familiaris,,,9615.0,In vivo,,1,,5600,N,50588,,1,,A,Cmax after 0.3 mg/kg po administration in dog,,Intermediate
5865,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Cmax after peroral administration in dogs at 2.4 uM/kg,,Intermediate
5866,Canis lupus familiaris,,,9615.0,In vivo,,1,,6123,N,50588,,1,,A,Cmax in dog after oral administration at 1 mg/kg,,Intermediate
5867,Canis lupus familiaris,,,9615.0,In vivo,,1,,6123,N,50588,,1,,A,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,Intermediate
5868,Canis lupus familiaris,,,9615.0,In vivo,,1,,6757,N,50588,,1,,A,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,Intermediate
5869,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Cmax value after 15 mg/kg iv dose in Dogs,,Intermediate
5870,Mus musculus,,178.0,10090.0,In vivo,,1,,7767,N,50594,,1,Blood,A,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5871,Mus musculus,,178.0,10090.0,In vivo,,1,,7767,N,50594,,1,Blood,A,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5872,Mus musculus,,10000001.0,10090.0,In vivo,,1,,7767,N,50594,,1,Bone,A,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5873,Mus musculus,,10000001.0,10090.0,In vivo,,1,,7767,N,50594,,1,Bone,A,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5874,Mus musculus,,10000001.0,10090.0,In vivo,,1,,7767,N,50594,,1,Bone,A,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5875,Mus musculus,,,10090.0,In vivo,,1,,7767,N,50594,,1,,A,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5876,Mus musculus,,,10090.0,In vivo,,1,,7767,N,50594,,1,,A,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5877,Mus musculus,,,10090.0,In vivo,,1,,7767,N,50594,,1,,A,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5878,Mus musculus,,948.0,10090.0,In vivo,,1,,7767,N,50594,,1,Heart,A,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5879,Mus musculus,,948.0,10090.0,In vivo,,1,,7767,N,50594,,1,Heart,A,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5880,Mus musculus,,948.0,10090.0,In vivo,,1,,7767,N,50594,,1,Heart,A,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5881,Mus musculus,,2113.0,10090.0,In vivo,,1,,7767,N,50594,,1,Kidney,A,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5882,Mus musculus,,2113.0,10090.0,In vivo,,1,,7767,N,50594,,1,Kidney,A,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5883,Mus musculus,,2113.0,10090.0,In vivo,,1,,7767,N,50594,,1,Kidney,A,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5884,Mus musculus,,160.0,10090.0,In vivo,,1,,7767,N,50594,,1,Intestine,A,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5885,Mus musculus,,160.0,10090.0,In vivo,,1,,7767,N,50594,,1,Intestine,A,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5886,Mus musculus,,160.0,10090.0,In vivo,,1,,7767,N,50594,,1,Intestine,A,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5887,Mus musculus,,2107.0,10090.0,In vivo,,1,,7767,N,50594,,1,Liver,A,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5888,Mus musculus,,2107.0,10090.0,In vivo,,1,,7767,N,50594,,1,Liver,A,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5889,Mus musculus,,2107.0,10090.0,In vivo,,1,,7767,N,50594,,1,Liver,A,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5890,Mus musculus,,2048.0,10090.0,In vivo,,1,,7767,N,50594,,1,Lung,A,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5891,Mus musculus,,2048.0,10090.0,In vivo,,1,,7767,N,50594,,1,Lung,A,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5892,Mus musculus,,2048.0,10090.0,In vivo,,1,,7767,N,50594,,1,Lung,A,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5893,Mus musculus,,2385.0,10090.0,In vivo,,1,,7767,N,50594,,1,Muscle tissue,A,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5894,Mus musculus,,2385.0,10090.0,In vivo,,1,,7767,N,50594,,1,Muscle tissue,A,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5895,Mus musculus,,2385.0,10090.0,In vivo,,1,,7767,N,50594,,1,Muscle tissue,A,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5896,Mus musculus,,,10090.0,In vivo,,1,,7767,N,50594,,1,,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5897,Mus musculus,,,10090.0,In vivo,,1,,7767,N,50594,,1,,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5898,Mus musculus,,,10090.0,In vivo,,1,,7767,N,50594,,1,,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5899,Mus musculus,,160.0,10090.0,In vivo,,1,,7767,N,50594,,1,Intestine,A,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5900,Mus musculus,,160.0,10090.0,In vivo,,1,,7767,N,50594,,1,Intestine,A,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5901,Mus musculus,,160.0,10090.0,In vivo,,1,,7767,N,50594,,1,Intestine,A,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5902,Mus musculus,,2106.0,10090.0,In vivo,,1,,7767,N,50594,,1,Spleen,A,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5903,Mus musculus,,2106.0,10090.0,In vivo,,1,,7767,N,50594,,1,Spleen,A,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5904,Mus musculus,,2106.0,10090.0,In vivo,,1,,7767,N,50594,,1,Spleen,A,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
5905,Mus musculus,,945.0,10090.0,In vivo,,1,,7767,N,50594,,1,Stomach,A,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
5906,Mus musculus,,945.0,10090.0,In vivo,,1,,7767,N,50594,,1,Stomach,A,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate
5907,Homo sapiens,,,9606.0,,,1,,2036,N,80012,A 172,1,,F,Cytotoxicity against A-172 human tumor cell lines,,Expert
5908,Homo sapiens,,,9606.0,,,1,,2357,N,80012,A 172,1,,F,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,Intermediate
5909,Homo sapiens,,,9606.0,,,1,,1457,N,80014,A204,1,,F,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,Intermediate
5910,Homo sapiens,,,9606.0,,,1,,4379,N,81034,A2780,1,,F,Tested for antiproliferative activity against A-2780 tumoral cell line,,Intermediate
5911,Homo sapiens,,,9606.0,,,1,,1093,N,80018,A-375,1,,F,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,Intermediate
5912,Homo sapiens,,,9606.0,,,1,,12152,N,80018,A-375,1,,F,Tested in vitro against A-375 cell line human melanoma,,Intermediate
5913,Homo sapiens,,,9606.0,,,1,,16464,N,80019,A-427,1,,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,Expert
5914,Homo sapiens,,,9606.0,,,1,,16464,N,80019,A-427,1,,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate
5915,Homo sapiens,,,9606.0,,,1,,16582,N,80019,A-427,1,,F,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,Expert
5916,Homo sapiens,,,9606.0,,,1,,16464,N,80019,A-427,1,,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate
5917,Homo sapiens,,,9606.0,,,1,,10413,N,80019,A-427,1,,F,Antitumor activity on A-427 lung carcinoma cell lines,,Intermediate
5918,Homo sapiens,,,9606.0,,,1,,6418,N,80019,A-427,1,,F,Cytotoxic activity against human A-427 lung tumor cell line,,Intermediate
5919,Homo sapiens,,,9606.0,,,1,,17134,N,80019,A-427,1,,F,In vitro antitumor effects against human A-427 cell lines.,,Expert
5920,Homo sapiens,,,9606.0,,,1,,16132,N,80019,A-427,1,,F,In vitro inhibition of A-427 (human lung cancer) cell growth.,,Expert
5921,Homo sapiens,,,9606.0,,,1,,16132,N,80019,A-427,1,,F,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,Intermediate
5922,Homo sapiens,,,9606.0,,,1,,16780,N,80019,A-427,1,,F,Cytotoxic activity of compound against A-427 lung human tumor cell line,,Intermediate
5923,Homo sapiens,,,9606.0,,,1,,4085,N,80852,A-431,1,,F,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,Expert
5924,Homo sapiens,,,9606.0,,,1,,1276,N,80021,A498,1,,F,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,Intermediate
5925,Homo sapiens,,,9606.0,,,1,,3498,N,80021,A498,1,,F,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,Expert
5926,Homo sapiens,,,9606.0,,,1,,1169,N,80021,A498,1,,F,Cytotoxicity against human kidney carcinoma A-498cell lines,,Intermediate
5927,Homo sapiens,,,9606.0,,,1,,4450,N,80021,A498,1,,F,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,Intermediate
5928,Homo sapiens,,,9606.0,,,1,,3311,N,80021,A498,1,,F,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,Intermediate
5929,Homo sapiens,,,9606.0,,,1,,4461,N,80021,A498,1,,F,Antitumor cytotoxic activity against A-498 cell line was determined,,Intermediate
5930,Homo sapiens,,,9606.0,,,1,,3311,N,80021,A498,1,,F,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,Intermediate
5931,Homo sapiens,,,9606.0,,,1,,3311,N,80021,A498,1,,F,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,Intermediate
5932,Homo sapiens,,,9606.0,,,1,,1457,N,80021,A498,1,,F,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,Intermediate
5933,Homo sapiens,,,9606.0,,,1,,3664,N,80021,A498,1,,F,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,Intermediate
5934,Homo sapiens,,,9606.0,,,1,,15895,N,80021,A498,1,,F,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,Intermediate
5935,Homo sapiens,,,9606.0,,,1,,11843,N,80682,A549,1,,F,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,Intermediate
5936,Homo sapiens,,,9606.0,,,1,,11843,N,80682,A549,1,,F,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,Intermediate
5937,Homo sapiens,,,9606.0,,,1,,17705,N,80682,A549,1,,F,In vitro antiproliferative activity against human A-549 NSCL cell line,,Intermediate
5938,Homo sapiens,,,9606.0,,,1,,17705,N,80682,A549,1,,F,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,Intermediate
5939,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,Intermediate
5940,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,Intermediate
5941,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,Intermediate
5942,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,Intermediate
5943,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,Intermediate
5944,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,Intermediate
5945,Homo sapiens,,,9606.0,,,1,,4369,N,80682,A549,1,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,Intermediate
5946,Homo sapiens,,,9606.0,,,1,,4787,N,80682,A549,1,,F,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,Expert
5947,Homo sapiens,,,9606.0,,,1,,4787,N,80682,A549,1,,F,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,Intermediate
5948,Homo sapiens,,,9606.0,,,1,,6513,N,80682,A549,1,,F,Cytotoxic activity against A-549 cell line,,Intermediate
5949,Homo sapiens,,,9606.0,,,1,,6690,N,80682,A549,1,,F,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,Intermediate
5950,Homo sapiens,,,9606.0,,,1,,6690,N,80682,A549,1,,F,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,Intermediate
5951,Homo sapiens,,,9606.0,,,1,,12263,N,80682,A549,1,,F,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,Expert
5952,Homo sapiens,,,9606.0,,,1,,1054,N,80682,A549,1,,F,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,Intermediate
5953,Homo sapiens,,,9606.0,,,1,,1359,N,80682,A549,1,,F,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,Intermediate
5954,Homo sapiens,,,9606.0,,,1,,3547,N,80682,A549,1,,F,Cytotoxic activity against human lung carcinoma (A-549) cell line,,Intermediate
5955,Homo sapiens,,,9606.0,,,1,,5771,N,80682,A549,1,,F,Cytotoxic activity towards A-549 cells,,Expert
5956,Homo sapiens,,,9606.0,,,1,,14425,N,80682,A549,1,,F,"In vitro percent inhibition of A549, lung carcinoma.",,Intermediate
5957,Homo sapiens,,,9606.0,,,1,,14425,N,80682,A549,1,,F,"In vitro percent inhibition of A549, lung carcinoma",,Intermediate
5958,Homo sapiens,,,9606.0,,,1,,14425,N,80682,A549,1,,F,"In vitro percent inhibition of A549, lung carcinoma.",,Intermediate
5959,Homo sapiens,,,9606.0,,,1,,14425,N,80682,A549,1,,F,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,Intermediate
5960,Homo sapiens,,,9606.0,,,1,,5280,N,80682,A549,1,,F,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,Intermediate
5961,Homo sapiens,,,9606.0,,,1,,15176,N,80682,A549,1,,F,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,Intermediate
5962,Homo sapiens,,,9606.0,,,1,,15300,N,80682,A549,1,,F,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,Intermediate
5963,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate
5964,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate
5965,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate
5966,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate
5967,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate
5968,Homo sapiens,,,9606.0,,,1,,17824,N,80682,A549,1,,F,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,Intermediate
5969,Homo sapiens,,,9606.0,,,1,,17528,N,80682,A549,1,,F,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,Intermediate
5970,Homo sapiens,,,9606.0,,,1,,6870,N,80682,A549,1,,F,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,Expert
5971,Homo sapiens,,,9606.0,,,1,,6870,N,80682,A549,1,,F,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Intermediate
5972,Homo sapiens,,,9606.0,,,1,,6870,N,80682,A549,1,,F,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,Intermediate
5973,Homo sapiens,,,9606.0,,,1,,6870,N,80682,A549,1,,F,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Intermediate
5974,Homo sapiens,,,9606.0,,,1,,16726,N,80682,A549,1,,F,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Intermediate
5975,Homo sapiens,,,9606.0,,,1,,6170,N,80682,A549,1,,F,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,Intermediate
5976,Homo sapiens,,,9606.0,,,1,,6583,N,80682,A549,1,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,Expert
5977,Homo sapiens,,,9606.0,,,1,,6583,N,80682,A549,1,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,Expert
5978,Homo sapiens,,,9606.0,,,1,,6583,N,80682,A549,1,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,Expert
5979,Homo sapiens,,,9606.0,,,1,,6583,N,80682,A549,1,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,Expert
5980,Homo sapiens,,,9606.0,,,1,,6583,N,80682,A549,1,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,Expert
5981,Homo sapiens,,,9606.0,,,1,,17321,N,80682,A549,1,,F,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,Intermediate
5982,Homo sapiens,,,9606.0,,,1,,17528,N,80682,A549,1,,F,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Expert
5983,Homo sapiens,,,9606.0,,,1,,12888,N,80682,A549,1,,F,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,Expert
5984,Homo sapiens,,,9606.0,,,1,,4312,N,80682,A549,1,,F,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,Intermediate
5985,Homo sapiens,,,9606.0,,,1,,4312,N,80682,A549,1,,F,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,Intermediate
5986,Homo sapiens,,,9606.0,,,1,,4312,N,80682,A549,1,,F,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,Intermediate
5987,Mus musculus,,,10090.0,,,1,,17737,N,80682,A549,1,,F,In vitro antiproliferative activity against A549 cell line,,Intermediate
5988,,,,,,,1,,6630,N,80682,A549,1,,F,Synergism with indomethacin in A549 cells,,Intermediate
5989,,,,,,,1,,6630,N,80682,A549,1,,F,Synergism with tolmetin in A549 cells,,Intermediate
5990,,,,,,,1,,6630,N,80682,A549,1,,F,Synergism with sulindac in A549 cells,,Intermediate
5991,,,,,,,1,,6630,N,80682,A549,1,,F,Antagonism of indomethacin in A549 cells,,Intermediate
5992,,,,,,,1,,6630,N,80682,A549,1,,F,Antagonism of sulindac in A549 cells,,Intermediate
5993,,,,,,,1,,6630,N,80682,A549,1,,F,Antagonism of tolmetin in A549 cells,,Intermediate
5994,,,,,,,1,,6630,N,80682,A549,1,,F,Synergism with indomethacin in A549 cells,,Intermediate
5995,,,,,,,1,,6630,N,80682,A549,1,,F,Synergism with sulindac in A549 cells,,Intermediate
5996,,,,,,,1,,6630,N,80682,A549,1,,F,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,Intermediate
5997,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Cmax value after 30 mg/kg po dose in Dogs,,Intermediate
5998,Canis lupus familiaris,,,9615.0,In vivo,,1,,5944,N,50588,,1,,A,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate
5999,Canis lupus familiaris,,,9615.0,In vivo,,1,,5944,N,50588,,1,,A,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,Intermediate
6000,Canis lupus familiaris,,,9615.0,In vivo,,1,,5944,N,50588,,1,,A,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate
6001,Canis lupus familiaris,,,9615.0,In vivo,,1,,5944,N,50588,,1,,A,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,Intermediate
6002,Canis lupus familiaris,,,9615.0,In vivo,,1,,2959,N,50588,,1,,A,Cmax value after administration of 4 mg/Kg oral dose in dog,,Intermediate
6003,Canis lupus familiaris,,,9615.0,In vivo,,1,,6241,N,50588,,1,,A,Cmax value in dog,,Intermediate
6004,Canis lupus familiaris,,,9615.0,In vivo,,1,,6241,N,50588,,1,,A,Cmax value in dogs after oral administration at 1 mg/kg,,Intermediate
6005,Canis lupus familiaris,,,9615.0,In vivo,,1,,2652,N,50588,,1,,A,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,Intermediate
6006,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1806,N,50588,,1,Plasma,A,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,Intermediate
6007,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1806,N,50588,,1,Plasma,A,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,Intermediate
6008,Canis lupus familiaris,,,9615.0,In vivo,,1,,1021,N,50588,,1,,A,Concentration maxima after oral dosing in dogs,,Intermediate
6009,Canis lupus familiaris,,,9615.0,In vivo,,1,,1021,N,50588,,1,,A,Concentration maxima after oral dosing in dogs; not available,,Intermediate
6010,Canis lupus familiaris,,,9615.0,In vivo,,1,,1021,N,50588,,1,,A,Concentration maxima after oral dosing in dogs; not available,,Intermediate
6011,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,Intermediate
6012,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,Intermediate
6013,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo maximal concentration was calculated at 1 mg/kg in dog,,Intermediate
6014,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,Intermediate
6015,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,Intermediate
6016,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5130,N,50588,,1,Plasma,A,Cmax in dog plasma after oral dose (1 mg/kg),,Intermediate
6017,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3249,N,50588,,1,Plasma,A,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,Intermediate
6018,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5473,N,50588,,1,Plasma,A,Maximal plasma concentration at a dose of 1 mg/kg,,Intermediate
6019,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5474,N,50588,,1,Plasma,A,Maximal plasma concentration at a dose of 1 mg/kg (oral),,Intermediate
6020,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,4657,N,50588,,1,Plasma,A,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,Intermediate
6021,Canis lupus familiaris,,,9615.0,In vivo,,1,,3031,N,50588,,1,,A,Maximum concentration of compound in dog was evaluated.,,Intermediate
6022,Canis lupus familiaris,,,9615.0,In vivo,,1,,4527,N,50588,,1,,A,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate
6023,Canis lupus familiaris,,,9615.0,In vivo,,1,,4186,N,50588,,1,,A,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,Intermediate
6024,Canis lupus familiaris,,,9615.0,In vivo,,1,,5007,N,50588,,1,,A,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate
6025,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3132,N,50588,,1,Plasma,A,Maximum concentration obtained in dog plasma was determined,,Intermediate
6026,Canis lupus familiaris,,,9615.0,In vivo,,1,,5006,N,50588,,1,,A,Maximum concentration was determined,,Intermediate
6027,Canis lupus familiaris,,,9615.0,In vivo,,1,,4727,N,50588,,1,,A,Maximum concentration at the dose of 2 mg/kg in dog,,Intermediate
6028,Canis lupus familiaris,,,9615.0,In vivo,,1,,1916,N,50588,,1,,A,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate
6029,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1918,N,50588,,1,Plasma,A,Maximum concentration was evaluated in dog plasma,,Intermediate
6030,Canis lupus familiaris,,,9615.0,In vivo,,1,,3045,N,50588,,1,,A,Maximum concentration was evaluated after 75 min after administration in dog,,Intermediate
6031,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,9579,N,50588,,1,Plasma,A,Maximum plasma concentration determined in dog after oral administration of 17b,,Intermediate
6032,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,9579,N,50588,,1,Plasma,A,Maximum plasma concentration determined in dog after oral administration of 2b,,Intermediate
6033,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,933,N,50588,,1,Plasma,A,Maximum plasma concentration in dog,,Intermediate
6034,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,17839,N,50588,,1,Plasma,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,Intermediate
6035,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,17839,N,50588,,1,Plasma,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,Intermediate
6036,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,17839,N,50588,,1,Plasma,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,Intermediate
6037,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,17839,N,50588,,1,Plasma,A,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,Intermediate
6038,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6348,N,50588,,1,Plasma,A,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate
6039,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,16367,N,50588,,1,Plasma,A,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,Intermediate
6040,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1337,N,50588,,1,Plasma,A,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
6041,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,1337,N,50588,,1,Plasma,A,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
6042,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5199,N,50588,,1,Plasma,A,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,Intermediate
6043,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,17650,N,50588,,1,Plasma,A,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,Intermediate
6044,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6679,N,50588,,1,Plasma,A,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,Intermediate
6045,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5356,N,50588,,1,Plasma,A,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,Intermediate
6046,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5356,N,50588,,1,Plasma,A,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,Intermediate
6047,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6227,N,50588,,1,Plasma,A,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,Intermediate
6048,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6227,N,50588,,1,Plasma,A,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,Intermediate
6049,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6227,N,50588,,1,Plasma,A,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,Intermediate
6050,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6227,N,50588,,1,Plasma,A,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,Intermediate
6051,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3598,N,50588,,1,Plasma,A,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert
6052,Canis lupus familiaris,,,9615.0,In vivo,,1,,4368,N,50588,,1,,A,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,Intermediate
6053,Canis lupus familiaris,,,9615.0,In vivo,,1,,6265,N,50588,,1,,A,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,Intermediate
6054,Mus musculus,,945.0,10090.0,In vivo,,1,,7767,N,50594,,1,Stomach,A,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate
6055,Mus musculus,,1088.0,10090.0,In vivo,,1,,7767,N,50594,,1,Urine,A,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate
6056,Mus musculus,,1088.0,10090.0,In vivo,,1,,7767,N,50594,,1,Urine,A,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,Intermediate
6057,Mus musculus,,1088.0,10090.0,In vivo,,1,,7767,N,50594,,1,Urine,A,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,Intermediate
6058,Mus musculus,,,10090.0,,,1,,17811,N,50594,,1,,A,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,Intermediate
6059,Mus musculus,,,10090.0,,,1,,17811,N,50594,,1,,A,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,Intermediate
6060,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,Intermediate
6061,Mus musculus,,178.0,10090.0,,,1,,17827,N,50594,,1,Blood,A,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,Intermediate
6062,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,Intermediate
6063,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,Intermediate
6064,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,Intermediate
6065,Mus musculus,,178.0,10090.0,,,1,,17827,N,50594,,1,Blood,A,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,Intermediate
6066,Mus musculus,,178.0,10090.0,,,1,,17827,N,50594,,1,Blood,A,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,Intermediate
6067,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Compound was evaluated for washout rate in mice (Radiolabeled compound),,Intermediate
6068,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,Intermediate
6069,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Intermediate
6070,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Intermediate
6071,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Intermediate
6072,Mus musculus,,,10090.0,,,1,,17257,N,50594,,1,,A,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,Intermediate
6073,Mus musculus,,,10090.0,,,1,,17257,N,50594,,1,,A,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,Intermediate
6074,Mus musculus,,,10090.0,,,1,,17257,N,50594,,1,,A,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,Intermediate
6075,Mus musculus,,,10090.0,,,1,,17257,N,50594,,1,,A,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,Intermediate
6076,Mus musculus,,,10090.0,,,1,,17827,N,50594,,1,,A,Time at maximum activity in mice (Radiolabeled compound),,Intermediate
6077,Mus musculus,,,10090.0,,,1,,3760,N,50594,,1,,A,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,Intermediate
6078,Mus musculus,,,10090.0,,,1,,3760,N,50594,,1,,A,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,Intermediate
6079,Mus musculus,,,10090.0,,,1,,17409,N,50594,,1,,A,Binding towards mouse plasma protein at 10 uM,,Intermediate
6080,Mus musculus,,,10090.0,,,1,,17409,N,50594,,1,,A,Binding towards mouse plasma protein at 100 uM,,Intermediate
6081,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Bioavailability was evaluated in mice after intravenous administration,,Intermediate
6082,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Bioavailability was evaluated in mice after oral administration,,Intermediate
6083,Mus musculus,,,10090.0,In vivo,,1,,3132,N,50594,,1,,A,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,Intermediate
6084,Mus musculus,,,10090.0,In vivo,,1,,3132,N,50594,,1,,A,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,Intermediate
6085,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,Intermediate
6086,Mus musculus,,,10090.0,In vivo,,1,,2862,N,50594,,1,,A,Oral bioavailability in mouse,,Intermediate
6087,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,Intermediate
6088,Mus musculus,,955.0,10090.0,In vivo,,1,,846,N,50594,,1,Brain,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6089,Mus musculus,,955.0,10090.0,In vivo,,1,,846,N,50594,,1,Brain,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6090,Mus musculus,,955.0,10090.0,In vivo,,1,,846,N,50594,,1,Brain,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6091,Mus musculus,,955.0,10090.0,In vivo,,1,,846,N,50594,,1,Brain,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6092,Mus musculus,,955.0,10090.0,In vivo,,1,,846,N,50594,,1,Brain,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6093,Mus musculus,,955.0,10090.0,In vivo,,1,,846,N,50594,,1,Brain,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6094,Mus musculus,,948.0,10090.0,In vivo,,1,,846,N,50594,,1,Heart,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6095,Mus musculus,,948.0,10090.0,In vivo,,1,,846,N,50594,,1,Heart,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6096,Mus musculus,,948.0,10090.0,In vivo,,1,,846,N,50594,,1,Heart,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6097,Mus musculus,,948.0,10090.0,In vivo,,1,,846,N,50594,,1,Heart,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6098,Homo sapiens,,,9606.0,,,1,,1276,N,80682,A549,1,,F,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,Intermediate
6099,Homo sapiens,,,9606.0,,,1,,3498,N,80682,A549,1,,F,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,Expert
6100,Homo sapiens,,,9606.0,,,1,,1169,N,80682,A549,1,,F,Cytotoxicity against human lung carcinoma A-549 cell lines,,Intermediate
6101,Homo sapiens,,,9606.0,,,1,,4450,N,80682,A549,1,,F,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,Intermediate
6102,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549,,Intermediate
6103,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,Intermediate
6104,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,Intermediate
6105,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,Intermediate
6106,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,Intermediate
6107,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,Intermediate
6108,Homo sapiens,,,9606.0,,,1,,358,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,Intermediate
6109,Homo sapiens,,,9606.0,,,1,,15167,N,80682,A549,1,,F,In vitro cytotoxicity against A-549 human lung cancer cells,,Intermediate
6110,Homo sapiens,,,9606.0,,,1,,4139,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,Intermediate
6111,Homo sapiens,,,9606.0,,,1,,833,N,80682,A549,1,,F,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,Intermediate
6112,Homo sapiens,,,9606.0,,,1,,15718,N,80682,A549,1,,F,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Expert
6113,Homo sapiens,,,9606.0,,,1,,12373,N,80682,A549,1,,F,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,Intermediate
6114,Homo sapiens,,,9606.0,,,1,,637,N,80682,A549,1,,F,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,Intermediate
6115,Homo sapiens,,,9606.0,,,1,,14867,N,80682,A549,1,,F,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,Expert
6116,Homo sapiens,,,9606.0,,,1,,4461,N,80682,A549,1,,F,Antitumor cytotoxic activity against A-549 cell line was determined,,Intermediate
6117,Homo sapiens,,,9606.0,,,1,,5406,N,80682,A549,1,,F,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,Intermediate
6118,Homo sapiens,,,9606.0,,,1,,4457,N,80682,A549,1,,F,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Intermediate
6119,Homo sapiens,,,9606.0,,,1,,1386,N,80682,A549,1,,F,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Expert
6120,Homo sapiens,,,9606.0,,,1,,3265,N,80682,A549,1,,F,Antitumoral activity was assayed against A-549 cell line,,Intermediate
6121,Homo sapiens,,,9606.0,,,1,,2359,N,80682,A549,1,,F,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,Intermediate
6122,Homo sapiens,,,9606.0,,,1,,4457,N,80682,A549,1,,F,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Intermediate
6123,Homo sapiens,,,9606.0,,,1,,12454,N,80682,A549,1,,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Expert
6124,Homo sapiens,,,9606.0,,,1,,1481,N,80682,A549,1,,F,Compound was tested for inhibition of cell growth of A-549 cells,,Intermediate
6125,Homo sapiens,,,9606.0,,,1,,1750,N,80682,A549,1,,F,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,Intermediate
6126,Homo sapiens,,,9606.0,,,1,,5065,N,80682,A549,1,,F,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,Intermediate
6127,Homo sapiens,,,9606.0,,,1,,808,N,80682,A549,1,,F,In vitro cytotoxicity against A549-human lung carcinoma cells.,,Expert
6128,Homo sapiens,,,9606.0,,,1,,16364,N,80682,A549,1,,F,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,Expert
6129,Homo sapiens,,,9606.0,,,1,,1847,N,80682,A549,1,,F,Cytotoxic activity against A-549 cell lines.,,Intermediate
6130,Homo sapiens,,,9606.0,,,1,,1747,N,80682,A549,1,,F,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,Expert
6131,Homo sapiens,,,9606.0,,,1,,1003,N,80682,A549,1,,F,Cytotoxicity against human A549 non small cell lung cell lines,,Intermediate
6132,Homo sapiens,,,9606.0,,,1,,15313,N,80682,A549,1,,F,Inhibition of cell growth in (A-549) lung cell line,,Expert
6133,Homo sapiens,,,9606.0,,,1,,3122,N,80682,A549,1,,F,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,Intermediate
6134,Homo sapiens,,,9606.0,,,1,,16049,N,80682,A549,1,,F,In vitro antitumor activity against A-549 tumor cells.,,Intermediate
6135,Homo sapiens,,,9606.0,,,1,,17134,N,80682,A549,1,,F,In vitro antitumor effects against human A-549 cell lines.,,Expert
6136,Homo sapiens,,,9606.0,,,1,,6406,N,80682,A549,1,,F,In vitro cytotoxic activity of compound against A-549 cell line,,Intermediate
6137,Homo sapiens,,,9606.0,,,1,,627,N,80682,A549,1,,F,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,Intermediate
6138,Homo sapiens,,,9606.0,,,1,,12307,N,80682,A549,1,,F,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,Intermediate
6139,Homo sapiens,,,9606.0,,,1,,17861,N,80682,A549,1,,F,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,Intermediate
6140,Homo sapiens,,,9606.0,,,1,,6682,N,80682,A549,1,,F,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,Expert
6141,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,Inhibitory concentration of compound against A-549 cell line,,Intermediate
6142,Homo sapiens,,,9606.0,,,1,,2454,N,80682,A549,1,,F,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,Intermediate
6143,Homo sapiens,,,9606.0,,,1,,14709,N,80682,A549,1,,F,cytotoxic activity against leukemia (A-549) cancer cell line,,Intermediate
6144,Homo sapiens,,,9606.0,,,1,,15718,N,80682,A549,1,,F,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Expert
6145,Homo sapiens,,,9606.0,,,1,,15718,N,80682,A549,1,,F,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,Intermediate
6146,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,Intermediate
6147,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,Intermediate
6148,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,Intermediate
6149,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,Intermediate
6150,,,,,,,1,,6630,N,80682,A549,1,,F,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,Intermediate
6151,Homo sapiens,,,9606.0,,,1,,16726,N,80682,A549,1,,F,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,Intermediate
6152,Homo sapiens,,,9606.0,,,1,,17846,N,80682,A549,1,,F,Cytotoxicity against A549 cells; No cytotoxicity,,Intermediate
6153,Homo sapiens,,,9606.0,,,1,,3415,N,80682,A549,1,,F,Cytotoxicity against human lung carcinoma (A549) cell lines,,Expert
6154,Homo sapiens,,,9606.0,,,1,,3415,N,80682,A549,1,,F,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,Expert
6155,Homo sapiens,,,9606.0,,,1,,5609,N,80682,A549,1,,F,In vitro anticancer activity against human lung (A549) cell line,,Intermediate
6156,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,Intermediate
6157,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,Intermediate
6158,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,Intermediate
6159,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,Intermediate
6160,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,Intermediate
6161,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Intermediate
6162,Homo sapiens,,,9606.0,,,1,,16295,N,80682,A549,1,,F,Inhibition of A549 human lung tumor cell proliferation,,Expert
6163,Homo sapiens,,,9606.0,,,1,,16825,N,80682,A549,1,,F,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,Intermediate
6164,Homo sapiens,,,9606.0,,,1,,3439,N,80682,A549,1,,F,In vitro cytotoxicity against human tumor cell line A549,,Expert
6165,Homo sapiens,,,9606.0,,,1,,10870,N,80682,A549,1,,F,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,Intermediate
6166,Homo sapiens,,,9606.0,,,1,,4845,N,80682,A549,1,,F,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,Intermediate
6167,Homo sapiens,,,9606.0,,,1,,5822,N,80682,A549,1,,F,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,Intermediate
6168,Homo sapiens,,,9606.0,,,1,,5822,N,80682,A549,1,,F,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,Intermediate
6169,Homo sapiens,,,9606.0,,,1,,5822,N,80682,A549,1,,F,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,Intermediate
6170,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Intermediate
6171,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Intermediate
6172,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Intermediate
6173,Homo sapiens,,,9606.0,,,1,,5609,N,80682,A549,1,,F,In vitro anticancer activity against human lung (A549) cell line,,Intermediate
6174,Homo sapiens,,,9606.0,,,1,,4644,N,80682,A549,1,,F,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,Intermediate
6175,Homo sapiens,,,9606.0,,,1,,4644,N,80682,A549,1,,F,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,Intermediate
6176,Homo sapiens,,,9606.0,,,1,,4644,N,80682,A549,1,,F,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,Intermediate
6177,Homo sapiens,,,9606.0,,,1,,4644,N,80682,A549,1,,F,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,Intermediate
6178,Homo sapiens,,,9606.0,,,1,,5822,N,80682,A549,1,,F,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,Intermediate
6179,Homo sapiens,,,9606.0,,,1,,3415,N,80682,A549,1,,F,Percentage inhibition of human lung carcinoma (A549) cell lines,,Expert
6180,Homo sapiens,,,9606.0,,,1,,16726,N,80682,A549,1,,F,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,Intermediate
6181,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,Intermediate
6182,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Intermediate
6183,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Intermediate
6184,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,Intermediate
6185,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,Intermediate
6186,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,Intermediate
6187,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,Intermediate
6188,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,Intermediate
6189,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,Intermediate
6190,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,Intermediate
6191,Homo sapiens,,,9606.0,,,1,,16726,N,80682,A549,1,,F,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Intermediate
6192,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,Intermediate
6193,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,Intermediate
6194,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,Intermediate
6195,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,Intermediate
6196,Canis lupus familiaris,,,9615.0,In vivo,,1,,6084,N,50588,,1,,A,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,Intermediate
6197,Canis lupus familiaris,,,9615.0,In vivo,,1,,6084,N,50588,,1,,A,Pharmacokinetic activity (Cmax) in dog,,Intermediate
6198,Canis lupus familiaris,,,9615.0,In vivo,,1,,4809,N,50588,,1,,A,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Intermediate
6199,Canis lupus familiaris,,,9615.0,In vivo,,1,,5983,N,50588,,1,,A,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,Intermediate
6200,Canis lupus familiaris,,,9615.0,In vivo,,1,,6251,N,50588,,1,,A,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,Intermediate
6201,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5932,N,50588,,1,Plasma,A,Cmax in dog plasma after 30mg/kg oral dose,,Intermediate
6202,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,4273,N,50588,,1,Blood,A,Tested for the peak blood level in dog,,Intermediate
6203,Canis lupus familiaris,,,9615.0,In vivo,,1,,5313,N,50588,,1,,A,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,Intermediate
6204,Canis lupus familiaris,,,9615.0,In vivo,,1,,5313,N,50588,,1,,A,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,Intermediate
6205,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,6221,N,50588,,1,Blood,A,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,Intermediate
6206,Canis lupus familiaris,,,9615.0,,,1,,4709,N,50588,,1,,A,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,Intermediate
6207,Canis lupus familiaris,,,9615.0,,,1,,167,N,50588,,1,,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,Intermediate
6208,Canis lupus familiaris,,1969.0,9615.0,,,1,,6241,N,50588,,1,Plasma,A,Final plasma concentration in dogs after oral administration at 1 mg/kg,,Intermediate
6209,Canis lupus familiaris,,,9615.0,,,1,,344,N,50588,,1,,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,Intermediate
6210,Canis lupus familiaris,,,9615.0,,,1,,344,N,50588,,1,,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,Intermediate
6211,Canis lupus familiaris,,,9615.0,,,1,,344,N,50588,,1,,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,Intermediate
6212,Canis lupus familiaris,,,9615.0,,,1,,2189,N,50588,,1,,A,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,Intermediate
6213,Canis lupus familiaris,,1088.0,9615.0,,,1,,2189,N,50588,,1,Urine,A,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,Intermediate
6214,Canis lupus familiaris,,1088.0,9615.0,,,1,,2189,N,50588,,1,Urine,A,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,Intermediate
6215,Canis lupus familiaris,,1088.0,9615.0,,,1,,2189,N,50588,,1,Urine,A,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,Intermediate
6216,Canis lupus familiaris,,,9615.0,In vivo,,1,,4257,N,50588,,1,,A,Absolute bioavailability was evaluated in dog,,Intermediate
6217,Canis lupus familiaris,,,9615.0,In vivo,,1,,6221,N,50588,,1,,A,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,Intermediate
6218,Canis lupus familiaris,,,9615.0,In vivo,,1,,6215,N,50588,,1,,A,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,Intermediate
6219,Canis lupus familiaris,,,9615.0,In vivo,,1,,17267,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6220,Canis lupus familiaris,,,9615.0,In vivo,,1,,6621,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6221,Canis lupus familiaris,,,9615.0,In vivo,,1,,3854,N,50588,,1,,A,Bioavailability after intravenous administration in dogs,,Intermediate
6222,Canis lupus familiaris,,,9615.0,In vivo,,1,,3854,N,50588,,1,,A,Bioavailability after peroral administration in dogs,,Intermediate
6223,Canis lupus familiaris,,,9615.0,In vivo,,1,,5007,N,50588,,1,,A,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,Intermediate
6224,Canis lupus familiaris,,,9615.0,In vivo,,1,,4333,N,50588,,1,,A,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,Intermediate
6225,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,4333,N,50588,,1,Plasma,A,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,Intermediate
6226,Canis lupus familiaris,,,9615.0,In vivo,,1,,5006,N,50588,,1,,A,Bioavailability,,Intermediate
6227,Canis lupus familiaris,,,9615.0,In vivo,,1,,5199,N,50588,,1,,A,Bioavailability,,Intermediate
6228,Canis lupus familiaris,,,9615.0,In vivo,,1,,4368,N,50588,,1,,A,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,Intermediate
6229,Canis lupus familiaris,,,9615.0,In vivo,,1,,3771,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6230,Canis lupus familiaris,,,9615.0,In vivo,,1,,4953,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6231,Canis lupus familiaris,,,9615.0,In vivo,,1,,5064,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6232,Canis lupus familiaris,,,9615.0,In vivo,,1,,17657,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6233,Canis lupus familiaris,,,9615.0,In vivo,,1,,17796,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6234,Canis lupus familiaris,,,9615.0,In vivo,,1,,17853,N,50588,,1,,A,Bioavailability in dog (p.o.) at 2.0 mpk,,Intermediate
6235,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,Intermediate
6236,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate
6237,Canis lupus familiaris,,,9615.0,In vivo,,1,,5006,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6238,Canis lupus familiaris,,,9615.0,In vivo,,1,,16365,N,50588,,1,,A,Bioavailability was evaluated after oral administration in dog,,Intermediate
6239,Canis lupus familiaris,,,9615.0,In vivo,,1,,1916,N,50588,,1,,A,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate
6240,Canis lupus familiaris,,,9615.0,In vivo,,1,,1918,N,50588,,1,,A,Bioavailability was evaluated in dog,,Intermediate
6241,Canis lupus familiaris,,,9615.0,In vivo,,1,,4239,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6242,Canis lupus familiaris,,,9615.0,In vivo,,1,,6505,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6243,Canis lupus familiaris,,,9615.0,In vivo,,1,,5334,N,50588,,1,,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Intermediate
6244,Canis lupus familiaris,,,9615.0,In vivo,,1,,5334,N,50588,,1,,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,Intermediate
6245,Canis lupus familiaris,,,9615.0,In vivo,,1,,4809,N,50588,,1,,A,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Intermediate
6246,Canis lupus familiaris,,,9615.0,In vivo,,1,,6348,N,50588,,1,,A,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate
6247,Canis lupus familiaris,,,9615.0,In vivo,,1,,6005,N,50588,,1,,A,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,Intermediate
6248,Canis lupus familiaris,,,9615.0,In vivo,,1,,17804,N,50588,,1,,A,Bioavailability of compound in dog was determined after peroral administration,,Intermediate
6249,Canis lupus familiaris,,,9615.0,In vivo,,1,,3184,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6250,Canis lupus familiaris,,,9615.0,In vivo,,1,,1806,N,50588,,1,,A,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,Intermediate
6251,Canis lupus familiaris,,,9615.0,In vivo,,1,,1806,N,50588,,1,,A,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,Intermediate
6252,Canis lupus familiaris,,,9615.0,In vivo,,1,,1806,N,50588,,1,,A,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,Intermediate
6253,Canis lupus familiaris,,,9615.0,In vivo,,1,,4839,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6254,Canis lupus familiaris,,,9615.0,In vivo,,1,,5017,N,50588,,1,,A,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,Intermediate
6255,Mus musculus,,948.0,10090.0,In vivo,,1,,846,N,50594,,1,Heart,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6256,Mus musculus,,948.0,10090.0,In vivo,,1,,846,N,50594,,1,Heart,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6257,Mus musculus,,2113.0,10090.0,In vivo,,1,,846,N,50594,,1,Kidney,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6258,Mus musculus,,2113.0,10090.0,In vivo,,1,,846,N,50594,,1,Kidney,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6259,Mus musculus,,2113.0,10090.0,In vivo,,1,,846,N,50594,,1,Kidney,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6260,Mus musculus,,2113.0,10090.0,In vivo,,1,,846,N,50594,,1,Kidney,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6261,Mus musculus,,2113.0,10090.0,In vivo,,1,,846,N,50594,,1,Kidney,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6262,Mus musculus,,2113.0,10090.0,In vivo,,1,,846,N,50594,,1,Kidney,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6263,Mus musculus,,2107.0,10090.0,In vivo,,1,,846,N,50594,,1,Liver,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6264,Mus musculus,,2107.0,10090.0,In vivo,,1,,846,N,50594,,1,Liver,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6265,Mus musculus,,2107.0,10090.0,In vivo,,1,,846,N,50594,,1,Liver,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6266,Mus musculus,,2107.0,10090.0,In vivo,,1,,846,N,50594,,1,Liver,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6267,Mus musculus,,2107.0,10090.0,In vivo,,1,,846,N,50594,,1,Liver,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6268,Mus musculus,,2107.0,10090.0,In vivo,,1,,846,N,50594,,1,Liver,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6269,Mus musculus,,2048.0,10090.0,In vivo,,1,,846,N,50594,,1,Lung,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6270,Mus musculus,,2048.0,10090.0,In vivo,,1,,846,N,50594,,1,Lung,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6271,Mus musculus,,2048.0,10090.0,In vivo,,1,,846,N,50594,,1,Lung,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6272,Mus musculus,,2048.0,10090.0,In vivo,,1,,846,N,50594,,1,Lung,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6273,Mus musculus,,2048.0,10090.0,In vivo,,1,,846,N,50594,,1,Lung,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6274,Mus musculus,,2048.0,10090.0,In vivo,,1,,846,N,50594,,1,Lung,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,Intermediate
6275,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,Intermediate
6276,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,Intermediate
6277,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,Intermediate
6278,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,Intermediate
6279,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,Intermediate
6280,Mus musculus,,955.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Brain,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,Intermediate
6281,Mus musculus,,955.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Brain,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,Intermediate
6282,Mus musculus,,955.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Brain,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,Intermediate
6283,Mus musculus,,955.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Brain,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,Intermediate
6284,Mus musculus,,955.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Brain,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,Intermediate
6285,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,Intermediate
6286,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,Intermediate
6287,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,Intermediate
6288,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,Intermediate
6289,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,Intermediate
6290,Mus musculus,,2113.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Kidney,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,Intermediate
6291,Mus musculus,,2113.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Kidney,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,Intermediate
6292,Mus musculus,,2113.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Kidney,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,Intermediate
6293,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,Intermediate
6294,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,Intermediate
6295,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,Intermediate
6296,Homo sapiens,,,9606.0,,,1,,17130,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,Intermediate
6297,Homo sapiens,,,9606.0,,,1,,3263,N,80682,A549,1,,F,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Expert
6298,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,Expert
6299,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,Expert
6300,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,Expert
6301,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,Expert
6302,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,Expert
6303,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,Intermediate
6304,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,Intermediate
6305,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,Intermediate
6306,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,Intermediate
6307,Homo sapiens,,,9606.0,,,1,,6663,N,80682,A549,1,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,Intermediate
6308,Homo sapiens,,,9606.0,,,1,,3983,N,80682,A549,1,,F,The compound was evaluated for its cytotoxic potency against A-549 cell line,,Intermediate
6309,Homo sapiens,,,9606.0,,,1,,11141,N,80682,A549,1,,F,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,Expert
6310,Homo sapiens,,,9606.0,,,1,,5076,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 tumor cell line.,,Intermediate
6311,Homo sapiens,,,9606.0,,,1,,3311,N,80682,A549,1,,F,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,Intermediate
6312,Homo sapiens,,,9606.0,,,1,,3311,N,80682,A549,1,,F,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,Intermediate
6313,Homo sapiens,,,9606.0,,,1,,3311,N,80682,A549,1,,F,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,Intermediate
6314,Homo sapiens,,,9606.0,,,1,,5076,N,80682,A549,1,,F,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,Intermediate
6315,Homo sapiens,,,9606.0,,,1,,4150,N,80682,A549,1,,F,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,Intermediate
6316,Homo sapiens,,,9606.0,,,1,,2150,N,80682,A549,1,,F,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,Expert
6317,Homo sapiens,,,9606.0,,,1,,4644,N,80682,A549,1,,F,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,Intermediate
6318,Homo sapiens,,,9606.0,,,1,,263,N,80682,A549,1,,F,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,Intermediate
6319,Homo sapiens,,,9606.0,,,1,,11333,N,80682,A549,1,,F,Cytotoxic concentration against A-549 tumor cells.,,Intermediate
6320,Homo sapiens,,,9606.0,,,1,,11333,N,80682,A549,1,,F,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,Intermediate
6321,Homo sapiens,,,9606.0,,,1,,15895,N,80682,A549,1,,F,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,Intermediate
6322,Acinetobacter baumannii,,,470.0,,,1,,16677,N,50191,,1,,F,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,Expert
6323,Acinetobacter calcoaceticus,,,471.0,,,1,,10624,N,50192,,1,,F,Activity against Acinetobacter calcoaceticus (AC54),,Intermediate
6324,Aspergillus flavus,,,5059.0,,,1,,16717,N,50274,,1,,F,In vitro antifungal activity against Aspergillus flavus CM74,,Expert
6325,Aspergillus flavus,,,5059.0,,,1,,16717,N,50274,,1,,F,In vitro antifungal activity against Aspergillus flavus CM74,,Expert
6326,Aspergillus fumigatus,,,746128.0,,,1,,5513,N,50416,,1,,F,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,Intermediate
6327,Aspergillus fumigatus,,,746128.0,,,1,,15962,N,50416,,1,,F,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,Intermediate
6328,Aspergillus fumigatus,,,746128.0,,,1,,15962,N,50416,,1,,F,Antimicrobial activity against Aspergillus fumigatus (MIC),,Intermediate
6329,Aspergillus fumigatus,,,746128.0,,,1,,15962,N,50416,,1,,F,Antimicrobial activity against Aspergillus fumigatus (MIC),,Intermediate
6330,Aspergillus fumigatus,,,746128.0,,,1,,15962,N,50416,,1,,F,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,Intermediate
6331,Aspergillus fumigatus,,,746128.0,,,1,,16717,N,50416,,1,,F,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Expert
6332,Aspergillus fumigatus,,,746128.0,,,1,,16717,N,50416,,1,,F,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Expert
6333,Actinomyces naeslundii,,,1655.0,,,1,,8117,N,50296,,1,,F,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,Intermediate
6334,Actinomyces viscosus,,,1656.0,,,1,,8117,N,50366,,1,,F,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,Intermediate
6335,Acanthocheilonema viteae,,,6277.0,,,1,,15472,N,50535,,1,,F,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Intermediate
6336,Acanthocheilonema viteae,,,6277.0,,,1,,15472,N,50535,,1,,F,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Intermediate
6337,Aggregatibacter actinomycetemcomitans,,,714.0,,,1,,16443,N,50169,,1,,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,Intermediate
6338,Aggregatibacter actinomycetemcomitans,,,714.0,,,1,,16443,N,50169,,1,,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,Intermediate
6339,Aggregatibacter actinomycetemcomitans,,,714.0,,,1,,16443,N,50169,,1,,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,Intermediate
6340,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Intermediate
6341,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,Intermediate
6342,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Intermediate
6343,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Intermediate
6344,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Intermediate
6345,Homo sapiens,,,9606.0,,,1,,16381,N,80682,A549,1,,F,GI values against A549 cells (lung cancer),,Intermediate
6346,Homo sapiens,,,9606.0,,,1,,17206,N,80682,A549,1,,F,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,Intermediate
6347,Homo sapiens,,,9606.0,,,1,,16325,N,80682,A549,1,,F,Inhibitory activity against A549 human adenocarcinoma,,Intermediate
6348,Homo sapiens,,,9606.0,,,1,,10708,N,80682,A549,1,,F,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,Intermediate
6349,Homo sapiens,,,9606.0,,,1,,10708,N,80682,A549,1,,F,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,Intermediate
6350,Homo sapiens,,,9606.0,,,1,,17376,N,80682,A549,1,,F,Inhibitory activity against A549 lung adenocarcinoma cell line,,Intermediate
6351,Homo sapiens,,,9606.0,,,1,,17376,N,80682,A549,1,,F,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,Intermediate
6352,Homo sapiens,,,9606.0,,,1,,17488,N,80682,A549,1,,F,Cytotoxicity against human A549 lung cells,,Intermediate
6353,Homo sapiens,,,9606.0,,,1,,17404,N,80682,A549,1,,F,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,Intermediate
6354,Homo sapiens,,,9606.0,,,1,,10958,N,80682,A549,1,,F,Growth inhibition of A549 (human lung carcinoma) cell line.,,Expert
6355,Homo sapiens,,,9606.0,,,1,,17099,N,80682,A549,1,,F,Effective dose required for inhibitory activity against A549 human tumor cell line.,,Expert
6356,Homo sapiens,,,9606.0,,,1,,17099,N,80682,A549,1,,F,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,Intermediate
6357,Homo sapiens,,,9606.0,,,1,,4096,N,80682,A549,1,,F,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,Intermediate
6358,Homo sapiens,,,9606.0,,,1,,4096,N,80682,A549,1,,F,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,Expert
6359,Homo sapiens,,,9606.0,,,1,,4096,N,80682,A549,1,,F,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,Intermediate
6360,Homo sapiens,,,9606.0,,,1,,2525,N,80682,A549,1,,F,In vitro inhibitory activity against A549 tumor cell culture,,Intermediate
6361,Homo sapiens,,,9606.0,,,1,,2525,N,80682,A549,1,,F,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,Intermediate
6362,Homo sapiens,,,9606.0,,,1,,5302,N,80682,A549,1,,F,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,Intermediate
6363,Homo sapiens,,,9606.0,,,1,,16325,N,80682,A549,1,,F,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,Intermediate
6364,Homo sapiens,,,9606.0,,,1,,16939,N,80682,A549,1,,F,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,Intermediate
6365,Homo sapiens,,,9606.0,,,1,,17229,N,80682,A549,1,,F,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,Intermediate
6366,Homo sapiens,,,9606.0,,,1,,17380,N,80682,A549,1,,F,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,Intermediate
6367,Homo sapiens,,,9606.0,,,1,,17380,N,80682,A549,1,,F,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,Intermediate
6368,Homo sapiens,,,9606.0,,,1,,1903,N,80682,A549,1,,F,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,Intermediate
6369,Homo sapiens,,,9606.0,,,1,,3838,N,80682,A549,1,,F,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Intermediate
6370,Homo sapiens,,,9606.0,,,1,,14696,N,80682,A549,1,,F,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Intermediate
6371,Homo sapiens,,,9606.0,,,1,,3838,N,80682,A549,1,,F,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Intermediate
6372,Homo sapiens,,,9606.0,,,1,,1522,N,80682,A549,1,,F,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,Intermediate
6373,Homo sapiens,,,9606.0,,,1,,12400,N,80682,A549,1,,F,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,Intermediate
6374,Homo sapiens,,,9606.0,,,1,,14696,N,80682,A549,1,,F,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Intermediate
6375,Homo sapiens,,,9606.0,,,1,,14769,N,80682,A549,1,,F,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,Intermediate
6376,Homo sapiens,,,9606.0,,,1,,14696,N,80682,A549,1,,F,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,Intermediate
6377,Homo sapiens,,,9606.0,,,1,,1888,N,80682,A549,1,,F,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,Intermediate
6378,Homo sapiens,,,9606.0,,,1,,12016,N,80682,A549,1,,F,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,Intermediate
6379,Homo sapiens,,,9606.0,,,1,,6058,N,80682,A549,1,,F,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,Intermediate
6380,Homo sapiens,,,9606.0,,,1,,17708,N,80682,A549,1,,F,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,Intermediate
6381,Homo sapiens,,,9606.0,,,1,,12301,N,80682,A549,1,,F,Antitumor activity against A549/ATCC cell line,,Intermediate
6382,Homo sapiens,,,9606.0,,,1,,11970,N,80682,A549,1,,F,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,Intermediate
6383,Homo sapiens,,,9606.0,,,1,,11818,N,80682,A549,1,,F,In vitro cytotoxicity against A549/ATCC cell line.,,Expert
6384,Homo sapiens,,,9606.0,,,1,,12400,N,80682,A549,1,,F,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,Intermediate
6385,Homo sapiens,,,9606.0,,,1,,3381,N,80682,A549,1,,F,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,Intermediate
6386,Homo sapiens,,,9606.0,,,1,,17376,N,80682,A549,1,,F,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,Intermediate
6387,Homo sapiens,,,9606.0,,,1,,10708,N,80682,A549,1,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,Intermediate
6388,Homo sapiens,,,9606.0,,,1,,2964,U,22226,,0,,F,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,Autocuration
6389,Canis lupus familiaris,,,9615.0,In vivo,,1,,5005,U,22224,,0,,A,Compound was tested for oral bioavailability in dogs,,Intermediate
6390,Canis lupus familiaris,,,9615.0,In vivo,,1,,6229,N,50588,,1,,A,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,Intermediate
6391,Canis lupus familiaris,,,9615.0,In vivo,,1,,6229,N,50588,,1,,A,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,Intermediate
6392,Canis lupus familiaris,,,9615.0,In vivo,,1,,5374,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6393,Canis lupus familiaris,,,9615.0,In vivo,,1,,5374,N,50588,,1,,A,Compound was tested for the oral bioavailability in dog; No availability,,Intermediate
6394,Canis lupus familiaris,,,9615.0,In vivo,,1,,6265,N,50588,,1,,A,Oral bioavailability in dog (dose 5 mg/kg),,Intermediate
6395,Canis lupus familiaris,,,9615.0,In vivo,,1,,5654,N,50588,,1,,A,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,Intermediate
6396,Canis lupus familiaris,,,9615.0,In vivo,,1,,5654,N,50588,,1,,A,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,Intermediate
6397,Canis lupus familiaris,,,9615.0,In vivo,,1,,16456,N,50588,,1,,A,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,Intermediate
6398,Canis lupus familiaris,,,9615.0,In vivo,,1,,5302,N,50588,,1,,A,Oral bioavailability in dog (dose 5 mg/kg),,Intermediate
6399,Canis lupus familiaris,,,9615.0,In vivo,,1,,3624,N,50588,,1,,A,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,Intermediate
6400,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Oral bioavailability of active FTIs in dogs,,Intermediate
6401,Canis lupus familiaris,,,9615.0,In vivo,,1,,5802,N,50588,,1,,A,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,Intermediate
6402,Canis lupus familiaris,,,9615.0,In vivo,,1,,3598,N,50588,,1,,A,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert
6403,Canis lupus familiaris,,,9615.0,In vivo,,1,,17839,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6404,Canis lupus familiaris,,,9615.0,In vivo,,1,,6762,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6405,Canis lupus familiaris,,,9615.0,In vivo,,1,,6821,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6406,Canis lupus familiaris,,,9615.0,In vivo,,1,,6821,N,50588,,1,,A,Oral bioavailability of compound was determined in dog; Not tested,,Intermediate
6407,Canis lupus familiaris,,,9615.0,In vivo,,1,,5210,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6408,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Oral bioavailability (10 mg/kg) was determined in dog,,Intermediate
6409,Canis lupus familiaris,,,9615.0,In vivo,,1,,761,N,50588,,1,,A,Oral bioavailability,,Intermediate
6410,Canis lupus familiaris,,,9615.0,In vivo,,1,,761,N,50588,,1,,A,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,Intermediate
6411,Canis lupus familiaris,,,9615.0,In vivo,,1,,761,N,50588,,1,,A,Oral bioavailability administered in solution in rats,,Intermediate
6412,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Oral bioavailability after 30 mg/kg po dose in Dogs,,Intermediate
6413,Canis lupus familiaris,,,9615.0,In vivo,,1,,5474,N,50588,,1,,A,Oral bioavailability at a dose of 1 mg/kg in dogs,,Intermediate
6414,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Oral bioavailability in dog (dose 1 mg/kg p.o.),,Intermediate
6415,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Oral bioavailability in Dog; ND = not determined,,Intermediate
6416,Canis lupus familiaris,,,9615.0,In vivo,,1,,3352,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6417,Canis lupus familiaris,,,9615.0,In vivo,,1,,6168,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6418,Canis lupus familiaris,,,9615.0,In vivo,,1,,5988,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6419,Canis lupus familiaris,,,9615.0,In vivo,,1,,4942,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6420,Canis lupus familiaris,,,9615.0,In vivo,,1,,4942,N,50588,,1,,A,Oral bioavailability in dogs; No data,,Intermediate
6421,Canis lupus familiaris,,,9615.0,In vivo,,1,,14541,N,50588,,1,,A,Oral bioavailability measured in dogs,,Intermediate
6422,Canis lupus familiaris,,,9615.0,In vivo,,1,,4449,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6423,Canis lupus familiaris,,,9615.0,In vivo,,1,,6057,N,50588,,1,,A,Oral bioavailability was calculated in dog,,Intermediate
6424,Canis lupus familiaris,,,9615.0,In vivo,,1,,5600,N,50588,,1,,A,Oral bioavailability after 0.3 mg/kg po administration in dog,,Intermediate
6425,Canis lupus familiaris,,,9615.0,In vivo,,1,,5542,N,50588,,1,,A,Oral bioavailability in dog (i.v. dosing),,Intermediate
6426,Canis lupus familiaris,,,9615.0,In vivo,,1,,5542,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6427,Canis lupus familiaris,,,9615.0,In vivo,,1,,5546,N,50588,,1,,A,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,Intermediate
6428,Canis lupus familiaris,,,9615.0,In vivo,,1,,4514,N,50588,,1,,A,Oral bioavailability in Beagle dogs,,Intermediate
6429,Canis lupus familiaris,,,9615.0,In vivo,,1,,3624,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6430,Canis lupus familiaris,,,9615.0,In vivo,,1,,3854,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6431,Canis lupus familiaris,,,9615.0,In vivo,,1,,5836,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6432,Canis lupus familiaris,,,9615.0,In vivo,,1,,5940,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6433,Canis lupus familiaris,,,9615.0,In vivo,,1,,6168,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6434,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6435,Canis lupus familiaris,,,9615.0,In vivo,,1,,6251,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6436,Canis lupus familiaris,,,9615.0,In vivo,,1,,6448,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6437,Canis lupus familiaris,,,9615.0,In vivo,,1,,6647,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6438,Canis lupus familiaris,,,9615.0,In vivo,,1,,5940,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6439,Canis lupus familiaris,,,9615.0,In vivo,,1,,933,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6440,Canis lupus familiaris,,,9615.0,In vivo,,1,,5210,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6441,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,Intermediate
6442,Canis lupus familiaris,,,9615.0,In vivo,,1,,6641,N,50588,,1,,A,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,Intermediate
6443,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,Intermediate
6444,Canis lupus familiaris,,,9615.0,In vivo,,1,,5472,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6445,Canis lupus familiaris,,,9615.0,In vivo,,1,,5985,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6446,Canis lupus familiaris,,,9615.0,In vivo,,1,,15660,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6447,Canis lupus familiaris,,,9615.0,In vivo,,1,,5530,N,50588,,1,,A,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,Intermediate
6448,Canis lupus familiaris,,,9615.0,In vivo,,1,,5530,N,50588,,1,,A,Oral bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate
6449,Canis lupus familiaris,,,9615.0,In vivo,,1,,6305,N,50588,,1,,A,Oral bioavailability (F) in dogs,,Intermediate
6450,Canis lupus familiaris,,,9615.0,In vivo,,1,,5210,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6451,Canis lupus familiaris,,,9615.0,In vivo,,1,,5238,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6452,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate
6453,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Oral bioavailability after peroral administration at 5 mpk in Dog,,Intermediate
6454,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Oral bioavailability in dog (dose 5 mg/kg),,Intermediate
6455,Canis lupus familiaris,,,9615.0,In vivo,,1,,6084,N,50588,,1,,A,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate
6456,Mus musculus,,2113.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Kidney,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,Intermediate
6457,Mus musculus,,2113.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Kidney,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,Intermediate
6458,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,Intermediate
6459,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,Intermediate
6460,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,Intermediate
6461,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,Intermediate
6462,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,Intermediate
6463,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,Intermediate
6464,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,Intermediate
6465,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,Intermediate
6466,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,Intermediate
6467,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,Intermediate
6468,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,Intermediate
6469,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,Intermediate
6470,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,Intermediate
6471,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,Intermediate
6472,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,Intermediate
6473,Mus musculus,,2106.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Spleen,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,Intermediate
6474,Mus musculus,,2106.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Spleen,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,Intermediate
6475,Mus musculus,,2106.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Spleen,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,Intermediate
6476,Mus musculus,,2106.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Spleen,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,Intermediate
6477,Mus musculus,,2106.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Spleen,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,Intermediate
6478,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,Intermediate
6479,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,Intermediate
6480,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,Intermediate
6481,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,Intermediate
6482,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,Intermediate
6483,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,Intermediate
6484,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,Intermediate
6485,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,Intermediate
6486,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,Intermediate
6487,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,Intermediate
6488,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,Intermediate
6489,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,Intermediate
6490,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,Intermediate
6491,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,Intermediate
6492,Mus musculus,,948.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Heart,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,Intermediate
6493,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,Intermediate
6494,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,Intermediate
6495,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,Intermediate
6496,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,Intermediate
6497,Mus musculus,,2107.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Liver,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,Intermediate
6498,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,Intermediate
6499,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,Intermediate
6500,aeinetobacter anitrotap,,,107673.0,,,1,,12269,N,50067,,1,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate
6501,Acinetobacter calcoaceticus subsp. anitratus,,,107673.0,,,1,,12269,N,50067,,1,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate
6502,Acinetobacter calcoaceticus subsp. anitratus,,,107673.0,,,1,,12269,N,50067,,1,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate
6503,aeinetobacter anitrotap,,,107673.0,,,1,,12269,N,50067,,1,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate
6504,Acinetobacter calcoaceticus,,,471.0,,,1,,10624,N,50192,,1,,F,Activity against Acinetobacter calcoaceticus (AC54),,Intermediate
6505,Anolis carolinensis,,,28377.0,,,1,,17216,N,50714,,1,,F,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,Intermediate
6506,Anolis carolinensis,,,28377.0,,,1,,17216,N,50714,,1,,F,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,Intermediate
6507,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Chlorohexidine coefficient for Actinomyces naeslundii 631,,Intermediate
6508,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Chlorohexidine coefficient for Actinomyces naeslundii B74,,Intermediate
6509,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,Intermediate
6510,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,Intermediate
6511,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Plaque bactericidal index against Actinomyces naeslundii 631,,Intermediate
6512,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Plaque bactericidal index against Actinomyces naeslundii N/9,,Intermediate
6513,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Plaque bactericidal index against Actinomyces naeslundii B74,,Intermediate
6514,Actinomyces naeslundii,,,1655.0,,,1,,9560,N,50296,,1,,F,Plaque bactericidal index against Actinomyces naeslundii N/3,,Intermediate
6515,Artemia salina,,,85549.0,,,1,,114,N,50056,,1,,F,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,Intermediate
6516,Artemia salina,,,85549.0,,,1,,114,N,50056,,1,,F,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,Intermediate
6517,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Intermediate
6518,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Intermediate
6519,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Intermediate
6520,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Intermediate
6521,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Intermediate
6522,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,Intermediate
6523,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Intermediate
6524,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Intermediate
6525,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Intermediate
6526,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Intermediate
6527,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Intermediate
6528,Ascaris suum,,,6253.0,,,1,,10841,N,50532,,1,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,Intermediate
6529,Actinomyces viscosus,,,1656.0,,,1,,8117,N,50366,,1,,F,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Intermediate
6530,Actinomyces viscosus,,,1656.0,,,1,,8117,N,50366,,1,,F,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Intermediate
6531,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,Intermediate
6532,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Chlorohexidine coefficient for Actinomyces viscosus M-100,,Expert
6533,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Chlorohexidine coefficient for Actinomyces viscosus M-626,,Intermediate
6534,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Chlorohexidine coefficient for Actinomyces viscosus T14V,,Intermediate
6535,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Plaque bactericidal index against Actinomyces viscosus 8A06,,Intermediate
6536,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Plaque bactericidal index against Actinomyces viscosus M-100,,Intermediate
6537,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,Expert
6538,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Intermediate
6539,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Intermediate
6540,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Plaque bactericidal index against Actinomyces viscosus 626,,Intermediate
6541,Actinomyces viscosus,,,1656.0,,,1,,9560,N,50366,,1,,F,Plaque bactericidal index against Actinomyces viscosus T14V,,Intermediate
6542,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,Intermediate
6543,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,Intermediate
6544,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,Intermediate
6545,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,Intermediate
6546,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,Intermediate
6547,Homo sapiens,,,9606.0,,,1,,10708,N,80023,A673,1,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,Intermediate
6548,Homo sapiens,,,9606.0,,,1,,10708,N,80661,A704,1,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,Intermediate
6549,Rattus norvegicus,,,10116.0,,,1,,416,U,22226,,0,,F,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,Autocuration
6550,Mus musculus,,,10090.0,,,1,,14354,N,80024,A9,1,,F,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Intermediate
6551,Mus musculus,,,10090.0,,,1,,14354,N,80024,A9,1,,F,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Intermediate
6552,Homo sapiens,,,9606.0,,,1,,5116,N,80024,A9,1,,F,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,Intermediate
6553,Homo sapiens,,,9606.0,,,1,,5116,N,80024,A9,1,,F,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,Intermediate
6554,Homo sapiens,,,9606.0,,,1,,15694,N,81037,Human ovarian carcinoma cell line,1,,F,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,Expert
6555,Mus musculus,,,10090.0,,,1,,13038,N,80024,A9,1,,F,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,Expert
6556,Mus musculus,,,10090.0,,,1,,13038,N,80024,A9,1,,F,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,Expert
6557,Mus musculus,,,10090.0,,,1,,10923,N,80024,A9,1,,F,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,Expert
6558,Mus musculus,,,10090.0,,,1,,10923,N,80024,A9,1,,F,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,Intermediate
6559,Mus musculus,,,10090.0,,,1,,10923,N,80024,A9,1,,F,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,Intermediate
6560,,,,,,,1,,10923,H,10649,,8,,F,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,Expert
6561,Mus musculus,,,10090.0,,,1,,10923,N,80024,A9,1,,F,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,Intermediate
6562,Mus musculus,,,10090.0,,,1,,10923,N,80024,A9,1,,F,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,Intermediate
6563,Cricetulus griseus,,,10029.0,,,1,,8158,N,80663,AA6,1,,F,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,Intermediate
6564,Homo sapiens,,,9606.0,,,1,,15494,U,22226,,0,,F,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,Autocuration
6565,Homo sapiens,,,9606.0,,,1,,15494,U,22226,,0,,F,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,Autocuration
6566,Homo sapiens,,,9606.0,,,1,,12348,N,80662,AA5,1,,F,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,Intermediate
6567,Homo sapiens,,,9606.0,,,1,,12348,N,80662,AA5,1,,F,Cytotoxicity was measured against AA5/HIV-1(IIIB),,Intermediate
6568,Homo sapiens,,,9606.0,,,1,,2726,N,80662,AA5,1,,F,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,Intermediate
6569,Homo sapiens,,,9606.0,,,1,,2726,N,80566,U-937,1,,F,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,Intermediate
6570,Cricetulus griseus,,,10029.0,,,1,,10747,N,80578,UV4,1,,F,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,Intermediate
6571,Cricetulus griseus,,,10029.0,,,1,,11005,N,80089,CHO-AA8,1,,F,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Expert
6572,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Average intracellular compound concentration when the hypoxic SER=1.6,,Intermediate
6573,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Average intracellular compound concentration when the hypoxic SER=1.6.,,Intermediate
6574,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,Intermediate
6575,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,Intermediate
6576,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,Intermediate
6577,Cricetulus griseus,,,10029.0,,,1,,13436,N,80089,CHO-AA8,1,,F,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,Intermediate
6578,Cricetulus griseus,,,10029.0,,,1,,13435,N,80089,CHO-AA8,1,,F,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,Intermediate
6579,Cricetulus griseus,,,10029.0,,,1,,13302,N,80089,CHO-AA8,1,,F,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,Intermediate
6580,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Intermediate
6581,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,A,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Intermediate
6582,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,A,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,Intermediate
6583,Cricetulus griseus,,,10029.0,,,1,,12878,N,80089,CHO-AA8,1,,A,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,Expert
6584,Cricetulus griseus,,,10029.0,,,1,,12878,N,80089,CHO-AA8,1,,A,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,Intermediate
6585,Cricetulus griseus,,,10029.0,,,1,,14367,N,80089,CHO-AA8,1,,F,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,Expert
6586,Cricetulus griseus,,,10029.0,,,1,,14367,N,80089,CHO-AA8,1,,F,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,Intermediate
6587,hampster,,,36483.0,,,1,,12398,N,80089,CHO-AA8,1,,F,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,Expert
6588,Cricetulus griseus,,,10029.0,,,1,,12878,N,80089,CHO-AA8,1,,F,Aerobic growth inhibition in Chinese hamster cell line AA8,,Expert
6589,Cricetulus griseus,,,10029.0,,,1,,13820,N,80089,CHO-AA8,1,,F,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,Expert
6590,Cricetulus griseus,,,10029.0,,,1,,13436,N,80089,CHO-AA8,1,,F,Inhibition of growth under aerobic conditions in AA8 cells,,Expert
6591,Canis lupus familiaris,,,9615.0,In vivo,,1,,6084,N,50588,,1,,A,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate
6592,Canis lupus familiaris,,,9615.0,In vivo,,1,,5711,N,50588,,1,,A,Oral bioavailability in dog at 10 mg/kg of the compound,,Intermediate
6593,Canis lupus familiaris,,,9615.0,In vivo,,1,,4353,N,50588,,1,,A,Oral bioavailability in dog (dose 5 uM/kg),,Intermediate
6594,Canis lupus familiaris,,,9615.0,In vivo,,1,,4353,N,50588,,1,,A,Oral bioavailability in dog (dose 5 uM/kg),,Intermediate
6595,Canis lupus familiaris,,,9615.0,In vivo,,1,,17800,N,50588,,1,,A,Oral bioavailability in dog (mongrel),,Intermediate
6596,Canis lupus familiaris,,,9615.0,In vivo,,1,,3994,N,50588,,1,,A,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate
6597,Canis lupus familiaris,,,9615.0,In vivo,,1,,3994,N,50588,,1,,F,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate
6598,Canis lupus familiaris,,,9615.0,In vivo,,1,,5145,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6599,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate
6600,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,Intermediate
6601,Canis lupus familiaris,,,9615.0,In vivo,,1,,5983,N,50588,,1,,A,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,Intermediate
6602,Canis lupus familiaris,,,9615.0,In vivo,,1,,4273,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6603,Canis lupus familiaris,,,9615.0,In vivo,,1,,12500,N,50588,,1,,A,Bioavailability in dog (dose 3-10 mg/kg),,Intermediate
6604,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,12500,N,50588,,1,Plasma,A,The compound was tested for bioavailability of compound in plasma of dog; Complete,,Intermediate
6605,Canis lupus familiaris,,,9615.0,In vivo,,1,,3639,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6606,Canis lupus familiaris,,,9615.0,In vivo,,1,,3880,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6607,Canis lupus familiaris,,,9615.0,In vivo,,1,,4838,N,50588,,1,,A,Bioavailability in dog,,Intermediate
6608,Canis lupus familiaris,,,9615.0,In vivo,,1,,15600,N,50588,,1,,A,oral bioavailability was measured in dogs,,Intermediate
6609,Canis lupus familiaris,,,9615.0,,,1,,17248,N,50588,,1,,A,Compound was tested for plasma protein binding in dog; Not determined,,Intermediate
6610,Canis lupus familiaris,,,9615.0,,,1,,17248,N,50588,,1,,A,Compound was tested for plasma protein binding of dog,,Intermediate
6611,Canis lupus familiaris,,,9615.0,,,1,,17248,N,50588,,1,,A,Compound was tested for plasma protein binding of dog; Not determined,,Intermediate
6612,Canis lupus familiaris,,,9615.0,,,1,,17443,N,50588,,1,,A,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,Intermediate
6613,Canis lupus familiaris,,,9615.0,In vivo,,1,,4186,N,50588,,1,,A,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,Intermediate
6614,Canis lupus familiaris,,,9615.0,,,1,,3749,N,50588,,1,,A,Half life was determined,,Intermediate
6615,Canis lupus familiaris,,,9615.0,In vivo,,1,,3249,N,50588,,1,,A,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,Intermediate
6616,Canis lupus familiaris,,,9615.0,,,1,,3022,N,50588,,1,,A,Half life was evaluated in dog,,Intermediate
6617,Canis lupus familiaris,,,9615.0,,,1,,3749,N,50588,,1,,A,Half life was determined,,Intermediate
6618,Canis lupus familiaris,,,9615.0,In vivo,,1,,2517,N,50588,,1,,A,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate
6619,Canis lupus familiaris,,948.0,9615.0,In vivo,,1,,2517,N,50588,,1,Heart,A,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate
6620,Canis lupus familiaris,,2113.0,9615.0,In vivo,,1,,2517,N,50588,,1,Kidney,A,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate
6621,Canis lupus familiaris,,2107.0,9615.0,In vivo,,1,,2517,N,50588,,1,Liver,A,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate
6622,Canis lupus familiaris,,2048.0,9615.0,In vivo,,1,,2517,N,50588,,1,Lung,A,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate
6623,Canis lupus familiaris,,2106.0,9615.0,In vivo,,1,,2517,N,50588,,1,Spleen,A,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate
6624,Canis lupus familiaris,,,9615.0,,,1,,3639,N,50588,,1,,A,LogP in dog,,Intermediate
6625,Canis lupus familiaris,,,9615.0,,,1,,6227,N,50588,,1,,A,Partition coefficient (logP),,Intermediate
6626,Canis lupus familiaris,,,9615.0,,,1,,6227,N,50588,,1,,A,Partition coefficient in dog,,Intermediate
6627,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,Intermediate
6628,Canis lupus familiaris,,,9615.0,In vivo,,1,,4809,N,50588,,1,,A,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,Intermediate
6629,Canis lupus familiaris,,,9615.0,,,1,,5600,N,50588,,1,,A,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,Intermediate
6630,Canis lupus familiaris,,,9615.0,,,1,,14294,N,50588,,1,,A,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,Intermediate
6631,Canis lupus familiaris,,,9615.0,,,1,,14294,N,50588,,1,,A,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,Intermediate
6632,Canis lupus familiaris,,,9615.0,,,1,,14294,N,50588,,1,,A,Metabolism of compound in dog S9 microsomes; Trace,,Intermediate
6633,Canis lupus familiaris,,2107.0,9615.0,,,1,,6251,N,50588,,1,Liver,A,In vitro metabolic potential in dog liver microsomes,,Intermediate
6634,Canis lupus familiaris,,,9615.0,In vivo,,1,,3748,N,50588,,1,,A,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,Intermediate
6635,Canis lupus familiaris,,,9615.0,In vivo,,1,,2713,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6636,Canis lupus familiaris,,,9615.0,In vivo,,1,,6512,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6637,Canis lupus familiaris,,,9615.0,In vivo,,1,,6679,N,50588,,1,,A,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate
6638,Canis lupus familiaris,,,9615.0,In vivo,,1,,3749,N,50588,,1,,A,The compound was tested for bioavailability in dogs,,Intermediate
6639,Canis lupus familiaris,,,9615.0,In vivo,,1,,3749,N,50588,,1,,A,The compound was tested for oral bioavailability in dogs,,Intermediate
6640,Canis lupus familiaris,,,9615.0,In vivo,,1,,6742,N,50588,,1,,A,Oral bioavailability in dog,,Intermediate
6641,Canis lupus familiaris,,,9615.0,,,1,,6227,N,50588,,1,,A,Compound was tested for percent protein binding (PB) in dog,,Intermediate
6642,Canis lupus familiaris,,,9615.0,,,1,,6874,N,50588,,1,,A,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,Intermediate
6643,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,2877,N,50588,,1,Plasma,A,Compound was evaluated for plasma clearance.,,Intermediate
6644,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,12500,N,50588,,1,Plasma,A,The compound was tested for plasma clearance in dog,,Intermediate
6645,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,12500,N,50588,,1,Plasma,A,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,Intermediate
6646,Canis lupus familiaris,,,9615.0,,,1,,4709,N,50588,,1,,A,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,Intermediate
6647,Canis lupus familiaris,,2107.0,9615.0,,,1,,5542,N,50588,,1,Liver,A,In vitro relative rate of metabolism was determined in dog liver microsomes,,Intermediate
6648,Canis lupus familiaris,,,9615.0,In vivo,,1,,17594,N,50588,,1,,A,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,Intermediate
6649,Canis lupus familiaris,,,9615.0,In vivo,,1,,2652,N,50588,,1,,A,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,Intermediate
6650,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Half life after intravenous administration in dogs at 1.2 uM/kg,,Intermediate
6651,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,Intermediate
6652,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,Intermediate
6653,Mus musculus,,2048.0,10090.0,,,1,,6599,N,50594,CCRF S-180,1,Lung,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,Intermediate
6654,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,Intermediate
6655,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,Intermediate
6656,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,Intermediate
6657,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,Intermediate
6658,Mus musculus,,,10090.0,,,1,,6599,N,50594,CCRF S-180,1,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,Intermediate
6659,Mus musculus,,955.0,10090.0,,,1,,17641,N,50594,,1,Brain,A,C2 in brain of mice at the oral dose of 50 mg/kg,,Intermediate
6660,Mus musculus,,2113.0,10090.0,,,1,,17641,N,50594,,1,Kidney,A,C2 in kidney of mice at the oral dose of 50 mg/kg,,Intermediate
6661,Mus musculus,,2107.0,10090.0,,,1,,17641,N,50594,,1,Liver,A,C2 in liver of mice at the oral dose of 50 mg/kg,,Intermediate
6662,Mus musculus,,2048.0,10090.0,,,1,,17641,N,50594,,1,Lung,A,C2 in lungs of mice at the oral dose of 50 mg/kg,,Intermediate
6663,Mus musculus,,2106.0,10090.0,,,1,,17641,N,50594,,1,Spleen,A,C2 in spleen of mice at the oral dose of 50 mg/kg,,Intermediate
6664,Mus musculus,,,10090.0,In vivo,,1,,17852,N,50594,,1,,A,Plasma clearance in mouse,,Intermediate
6665,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Clearance of compound after intravenous administration in mice at 24 uM/kg,,Intermediate
6666,Mus musculus,,,10090.0,In vivo,,1,,17837,N,50594,,1,,A,Clearance from mouse blood following i.v. administration of 10 mg/kg,,Intermediate
6667,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Clearance was evaluated in mice after intravenous administration,,Intermediate
6668,Mus musculus,,,10090.0,In vivo,,1,,2675,N,50594,,1,,A,Clearance was evaluated in mice after oral administration,,Intermediate
6669,Mus musculus,,,10090.0,In vivo,,1,,4239,N,50594,,1,,A,Pharmacokinetic property (Plasma clearance) was measured in mouse,,Intermediate
6670,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Plasma clearance of compound was determined at 40 mg/Kg,,Intermediate
6671,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Plasma clearance of at 24 mg/Kg,,Intermediate
6672,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Plasma clearance at 24 mg/Kg,,Intermediate
6673,Mus musculus,,,10090.0,In vivo,,1,,17753,N,50594,,1,,A,Plasma clearance at 5 mg/Kg,,Intermediate
6674,Mus musculus,,,10090.0,In vivo,,1,,5727,N,50594,,1,,A,Plasma clearance in mice,,Intermediate
6675,Mus musculus,,,10090.0,In vivo,,1,,2862,N,50594,,1,,A,Plasma clearance value upon iv administration in mouse,,Intermediate
6676,Mus musculus,,1969.0,10090.0,In vivo,,1,,5980,N,50594,,1,Plasma,A,Total plasma clearance in mice,,Intermediate
6677,Mus musculus,,,10090.0,In vivo,,1,,17592,N,50594,,1,,A,Clearance in mouse,,Intermediate
6678,Mus musculus,,,10090.0,In vivo,,1,,17718,N,50594,,1,,A,Clearance value was determined,,Intermediate
6679,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
6680,,,,,,,1,,17384,U,22229,,0,,P,Calculated partition coefficient (clogP),,Intermediate
6681,Mus musculus,,,10090.0,In vivo,,1,,6062,N,50594,,1,,A,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,Intermediate
6682,Mus musculus,,,10090.0,In vivo,,1,,17734,N,50594,,1,,A,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
6683,Mus musculus,,,10090.0,In vivo,,1,,6348,N,50594,,1,,A,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate
6684,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,Intermediate
6685,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,Intermediate
6686,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Intermediate
6687,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,Intermediate
6688,Mus musculus,,,10090.0,In vivo,,1,,5781,N,50594,,1,,A,Cmax after oral administration at 30 mg/kg in ICR mouse,,Intermediate
6689,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,A,Cmax after peroral administration in mice at 2.4 uM/kg,,Intermediate
6690,Mus musculus,,955.0,10090.0,In vivo,,1,,17641,N,50594,,1,Brain,A,Cmax in brain of mice at the oral dose of 50 mg/kg,,Intermediate
6691,Mus musculus,,2113.0,10090.0,In vivo,,1,,17641,N,50594,,1,Kidney,A,Cmax in kidney of mice at the oral dose of 50 mg/kg,,Intermediate
6692,Mus musculus,,2107.0,10090.0,In vivo,,1,,17641,N,50594,,1,Liver,A,Cmax in liver of mice at the oral dose of 50 mg/kg,,Intermediate
6693,Mus musculus,,2048.0,10090.0,In vivo,,1,,17641,N,50594,,1,Lung,A,Cmax in lungs of mice at the oral dose of 50 mg/kg,,Intermediate
6694,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Cmax in mice at 18 uM/kg i.p. administration,,Intermediate
6695,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Cmax in mice at 23 uM/kg i.v. administration,,Intermediate
6696,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Cmax in mice at 24 uM/kg i.p. administration,,Intermediate
6697,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Cmax in mice at 25 uM/kg i.p. administration,,Intermediate
6698,Mus musculus,,,10090.0,In vivo,,1,,17764,N,50594,,1,,F,Cmax in mice at 26 uM/kg i.p. administration,,Intermediate
6699,Mus musculus,,2106.0,10090.0,In vivo,,1,,17641,N,50594,,1,Spleen,A,Cmax in spleen of mice at the oral dose of 50 mg/kg,,Intermediate
6700,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate
6701,Mus musculus,,,10090.0,In vivo,,1,,16597,N,50594,,1,,A,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate
6702,Mus musculus,,,10090.0,In vivo,,1,,5727,N,50594,,1,,A,Cmax value was determined,,Intermediate
6703,Mus musculus,,,10090.0,In vivo,,1,,5951,N,50594,,1,,A,Cmax value in IRC mice,,Intermediate
6704,Mus musculus,,,10090.0,In vivo,,1,,5506,N,50594,,1,,A,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,Intermediate
6705,Mus musculus,,,10090.0,In vivo,,1,,5506,N,50594,,1,,A,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,Intermediate
6706,Mus musculus,,1969.0,10090.0,In vivo,,1,,14239,N,50594,,1,Plasma,A,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,Intermediate
6707,Mus musculus,,1969.0,10090.0,In vivo,,1,,4890,N,50594,,1,Plasma,A,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,Intermediate
6708,Mus musculus,,,10090.0,In vivo,,1,,429,N,50594,,1,,A,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,Intermediate
6709,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,Intermediate
6710,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,Intermediate
6711,Acanthocheilonema viteae,,,6277.0,,,1,,10986,N,50535,,1,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,Intermediate
6712,Homo sapiens,,,9606.0,,,1,,13227,N,80018,A-375,1,,F,Inhibitory activity against human tumor cell line A0375 melanoma.,,Intermediate
6713,Rattus norvegicus,,,10116.0,,,1,,4481,D,12512,,9,,B,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Brain membranes,Expert
6714,Homo sapiens,,,9606.0,,,1,,16931,D,114,,9,,F,Forskolin-induced cAMP production at human A1 adenosine receptor,,Expert
6715,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,Autocuration
6716,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,Autocuration
6717,,,,,,,1,,3850,H,114,CHO,8,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,Expert
6718,,,,,,,1,,3850,H,114,CHO,8,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,Expert
6719,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,Autocuration
6720,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,Autocuration
6721,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,Autocuration
6722,Homo sapiens,,,9606.0,,,1,,3850,D,114,CHO,9,,F,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,Expert
6723,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,Autocuration
6724,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,Autocuration
6725,,,,,,,1,,3850,H,114,CHO,8,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,Expert
6726,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,Autocuration
6727,,,,,,,1,,3850,H,114,CHO,8,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,Expert
6728,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,Autocuration
6729,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,Autocuration
6730,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,Autocuration
6731,,,,,,,1,,3850,H,114,CHO,8,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,Expert
6732,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,Autocuration
6733,,,,,,,1,,3850,H,114,CHO,8,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,Autocuration
6734,,,,,,,1,,3850,H,114,CHO,8,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,Expert
6735,Oryctolagus cuniculus,,,9986.0,,,1,,12680,N,80013,A10,1,,F,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,Intermediate
6736,Rattus norvegicus,,,10116.0,,,1,,1313,U,22226,A10,0,,F,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,Autocuration
6737,Rattus norvegicus,,,10116.0,,,1,,1313,U,22226,A10,0,,F,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,Autocuration
6738,Rattus norvegicus,,,10116.0,,,1,,17567,N,80013,A10,1,,F,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,Intermediate
6739,Rattus norvegicus,,,10116.0,,,1,,17567,N,80013,A10,1,,F,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,Intermediate
6740,Rattus norvegicus,,,10116.0,,,1,,11819,N,80013,A10,1,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,Intermediate
6741,Cricetulus griseus,,,10029.0,,,1,,13436,N,80089,CHO-AA8,1,,F,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,Intermediate
6742,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,Intermediate
6743,Cricetulus griseus,,,10029.0,,,1,,12651,N,80089,CHO-AA8,1,,F,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,Intermediate
6744,Cricetulus griseus,,,10029.0,,,1,,13300,N,80089,CHO-AA8,1,,F,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,Intermediate
6745,Cricetulus griseus,,,10029.0,,,1,,15296,N,80089,CHO-AA8,1,,F,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Intermediate
6746,Cricetulus griseus,,,10029.0,,,1,,15328,N,80089,CHO-AA8,1,,F,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,Intermediate
6747,Cricetulus griseus,,,10029.0,,,1,,13302,N,80089,CHO-AA8,1,,F,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,Intermediate
6748,Cricetulus griseus,,,10029.0,,,1,,14367,N,80089,CHO-AA8,1,,F,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,Expert
6749,Cricetulus griseus,,,10029.0,,,1,,17002,N,80089,CHO-AA8,1,,F,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,Expert
6750,Cricetulus griseus,,,10029.0,,,1,,13436,N,80089,CHO-AA8,1,,F,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,Intermediate
6751,Cricetulus griseus,,,10029.0,,,1,,13435,N,80089,CHO-AA8,1,,F,Inhibitory activity against aerobic growth of AA8 cells.,,Intermediate
6752,Cricetulus griseus,,,10029.0,,,1,,10503,N,80089,CHO-AA8,1,,A,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Intermediate
6753,Cricetulus griseus,,,10029.0,,,1,,10503,N,80089,CHO-AA8,1,,F,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Expert
6754,Cricetulus griseus,,,10029.0,,,1,,10503,N,80089,CHO-AA8,1,,F,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Intermediate
6755,Cricetulus griseus,,,10029.0,,,1,,15090,N,80089,CHO-AA8,1,,F,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,Expert
6756,Cricetulus griseus,,,10029.0,,,1,,10368,N,80089,CHO-AA8,1,,F,Cytotoxicity against AA8 cell line,,Expert
6757,Cricetulus griseus,,,10029.0,,,1,,12651,N,80089,CHO-AA8,1,,F,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,Intermediate
6758,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,A,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Intermediate
6759,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,F,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Intermediate
6760,Cricetulus griseus,,,10029.0,,,1,,12687,N,80089,CHO-AA8,1,,A,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Intermediate
6761,Cricetulus griseus,,,10029.0,,,1,,1890,N,80089,CHO-AA8,1,,F,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,Intermediate
6762,Cricetulus griseus,,,10029.0,,,1,,10747,N,80089,CHO-AA8,1,,F,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Intermediate
6763,Cricetulus griseus,,,10029.0,,,1,,10747,N,80089,CHO-AA8,1,,F,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Intermediate
6764,Cricetulus griseus,,,10029.0,,,1,,11616,U,22224,,0,,F,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,Autocuration
6765,Cricetulus griseus,,,10029.0,,,1,,11616,N,80089,CHO-AA8,1,,F,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,Expert
6766,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,Autocuration
6767,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,Autocuration
6768,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,Autocuration
6769,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,Autocuration
6770,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,Autocuration
6771,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,Autocuration
6772,Cricetulus griseus,,,10029.0,,,1,,3471,U,22224,CHO-AA8,0,,F,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,Autocuration
6773,Cricetulus griseus,,,10029.0,,,1,,11616,N,80089,CHO-AA8,1,,F,Concentration required to reduce AA8 cell survival by 10%,,Expert
6774,Cricetulus griseus,,,10029.0,,,1,,2656,U,22224,CHO-AA8,0,,F,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,Autocuration
6775,Cricetulus griseus,,,10029.0,,,1,,10518,U,22224,CHO-AA8,0,,F,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Autocuration
6776,Cricetulus griseus,,,10029.0,,,1,,10518,U,22224,CHO-AA8,0,,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Autocuration
6777,Cricetulus griseus,,,10029.0,,,1,,10518,U,22224,CHO-AA8,0,,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,Autocuration
6778,Cricetulus griseus,,,10029.0,,,1,,10518,U,22224,CHO-AA8,0,,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,Autocuration
6779,Cricetulus griseus,,,10029.0,,,1,,16156,U,22224,CHO-AA8,0,,F,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,Autocuration
6780,Cricetulus griseus,,,10029.0,,,1,,2656,U,22224,CHO-AA8,0,,F,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,Autocuration
6781,Cricetulus griseus,,,10029.0,,,1,,11005,U,22224,,0,,F,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Autocuration
6782,Cricetulus griseus,,,10029.0,,,1,,11942,U,22224,CHO-AA8,0,,F,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,Autocuration
6783,Cricetulus griseus,,,10029.0,,,1,,2128,U,22224,CHO-AA8,0,,F,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,Autocuration
6784,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Half life period after 15 mg/kg iv dose in Dogs,,Intermediate
6785,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Half life period after 30 mg/kg po dose in Dogs,,Intermediate
6786,Canis lupus familiaris,,,9615.0,In vivo,,1,,9579,N,50588,,1,,A,Half life was measured after oral 2b administration (tested in 6 dogs),,Intermediate
6787,Canis lupus familiaris,,,9615.0,In vivo,,1,,9579,N,50588,,1,,A,Half life was measured in dog after oral 17b administration,,Intermediate
6788,Canis lupus familiaris,,,9615.0,In vivo,,1,,9579,N,50588,,1,,A,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,Intermediate
6789,Canis lupus familiaris,,,9615.0,In vivo,,1,,9579,N,50588,,1,,A,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,Intermediate
6790,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Tmax value after 15 mg/kg iv dose in Dogs,,Intermediate
6791,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Tmax value after 30 mg/kg po dose in Dogs,,Intermediate
6792,Canis lupus familiaris,,,9615.0,In vivo,,1,,3184,N,50588,,1,,A,Compound was evaluated for its half life when administered intravenously in dog,,Intermediate
6793,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5017,N,50588,,1,Plasma,A,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,Intermediate
6794,Canis lupus familiaris,,,9615.0,,,1,,6821,N,50588,,1,,A,Elimination Half-life of compound was determined in dog,,Intermediate
6795,Canis lupus familiaris,,,9615.0,In vivo,,1,,17839,N,50588,,1,,A,Half life of compound in dog following oral administration,,Intermediate
6796,Canis lupus familiaris,,,9615.0,,,1,,17267,N,50588,,1,,A,Half life of compound was determined in dog,,Intermediate
6797,Canis lupus familiaris,,178.0,9615.0,,,1,,4727,N,50588,,1,Blood,A,Half life of compound was determined in dog blood,,Intermediate
6798,Canis lupus familiaris,,,9615.0,In vivo,,1,,5238,N,50588,,1,,A,Half life after oral and iv dosing in dogs,,Intermediate
6799,Canis lupus familiaris,,,9615.0,,,1,,4942,N,50588,,1,,A,Half life in dogs in hours,,Intermediate
6800,Canis lupus familiaris,,,9615.0,In vivo,,1,,6505,N,50588,,1,,A,Half life on i.v. administration of 2 mg/kg was measured in dog,,Intermediate
6801,Canis lupus familiaris,,,9615.0,In vivo,,1,,5130,N,50588,,1,,A,t1/2 in dog after oral dose (1 mg/kg),,Intermediate
6802,Canis lupus familiaris,,,9615.0,,,1,,1475,N,50588,,1,,A,Half life was evaluated in dog,,Intermediate
6803,Canis lupus familiaris,,,9615.0,In vivo,,1,,17804,N,50588,,1,,A,Half life period of compound was determined after intravenous administration at 2 mg/kg,,Intermediate
6804,Canis lupus familiaris,,,9615.0,In vivo,,1,,17804,N,50588,,1,,A,Half life period of compound was determined after peroral administration at 2 mg/kg,,Intermediate
6805,Canis lupus familiaris,,,9615.0,In vivo,,1,,6084,N,50588,,1,,A,Half life period (10 mg/kg) was determined in dog,,Intermediate
6806,Canis lupus familiaris,,,9615.0,In vivo,,1,,6084,N,50588,,1,,A,Half life period (10 mg/kg) was determined in dog,,Intermediate
6807,Canis lupus familiaris,,,9615.0,In vivo,,1,,5542,N,50588,,1,,A,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,Intermediate
6808,Canis lupus familiaris,,,9615.0,In vivo,,1,,5542,N,50588,,1,,A,Half life period by po administration in dog at a dose of 0.3 mg/kg,,Intermediate
6809,Canis lupus familiaris,,,9615.0,,,1,,6084,N,50588,,1,,A,Half life period in dog,,Intermediate
6810,Canis lupus familiaris,,,9615.0,In vivo,,1,,6241,N,50588,,1,,A,Half life period in dogs after oral administration at 1 mg/kg,,Intermediate
6811,Canis lupus familiaris,,,9615.0,In vivo,,1,,1916,N,50588,,1,,A,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate
6812,Canis lupus familiaris,,,9615.0,,,1,,6621,N,50588,,1,,A,Half-life of compound was determined in dogs,,Intermediate
6813,Canis lupus familiaris,,1969.0,9615.0,,,1,,1696,N,50588,,1,Plasma,A,Half-life in dog plasma,,Intermediate
6814,Canis lupus familiaris,,,9615.0,,,1,,17800,N,50588,,1,,A,Half-life in mongrel dogs was determined,,Intermediate
6815,Canis lupus familiaris,,,9615.0,In vivo,,1,,17657,N,50588,,1,,A,Half-life in dog upon oral administration,,Intermediate
6816,Canis lupus familiaris,,,9615.0,In vivo,,1,,17657,N,50588,,1,,A,Half-life in dog upon oral administration; Unable to calculate,,Intermediate
6817,Canis lupus familiaris,,,9615.0,,,1,,4239,N,50588,,1,,A,Half-life was measured in dog,,Intermediate
6818,Canis lupus familiaris,,,9615.0,,,1,,5985,N,50588,,1,,A,Half-life was measured in dog,,Intermediate
6819,Canis lupus familiaris,,,9615.0,,,1,,9932,N,50588,,1,,A,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,Intermediate
6820,Canis lupus familiaris,,,9615.0,In vivo,,1,,5199,N,50588,,1,,A,Oral half life was determined,,Intermediate
6821,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5199,N,50588,,1,Plasma,A,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,Intermediate
6822,Canis lupus familiaris,,1969.0,9615.0,,,1,,1475,N,50588,,1,Plasma,A,Plasma half life was evaluated,,Intermediate
6823,Canis lupus familiaris,,1969.0,9615.0,,,1,,1475,N,50588,,1,Plasma,A,Plasma half life was evaluated in Dog,,Intermediate
6824,Canis lupus familiaris,,1969.0,9615.0,,,1,,1475,N,50588,,1,Plasma,A,Plasma half life was evaluated in dog,,Intermediate
6825,Canis lupus familiaris,,,9615.0,In vivo,,1,,6316,N,50588,,1,,A,T1/2 (Half-life) was after oral administration at 5 mg/kg,,Intermediate
6826,Canis lupus familiaris,,,9615.0,,,1,,4883,N,50588,,1,,A,Tested for the half life value in dog,,Intermediate
6827,Canis lupus familiaris,,,9615.0,In vivo,,1,,4727,N,50588,,1,,A,Maximum time at the dose of 2 mg/kg in dog,,Intermediate
6828,Canis lupus familiaris,,,9615.0,In vivo,,1,,1916,N,50588,,1,,A,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate
6829,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,1337,N,50588,,1,Blood,A,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
6830,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,1337,N,50588,,1,Blood,A,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
6831,Canis lupus familiaris,,,9615.0,In vivo,,1,,6265,N,50588,,1,,A,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,Intermediate
6832,Canis lupus familiaris,,,9615.0,In vivo,,1,,4809,N,50588,,1,,A,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Intermediate
6833,Canis lupus familiaris,,,9615.0,In vivo,,1,,5983,N,50588,,1,,A,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,Intermediate
6834,Canis lupus familiaris,,,9615.0,,,1,,5313,N,50588,,1,,A,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,Intermediate
6835,Canis lupus familiaris,,,9615.0,In vivo,,1,,5313,N,50588,,1,,A,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,Intermediate
6836,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,17650,N,50588,,1,Plasma,A,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,Intermediate
6837,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,5199,N,50588,,1,Plasma,A,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,Intermediate
6838,Canis lupus familiaris,,1969.0,9615.0,,,1,,933,N,50588,,1,Plasma,A,Time taken for maximum plasma concentration in dog,,Intermediate
6839,Canis lupus familiaris,,,9615.0,In vivo,,1,,16367,N,50588,,1,,A,Time to reach Cmax after oral administration to dogs,,Intermediate
6840,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6348,N,50588,,1,Plasma,A,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate
6841,Canis lupus familiaris,,,9615.0,In vivo,,1,,6316,N,50588,,1,,A,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,Intermediate
6842,Canis lupus familiaris,,,9615.0,In vivo,,1,,6215,N,50588,,1,,A,Tmax after peroral administration (1 mg/kg) was determined in dog,,Intermediate
6843,Canis lupus familiaris,,,9615.0,In vivo,,1,,3598,N,50588,,1,,A,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert
6844,Canis lupus familiaris,,,9615.0,In vivo,,1,,4527,N,50588,,1,,A,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate
6845,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Tmax after peroral administration in dogs at 2.4 uM/kg,,Intermediate
6846,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo Cmax in mice at dose of 100 mg/kg,,Intermediate
6847,Mus musculus,,,10090.0,In vivo,,1,,5969,N,50594,,1,,A,In vivo Cmax in mice at dose of 50 mg/kg,,Intermediate
6848,Mus musculus,,,10090.0,In vivo,,1,,4573,N,50594,,1,,A,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,Intermediate
6849,Mus musculus,,1969.0,10090.0,In vivo,,1,,3277,N,50594,,1,Plasma,A,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Intermediate
6850,Mus musculus,,1969.0,10090.0,In vivo,,1,,17734,N,50594,,1,Plasma,A,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,Intermediate
6851,Mus musculus,,1969.0,10090.0,In vivo,,1,,3132,N,50594,,1,Plasma,A,Maximum concentration obtained in mouse plasma was determined,,Intermediate
6852,Mus musculus,,1969.0,10090.0,In vivo,,1,,3132,N,50594,,1,Plasma,A,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,Intermediate
6853,Mus musculus,,1969.0,10090.0,In vivo,,1,,6348,N,50594,,1,Plasma,A,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate
6854,Mus musculus,,1969.0,10090.0,In vivo,,1,,17729,N,50594,,1,Plasma,A,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,Intermediate
6855,Mus musculus,,1969.0,10090.0,In vivo,,1,,17729,N,50594,,1,Plasma,A,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,Intermediate
6856,Mus musculus,,1969.0,10090.0,In vivo,,1,,17729,N,50594,,1,Plasma,A,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,Intermediate
6857,Mus musculus,,1969.0,10090.0,In vivo,,1,,17728,N,50594,,1,Plasma,A,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,Intermediate
6858,Mus musculus,,1969.0,10090.0,In vivo,,1,,17728,N,50594,,1,Plasma,A,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,Intermediate
6859,Mus musculus,,1969.0,10090.0,In vivo,,1,,17728,N,50594,,1,Plasma,A,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,Intermediate
6860,Mus musculus,,,10090.0,In vivo,,1,,4066,N,50594,,1,,A,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate
6861,Mus musculus,,,10090.0,In vivo,,1,,6178,N,50594,,1,,A,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,Intermediate
6862,Mus musculus,,,10090.0,In vivo,,1,,6178,N,50594,,1,,A,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,Intermediate
6863,Mus musculus,,,10090.0,In vivo,,1,,3760,N,50594,,1,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,Intermediate
6864,Mus musculus,,,10090.0,In vivo,,1,,3760,N,50594,,1,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,Intermediate
6865,Mus musculus,,,10090.0,In vivo,,1,,3760,N,50594,,1,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,Intermediate
6866,Mus musculus,,,10090.0,In vivo,,1,,3760,N,50594,,1,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,Intermediate
6868,Mus musculus,,,10090.0,In vivo,,1,,5961,N,50594,,1,,A,Cmax in male mice after 2 mg/kg oral dose,,Intermediate
6869,Mus musculus,,,10090.0,In vivo,,1,,6137,N,50594,,1,,A,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,Intermediate
6870,Mus musculus,,,10090.0,In vivo,,1,,3802,N,50594,,1,,A,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,Intermediate
6871,Mus musculus,,,10090.0,,,1,,3535,N,50594,,1,,A,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,Intermediate
6872,Mus musculus,,,10090.0,,,1,,3535,N,50594,,1,,A,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,Intermediate
6873,Mus musculus,,,10090.0,,,1,,3535,N,50594,,1,,A,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,Intermediate
6874,Mus musculus,,,10090.0,,,1,,3535,N,50594,,1,,A,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,Intermediate
6875,Mus musculus,,,10090.0,,,1,,3535,N,50594,,1,,A,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,Intermediate
6876,Mus musculus,,,10090.0,,,1,,3535,N,50594,,1,,A,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,Intermediate
6877,Mus musculus,,1969.0,10090.0,,,1,,2862,N,50594,,1,Plasma,A,Maximum concentration in plasma upon oral administration in mouse,,Intermediate
6878,Mus musculus,,1969.0,10090.0,,,1,,2675,N,50594,,1,Plasma,A,Maximum plasma concentration was evaluated in mice after oral administration,,Intermediate
6879,Mus musculus,,1969.0,10090.0,In vivo,,1,,2675,N,50594,,1,Plasma,A,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,Intermediate
6880,Mus musculus,,,10090.0,,,1,,5399,N,50594,,1,,A,Dose at which the compound induced fecal excretion in mice,,Intermediate
6893,Rattus norvegicus,,,10116.0,,,1,,11819,N,80013,A10,1,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,Expert
6894,Rattus norvegicus,,,10116.0,,,1,,11819,N,80013,A10,1,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,Expert
6895,Rattus norvegicus,,,10116.0,,,1,,11819,N,80013,A10,1,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,Expert
6896,Rattus norvegicus,,,10116.0,,,1,,11819,N,80013,A10,1,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,Expert
6897,Rattus norvegicus,,,10116.0,,,1,,16361,N,80013,A10,1,,F,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,Intermediate
6898,Homo sapiens,,,9606.0,,,1,,2288,N,80655,A121,1,,F,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,Intermediate
6899,Homo sapiens,,,9606.0,,,1,,10404,N,80655,A121,1,,F,Anticancer activity against human ovarian carcinoma A121 cells,,Intermediate
6900,Homo sapiens,,,9606.0,,,1,,14790,N,80655,A121,1,,F,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,Intermediate
6901,Homo sapiens,,,9606.0,,,1,,14790,N,80655,A121,1,,F,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,Intermediate
6902,Homo sapiens,,,9606.0,,,1,,14253,N,80655,A121,1,,F,Growth inhibition of human ovarian carcinoma (A121) cell line,,Expert
6903,Homo sapiens,,,9606.0,,,1,,13617,N,80655,A121,1,,F,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,Expert
6904,Homo sapiens,,,9606.0,,,1,,1003,N,80655,A121,1,,F,Cytotoxicity against human A121 ovarian cells,,Intermediate
6905,Homo sapiens,,,9606.0,,,1,,830,N,80655,A121,1,,F,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,Intermediate
6906,Homo sapiens,,,9606.0,,,1,,12307,N,80655,A121,1,,F,In vitro cytotoxicity against human ovarian carcinoma A21,,Intermediate
6907,Homo sapiens,,,9606.0,,,1,,14254,N,80655,A121,1,,F,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,Intermediate
6908,Homo sapiens,,,9606.0,,,1,,13370,N,80655,A121,1,,F,Inhibitory activity of compound against human A121 ovarian cell line.,,Intermediate
6909,Homo sapiens,,,9606.0,,,1,,14790,N,80655,A121,1,,F,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,Intermediate
6910,Homo sapiens,,,9606.0,,,1,,3614,N,80655,A121,1,,F,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,Intermediate
6911,Homo sapiens,,,9606.0,,,1,,2664,N,80012,A 172,1,,F,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,Intermediate
6912,Homo sapiens,,,9606.0,,,1,,2037,N,80012,A 172,1,,F,In vitro cytotoxicity against A172 human tumor cell lines.,,Expert
6913,Homo sapiens,,,9606.0,,,1,,14539,N,80012,A 172,1,,F,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,Intermediate
6914,Homo sapiens,,,9606.0,,,1,,2836,N,80012,A 172,1,,F,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,Intermediate
6915,Homo sapiens,,,9606.0,,,1,,10708,N,80012,A 172,1,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,Intermediate
6916,Canis lupus familiaris,,,9615.0,,,1,,8975,H,104729,,4,,B,Association constant against A2 adenosine receptor,,Autocuration
6917,fish,,,,,,1,,7645,N,80656,A2,1,,F,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,Intermediate
6918,Rattus norvegicus,,,10116.0,,,1,,11377,D,104713,,5,,B,Ratio of Ki for adenosine A2 and A1 receptor binding,,Autocuration
6919,Homo sapiens,,,9606.0,,,1,,13528,N,80014,A204,1,,F,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,Expert
6920,Homo sapiens,,,9606.0,,,1,,10160,N,80014,A204,1,,F,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,Expert
6921,Homo sapiens,,,9606.0,,,1,,15144,N,80015,A2058,1,,F,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,Intermediate
6922,Homo sapiens,,,9606.0,,,1,,13160,N,80657,A253 cell line,1,,F,Growth inhibition against Human squamous cell line(A 253),,Intermediate
6923,Homo sapiens,,,9606.0,,,1,,12898,N,80657,A253 cell line,1,,F,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,Intermediate
6924,Homo sapiens,,,9606.0,,,1,,13069,N,80657,A253 cell line,1,,F,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,Intermediate
6925,Homo sapiens,,,9606.0,,,1,,15984,N,80657,A253 cell line,1,,F,Growth inhibition of A253 cell lines.,,Intermediate
6926,Homo sapiens,,,9606.0,,,1,,15564,N,80657,A253 cell line,1,,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,Intermediate
6927,Homo sapiens,,,9606.0,,,1,,15564,N,80657,A253 cell line,1,,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Intermediate
6928,Homo sapiens,,,9606.0,,,1,,15564,N,80657,A253 cell line,1,,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Intermediate
6929,Homo sapiens,,,9606.0,,,1,,4720,N,81034,A2780,1,,F,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,Intermediate
6930,Homo sapiens,,,9606.0,,,1,,16112,N,81034,A2780,1,,F,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,Intermediate
6931,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,Expert
6932,Homo sapiens,,,9606.0,,,1,,16378,N,81034,A2780,1,,F,Cytotoxicity against human cancer cell lines A2780 (ovarian),,Intermediate
6933,Homo sapiens,,,9606.0,,,1,,16085,N,81034,A2780,1,,F,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,Expert
6934,Homo sapiens,,,9606.0,,,1,,16317,N,81034,A2780,1,,F,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,Intermediate
6935,Homo sapiens,,,9606.0,,,1,,15748,N,81034,A2780,1,,F,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Intermediate
6936,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,Expert
6937,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,Expert
6938,Homo sapiens,,,9606.0,,,1,,16597,N,81034,A2780,1,,F,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,Expert
6939,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,Intermediate
6940,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,Intermediate
6941,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,Intermediate
6942,Cricetulus griseus,,,10029.0,,,1,,15296,U,22224,,0,,F,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Autocuration
6943,Cricetulus griseus,,,10029.0,,,1,,10251,U,22224,CHO-AA8,0,,A,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,Autocuration
6944,Cricetulus griseus,,,10029.0,,,1,,10251,U,22224,CHO-AA8,0,,F,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,Autocuration
6945,Cricetulus griseus,,,10029.0,,,1,,10251,U,22224,CHO-AA8,0,,F,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,Autocuration
6946,Cricetulus griseus,,,10029.0,,,1,,10251,U,22224,CHO-AA8,0,,F,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,Autocuration
6947,Cricetulus griseus,,,10029.0,,,1,,11858,U,22224,,0,,F,Growth inhibition against CHO-derived cell line AA8,,Autocuration
6948,Cricetulus griseus,,,10029.0,,,1,,11858,U,22224,CHO-AA8,0,,F,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,Autocuration
6949,hampster,,,36483.0,,,1,,11616,N,80089,CHO-AA8,1,,F,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,Expert
6950,Cricetulus griseus,,,10029.0,,,1,,11616,N,80089,CHO-AA8,1,,F,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,Expert
6951,Cricetulus griseus,,,10029.0,,,1,,10518,U,22224,CHO-AA8,0,,F,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,Autocuration
6952,Cricetulus griseus,,,10029.0,,,1,,11396,U,22224,CHO-AA8,0,,F,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,Autocuration
6953,Cricetulus griseus,,,10029.0,,,1,,10518,U,22224,CHO-AA8,0,,F,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,Autocuration
6954,Cricetulus griseus,,,10029.0,,,1,,11616,N,80089,CHO-AA8,1,,F,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,Expert
6955,,,,,,,1,,14837,H,12675,,8,,F,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,Autocuration
6956,,,,,,,1,,14837,H,12675,,8,,F,Number of binding sites (n) of isolated serum protein AAG,,Autocuration
6957,,,,,,,1,,16037,M,22222,,3,,B,Association constant for binding to AATT duplex,,Intermediate
6958,Homo sapiens,,,9606.0,,,1,,16597,N,100090,ABAE,1,,F,Inhibition of ABAE human fibroblast cell proliferation,,Expert
6959,Mus musculus,,,10090.0,,,1,,8831,N,80668,AC755,1,,F,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,Intermediate
6960,Oryctolagus cuniculus,,,9986.0,,,1,,13419,D,102444,,9,,F,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,Expert
6961,Oryctolagus cuniculus,,,9986.0,In vivo,,1,,13419,D,102444,,9,,F,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,Expert
6962,,,,,,,1,,15778,H,69,,8,,B,Inhibitory activity against angiotensin-converting enzyme (ACE).,,Autocuration
6963,,,,,,,1,,15778,H,69,,8,,B,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,Autocuration
6964,Homo sapiens,,,9606.0,,,1,,12988,N,80669,ACH-2 cell line,1,,F,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,Intermediate
6965,Homo sapiens,,,9606.0,,,1,,12988,N,80669,ACH-2 cell line,1,,F,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,Intermediate
6966,Human immunodeficiency virus 1,,,11676.0,,,1,,12988,U,22224,T cell line,0,,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,Autocuration
6967,Human immunodeficiency virus 1,,,11676.0,,,1,,12988,U,22224,T cell line,0,,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,Autocuration
6968,Human immunodeficiency virus 1,,,11676.0,,,1,,12988,U,22224,T cell line,0,,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,Autocuration
6969,Homo sapiens,,,9606.0,,,1,,11843,N,80025,ACHN,1,,F,Inhibition of growth of renal cancer ACHN cell line,,Intermediate
6970,Homo sapiens,,,9606.0,,,1,,16939,N,80025,ACHN,1,,F,Inhibition of growth of ACHN renal cancer cell line,,Intermediate
6971,Homo sapiens,,,9606.0,,,1,,4782,N,80025,ACHN,1,,F,Inhibitory concentration required against ACHN renal cancer cell line,,Intermediate
6972,Homo sapiens,,,9606.0,,,1,,6310,N,80025,ACHN,1,,F,Concentration required to inhibit growth of human renal (ACHN) cell line,,Expert
6973,Homo sapiens,,,9606.0,,,1,,6310,N,80025,ACHN,1,,F,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,Intermediate
6974,Homo sapiens,,,9606.0,,,1,,12858,N,80025,ACHN,1,,F,Cytotoxic activity against ACHN Renal cancer cell line,,Intermediate
6975,Homo sapiens,,,9606.0,,,1,,17380,N,80025,ACHN,1,,F,Cytotoxicity evaluation against ACHN renal cancer cells,,Intermediate
6976,Homo sapiens,,,9606.0,,,1,,5858,N,80025,ACHN,1,,F,In vitro antitumor activity against human renal ACHN cell line,,Intermediate
6977,Homo sapiens,,,9606.0,,,1,,3838,N,80025,ACHN,1,,F,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Intermediate
6978,Homo sapiens,,,9606.0,,,1,,3838,N,80025,ACHN,1,,F,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Intermediate
6979,Homo sapiens,,,9606.0,,,1,,5406,N,80025,ACHN,1,,F,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,Intermediate
6980,Homo sapiens,,,9606.0,,,1,,4071,N,80025,ACHN,1,,F,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Intermediate
6981,Homo sapiens,,,9606.0,,,1,,4071,N,80025,ACHN,1,,F,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Expert
6982,Homo sapiens,,,9606.0,,,1,,4071,N,80025,ACHN,1,,F,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,Intermediate
6983,Homo sapiens,,,9606.0,,,1,,15002,N,80025,ACHN,1,,F,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,Intermediate
6984,Homo sapiens,,,9606.0,,,1,,14769,N,80025,ACHN,1,,F,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Intermediate
6985,Homo sapiens,,,9606.0,,,1,,13958,N,80025,ACHN,1,,F,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,Intermediate
6986,Homo sapiens,,,9606.0,,,1,,1665,N,80025,ACHN,1,,F,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,Intermediate
6987,Homo sapiens,,,9606.0,,,1,,15354,N,80025,ACHN,1,,F,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,Intermediate
6988,Homo sapiens,,,9606.0,,,1,,15354,N,80025,ACHN,1,,F,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,Intermediate
6989,Homo sapiens,,,9606.0,,,1,,13978,N,80025,ACHN,1,,F,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,Intermediate
6990,Homo sapiens,,,9606.0,,,1,,6798,N,80025,ACHN,1,,F,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,Intermediate
6991,Canis lupus familiaris,,,9615.0,In vivo,,1,,2959,N,50588,,1,,A,Tmax value after administration of 4 mg/Kg oral dose in dog,,Intermediate
6992,Canis lupus familiaris,,,9615.0,,,1,,9932,N,50588,,1,,A,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,Intermediate
6993,Canis lupus familiaris,,,9615.0,,,1,,5546,N,50588,,1,,A,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Intermediate
6994,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Volume distribution after 15 mg/kg iv dose in Dogs,,Intermediate
6995,Canis lupus familiaris,,,9615.0,In vivo,,1,,16907,N,50588,,1,,A,Volume distribution after 30 mg/kg po dose in Dogs,,Intermediate
6996,Canis lupus familiaris,,,9615.0,In vivo,,1,,4257,N,50588,,1,,A,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,Intermediate
6997,Canis lupus familiaris,,,9615.0,In vivo,,1,,4305,N,50588,,1,,A,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,Intermediate
6998,Canis lupus familiaris,,,9615.0,In vivo,,1,,5472,N,50588,,1,,A,Volume of distribution was evaluated in dog,,Intermediate
6999,Canis lupus familiaris,,,9615.0,In vivo,,1,,6062,N,50588,,1,,A,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,Intermediate
7000,Canis lupus familiaris,,,9615.0,,,1,,3598,N,50588,,1,,A,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert
7001,Canis lupus familiaris,,,9615.0,In vivo,,1,,12500,N,50588,,1,,A,The compound was tested for volume of distribution in dog,,Intermediate
7002,Canis lupus familiaris,,,9615.0,In vivo,,1,,12500,N,50588,,1,,A,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,Intermediate
7003,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Vd (1 mg/kg) was determined in dog (in vivo),,Intermediate
7004,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Vd in dog,,Intermediate
7005,Canis lupus familiaris,,,9615.0,In vivo,,1,,4219,N,50588,,1,,A,Volume distribution was determined,,Intermediate
7006,Canis lupus familiaris,,,9615.0,In vivo,,1,,1696,N,50588,,1,,A,Volume of distribution in dog,,Intermediate
7007,Canis lupus familiaris,,,9615.0,In vivo,,1,,5542,N,50588,,1,,A,Volume of distribution by as 4 fold increase by iv administration in dogs,,Intermediate
7008,Canis lupus familiaris,,,9615.0,In vivo,,1,,5199,N,50588,,1,,A,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,Intermediate
7009,Canis lupus familiaris,,,9615.0,In vivo,,1,,6348,N,50588,,1,,A,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate
7010,Canis lupus familiaris,,,9615.0,In vivo,,1,,4727,N,50588,,1,,A,Volume distribution at the dose of 2 mg/kg in dog,,Intermediate
7011,Canis lupus familiaris,,,9615.0,In vivo,,1,,16367,N,50588,,1,,A,Steady state volume of distribution was determined,,Intermediate
7012,Canis lupus familiaris,,,9615.0,In vivo,,1,,2652,N,50588,,1,,A,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,Intermediate
7013,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Intermediate
7014,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Intermediate
7015,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate
7016,Canis lupus familiaris,,,9615.0,In vivo,,1,,5334,N,50588,,1,,A,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Intermediate
7017,Canis lupus familiaris,,,9615.0,In vivo,,1,,4239,N,50588,,1,,A,Pharmacokinetic property (vdss) was measured in dog,,Intermediate
7018,Canis lupus familiaris,,,9615.0,In vivo,,1,,4709,N,50588,,1,,A,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,Intermediate
7019,Canis lupus familiaris,,,9615.0,In vivo,,1,,5600,N,50588,,1,,A,Vdss was determined after iv 0.1 mg/kg administration in dog,,Intermediate
7020,Canis lupus familiaris,,,9615.0,In vivo,,1,,6057,N,50588,,1,,A,Volume displacement was calculated in dog,,Intermediate
7021,Canis lupus familiaris,,,9615.0,In vivo,,1,,5654,N,50588,,1,,A,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Intermediate
7022,Canis lupus familiaris,,,9615.0,In vivo,,1,,5505,N,50588,,1,,A,Volume distribution constant was determined,,Intermediate
7023,Canis lupus familiaris,,,9615.0,In vivo,,1,,4527,N,50588,,1,,A,Volume distribution at a dose of 1 uM/kg in dog was determined,,Intermediate
7024,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Intermediate
7025,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate
7026,Canis lupus familiaris,,,9615.0,In vivo,,1,,15660,N,50588,,1,,A,Volume distribution (Vdss) was measured in dog,,Intermediate
7027,Canis lupus familiaris,,,9615.0,In vivo,,1,,15660,N,50588,,1,,A,Volume distribution (Vdss) was measured in dog,,Intermediate
7028,Canis lupus familiaris,,,9615.0,In vivo,,1,,6679,N,50588,,1,,A,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate
7029,Canis lupus familiaris,,,9615.0,In vivo,,1,,5145,N,50588,,1,,A,Volume of distribution in steady state was determined in dog,,Intermediate
7030,Canis lupus familiaris,,,9615.0,In vivo,,1,,6821,N,50588,,1,,A,Volume of distribution of compound was determined in dog,,Intermediate
7031,Canis lupus familiaris,,,9615.0,In vivo,,1,,4137,N,50588,,1,,A,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,Intermediate
7032,Canis lupus familiaris,,,9615.0,In vivo,,1,,5334,N,50588,,1,,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,Intermediate
7033,Canis lupus familiaris,,,9615.0,In vivo,,1,,15660,N,50588,,1,,A,Volume of distribution (Vdss) was measured in dog,,Intermediate
7034,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate
7035,Canis lupus familiaris,,,9615.0,In vivo,,1,,6641,N,50588,,1,,A,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate
7036,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate
7037,Canis lupus familiaris,,,9615.0,,,1,,11659,N,50588,,1,,A,Maximum rate of depolarization of the upstroke of the action potential,,Intermediate
7038,Canis lupus familiaris,,,9615.0,In vivo,,1,,6448,N,50588,,1,,A,Steady state volume distribution in dog,,Intermediate
7039,Canis lupus familiaris,,,9615.0,In vivo,,1,,5474,N,50588,,1,,A,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,Intermediate
7040,Canis lupus familiaris,,,9615.0,In vivo,,1,,1466,N,50588,,1,,A,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,Intermediate
7041,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,Intermediate
7042,Canis lupus familiaris,,,9615.0,In vivo,,1,,6535,N,50588,,1,,A,Volume distribution in dog after administration of 1 mg/kg iv,,Intermediate
7043,Canis lupus familiaris,,,9615.0,In vivo,,1,,17764,N,50588,,1,,A,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,Intermediate
7044,Canis lupus familiaris,,,9615.0,In vivo,,1,,6215,N,50588,,1,,A,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,Intermediate
7045,Canis lupus familiaris,,,9615.0,In vivo,,1,,6505,N,50588,,1,,A,Vss on i.v. administration of 2 mg/kg was measured in dog,,Intermediate
7046,Canis lupus familiaris,,,9615.0,,,1,,3639,N,50588,,1,,A,Vss was determined,,Intermediate
7047,Canis lupus familiaris,,,9615.0,,,1,,3639,N,50588,,1,,A,Vss in dog,,Intermediate
7048,Canis lupus familiaris,,,9615.0,In vivo,,1,,6062,N,50588,,1,,A,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,Intermediate
7049,Canis lupus familiaris,,,9615.0,In vivo,,1,,4942,N,50588,,1,,A,Volume distribution in dogs,,Intermediate
7050,Canis lupus familiaris,,,9615.0,In vivo,,1,,17796,N,50588,,1,,A,Volume of distribution in dog,,Intermediate
7051,Canis lupus familiaris,,,9615.0,In vivo,,1,,4883,N,50588,,1,,A,Tested for the oral bioavailability in dog,,Intermediate
7060,Mus musculus,,,10090.0,In vivo,,1,,17837,N,50594,,1,,A,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,Intermediate
7061,Mus musculus,,,10090.0,In vivo,,1,,17729,N,50594,,1,,A,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,Intermediate
7062,Mus musculus,,,10090.0,In vivo,,1,,17729,N,50594,,1,,A,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,Intermediate
7063,Mus musculus,,,10090.0,In vivo,,1,,4239,N,50594,,1,,A,Bioavailability was measured in mouse,,Intermediate
7064,Mus musculus,,,10090.0,In vivo,,1,,17592,N,50594,,1,,A,Bioavailability in mouse,,Intermediate
7065,Mus musculus,,,10090.0,In vivo,,1,,6348,N,50594,,1,,A,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate
7066,Mus musculus,,,10090.0,In vivo,,1,,2801,N,50594,,1,,A,Bioavailability in mouse,,Intermediate
7067,Mus musculus,,,10090.0,In vivo,,1,,2801,N,50594,,1,,A,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,Intermediate
7068,Mus musculus,,,10090.0,In vivo,,1,,17718,N,50594,,1,,A,Oral bioavailability in mouse,,Intermediate
7069,Mus musculus,,,10090.0,In vivo,,1,,5727,N,50594,,1,,A,Oral availability at 50 mg/kg po in male mice,,Intermediate
7070,Mus musculus,,,10090.0,In vivo,,1,,5302,N,50594,,1,,A,Oral bioavailability in mouse (dose 10 mg/kg),,Intermediate
7071,Mus musculus,,,10090.0,In vivo,,1,,3598,N,50594,,1,,A,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,Expert
7072,Mus musculus,,,10090.0,In vivo,,1,,5961,N,50594,,1,,A,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,Intermediate
7074,Mus musculus,,,10090.0,In vivo,,1,,6091,N,50594,,1,,A,Oral bioavailability in mouse,,Intermediate
7075,Mus musculus,,,10090.0,In vivo,,1,,6091,N,50594,,1,,A,Oral bioavailability in vivo in mice;ND=Not determined,,Intermediate
7076,Mus musculus,,,10090.0,In vivo,,1,,5711,N,50594,,1,,A,Oral bioavailability in mouse at 10 mg/kg of the compound,,Intermediate
7077,Mus musculus,,,10090.0,In vivo,,1,,17728,N,50594,,1,,A,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,Intermediate
7078,Mus musculus,,,10090.0,In vivo,,1,,17728,N,50594,,1,,A,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,Intermediate
7079,Mus musculus,,,10090.0,In vivo,,1,,3802,N,50594,,1,,A,Tested for bioavailability of the compound,,Intermediate
7080,Mus musculus,,,10090.0,In vivo,,1,,3802,N,50594,,1,,A,Tested for half life at the dose of 10 mg/kg when administered intravenously,,Intermediate
7081,Mus musculus,,1969.0,10090.0,,,1,,14029,N,50594,,1,Plasma,A,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,Intermediate
7082,Mus musculus,,1969.0,10090.0,,,1,,14029,N,50594,,1,Plasma,A,The plasma half life of compound was determined on heparin prepared by human plasma. ,,Intermediate
7083,Mus musculus,,1969.0,10090.0,,,1,,14029,N,50594,,1,Plasma,A,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,Intermediate
7084,Mus musculus,,1969.0,10090.0,,,1,,14029,N,50594,,1,Plasma,A,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,Intermediate
7085,Mus musculus,,1969.0,10090.0,,,1,,14029,N,50594,,1,Plasma,A,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,Intermediate
7086,Mus musculus,,,10090.0,,,1,,17753,N,50594,,1,,F,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,Intermediate
7087,Mus musculus,,,10090.0,,,1,,17753,N,50594,,1,,A,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,Intermediate
7088,Mus musculus,,,10090.0,,,1,,17753,N,50594,,1,,A,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,Intermediate
7089,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7090,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7091,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7092,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7093,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7094,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7095,Mus musculus,,178.0,10090.0,In vivo,,1,,10107,N,50594,,1,Blood,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7096,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7097,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,Intermediate
7098,Homo sapiens,,,9606.0,,,1,,15608,N,81034,A2780,1,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,Intermediate
7099,Homo sapiens,,,9606.0,,,1,,3290,N,81034,A2780,1,,F,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,Expert
7100,Homo sapiens,,,9606.0,,,1,,2859,N,81034,A2780,1,,F,Compound was evaluated for cytotoxicity against A2780 cell line,,Intermediate
7101,Homo sapiens,,,9606.0,,,1,,15688,N,81034,A2780,1,,F,Inhibition of A2780 cell clonogenic assay,,Expert
7102,Homo sapiens,,,9606.0,,,1,,5642,N,81034,A2780,1,,F,Cytotoxic effect on ovarian cancer cell line (A2780),,Expert
7103,Homo sapiens,,,9606.0,,,1,,6633,N,81034,A2780,1,,F,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,Intermediate
7104,Homo sapiens,,,9606.0,,,1,,3906,N,81034,A2780,1,,F,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,Intermediate
7105,Homo sapiens,,,9606.0,,,1,,6788,N,81034,A2780,1,,F,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,Expert
7106,Homo sapiens,,,9606.0,,,1,,17582,N,81034,A2780,1,,F,Antiproliferative activity against human A2780 cells,,Expert
7107,Homo sapiens,,,9606.0,,,1,,17764,N,81034,A2780,1,,F,Inhibition of human A2780 cell proliferation,,Expert
7108,Homo sapiens,,,9606.0,,,1,,17764,N,81034,A2780,1,,F,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,Expert
7109,Homo sapiens,,,9606.0,,,1,,17764,N,81034,A2780,1,,F,Inhibition of human A2780 cell proliferation (No data),,Expert
7110,Homo sapiens,,,9606.0,,,1,,2815,N,81034,A2780,1,,F,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,Intermediate
7111,Homo sapiens,,,9606.0,,,1,,16930,N,81034,A2780,1,,F,Compound was evaluated against human Ovarian carcinoma cell line A2780,,Intermediate
7112,Homo sapiens,,,9606.0,,,1,,17777,N,81034,A2780,1,,F,Growth inhibition against A2780 wild-type ovarian cell lines,,Expert
7113,Homo sapiens,,,9606.0,,,1,,17777,N,81034,A2780,1,,F,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,Intermediate
7114,Homo sapiens,,,9606.0,,,1,,16936,D,104766,,5,,F,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,Autocuration
7115,Homo sapiens,,,9606.0,,,1,,13759,N,81034,A2780,1,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Intermediate
7116,Homo sapiens,,,9606.0,,,1,,13759,N,81034,A2780,1,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Intermediate
7117,Homo sapiens,,,9606.0,,,1,,13759,N,81034,A2780,1,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Intermediate
7118,Homo sapiens,,,9606.0,,,1,,13759,N,81034,A2780,1,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Intermediate
7119,Homo sapiens,,,9606.0,,,1,,15292,N,81034,A2780,1,,F,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Intermediate
7120,Homo sapiens,,,9606.0,,,1,,15292,N,81034,A2780,1,,F,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Intermediate
7121,Homo sapiens,,,9606.0,,,1,,15069,N,81034,A2780,1,,F,In vitro inhibition of human ovarian cell line A2780,,Expert
7122,Homo sapiens,,,9606.0,,,1,,15069,N,81034,A2780,1,,F,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,Expert
7123,Homo sapiens,,,9606.0,,,1,,14073,N,81034,A2780,1,,F,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,Intermediate
7124,Homo sapiens,,,9606.0,,,1,,14553,N,81034,A2780,1,,F,Concentration required to inhibit A2780-cell growth by 50%,,Expert
7125,Homo sapiens,,,9606.0,,,1,,13040,N,81034,A2780,1,,F,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,Expert
7126,Homo sapiens,,,9606.0,,,1,,6891,N,81034,A2780,1,,F,Cytotoxic effect on human ovarian (A2780) cancer cell line,,Expert
7127,Homo sapiens,,,9606.0,,,1,,15569,N,81034,A2780,1,,F,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,Intermediate
7128,Homo sapiens,,,9606.0,,,1,,14190,N,81034,A2780,1,,F,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,Expert
7129,Homo sapiens,,,9606.0,,,1,,15014,N,81034,A2780,1,,F,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Expert
7130,Homo sapiens,,,9606.0,,,1,,15014,N,81034,A2780,1,,F,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Intermediate
7131,Homo sapiens,,,9606.0,,,1,,17496,N,81034,A2780,1,,F,Cytotoxicity against human ovarian carcinoma A2780 cell line,,Intermediate
7132,Homo sapiens,,,9606.0,,,1,,13617,N,81034,A2780,1,,F,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,Intermediate
7133,Homo sapiens,,,9606.0,,,1,,13617,N,81034,A2780,1,,F,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,Intermediate
7134,Homo sapiens,,,9606.0,,,1,,13617,N,81034,A2780,1,,F,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,Intermediate
7135,Homo sapiens,,,9606.0,,,1,,13617,N,81034,A2780,1,,F,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,Intermediate
7136,Homo sapiens,,,9606.0,,,1,,17672,N,81034,A2780,1,,F,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,Intermediate
7137,Homo sapiens,,,9606.0,,,1,,4544,N,81034,A2780,1,,F,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Intermediate
7138,Homo sapiens,,,9606.0,,,1,,4544,N,81034,A2780,1,,F,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Intermediate
7139,Homo sapiens,,,9606.0,,,1,,16317,N,81034,A2780,1,,F,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,Intermediate
7140,Homo sapiens,,,9606.0,,,1,,15099,N,81034,A2780,1,,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,Intermediate
7141,Homo sapiens,,,9606.0,,,1,,13978,N,81034,A2780,1,,F,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,Intermediate
7142,Homo sapiens,,,9606.0,,,1,,12989,N,81034,A2780,1,,F,In vitro antitumor activity against A2780 cell line.,,Expert
7143,Homo sapiens,,,9606.0,,,1,,5574,N,81034,A2780,1,,F,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,Intermediate
7144,Homo sapiens,,,9606.0,,,1,,13528,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,Expert
7145,Homo sapiens,,,9606.0,,,1,,12782,N,80025,ACHN,1,,F,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,Intermediate
7146,Homo sapiens,,,9606.0,,,1,,14255,N,80025,ACHN,1,,F,The IC50 value was measured on ACHN cell line in renal tumor type.,,Intermediate
7147,Homo sapiens,,,9606.0,,,1,,16364,N,80025,ACHN,1,,F,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,Intermediate
7148,Homo sapiens,,,9606.0,,,1,,17376,N,80025,ACHN,1,,F,In vitro lethal concentration against most sensitive ACHN cell line,,Expert
7149,Homo sapiens,,,9606.0,,,1,,12016,N,80025,ACHN,1,,F,Tested for cytotoxic activity against renal cancer ACHN cell line,,Intermediate
7150,Homo sapiens,,,9606.0,,,1,,6058,N,80025,ACHN,1,,F,Compound tested for growth inhibition of renal cancer cell line ACHN,,Intermediate
7151,Homo sapiens,,,9606.0,,,1,,17708,N,80025,ACHN,1,,F,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,Intermediate
7152,Homo sapiens,,,9606.0,,,1,,15176,N,80025,ACHN,1,,F,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,Intermediate
7153,Homo sapiens,,,9606.0,,,1,,2806,N,80025,ACHN,1,,F,In vitro anticancer activity against ACHN renal cancer cell line,,Intermediate
7154,Homo sapiens,,,9606.0,,,1,,15300,N,80025,ACHN,1,,F,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,Intermediate
7155,Homo sapiens,,,9606.0,,,1,,16364,N,80025,ACHN,1,,F,Percent selectivity was evaluated in renal ACHN cell lines,,Intermediate
7156,Homo sapiens,,,9606.0,,,1,,13859,N,80025,ACHN,1,,F,In vitro inhibitory activity against renal ACHN cancer cell line,,Intermediate
7157,Homo sapiens,,,9606.0,,,1,,11970,N,80025,ACHN,1,,F,Tested for cytotoxicity against ACHN cell lines in renal cancer,,Intermediate
7158,Homo sapiens,,,9606.0,,,1,,2450,N,80025,ACHN,1,,F,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,Intermediate
7159,Homo sapiens,,,9606.0,,,1,,12696,N,80025,ACHN,1,,F,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Intermediate
7160,Homo sapiens,,,9606.0,,,1,,12400,N,80025,ACHN,1,,F,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,Intermediate
7161,Homo sapiens,,,9606.0,,,1,,12888,N,80025,ACHN,1,,F,Cytotoxic effect on renal cancer line ACHN,,Expert
7162,Homo sapiens,,,9606.0,,,1,,3156,N,80025,ACHN,1,,F,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,Intermediate
7163,Homo sapiens,,,9606.0,,,1,,3381,N,80025,ACHN,1,,F,In vitro inhibition of Renal Cancer ACHN cell lines,,Intermediate
7164,Homo sapiens,,,9606.0,,,1,,16747,N,80025,ACHN,1,,F,Antitumor activity against human renal adenocarcinoma ACHN cells,,Intermediate
7165,Homo sapiens,,,9606.0,,,1,,16748,N,80025,ACHN,1,,F,Antitumor activity against human renal adenocarcinoma ACHN cells.,,Expert
7166,Homo sapiens,,,9606.0,,,1,,12062,N,80025,ACHN,1,,F,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,Intermediate
7167,Homo sapiens,,,9606.0,,,1,,14769,N,80025,ACHN,1,,F,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Intermediate
7168,Homo sapiens,,,9606.0,,,1,,15895,N,80025,ACHN,1,,F,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,Intermediate
7169,Homo sapiens,,,9606.0,,,1,,17376,N,80025,ACHN,1,,F,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,Intermediate
7170,Homo sapiens,,,9606.0,,,1,,14882,N,80025,ACHN,1,,F,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Intermediate
7171,Homo sapiens,,,9606.0,,,1,,14882,N,80025,ACHN,1,,F,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,Intermediate
7172,Homo sapiens,,,9606.0,,,1,,15661,N,80025,ACHN,1,,F,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,Intermediate
7173,,,,,,,1,,9680,U,22224,,0,,A,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,Autocuration
7174,,,,,,,1,,14579,H,10647,,8,,F,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,Autocuration
7175,Cytomegalovirus,,,10358.0,,,1,,17290,N,50529,HEL,1,,F,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,Expert
7176,Cytomegalovirus,,,10358.0,,,1,,17290,N,50529,,1,,F,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,Intermediate
7177,,,,,,,1,,15891,H,12159,,8,,B,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,Autocuration
7178,,,,,,,1,,15890,H,12159,,8,,B,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,Autocuration
7179,Bos taurus,,,9913.0,,,1,,3801,N,80670,ADDP cell line,1,,F,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,Intermediate
7180,Mus musculus,,,10090.0,,,1,,9222,N,80671,ADJ/PC6,1,,F,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,Intermediate
7181,Mus musculus,,,10090.0,,,1,,9222,N,80671,ADJ/PC6,1,,F,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,Intermediate
7182,Mus musculus,,,10090.0,,,1,,7257,N,80671,ADJ/PC6,1,,F,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,Intermediate
7183,Mus musculus,,,10090.0,,,1,,7257,N,80671,ADJ/PC6,1,,F,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,Intermediate
7184,Mus musculus,,,10090.0,,,1,,7257,N,80671,ADJ/PC6,1,,A,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,Intermediate
7185,Mus musculus,,,10090.0,,,1,,8084,N,80671,ADJ/PC6,1,,F,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,Intermediate
7186,Mus musculus,,,10090.0,,,1,,14943,U,22224,,0,,F,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,Autocuration
7187,Mus musculus,,,10090.0,,,1,,14943,U,22224,,0,,F,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,Autocuration
7188,Mus musculus,,,10090.0,,,1,,14943,U,22224,,0,,F,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,Autocuration
7189,Bacillus subtilis,,,1423.0,In vivo,,1,,10524,U,22224,,0,,A,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Autocuration
7190,Canis lupus familiaris,,1969.0,9615.0,,,1,,3546,N,50588,,1,Plasma,A,AUC value in dog after IV administration at a dose of 5 mg/kg,,Intermediate
7191,Canis lupus familiaris,,1969.0,9615.0,,,1,,3546,N,50588,,1,Plasma,A,AUC value in dog after oral administration at a dose of 5 mg/kg,,Intermediate
7192,Canis lupus familiaris,,,9615.0,In vivo,,1,,3546,N,50588,,1,,A,Cmax value in dog after oral administration at a dose of 5 mg/kg,,Intermediate
7193,Canis lupus familiaris,,,9615.0,In vivo,,1,,3546,N,50588,,1,,A,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,Intermediate
7194,Canis lupus familiaris,,,9615.0,In vivo,,1,,3546,N,50588,,1,,A,Tmax value in dog after oral administration at a dose of 5 mg/kg,,Intermediate
7195,Canis lupus familiaris,,,9615.0,In vivo,,1,,3184,N,50588,,1,,A,Compound was evaluated for its clearance when administered intravenously in dog,,Intermediate
7196,Canis lupus familiaris,,,9615.0,In vivo,,1,,16456,N,50588,,1,,A,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate
7197,Canis lupus familiaris,,,9615.0,In vivo,,1,,4809,N,50588,,1,,A,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,Intermediate
7198,,,,,,,1,,4219,U,22229,,0,,P,Calculated partition coefficient (clogP),,Intermediate
7199,Canis lupus familiaris,,,9615.0,,,1,,3748,N,50588,,1,,A,Half life in dog,,Intermediate
7200,Canis lupus familiaris,,,9615.0,,,1,,3132,N,50588,,1,,A,Time taken for EC90 was determined when tested in dog,,Intermediate
7201,Canis lupus familiaris,,,9615.0,,,1,,4219,N,50588,,1,,A,Half life (iv) was determined,,Intermediate
7202,Canis lupus familiaris,,2107.0,9615.0,,,1,,16907,N,50588,,1,Liver,A,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,Intermediate
7203,Canis lupus familiaris,,,9615.0,,,1,,6057,N,50588,,1,,A,Area under the curve was calculated in dog after iv administration,,Intermediate
7204,Canis lupus familiaris,,,9615.0,,,1,,6057,N,50588,,1,,A,Area under the curve was calculated in dog after peroral administration,,Intermediate
7205,Canis lupus familiaris,,,9615.0,,,1,,17853,N,50588,,1,,A,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,Intermediate
7206,Canis lupus familiaris,,,9615.0,,,1,,3639,N,50588,,1,,A,pKa was evaluated in dog,,Intermediate
7207,Canis lupus familiaris,,,9615.0,,,1,,14541,N,50588,,1,,A,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,Intermediate
7208,Canis lupus familiaris,,,9615.0,In vivo,,1,,16456,N,50588,,1,,A,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate
7209,Canis lupus familiaris,,,9615.0,In vivo,,1,,16456,N,50588,,1,,A,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate
7210,Canis lupus familiaris,,,9615.0,In vivo,,1,,2652,N,50588,,1,,A,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,Intermediate
7211,Canis lupus familiaris,,,9615.0,,,1,,3624,N,50588,,1,,A,Compound was evaluated for the half-life (t 1/2) in hours,,Intermediate
7212,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,1337,N,50588,,1,Blood,A,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
7213,Canis lupus familiaris,,178.0,9615.0,In vivo,,1,,1337,N,50588,,1,Blood,A,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Intermediate
7214,Canis lupus familiaris,,,9615.0,In vivo,,1,,4709,N,50588,,1,,A,Half life after intravenous administration of 1 mg/kg in dog,,Intermediate
7215,Canis lupus familiaris,,,9615.0,,,1,,15660,N,50588,,1,,A,Half life was measured in dog,,Intermediate
7216,Canis lupus familiaris,,,9615.0,In vivo,,1,,5302,N,50588,,1,,A,Half life period in dog after 5 mg/kg dose,,Intermediate
7217,Canis lupus familiaris,,,9615.0,,,1,,17791,N,50588,,1,,A,Half life period was evaluated in dog; 4-4.8,,Intermediate
7218,Canis lupus familiaris,,,9615.0,In vivo,,1,,6348,N,50588,,1,,A,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate
7219,Canis lupus familiaris,,,9615.0,In vivo,,1,,4257,N,50588,,1,,A,Half-life was determined in dog after a3 mg/kg of iv dose,,Intermediate
7220,Canis lupus familiaris,,,9615.0,,,1,,3771,N,50588,,1,,A,Half-life was determined,,Intermediate
7221,Canis lupus familiaris,,,9615.0,,,1,,6305,N,50588,,1,,A,Half life in dogs,,Intermediate
7222,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,13501,N,50588,,1,Plasma,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,Intermediate
7223,Canis lupus familiaris,,,9615.0,In vivo,,1,,17594,N,50588,,1,,A,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,Intermediate
7224,Canis lupus familiaris,,,9615.0,In vivo,,1,,3045,N,50588,,1,,A,Compound was evaluated for the half life period after iv administration in Beagle dog.,,Intermediate
7225,Canis lupus familiaris,,,9615.0,In vivo,,1,,3043,N,50588,,1,,A,Compound was evaluated for the half life period after oral administration in conscious dog.,,Intermediate
7226,Canis lupus familiaris,,,9615.0,,,1,,4839,N,50588,,1,,A,Compound was tested for half life in dog,,Intermediate
7227,Canis lupus familiaris,,,9615.0,,,1,,4839,N,50588,,1,,A,Compound was tested for its half life in dog,,Intermediate
7228,Canis lupus familiaris,,,9615.0,In vivo,,1,,5802,N,50588,,1,,A,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate
7229,Canis lupus familiaris,,,9615.0,,,1,,17839,N,50588,,1,,A,Half life of compound in dog was determined,,Intermediate
7230,Canis lupus familiaris,,,9615.0,In vivo,,1,,4219,N,50588,,1,,A,Half life (iv) was determined,,Intermediate
7231,Canis lupus familiaris,,178.0,9615.0,,,1,,13966,N,50588,,1,Blood,A,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,Intermediate
7232,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3994,N,50588,,1,Plasma,A,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,Intermediate
7233,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3994,N,50588,,1,Plasma,F,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,Intermediate
7234,Canis lupus familiaris,,,9615.0,,,1,,4453,N,50588,,1,,A,Half life in dog,,Intermediate
7235,Canis lupus familiaris,,1969.0,9615.0,,,1,,6535,N,50588,,1,Plasma,A,Half life in dog plasma,,Intermediate
7236,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6535,N,50588,,1,Plasma,A,Half life in dog plasma after administration of 0.25 mg/kg iv,,Intermediate
7237,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,6535,N,50588,,1,Plasma,A,Half life in dog plasma after administration of 1 mg/kg iv,,Intermediate
7238,Canis lupus familiaris,,1969.0,9615.0,In vivo,,1,,3132,N,50588,,1,Plasma,A,Half life in dog plasma was determined at dose 10 mg/kg,,Intermediate
7239,Canis lupus familiaris,,,9615.0,,,1,,5374,N,50588,,1,,A,Half life in dog was determined,,Intermediate
7240,Canis lupus familiaris,,,9615.0,In vivo,,1,,5007,N,50588,,1,,A,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate
7241,Canis lupus familiaris,,1969.0,9615.0,,,1,,16907,N,50588,,1,Plasma,A,Half life upon exposure to human plasma,,Intermediate
7242,Canis lupus familiaris,,,9615.0,,,1,,6057,N,50588,,1,,A,Half life was calculated in dog,,Intermediate
7243,Canis lupus familiaris,,,9615.0,,,1,,5006,N,50588,,1,,A,Half life was determined,,Intermediate
7244,Canis lupus familiaris,,,9615.0,,,1,,5473,N,50588,,1,,A,Half life was determined,,Intermediate
7245,Canis lupus familiaris,,,9615.0,In vivo,,1,,4368,N,50588,,1,,A,Half life by intravenous administration of 1.2 mg/kg in dog,,Intermediate
7246,Canis lupus familiaris,,,9615.0,,,1,,6448,N,50588,,1,,A,Half life in dog,,Intermediate
7247,Canis lupus familiaris,,,9615.0,,,1,,4353,N,50588,,1,,A,Half life in dog after intra venous administration of the compound,,Intermediate
7248,Canis lupus familiaris,,,9615.0,,,1,,4353,N,50588,,1,,A,Half life in dog after intra venous administration of the compound; ND means Not determined,,Intermediate
7249,Canis lupus familiaris,,,9615.0,In vivo,,1,,4353,N,50588,,1,,A,Half life in dog after po administration of the compound,,Intermediate
7250,Canis lupus familiaris,,,9615.0,In vivo,,1,,4353,N,50588,,1,,A,Half life in dog after po administration of the compound; ND means Not determined,,Intermediate
7251,Canis lupus familiaris,,,9615.0,In vivo,,1,,6265,N,50588,,1,,A,Half life in dog at the single oral dose of 1 mg/kg,,Intermediate
7252,Canis lupus familiaris,,,9615.0,,,1,,5006,N,50588,,1,,A,Half life in dogs,,Intermediate
7253,Canis lupus familiaris,,,9615.0,In vivo,,1,,5356,N,50588,,1,,A,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,Intermediate
7254,Canis lupus familiaris,,,9615.0,,,1,,405,N,50588,,1,,A,Half life in rat,,Intermediate
7255,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate
7256,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7257,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7258,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7259,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7260,Mus musculus,,10000001.0,10090.0,In vivo,,1,,10107,N,50594,,1,Bone,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7261,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7262,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7263,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7264,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7265,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7266,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7267,Mus musculus,,10000004.0,10090.0,In vivo,,1,,10107,N,50594,,1,Gut,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7268,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7269,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7270,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7271,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7272,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7273,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7274,Mus musculus,,948.0,10090.0,In vivo,,1,,10107,N,50594,,1,Heart,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7275,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7276,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,Intermediate
7277,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7278,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7279,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7280,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7281,Mus musculus,,2113.0,10090.0,In vivo,,1,,10107,N,50594,,1,Kidney,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7282,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7283,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7284,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7285,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7286,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7287,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7288,Mus musculus,,2107.0,10090.0,In vivo,,1,,10107,N,50594,,1,Liver,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7289,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7290,Homo sapiens,,,9606.0,,,1,,5895,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780 (human ovarian cancer),,Intermediate
7291,Homo sapiens,,,9606.0,,,1,,6338,N,81034,A2780,1,,F,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,Intermediate
7292,Homo sapiens,,,9606.0,,,1,,15163,N,81034,A2780,1,,F,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,Intermediate
7293,Homo sapiens,,,9606.0,,,1,,15163,N,81034,A2780,1,,F,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,Intermediate
7294,Homo sapiens,,,9606.0,,,1,,15000,N,81034,A2780,1,,F,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,Expert
7295,Homo sapiens,,,9606.0,,,1,,15000,N,81034,A2780,1,,F,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,Expert
7296,Homo sapiens,,,9606.0,,,1,,14729,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,Expert
7297,Homo sapiens,,,9606.0,,,1,,17270,N,81034,A2780,1,,F,In vitro cytotoxicity against A2780 cell line,,Intermediate
7298,Homo sapiens,,,9606.0,,,1,,5685,N,81034,A2780,1,,F,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,Intermediate
7299,Homo sapiens,,,9606.0,,,1,,3563,N,81034,A2780,1,,F,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,Intermediate
7300,Homo sapiens,,,9606.0,,,1,,17753,N,81034,A2780,1,,F,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,Intermediate
7301,Homo sapiens,,,9606.0,,,1,,16317,N,81034,A2780,1,,F,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,Intermediate
7302,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Inhibition of tubulin polymerization in analogy of ca.,,Intermediate
7303,Homo sapiens,,,9606.0,,,1,,3801,N,81034,A2780,1,,F,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,Intermediate
7304,Homo sapiens,,,9606.0,,,1,,6181,N,81034,A2780,1,,F,Cytotoxic effect in ovarian cancer cell line (A2780),,Expert
7305,Homo sapiens,,,9606.0,,,1,,5318,N,81034,A2780,1,,F,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,Intermediate
7306,Homo sapiens,,,9606.0,,,1,,4840,N,81034,A2780,1,,F,Tested for the cytotoxicity in A2780 ovarian cell line,,Intermediate
7307,Homo sapiens,,,9606.0,,,1,,15748,N,81034,A2780,1,,F,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Intermediate
7308,Homo sapiens,,,9606.0,,,1,,15748,N,81034,A2780,1,,F,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,Intermediate
7309,,,,,,,1,,15748,N,80017,A2780cisR,1,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,Intermediate
7310,,,,,,,1,,15748,N,80017,A2780cisR,1,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,Intermediate
7311,,,,,,,1,,15748,N,80017,A2780cisR,1,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,Intermediate
7312,,,,,,,1,,15748,N,80017,A2780cisR,1,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,Intermediate
7313,Homo sapiens,,,9606.0,,,1,,17753,N,81034,A2780,1,,F,In vivo log of cells killed after administration of compound in A2780 cell line,,Intermediate
7314,Homo sapiens,,,9606.0,In vivo,,1,,17753,N,81034,A2780,1,,F,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,Intermediate
7315,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,Intermediate
7316,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,Intermediate
7317,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,Intermediate
7318,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,Intermediate
7319,Homo sapiens,,,9606.0,,,1,,17528,N,81034,A2780,1,,F,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,Intermediate
7320,Homo sapiens,,,9606.0,,,1,,6633,N,81034,A2780,1,,F,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,Intermediate
7321,Homo sapiens,,,9606.0,,,1,,15000,N,81034,A2780,1,,F,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,Expert
7322,Homo sapiens,,,9606.0,,,1,,17528,N,81034,A2780,1,,F,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Expert
7323,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,Intermediate
7324,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,Intermediate
7325,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,Intermediate
7326,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,Intermediate
7327,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,Intermediate
7328,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,Expert
7329,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Intermediate
7330,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Intermediate
7331,Homo sapiens,,,9606.0,,,1,,16936,N,81034,A2780,1,,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Intermediate
7332,Mus musculus,,,10090.0,,,1,,17737,N,81034,A2780,1,,F,In vitro antiproliferative activity against A2780 cell line,,Intermediate
7333,Mus musculus,,,10090.0,,,1,,17764,N,81034,A2780,1,,F,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,Expert
7334,Homo sapiens,,,9606.0,,,1,,3830,N,81034,A2780,1,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,Intermediate
7335,Homo sapiens,,,9606.0,,,1,,3829,N,81034,A2780,1,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,Intermediate
7336,Canis lupus familiaris,,,9615.0,,,1,,3546,N,50588,,1,,A,Vc value in dog after IV administration at a dose of 5 mg/kg,,Intermediate
7337,Canis lupus familiaris,,,9615.0,In vivo,,1,,3546,N,50588,,1,,A,Half life period in dog after IV administration at a dose of 5 mg/kg,,Intermediate
7338,Cercopithecidae,,,9527.0,,,1,,5668,U,22224,,0,,A,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,Autocuration
7339,Cercopithecidae,,1969.0,9527.0,,,1,,3443,U,22224,,0,Plasma,A,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
7340,Cercopithecidae,,1969.0,9527.0,,,1,,3443,U,22224,,0,Plasma,A,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
7341,Macaca fascicularis,,,9541.0,In vivo,,1,,4256,U,22224,,0,,A,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,Autocuration
7342,Macaca fascicularis,,,9541.0,In vivo,,1,,4256,U,22224,,0,,A,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,Autocuration
7343,Macaca fascicularis,,,9541.0,In vivo,,1,,4256,U,22224,,0,,A,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,Autocuration
7344,Rattus norvegicus,,,10116.0,In vivo,,1,,4256,U,22224,,0,,A,Oral Bioavailability in rat,,Autocuration
7345,Cercopithecidae,,,9527.0,,,1,,1916,U,22224,,0,,A,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration
7346,Cercopithecidae,,,9527.0,,,1,,5302,U,22224,,0,,A,Area under curve value in monkey at a dose of 5 mg/kg,,Autocuration
7347,Cercopithecidae,,,9527.0,,,1,,4257,U,22224,,0,,A,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,Autocuration
7348,Cercopithecidae,,,9527.0,,,1,,5355,U,22224,,0,,A,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,Autocuration
7349,Cercopithecidae,,,9527.0,,,1,,5355,U,22224,,0,,A,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,Autocuration
7350,Cercopithecidae,,,9527.0,,,1,,5355,U,22224,,0,,A,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,Autocuration
7351,Cercopithecidae,,,9527.0,,,1,,6078,U,22224,,0,,A,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,Autocuration
7352,Cercopithecidae,,,9527.0,,,1,,6078,U,22224,,0,,A,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,Autocuration
7353,Cercopithecidae,,,9527.0,,,1,,6062,U,22224,,0,,A,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,Autocuration
7354,Cercopithecidae,,,9527.0,,,1,,2661,U,22224,,0,,A,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration
7355,Cercopithecidae,,,9527.0,,,1,,2661,U,22224,,0,,A,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration
7356,Cercopithecidae,,,9527.0,,,1,,5394,U,22224,,0,,A,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,Autocuration
7357,Cercopithecidae,,,9527.0,,,1,,4397,U,22224,,0,,A,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,Autocuration
7358,Cercopithecidae,,,9527.0,,,1,,17509,U,22224,,0,,A,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,Autocuration
7359,Cercopithecidae,,,9527.0,,,1,,17509,U,22224,,0,,A,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,Autocuration
7360,Cercopithecidae,,,9527.0,In vivo,,1,,6641,U,22224,,0,,A,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,Autocuration
7361,Cercopithecidae,,,9527.0,,,1,,5355,U,22224,,0,,A,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,Autocuration
7362,Cercopithecidae,,,9527.0,In vivo,,1,,3443,U,22224,,0,,A,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
7363,Cercopithecidae,,,9527.0,In vivo,,1,,3443,U,22224,,0,,A,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration
7364,Cercopithecidae,,,9527.0,,,1,,17409,U,22224,,0,,A,Binding towards monkey plasma protein at 10 uM,,Autocuration
7365,Cercopithecidae,,,9527.0,,,1,,17409,U,22224,,0,,A,Binding towards monkey plasma protein at 100 uM,,Autocuration
7366,Cercopithecidae,,,9527.0,In vivo,,1,,1052,U,22224,,0,,A,Apparent bioavailability in squirrel monkey was determined,,Autocuration
7367,Cercopithecidae,,,9527.0,In vivo,,1,,13501,U,22224,,0,,A,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,Autocuration
7368,monkey,,,9443.0,In vivo,,1,,17509,U,22224,,0,,A,Bioavailability in monkey (dose 2 mg/kg),,Autocuration
7369,Cercopithecidae,,,9527.0,In vivo,,1,,5394,U,22224,,0,,A,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,Autocuration
7370,Cercopithecidae,,,9527.0,In vivo,,1,,2661,U,22224,,0,,A,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration
7371,monkey,,,9443.0,In vivo,,1,,11219,U,22224,,0,,A,Bioavailability in monkey (i.d. dosing),,Autocuration
7372,Cercopithecidae,,,9527.0,In vivo,,1,,3045,U,22224,,0,,A,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,Autocuration
7373,Cercopithecidae,,,9527.0,,,1,,17796,U,22224,,0,,A,Clearance of the drug was measured in cynomolgus,,Autocuration
7374,Cercopithecidae,,,9527.0,In vivo,,1,,1399,U,22224,,0,,A,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,Autocuration
7375,Cercopithecidae,,,9527.0,In vivo,,1,,2661,U,22224,,0,,A,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration
7376,Macaca mulatta,,1969.0,9544.0,In vivo,,1,,5005,U,22224,,0,Plasma,A,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Autocuration
7377,Cercopithecidae,,,9527.0,In vivo,,1,,17267,U,22224,,0,,A,Plasma clearance in rhesus monkey was determined,,Autocuration
7378,Cercopithecidae,,,9527.0,In vivo,,1,,6535,U,22224,,0,,A,Plasma clearance in monkey after administration of 1 mg/kg iv,,Autocuration
7379,Cercopithecidae,,,9527.0,In vivo,,1,,5922,U,22224,,0,,A,Plasma clearance in cynomolgus monkey,,Autocuration
7380,Cercopithecidae,,,9527.0,In vivo,,1,,6221,U,22224,,0,,A,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration
7381,Cercopithecidae,,,9527.0,In vivo,,1,,5668,U,22224,,0,,A,Plasma clearance after peroral administration at 10 mpk in Rhesus,,Autocuration
7382,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The total clearance was determined after intravenous administration in cynomolgus monkeys,,Autocuration
7383,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,Autocuration
7384,Cercopithecidae,,,9527.0,In vivo,,1,,5355,U,22224,,0,,A,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,Autocuration
7385,Cercopithecidae,,,9527.0,In vivo,,1,,4578,U,22224,,0,,A,Tested for Clearance upon iv administration to african green monkey,,Autocuration
7386,Cercopithecidae,,,9527.0,In vivo,,1,,17592,U,22224,,0,,A,Clearance in monkey,,Autocuration
7387,Canis lupus familiaris,,,9615.0,In vivo,,1,,6641,N,50588,,1,,A,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate
7388,Canis lupus familiaris,,,9615.0,In vivo,,1,,6642,N,50588,,1,,A,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate
7389,Canis lupus familiaris,,,9615.0,In vivo,,1,,16367,N,50588,,1,,A,Half life was evaluated after intravenous administration to dogs,,Intermediate
7390,Canis lupus familiaris,,,9615.0,,,1,,5472,N,50588,,1,,A,Half life was evaluated in dog,,Intermediate
7391,Canis lupus familiaris,,,9615.0,,,1,,5474,N,50588,,1,,A,Half life was evaluated in dog,,Intermediate
7392,Canis lupus familiaris,,,9615.0,In vivo,,1,,5654,N,50588,,1,,A,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Intermediate
7393,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,Intermediate
7394,Canis lupus familiaris,,,9615.0,In vivo,,1,,6227,N,50588,,1,,A,Half life period after intravenous administration in dog,,Intermediate
7395,Canis lupus familiaris,,,9615.0,In vivo,,1,,6221,N,50588,,1,,A,Half life period after oral administration (2.5 mg/kg) in dog was determined,,Intermediate
7396,Canis lupus familiaris,,,9615.0,,,1,,4527,N,50588,,1,,A,Half life period at a dose of 1 uM/kg in dog was determined,,Intermediate
7397,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Half life period was determine after peroral administration at 10 mpk in dog,,Intermediate
7398,Canis lupus familiaris,,,9615.0,In vivo,,1,,5668,N,50588,,1,,A,Half life period was determine after peroral administration at 5 mpk in dog,,Intermediate
7399,Canis lupus familiaris,,,9615.0,,,1,,3854,N,50588,,1,,A,Half life period was determined,,Intermediate
7400,Canis lupus familiaris,,,9615.0,,,1,,5505,N,50588,,1,,A,Half life period was determined,,Intermediate
7401,Canis lupus familiaris,,,9615.0,In vivo,,1,,6251,N,50588,,1,,A,Half life period by iv administration in dog at a dose of 6 mg/kg,,Intermediate
7402,Canis lupus familiaris,,,9615.0,,,1,,1918,N,50588,,1,,A,Half life period was evaluated in dog,,Intermediate
7403,Canis lupus familiaris,,,9615.0,In vivo,,1,,5546,N,50588,,1,,A,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Intermediate
7404,Canis lupus familiaris,,,9615.0,In vivo,,1,,4809,N,50588,,1,,A,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,Intermediate
7405,Canis lupus familiaris,,,9615.0,In vivo,,1,,6215,N,50588,,1,,A,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,Intermediate
7406,Canis lupus familiaris,,,9615.0,In vivo,,1,,4527,N,50588,,1,,A,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate
7407,Canis lupus familiaris,,,9615.0,In vivo,,1,,17594,N,50588,,1,,A,Half-life after oral dose of compound at 3 mg/kg in dogs,,Intermediate
7408,Canis lupus familiaris,,,9615.0,In vivo,,1,,17839,N,50588,,1,,A,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,Intermediate
7409,Canis lupus familiaris,,,9615.0,In vivo,,1,,17839,N,50588,,1,,A,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,Intermediate
7410,Canis lupus familiaris,,,9615.0,In vivo,,1,,17839,N,50588,,1,,A,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,Intermediate
7411,Canis lupus familiaris,,,9615.0,In vivo,,1,,17839,N,50588,,1,,A,Half-life of compound in dog following p.o. administration of 1 mg/kg,,Intermediate
7412,Canis lupus familiaris,,1969.0,9615.0,,,1,,5210,N,50588,,1,Plasma,A,Half-life of compound in plasma of dog was determined,,Intermediate
7413,Canis lupus familiaris,,,9615.0,,,1,,5210,N,50588,,1,,A,Half-life of compound was determined in dogs,,Intermediate
7414,Canis lupus familiaris,,,9615.0,In vivo,,1,,2959,N,50588,,1,,A,Half-life after administration of 4 mg/Kg oral dose in dog,,Intermediate
7415,Canis lupus familiaris,,,9615.0,In vivo,,1,,4137,N,50588,,1,,A,Half-life after intravenous administration of 1 mg/kg/h in dog,,Intermediate
7416,Canis lupus familiaris,,,9615.0,,,1,,5064,N,50588,,1,,A,Half-life in Dog,,Intermediate
7417,Canis lupus familiaris,,,9615.0,,,1,,5147,N,50588,,1,,A,Half-life in Dog,,Intermediate
7418,Canis lupus familiaris,,,9615.0,,,1,,5145,N,50588,,1,,A,Half-life in dog,,Intermediate
7419,Canis lupus familiaris,,,9615.0,In vivo,,1,,6123,N,50588,,1,,A,Half-life in dog after oral administration at 1 mg/kg,,Intermediate
7420,Canis lupus familiaris,,,9615.0,In vivo,,1,,6123,N,50588,,1,,A,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,Intermediate
7421,Canis lupus familiaris,,,9615.0,,,1,,4333,N,50588,,1,,A,Half-life in dogs,,Intermediate
7422,Canis lupus familiaris,,,9615.0,,,1,,4333,N,50588,,1,,A,Half-life in dogs; ND indicates not determined,,Intermediate
7423,Canis lupus familiaris,,1969.0,9615.0,,,1,,12500,N,50588,,1,Plasma,A,Half-life in plasma of dog,,Intermediate
7424,Canis lupus familiaris,,1969.0,9615.0,,,1,,12500,N,50588,,1,Plasma,A,Half-life in plasma of dog at dose of 3-10 mgkg,,Intermediate
7425,Canis lupus familiaris,,,9615.0,In vivo,,1,,6005,N,50588,,1,,A,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,Intermediate
7426,Canis lupus familiaris,,,9615.0,In vivo,,1,,6062,N,50588,,1,,A,Half-life was measured in dog after an iv dose of 1 mg/kg,,Intermediate
7427,Canis lupus familiaris,,,9615.0,In vivo,,1,,17650,N,50588,,1,,A,Half-life was measured in dogs after an oral dose of 10 uM/kg,,Intermediate
7428,Canis lupus familiaris,,,9615.0,In vivo,,1,,5530,N,50588,,1,,A,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,Intermediate
7429,Canis lupus familiaris,,,9615.0,In vivo,,1,,5530,N,50588,,1,,A,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,Intermediate
7430,Canis lupus familiaris,,,9615.0,In vivo,,1,,5600,N,50588,,1,,A,Half-life of the compound after 0.3 mg/kg po administration in dog,,Intermediate
7431,Canis lupus familiaris,,,9615.0,In vivo,,1,,6039,N,50588,,1,,A,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,Intermediate
7432,Canis lupus familiaris,,,9615.0,In vivo,,1,,6039,N,50588,,1,,A,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,Intermediate
7433,Canis lupus familiaris,,,9615.0,In vivo,,1,,6039,N,50588,,1,,A,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,Intermediate
7434,Canis lupus familiaris,,,9615.0,,,1,,6227,N,50588,,1,,A,t1/2 in dog,,Intermediate
7435,Canis lupus familiaris,,,9615.0,,,1,,14541,N,50588,,1,,A,Half-life period measured in dogs,,Intermediate
7436,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Intermediate
7437,Canis lupus familiaris,,,9615.0,In vivo,,1,,4521,N,50588,,1,,A,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate
7438,Canis lupus familiaris,,,9615.0,In vivo,,1,,6679,N,50588,,1,,A,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate
7439,Canis lupus familiaris,,1969.0,9615.0,In vitro,,1,,1116,N,50588,,1,Plasma,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,Intermediate
7440,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo half life period was calculated at 1 mg/kg in dog,,Intermediate
7441,Canis lupus familiaris,,,9615.0,In vivo,,1,,5444,N,50588,,1,,A,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,Intermediate
7442,Canis lupus familiaris,,,9615.0,In vivo,,1,,17853,N,50588,,1,,A,Longer half-life in dog (i.v.) at 0.5 mpk,,Intermediate
7443,Canis lupus familiaris,,,9615.0,In vivo,,1,,4353,N,50588,,1,,A,Oral bioavailability in dog (dose 5 uM/kg),,Intermediate
7444,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Intermediate
7445,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Intermediate
7446,Canis lupus familiaris,,,9615.0,In vivo,,1,,16452,N,50588,,1,,A,Bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate
7447,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,Intermediate
7448,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7449,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7450,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7451,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7452,Mus musculus,,2048.0,10090.0,In vivo,,1,,10107,N,50594,,1,Lung,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7453,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7454,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,Intermediate
7455,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7456,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7457,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7458,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7459,Mus musculus,,2385.0,10090.0,In vivo,,1,,10107,N,50594,,1,Muscle tissue,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7460,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7461,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7462,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7463,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7464,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7465,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7466,Mus musculus,,14.0,10090.0,In vivo,,1,,10107,N,50594,,1,Zone of skin,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7467,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7468,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7469,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7470,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7471,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7472,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7473,Mus musculus,,2106.0,10090.0,In vivo,,1,,10107,N,50594,,1,Spleen,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7474,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate
7475,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate
7476,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate
7477,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate
7478,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate
7479,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,Intermediate
7480,Mus musculus,,945.0,10090.0,In vivo,,1,,10107,N,50594,,1,Stomach,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate
7481,Rattus norvegicus,,,10116.0,In vivo,,1,,4689,N,50597,,1,,A,Oral bioavailability in rat,,Intermediate
7482,Rattus norvegicus,,,10116.0,In vivo,,1,,4950,N,50597,,1,,A,Tested for the bioavailability in rat,,Intermediate
7483,Rattus norvegicus,,,10116.0,In vivo,,1,,5328,N,50597,,1,,A,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Intermediate
7484,Rattus norvegicus,,,10116.0,In vivo,,1,,406,N,50597,,1,,A,Bioavailability in rat,,Intermediate
7485,Rattus norvegicus,,,10116.0,In vivo,,1,,12500,N,50597,,1,,A,Bioavailability in rat,,Intermediate
7486,Rattus norvegicus,,,10116.0,In vivo,,1,,12500,N,50597,,1,,A,Bioavailability in rat (dose 3-10 mg/kg),,Intermediate
7487,Rattus norvegicus,,,10116.0,In vivo,,1,,5247,N,50597,,1,,A,Bioavailability in rat,,Intermediate
7488,Rattus norvegicus,,1969.0,10116.0,In vivo,,1,,4186,N,50597,,1,Plasma,A,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,Intermediate
7489,Rattus norvegicus,,1969.0,10116.0,In vivo,,1,,4186,N,50597,,1,Plasma,A,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,Intermediate
7490,Rattus norvegicus,,,10116.0,In vivo,,1,,6647,N,50597,,1,,A,Half life after oral administration was determined in rats at 6 mg/kg,,Intermediate
7491,Rattus norvegicus,,,10116.0,,,1,,6484,N,50597,,1,,A,Half life was determined,,Intermediate
7492,Rattus norvegicus,,,10116.0,In vivo,,1,,3249,N,50597,,1,,A,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,Intermediate
7493,Rattus norvegicus,,1969.0,10116.0,In vivo,,1,,6281,N,50597,,1,Plasma,A,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,Intermediate
7494,Rattus norvegicus,,,10116.0,,,1,,3307,N,50597,,1,,A,Half life in rats,,Intermediate
7495,Rattus norvegicus,,178.0,10116.0,In vivo,,1,,12058,N,50597,,1,Blood,A,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,Intermediate
7496,Rattus norvegicus,,,10116.0,,,1,,8833,N,50597,,1,,A,Hill coefficient of the compound,,Intermediate
7497,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,Intermediate
7498,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,Intermediate
7499,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,Intermediate
7500,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,Intermediate
7501,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,Intermediate
7502,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,Intermediate
7503,Rattus norvegicus,,178.0,10116.0,,,1,,3193,N,50597,,1,Blood,A,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,Intermediate
7504,Rattus norvegicus,,,10116.0,,,1,,5960,N,50597,,1,,A,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,Intermediate
7505,Rattus norvegicus,,955.0,10116.0,In vivo,,1,,13950,N,50597,,1,Brain,A,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,Intermediate
7506,Rattus norvegicus,,955.0,10116.0,In vivo,,1,,13950,N,50597,,1,Brain,A,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,Intermediate
7507,Rattus norvegicus,,955.0,10116.0,In vivo,,1,,13950,N,50597,,1,Brain,A,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,Intermediate
7508,Rattus norvegicus,,955.0,10116.0,In vivo,,1,,13950,N,50597,,1,Brain,A,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,Intermediate
7509,Rattus norvegicus,,955.0,10116.0,In vivo,,1,,13950,N,50597,,1,Brain,A,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,Intermediate
7510,Rattus norvegicus,,2046.0,10116.0,In vivo,,1,,13950,N,50597,,1,Thyroid gland,A,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,Intermediate
7511,Rattus norvegicus,,2046.0,10116.0,In vivo,,1,,13950,N,50597,,1,Thyroid gland,A,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,Intermediate
7512,Rattus norvegicus,,2046.0,10116.0,In vivo,,1,,13950,N,50597,,1,Thyroid gland,A,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,Intermediate
7513,Rattus norvegicus,,2046.0,10116.0,In vivo,,1,,13950,N,50597,,1,Thyroid gland,A,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,Intermediate
7514,Rattus norvegicus,,2046.0,10116.0,In vivo,,1,,13950,N,50597,,1,Thyroid gland,A,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,Intermediate
7515,Rattus norvegicus,,178.0,10116.0,In vivo,,1,,9866,N,50597,,1,Blood,A,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Intermediate
7516,Rattus norvegicus,,178.0,10116.0,In vivo,,1,,9866,N,50597,,1,Blood,A,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,Intermediate
7517,Rattus norvegicus,,178.0,10116.0,In vivo,,1,,9866,N,50597,,1,Blood,A,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,Intermediate
7518,Rattus norvegicus,,10000001.0,10116.0,In vivo,,1,,9866,N,50597,,1,Bone,A,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Intermediate
7519,Rattus norvegicus,,10000001.0,10116.0,In vivo,,1,,9866,N,50597,,1,Bone,A,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,Intermediate
7520,Rattus norvegicus,,10000001.0,10116.0,In vivo,,1,,9866,N,50597,,1,Bone,A,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,Intermediate
7521,Rattus norvegicus,,948.0,10116.0,In vivo,,1,,9866,N,50597,,1,Heart,A,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,Intermediate
7522,Rattus norvegicus,,948.0,10116.0,In vivo,,1,,9866,N,50597,,1,Heart,A,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,Intermediate
7523,Rattus norvegicus,,948.0,10116.0,In vivo,,1,,9866,N,50597,,1,Heart,A,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,Intermediate
